,sentence_text,e1,e2,relation_type,normalized_sentence_without_suffix
0,"Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.",calcium,EMCYT,mechanism,Milk milk products calcium-rich foods drugs may impair absorption OTHER_DRUG .
1,The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.,allopurinol,ampicillin,effect,The concurrent administration DRUG OTHER_DRUG increases substantially incidence rashes patients receiving drugs compared patients receiving OTHER_DRUG alone .
2,It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.,ampicillin,allopurinol,effect,It known whether potentiation DRUG rashes due OTHER_DRUG hyperuricemia present patients .
3,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",broad-spectrum antibiotics,contraceptives,effect,In common broad-spectrum antibiotics AUGMENTIN XR may reduce efficacy oral OTHER_DRUG
4,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",AUGMENTIN XR,contraceptives,effect,In common broad-spectrum antibiotics AUGMENTIN XR may reduce efficacy oral OTHER_DRUG
5,Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.,ROMAZICON,cyclic antidepressants,effect,Particular caution necessary using DRUG cases mixed drug overdosage since toxic effects (such convulsions cardiac dysrhythmias) drugs taken overdose (especially cyclic antidepressants) may emerge reversal benzodiazepine effect flumazenil .
6,"Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.",ROMAZICON,benzodiazepine,effect,Although DRUG exerts slight intrinsic anticonvulsant effect abrupt suppression protective effect OTHER_DRUG agonist give rise convulsions epileptic patients .
7,ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.,ROMAZICON,benzodiazepines,effect,DRUG blocks central effects OTHER_DRUG competitive interaction receptor level .
8,"The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.",zopiclone,ROMAZICON,effect,The effects nonbenzodiazepine agonists benzodiazepine receptors DRUG triazolopyridazines others also blocked OTHER_DRUG .
9,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,antiarrhythmics,advise,Caution advised DRUG coadministered medications prolong QT interval (e . g . certain OTHER_DRUG thioridazine) lead electrolyte abnormalities (such diuretics amphotericin B) .
10,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,thioridazine,advise,Caution advised DRUG coadministered medications prolong QT interval (e . g . certain antiarrhythmics thioridazine) lead electrolyte abnormalities (such diuretics amphotericin B) .
11,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,diuretics,advise,Caution advised DRUG coadministered medications prolong QT interval (e . g . certain antiarrhythmics thioridazine) lead electrolyte abnormalities (such OTHER_DRUG amphotericin B) .
12,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,amphotericin B,advise,Caution advised DRUG coadministered medications prolong QT interval (e . g . certain antiarrhythmics thioridazine) lead electrolyte abnormalities (such diuretics amphotericin B) .
13,Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.,steroids,aspirin,effect,Rarely salicylate toxicity may occur patients discontinue DRUG concurrent high-dose OTHER_DRUG therapy .
14,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",Barbiturates,fludrocortisone acetate,mechanism,DRUG phenytoin rifampin increased metabolic clearance fludrocortisone acetate induction hepatic enzymes .
15,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",phenytoin,fludrocortisone acetate,mechanism,Barbiturates DRUG rifampin increased metabolic clearance fludrocortisone acetate induction hepatic enzymes .
16,"Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.",rifampin,fludrocortisone acetate,mechanism,Barbiturates phenytoin DRUG increased metabolic clearance fludrocortisone acetate induction hepatic enzymes .
17,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",Oxytocin,dinoprost,effect,DRUG oxytocics (concurrent use OTHER_DRUG may result uterine hypertonus possibly causing uterine rupture cervical laceration especially absence adequate cervical dilatation;
18,"Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;",oxytocics,dinoprost,effect,Oxytocin DRUG (concurrent use OTHER_DRUG may result uterine hypertonus possibly causing uterine rupture cervical laceration especially absence adequate cervical dilatation;
19,Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.,acetaminophen,Isoniazid,effect,Acetaminophen: A report severe DRUG toxicity reported patient receiving OTHER_DRUG .
20,It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.,isoniazid,acetaminophen,effect,It believed toxicity may resulted previously unrecognized interaction DRUG OTHER_DRUG molecular basis interaction proposed .
21,"Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.",isoniazid,acetaminophen,mechanism,Furthermore proposed DRUG resulted In induction P-450IIE1 patients liver turn resulted greater proportion ingested OTHER_DRUG converted toxic metabolites .
22,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Isoniazid,carbamazepine,mechanism,Carbamazepine: DRUG known slow metabolism OTHER_DRUG increase serum levels OTHER_DRUG levels determined prior concurrent administration DRUG signs symptoms OTHER_DRUG toxicity monitored closely appropriate dosage adjustment anticonvulsant made .
23,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Carbamazepine,isoniazid,advise,Carbamazepine: OTHER_DRUG known slow metabolism DRUG increase serum levels DRUG levels determined prior concurrent administration OTHER_DRUG signs symptoms DRUG toxicity monitored closely appropriate dosage adjustment anticonvulsant made .
24,Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.,Ketoconazole,Isoniazid,int,Ketoconazole: Potential interaction DRUG OTHER_DRUG may exist .
25,Phenytoin: Isoniazid may increase serum levels of phenytoin.,Isoniazid,phenytoin,mechanism,Phenytoin: DRUG may increase serum levels OTHER_DRUG .
26,"Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.",isoniazid,theophylline,mechanism,Therophylline: A recent study shown concomitan administration DRUG OTHER_DRUG may cause elevated plasma levels OTHER_DRUG instances slight decrease elimination DRUG .
27,Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.,valproate,isoniazid,mechanism,Valproate: A recent case study shown possible increase plasma level DRUG co administered OTHER_DRUG .
28,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.",isoniazid,valproate,advise,Plasma OTHER_DRUG concentration monitored DRUG OTHER_DRUG co administered appropriate dosage adjustments OTHER_DRUG made .
29,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,aminoglycosides,advise,Co-administration DRUG OTHER_DRUG agents interfering neuromuscular transmission (e . g . curare-like compounds) performed caution effect toxin may potentiated .
30,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,curare-like compounds,advise,Co-administration DRUG aminoglycosides agents interfering neuromuscular transmission (e . g . curare-like compounds) performed caution effect toxin may potentiated .
31,"Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.",bosentan,Ortho-Novum,mechanism,Hormonal Contraceptives Including Oral Injectable Transdermal Implantable Contraceptives: An interaction study demonstrated co-administration DRUG oral hormonal contraceptive OTHER_DRUG produced average decreases norethindrone ethinyl estradiol levels 14% 31% respectively .
32,"Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.",hormonal contraceptives,TRACLEER,effect,Therefore hormonal contraceptives including oral injectable transdermal implantable forms may reliable OTHER_DRUG co-administered .
33,Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.,bosentan,cyclosporine A,mechanism,Steady-state DRUG plasma concentrations 3- 4-fold higher absence cyclosporine A .
34,The concomitant administration of bosentan and cyclosporine A is contraindicated.,bosentan,cyclosporine A,advise,The concomitant administration DRUG cyclosporine A contraindicated .
35,Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.,bosentan,cyclosporine A,mechanism,Co-administration DRUG decreased plasma concentrations cyclosporine A (a CYP3A4 substrate) approximately 50% .
36,Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.,tacrolimus,bosentan,mechanism,Co-administration DRUG OTHER_DRUG resulted markedly increased plasma concentrations OTHER_DRUG animals .
37,Caution should be exercised if tacrolimus and bosentan are used together.,tacrolimus,bosentan,advise,Caution exercised DRUG OTHER_DRUG used together .
38,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.",TRACLEER,glyburide,advise,Therefore concomitant administration DRUG OTHER_DRUG contraindicated alternative hypoglycemic agents considered .
39,Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.,bosentan,glyburide,mechanism,Co-administration DRUG decreased plasma concentrations OTHER_DRUG approximately 40% .
40,Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.,Bosentan,hypoglycemic agents,mechanism,DRUG also expected reduce plasma concentrations oral hypoglycemic agents predominantly metabolized CYP2C9 CYP3A4 .
41,"Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",bosentan,ketoconazole,mechanism,Ketoconazole: Co-administration DRUG 125 mg b . . . OTHER_DRUG potent CYP3A4 inhibitor increased plasma concentrations DRUG approximately 2-fold .
42,"Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",bosentan,simvastatin,mechanism,OTHER_DRUG Other Statins: Co-administration DRUG decreased plasma concentrations OTHER_DRUG (a CYP3A4 substrate) active -hydroxy acid metabolite approximately 50% .
43,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,statins,mechanism,DRUG also expected reduce plasma concentrations OTHER_DRUG significant metabolism CYP3A4 lovastatin atorvastatin .
44,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,lovastatin,mechanism,DRUG also expected reduce plasma concentrations statins significant metabolism CYP3A4 OTHER_DRUG atorvastatin .
45,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,atorvastatin,mechanism,DRUG also expected reduce plasma concentrations statins significant metabolism CYP3A4 lovastatin OTHER_DRUG .
46,Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.,statins,TRACLEER,advise,Patients using CYP3A4 metabolized DRUG cholesterol levels monitored OTHER_DRUG initiated see whether statin dose needs adjustment .
47,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,S-warfarin,mechanism,Warfarin: Co-administration DRUG 500 mg b . . . 6 days decreased plasma concentrations OTHER_DRUG (a CYP2C9 substrate) R-warfarin (a CYP3A4 substrate) 29 38% respectively .
48,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,R-warfarin,mechanism,Warfarin: Co-administration DRUG 500 mg b . . . 6 days decreased plasma concentrations S-warfarin (a CYP2C9 substrate) OTHER_DRUG (a CYP3A4 substrate) 29 38% respectively .
49,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,orphenadrine,int,Therefore potential exists drug interaction DRUG drugs affect CYP2B6 isoenzyme (e . g . OTHER_DRUG cyclophosphamide) .
50,"Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).",WELLBUTRIN,cyclophosphamide,int,Therefore potential exists drug interaction DRUG drugs affect CYP2B6 isoenzyme (e . g . orphenadrine cyclophosphamide) .
51,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,carbamazepine,mechanism,While systematically studied certain drugs may induce metabolism DRUG (e . g . OTHER_DRUG phenobarbital phenytoin) .
52,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenobarbital,mechanism,While systematically studied certain drugs may induce metabolism DRUG (e . g . carbamazepine OTHER_DRUG phenytoin) .
53,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenytoin,mechanism,While systematically studied certain drugs may induce metabolism DRUG (e . g . carbamazepine phenobarbital phenytoin) .
54,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.",bupropion,desipramine,mechanism,In study 15 male subjects (ages 19 35 years) extensive metabolizers CYP2D6 isoenzyme daily doses DRUG given 150 mg twice daily followed single dose 50 mg OTHER_DRUG increased Cmax AUC t1/2 OTHER_DRUG average approximately 2- 5- 2-fold respectively .
55,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antidepressants,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain OTHER_DRUG (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
56,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,nortriptyline,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . OTHER_DRUG imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
57,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,imipramine,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline OTHER_DRUG desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
58,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,desipramine,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine OTHER_DRUG paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
59,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,paroxetine,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine OTHER_DRUG fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
60,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,fluoxetine,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine OTHER_DRUG sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
61,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,sertraline,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
62,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antipsychotics,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) OTHER_DRUG (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
63,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,haloperidol,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . OTHER_DRUG risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
64,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,risperidone,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol OTHER_DRUG thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
65,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,thioridazine,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
66,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,beta-blockers,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) OTHER_DRUG (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
67,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,metoprolol,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
68,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,Type 1C antiarrhythmics,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
69,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,propafenone,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . OTHER_DRUG flecainide) approached caution initiated lower end dose range concomitant medication .
70,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,flecainide,advise,Therefore co-administration DRUG drugs metabolized CYP2D6 isoenzyme including certain antidepressants (e . g . nortriptyline imipramine desipramine paroxetine fluoxetine sertraline) antipsychotics (e . g . haloperidol risperidone thioridazine) beta-blockers (e . g . metoprolol) Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution initiated lower end dose range concomitant medication .
71,MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .,bupropion,phenelzine,effect,MAO Inhibitors: Studies animals demonstrate acute toxicity DRUG enhanced MAO inhibitor OTHER_DRUG .
72,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,levodopa,effect,OTHER_DRUG Amantadine: Limited clinical data suggest higher incidence adverse experiences patients receiving DRUG concurrently either OTHER_DRUG amantadine .
73,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,amantadine,effect,Levodopa Amantadine: Limited clinical data suggest higher incidence adverse experiences patients receiving DRUG concurrently either levodopa OTHER_DRUG .
74,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,levodopa,advise,Administration DRUG Tablets patients receiving either OTHER_DRUG amantadine concurrently undertaken caution using small initial doses small gradual dose increases .
75,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,amantadine,advise,Administration DRUG Tablets patients receiving either levodopa OTHER_DRUG concurrently undertaken caution using small initial doses small gradual dose increases .
76,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antipsychotics,advise,Drugs Lower Seizure Threshold: Concurrent administration DRUG agents (e . g . OTHER_DRUG antidepressants theophylline systemic steroids etc . ) lower seizure threshold undertaken extreme caution .
77,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antidepressants,advise,Drugs Lower Seizure Threshold: Concurrent administration DRUG agents (e . g . antipsychotics OTHER_DRUG theophylline systemic steroids etc . ) lower seizure threshold undertaken extreme caution .
78,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,theophylline,advise,Drugs Lower Seizure Threshold: Concurrent administration DRUG agents (e . g . antipsychotics antidepressants OTHER_DRUG systemic steroids etc . ) lower seizure threshold undertaken extreme caution .
79,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,steroids,advise,Drugs Lower Seizure Threshold: Concurrent administration DRUG agents (e . g . antipsychotics antidepressants theophylline systemic OTHER_DRUG etc . ) lower seizure threshold undertaken extreme caution .
80,"Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.",alcohol,WELLBUTRIN,effect,Alcohol: In post-marketing experience rare reports adverse neuropsychiatric events reduced DRUG tolerance patients drinking DRUG treatment OTHER_DRUG .
81,The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS),alcohol,WELLBUTRIN,advise,The consumption DRUG treatment OTHER_DRUG minimized avoided (also see href= bupropz_od . htm#CI CONTRAINDICATIONS)
82,Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.,TNF antagonist,ORENCIA,effect,Concurrent administration TNF antagonist OTHER_DRUG associated increased risk serious infections significant additional efficacy use TNF antagonists alone .
83,Concurrent therapy with ORENCIA and TNF antagonists is not recommended.,ORENCIA,TNF antagonists,advise,Concurrent therapy DRUG TNF antagonists recommended .
84,"There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.",ORENCIA,anakinra,advise,There insufficient experience assess safety efficacy DRUG administered concurrently OTHER_DRUG therefore use recommended .
85,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,cholestyramine,leflunomide,mechanism,DRUG Charcoal Administration DRUG activated charcoal patients (n=13) volunteers (n=96) resulted rapid significant decrease plasma M1 (the active metabolite leflunomide) concentration .
86,Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .,activated charcoal,leflunomide,mechanism,Cholestyramine Charcoal Administration cholestyramine activated charcoal patients (n=13) volunteers (n=96) resulted rapid significant decrease plasma M1 (the active metabolite leflunomide) concentration .
87,"In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.",ARAVA,methotrexate,effect,In small (n=30) combination study DRUG OTHER_DRUG 2- 3-fold elevation liver enzymes seen 5 30 patients .
88,"Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.",ARAVA,rifampin,mechanism,Rifampin: Following concomitant administration single dose DRUG subjects receiving multiple doses OTHER_DRUG M1 peak levels increased (~40%) seen DRUG given alone .
89,"Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.",ARAVA,rifampin,advise,Because potential DRUG levels continue increase multiple dosing caution used patients receiving DRUG OTHER_DRUG .
90,Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.,ARAVA,warfarin,effect,Warfarin: Increased INR (International Normalized Ratio) DRUG OTHER_DRUG co-administered rarely reported .
91,Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.,dobutamine,b-blocking drug,effect,Animal studies indicate DRUG may ineffective patient recently received b-blocking drug .
92,"Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.",dobutamine,nitroprusside,effect,Preliminary studies indicate concomitant use DRUG OTHER_DRUG results higher cardiac output usually lower pulmonary wedge pressure either drug used alone .
93,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,dicumarol,advise,Therefore heparin sodium given OTHER_DRUG warfarin sodium period least 5 hours last intravenous dose 24 hours last subcutaneous dose elapse blood drawn valid prothrombin time obtained .
94,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,warfarin sodium,advise,Therefore heparin sodium given dicumarol warfarin sodium period least 5 hours last intravenous dose 24 hours last subcutaneous dose elapse blood drawn valid prothrombin time obtained .
95,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",acetylsalicylic acid,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet-aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium .
96,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dextran,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid DRUG phenylbutazone ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet-aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium .
97,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",phenylbutazone,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran DRUG ibuprofen indomethacin dipyridamole hydroxychloroquine others interfere platelet-aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium .
98,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",ibuprofen,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone DRUG indomethacin dipyridamole hydroxychloroquine others interfere platelet-aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium .
99,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",indomethacin,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen DRUG dipyridamole hydroxychloroquine others interfere platelet-aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium .
100,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",dipyridamole,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin DRUG hydroxychloroquine others interfere platelet-aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium .
101,"Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.",hydroxychloroquine,heparin sodium,effect,Platelet inhibitors: Drugs acetylsalicylic acid dextran phenylbutazone ibuprofen indomethacin dipyridamole DRUG others interfere platelet-aggregation reactions (the main hemostatic defense heparinized patients) may induce bleeding used caution patients receiving heparin sodium .
102,The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.,heparin,antithrombin III,effect,The anticoagulant effect DRUG enhanced concurrent treatment antithrombin III (human) patients hereditary antithrombin III deficiency .
103,"Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).",heparin,antithrombin III,advise,Thus order avoid bleeding reduced dosage DRUG recommended treatment antithrombin III (human) .
104,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",Digitalis,heparin sodium,effect,Drugs Decreasing Heparin Effect: DRUG tetracyclines nicotine antihistamines may partially counteract anticoagulant action heparin sodium .
105,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",tetracyclines,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis DRUG nicotine antihistamines may partially counteract anticoagulant action heparin sodium .
106,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",nicotine,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis tetracyclines DRUG antihistamines may partially counteract anticoagulant action heparin sodium .
107,"Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.",antihistamines,heparin sodium,effect,Drugs Decreasing Heparin Effect: Digitalis tetracyclines nicotine DRUG may partially counteract anticoagulant action heparin sodium .
108,Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.,tricyclic antidepressants,cimetidine,mechanism,Steady-state serum concentrations tricyclic antidepressants reported fluctuate significantly OTHER_DRUG either added deleted drug regimen .
109,"Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.",tricyclic antidepressants,cimetidine,effect,Serious anticholinergic symptoms (severe dry mouth urinary retention blurred vision) associated elevations serum levels tricyclic antidepressants OTHER_DRUG added drug regimen .
110,"In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.",tricyclic antidepressants,cimetidine,mechanism,In addition higher-than expected steady-state serum concentrations tricyclic antidepressants observed therapy initiated patients already taking OTHER_DRUG .
111,"In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.",cimetidine,tricyclic antidepressants,mechanism,In well-controlled patients undergoing concurrent therapy DRUG decrease steady-state serum concentrations tricyclic antidepressants may occur cime-tidine therapy discontinued .
112,The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.,tricyclic antidepressants,cimetidine,effect,The therapeutic efficacy tricyclic antidepressants may compromised patients OTHER_DRUG discontinued .
113,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",antidepressants,fluoxetine hydrochloride,mechanism,There greater 2-fold increases previously stable plasma levels DRUG including nortriptyline fluoxetine hydrochloride administered combination agents .
114,"There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.",nortriptyline,fluoxetine hydrochloride,mechanism,There greater 2-fold increases previously stable plasma levels antidepressants including DRUG fluoxetine hydrochloride administered combination agents .
115,Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.,reserpine,tricyclic antidepressant,effect,Administration DRUG therapy tricyclic antidepressant shown produce stimulating effect depressed patients .
116,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,anticholinergic drugs,advise,Close supervision careful adjustment dosage required nortriptyline hydrochloride used anticholinergic drugs sympathomimetic drugs .
117,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,sympathomimetic drugs,advise,Close supervision careful adjustment dosage required nortriptyline hydrochloride used anticholinergic drugs sympathomimetic drugs .
118,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,antidepressants,advise,Therefore co-administration tricyclic OTHER_DRUG drugs metabolized isoenzyme including OTHER_DRUG phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution .
119,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,phenothiazines,advise,Therefore co-administration tricyclic antidepressants drugs metabolized isoenzyme including antidepressants OTHER_DRUG carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution .
120,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,carbamazepine,advise,Therefore co-administration tricyclic antidepressants drugs metabolized isoenzyme including antidepressants phenothiazines OTHER_DRUG Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution .
121,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,Type 1C antiarrhythmics,advise,Therefore co-administration tricyclic antidepressants drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution .
122,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,propafenone,advise,Therefore co-administration tricyclic antidepressants drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg OTHER_DRUG flecainide encainide) inhibit enzyme (eg quinidine) approached caution .
123,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,flecainide,advise,Therefore co-administration tricyclic antidepressants drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone OTHER_DRUG encainide) inhibit enzyme (eg quinidine) approached caution .
124,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,encainide,advise,Therefore co-administration tricyclic antidepressants drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution .
125,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,quinidine,advise,Therefore co-administration tricyclic antidepressants drugs metabolized isoenzyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (eg propafenone flecainide encainide) inhibit enzyme (eg quinidine) approached caution .
126,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,CNS depressants,advise,Although specific drug interaction studies conducted ALPHAGAN P possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics) considered .
127,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,alcohol,advise,Although specific drug interaction studies conducted ALPHAGAN P possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics) considered .
128,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,barbiturates,advise,Although specific drug interaction studies conducted ALPHAGAN P possibility additive potentiating effect CNS depressants (alcohol OTHER_DRUG opiates sedatives anesthetics) considered .
129,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,opiates,advise,Although specific drug interaction studies conducted ALPHAGAN P possibility additive potentiating effect CNS depressants (alcohol barbiturates OTHER_DRUG sedatives anesthetics) considered .
130,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,sedatives,advise,Although specific drug interaction studies conducted ALPHAGAN P possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates OTHER_DRUG anesthetics) considered .
131,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,anesthetics,advise,Although specific drug interaction studies conducted ALPHAGAN P possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics) considered .
132,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.,Tricyclic antidepressants,clonidine,effect,Tricyclic antidepressants reported blunt hypotensive effect systemic OTHER_DRUG . It known whether concurrent use agents ALPHAGAN P humans lead resulting interference IOP lowering effect .
133,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ketoconazole,advise,The daily dose DRUG exceed 7 . 5 mg coadministered potent CYP3A4 inhibitors (e . g . OTHER_DRUG itraconazole ritonavir nelfinavir clarithromycin nefazadone) .
134,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,itraconazole,advise,The daily dose DRUG exceed 7 . 5 mg coadministered potent CYP3A4 inhibitors (e . g . ketoconazole OTHER_DRUG ritonavir nelfinavir clarithromycin nefazadone) .
135,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ritonavir,advise,The daily dose DRUG exceed 7 . 5 mg coadministered potent CYP3A4 inhibitors (e . g . ketoconazole itraconazole OTHER_DRUG nelfinavir clarithromycin nefazadone) .
136,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,nelfinavir,advise,The daily dose DRUG exceed 7 . 5 mg coadministered potent CYP3A4 inhibitors (e . g . ketoconazole itraconazole ritonavir OTHER_DRUG clarithromycin nefazadone) .
137,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,clarithromycin,advise,The daily dose DRUG exceed 7 . 5 mg coadministered potent CYP3A4 inhibitors (e . g . ketoconazole itraconazole ritonavir nelfinavir OTHER_DRUG nefazadone) .
138,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,flecainide,advise,Caution taken DRUG used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window OTHER_DRUG thioridazine tricyclic antidepressants (see CLINICAL PHARMACOLOGY) .
139,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,thioridazine,advise,Caution taken DRUG used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window flecainide OTHER_DRUG tricyclic antidepressants (see CLINICAL PHARMACOLOGY) .
140,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,tricyclic antidepressants,advise,Caution taken DRUG used concomitantly medications predominantly metabolized CYP2D6 narrow therapeutic window flecainide thioridazine tricyclic antidepressants (see CLINICAL PHARMACOLOGY) .
141,"The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.",ENABLEX,anticholinergic agents,effect,The concomitant use DRUG anticholinergic agents may increase frequency and/or severity dry mouth constipation blurred vision anticholinergic pharmacological effects .
142,Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.,ETHYOL,antihypertensive medications,advise,Special consideration given administration DRUG patients receiving antihypertensive medications drugs could cause potentiate hypotension .
143,Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.,Tiagabine,valproate,mechanism,Valproate: DRUG causes slight decrease (about 10%) steady-state OTHER_DRUG concentrations .
144,Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.,tiagabine,carbamazepine,mechanism,Effects Antiepilepsy Drugs (AEDs) GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking OTHER_DRUG without enzyme- inducing AEDs .
145,Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.,tiagabine,phenytoin,mechanism,Phenytoin: Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking OTHER_DRUG without enzyme- inducing AEDs .
146,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,phenobarbital,mechanism,OTHER_DRUG (Primidone): Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking OTHER_DRUG (primidone) without enzyme-inducing AEDs .
147,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.,tiagabine,primidone,mechanism,Phenobarbital (Primidone): Population pharmacokinetic analyses indicate DRUG clearance 60% greater patients taking phenobarbital (primidone) without enzyme-inducing AEDs .
148,"Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.",valproate,tiagabine,mechanism,Valproate: The addition OTHER_DRUG patients taking DRUG chronically effect OTHER_DRUG pharmacokinetics DRUG significantly decreased OTHER_DRUG binding vitro 96 . 3 94 . 8% resulted increase approximately 40% free OTHER_DRUG concentration .
149,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",ethanol,tiagabine,advise,Because possible additive effects drugs may depress nervous system DRUG triazolam used cautiously combination OTHER_DRUG .
150,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",triazolam,tiagabine,advise,Because possible additive effects drugs may depress nervous system ethanol DRUG used cautiously combination OTHER_DRUG .
151,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Acetaminophen,int,DRUG may interact following: - OTHER_DRUG (e . g . Tylenol) (with long-term high-dose use)
152,"Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or",Sulfapyridine,Tylenol,int,DRUG may interact following: - Acetaminophen (e . g . Tylenol) (with long-term high-dose use)
153,"- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics",antidiabetics,sulfapyridine,effect,- DRUG oral (diabetes medicine take mouth) Use oral DRUG OTHER_DRUG may increase chance side effects affecting blood and/or side effects oral DRUG
154,"- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate",methotrexate,sulfapyridine,effect,- DRUG (e . g . Mexate) Use DRUG OTHER_DRUG may increase chance side effects affecting liver and/or side effects DRUG
155,"- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood",methyldopa,sulfapyridine,effect,- DRUG (e . g . Aldomet) Use DRUG OTHER_DRUG may increase chance side effects affecting liver and/or blood
156,"- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin",phenytoin,sulfapyridine,effect,- DRUG (e . g . Dilantin) Use DRUG OTHER_DRUG may increase chance side effects affecting liver and/or side effects DRUG
157,Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.,theophylline,quinolones,mechanism,Elevated plasma levels DRUG reported concomitant use OTHER_DRUG .
158,There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.,theophylline,quinolone,effect,There reports theophylline-related side-effects patients concomitant theophylline-quinolone therapy .
159,Quinolones have also been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,DRUG also shown interfere metabolism OTHER_DRUG .
160,"Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.",cinoxacin,caffeine,advise,Although interaction reported DRUG caution exercised DRUG given concomitantly caffeine-containing products .
161,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",Antacids,quinolones,mechanism,DRUG sucralfate substantially interfere absorption OTHER_DRUG resulting low urine levels .
162,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",sucralfate,quinolones,mechanism,Antacids DRUG substantially interfere absorption OTHER_DRUG resulting low urine levels .
163,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,iron,mechanism,Also concomitant administration DRUG products containing OTHER_DRUG multivitamins containing zinc Videx (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels .
164,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,zinc,mechanism,Also concomitant administration DRUG products containing iron multivitamins containing OTHER_DRUG Videx (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels .
165,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,Videx,mechanism,Also concomitant administration DRUG products containing iron multivitamins containing zinc OTHER_DRUG (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels .
166,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,didanosine,mechanism,Also concomitant administration DRUG products containing iron multivitamins containing zinc Videx (didanosine) chewable/buffered tablets pediatric powder oral solution may result low urine levels .
167,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,anticoagulants,effect,DRUG including cinoxacin may enhance effects oral OTHER_DRUG warfarin derivatives .
168,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,warfarin,effect,DRUG including cinoxacin may enhance effects oral anticoagulants OTHER_DRUG derivatives .
169,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,anticoagulants,effect,Quinolones including DRUG may enhance effects oral OTHER_DRUG warfarin derivatives .
170,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,warfarin,effect,Quinolones including DRUG may enhance effects oral anticoagulants OTHER_DRUG derivatives .
171,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,nonsteroidal anti-inflammatory drug,effect,Seizures reported patients taking another quinolone class antimicrobial nonsteroidal anti-inflammatory drug fenbufen concurrently .
172,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,fenbufen,effect,Seizures reported patients taking another quinolone class antimicrobial nonsteroidal anti-inflammatory drug OTHER_DRUG concurrently .
173,Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.,cinoxacin,nonsteroidal anti-inflammatory agents,advise,Physicians provided information increase awareness potential serious interactions DRUG certain nonsteroidal anti-inflammatory agents administered concomitantly .
174,Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated OTHER_DRUG serum levels reported concomitant use DRUG OTHER_DRUG .
175,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,aluminum,mechanism,Administration DRUG antacids containing OTHER_DRUG magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
176,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,magnesium,mechanism,Administration DRUG antacids containing aluminum OTHER_DRUG calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
177,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,calcium,mechanism,Administration DRUG antacids containing aluminum magnesium OTHER_DRUG sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
178,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,sucralfate,mechanism,Administration DRUG antacids containing aluminum magnesium calcium OTHER_DRUG metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
179,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,Administration DRUG antacids containing aluminum magnesium calcium sucralfate metal cations OTHER_DRUG multivitamins containing OTHER_DRUG zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
180,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,multivitamins,mechanism,Administration DRUG antacids containing aluminum magnesium calcium sucralfate metal cations iron OTHER_DRUG containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
181,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,iron,mechanism,Administration DRUG antacids containing aluminum magnesium calcium sucralfate metal cations OTHER_DRUG multivitamins containing OTHER_DRUG zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
182,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,zinc,mechanism,Administration DRUG antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron OTHER_DRUG formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
183,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,VIDEX,mechanism,Administration DRUG antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations OTHER_DRUG (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
184,"Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.",quinolones,didanosine,mechanism,Administration DRUG antacids containing aluminum magnesium calcium sucralfate metal cations iron multivitamins containing iron zinc formulations containing divalent trivalent cations VIDEX (didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption DRUG resulting systemic concentrations considerably lower desired .
185,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,caffeine,mechanism,OTHER_DRUG Theobromine DRUG like quinolones may inhibit metabolism OTHER_DRUG theobromine .
186,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",Grepafloxacin,theobromine,mechanism,Caffeine OTHER_DRUG DRUG like quinolones may inhibit metabolism caffeine OTHER_DRUG .
187,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,caffeine,mechanism,OTHER_DRUG Theobromine Grepafloxacin like DRUG may inhibit metabolism OTHER_DRUG theobromine .
188,"Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.",quinolones,theobromine,mechanism,Caffeine OTHER_DRUG Grepafloxacin like DRUG may inhibit metabolism caffeine OTHER_DRUG .
189,Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.,Grepafloxacin,theophylline,mechanism,Theophylline: DRUG competitive inhibitor metabolism OTHER_DRUG .
190,Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.,grepafloxacin,theophylline,mechanism,Serum OTHER_DRUG concentrations increase DRUG initiated patient maintained OTHER_DRUG .
191,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",theophylline,grepafloxacin,advise,When initiating multi-day course OTHER_DRUG patient maintained DRUG DRUG maintenance dose halved period concurrent use OTHER_DRUG monitoring serum DRUG concentrations initiated guide dosage adjustments .
192,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolones,warfarin,effect,However DRUG reported enhance effects OTHER_DRUG derivatives prothrombin time suitable anticoagulation test monitored closely quinolone antimicrobial administered OTHER_DRUG derivatives .
193,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,However quinolones reported enhance effects OTHER_DRUG derivatives prothrombin time suitable anticoagulation test monitored closely quinolone antimicrobial administered OTHER_DRUG derivatives .
194,"Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.",grepafloxacin,theophylline,mechanism,Drugs Metabolized Cytochrome P450 Enzymes The drug interaction study evaluating effect DRUG OTHER_DRUG indicates DRUG inhibits OTHER_DRUG metabolism mediated CYP1A2 .
195,"In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.",quinolones,cyclosporine,mechanism,In addition DRUG reported decrease CYP3A4-mediated metabolism OTHER_DRUG .
196,Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.,nonsteroidal anti inflammatory drug,quinolone,effect,Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration nonsteroidal anti inflammatory drug OTHER_DRUG may increase risks CNS stimulation convulsions .
197,"Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.",quinolones,antidiabetic agent,effect,Antidiabetic Agents: Disturbances blood glucose including hyperglycemia hypoglycemia reported patients treated concomitantly DRUG antidiabetic agent .
198,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,anticholinergics,effect,The concurrent use DRUG Injection OTHER_DRUG medications anticholinergic activity phenothiazines antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects .
199,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,phenothiazines,effect,The concurrent use DRUG Injection anticholinergics medications anticholinergic activity OTHER_DRUG antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects .
200,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,antiparkinson drugs,effect,The concurrent use DRUG Injection anticholinergics medications anticholinergic activity phenothiazines antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects .
201,"The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.",Robinul,tricyclic antidepressants,effect,The concurrent use DRUG Injection anticholinergics medications anticholinergic activity phenothiazines antiparkinson drugs tricyclic antidepressants may intensify antimuscarinic effects may result increase anticholinergic side effects .
202,Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.,Robinul,potassium chloride,mechanism,Concomitant administration DRUG Injection potassium chloride wax matrix may increase severity potassium chloride-induced gastrointestinal lesions result slower gastrointestinal transit time .
203,"When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.",beta-adrenergic receptor blocking agents,Anesthetics,int,When administered concurrently following drugs may interact beta-adrenergic receptor blocking agents: OTHER_DRUG general: exaggeration hypotension induced general OTHER_DRUG .
204,Elevated plasma levels of theophylline have been reported with concomitant quinolone use.,theophylline,quinolone,mechanism,Elevated plasma levels DRUG reported concomitant OTHER_DRUG use .
205,There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.,quinolones,theophylline,effect,There reports theophylline-related side effects patients concomitant therapy DRUG OTHER_DRUG .
206,Quinolones have been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,DRUG shown interfere metabolism OTHER_DRUG .
207,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",Quinolones,warfarin,effect,DRUG including nalidixic acid may enhance effects oral anticoagulant OTHER_DRUG derivatives .
208,"Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.",nalidixic acid,warfarin,effect,Quinolones including nalidixic acid may enhance effects oral anticoagulant OTHER_DRUG derivatives .
209,Nitrofurantoin interferes with the therapeutic action of nalidixic acid.,Nitrofurantoin,nalidixic acid,effect,DRUG interferes therapeutic action nalidixic acid .
210,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Videx,quinolones,mechanism,DRUG (Didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption OTHER_DRUG resulting systemic levels considerably lower desired .
211,"and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.",Didanosine,quinolones,mechanism,Videx (Didanosine) chewable/buffered tablets pediatric powder oral solution may substantially interfere absorption OTHER_DRUG resulting systemic levels considerably lower desired .
212,Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated serum levels OTHER_DRUG reported concomitant use DRUG OTHER_DRUG .
213,"Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.",cephalexin,metformin,mechanism,Metformin: In healthy subjects given single 500 mg doses DRUG OTHER_DRUG plasma OTHER_DRUG mean cmax AUC increased average 34% 24% respectively OTHER_DRUG mean renal clearance decreased 14% .
214,"Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.",cephalexin,metformin,mechanism,Although observed study adverse effects could potentially arise co-administration DRUG OTHER_DRUG inhibition tubular secretion via organic cationic transporter systems .
215,"Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.",cephalexin,metformin,advise,Accordingly careful patient monitoring dose adjustment OTHER_DRUG recommended patients concomitantly taking DRUG OTHER_DRUG .
216,"Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.",cephalexin,probenecid,mechanism,Probenecid: As b-lactams renal excretion DRUG inhibited OTHER_DRUG .
217,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Monoamine oxidase inhibitors,int,Drug Interactions: DRUG may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect DRUG pharmacodynamics - Arecoline - Eproxindine - Ethanol: DRUG Ethanol cause additive CNS depression - Tricyclic antidepressants: DRUG increases effect Tricyclic antidepressants
218,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,MAOI,int,Drug Interactions: DRUG may interact drugs like Monoamine oxidase inhibitors (MAOI): OTHER_DRUG could theoretically affect DRUG pharmacodynamics - Arecoline - Eproxindine - Ethanol: DRUG Ethanol cause additive CNS depression - Tricyclic antidepressants: DRUG increases effect Tricyclic antidepressants
219,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",MAOI,flupenthixol,effect,Drug Interactions: OTHER_DRUG may interact drugs like Monoamine oxidase inhibitors (MAOI): DRUG could theoretically affect OTHER_DRUG pharmacodynamics - Arecoline - Eproxindine - Ethanol: OTHER_DRUG Ethanol cause additive CNS depression - Tricyclic antidepressants: OTHER_DRUG increases effect Tricyclic antidepressants
220,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Ethanol,effect,Drug Interactions: DRUG may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect DRUG pharmacodynamics - Arecoline - Eproxindine - Ethanol: DRUG OTHER_DRUG cause additive CNS depression - Tricyclic antidepressants: DRUG increases effect Tricyclic antidepressants
221,"Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants",Flupenthixol,Tricyclic antidepressants,effect,Drug Interactions: DRUG may interact drugs like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect DRUG pharmacodynamics - Arecoline - Eproxindine - Ethanol: DRUG Ethanol cause additive CNS depression - Tricyclic antidepressants: DRUG increases effect Tricyclic antidepressants
222,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",Curariform muscle relaxants,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M Parenteral .
223,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",tubocurarine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M Parenteral .
224,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",succinylcholine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether DRUG gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M Parenteral .
225,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",gallamine,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine DRUG decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M Parenteral .
226,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",decamethonium,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine DRUG sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M Parenteral .
227,"Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.",sodium citrate,Coly-Mycin M,effect,Curariform muscle relaxants (eg tubocurarine) drugs including ether succinylcholine gallamine decamethonium sodium citrate potentiate neuromuscular blocking effect used extreme caution patients treated Coly-Mycin M Parenteral .
228,Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.,Sodium cephalothin,Coly-Mycin M,effect,Sodium cephalothin may enhance nephrotoxicity Coly-Mycin M Parenteral .
229,The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.,sodium cephalothin,Coly-Mycin M,advise,The concomitant use sodium cephalothin Coly-Mycin M Parenteral avoided .
230,"Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.",diuretics,PRINIVIL,effect,Hypotension - Patients Diuretic Therapy: Patients DRUG especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy OTHER_DRUG .
231,The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.,diuretic,PRINIVIL,effect,The possibility hypotensive effects OTHER_DRUG minimized either discontinuing DRUG increasing salt intake prior initiation treatment OTHER_DRUG .
232,"If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.",diuretic,PRINIVIL,advise,If necessary continue DRUG initiate therapy OTHER_DRUG dose 5 mg daily provide close medical supervision initial dose blood pressure stabilized .
233,"When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.",diuretic,PRINIVIL,effect,When DRUG added therapy patient receiving OTHER_DRUG additional antihypertensive effect usually observed .
234,Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.,ACE inhibitor,diuretic,advise,Studies ACE inhibitors combination diuretics indicate dose ACE inhibitor reduced given OTHER_DRUG .
235,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.",non-steroidal anti-inflammatory drugs,lisinopril,effect,Non-steroidal Anti-inflammatory Agents: In patients compromised renal function treated non-steroidal anti-inflammatory drugs co-administration OTHER_DRUG may result deterioration renal function .
236,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,ACE inhibitors,effect,Reports suggest DRUG may diminish antihypertensive effect ACE inhibitors including lisinopril .
237,"Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.",NSAIDs,lisinopril,effect,Reports suggest DRUG may diminish antihypertensive effect ACE inhibitors including OTHER_DRUG .
238,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This interaction given consideration patients taking DRUG concomitantly ACE inhibitors .
239,Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.,PRINIVIL,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: DRUG attenuates potassium loss caused thiazide-type diuretics .
240,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium-sparing diuretics,effect,Use DRUG potassium-sparing diuretics (e . g . spironolactone triamterene amiloride) potassium supplements potassium-containing salt substitutes may lead significant increases serum potassium .
241,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,spironolactone,effect,Use DRUG potassium-sparing diuretics (e . g . OTHER_DRUG triamterene amiloride) potassium supplements potassium-containing salt substitutes may lead significant increases serum potassium .
242,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,triamterene,effect,Use DRUG potassium-sparing diuretics (e . g . spironolactone OTHER_DRUG amiloride) potassium supplements potassium-containing salt substitutes may lead significant increases serum potassium .
243,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,amiloride,effect,Use DRUG potassium-sparing diuretics (e . g . spironolactone triamterene amiloride) potassium supplements potassium-containing salt substitutes may lead significant increases serum potassium .
244,"Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.",PRINIVIL,potassium,effect,Use DRUG potassium-sparing diuretics (e . g . spironolactone triamterene amiloride) OTHER_DRUG supplements potassium-containing salt substitutes may lead significant increases serum OTHER_DRUG .
245,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,Lithium: DRUG toxicity reported patients receiving DRUG concomitantly drugs cause elimination sodium including ACE inhibitors .
246,Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.,lithium,ACE inhibitor,effect,DRUG toxicity usually reversible upon discontinuation DRUG ACE inhibitor .
247,It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.,PRINIVIL,lithium,advise,It recommended serum OTHER_DRUG levels monitored frequently DRUG administered concomitantly OTHER_DRUG .
248,The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.,butalbital,monoamine oxidase (MAO) inhibitors,effect,The CNS effects DRUG may enhanced monoamine oxidase (MAO) inhibitors .
249,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,narcotic analgesic,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
250,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,alcohol,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics OTHER_DRUG general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
251,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,anesthetics,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general OTHER_DRUG tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
252,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,tranquilizers,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics OTHER_DRUG chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
253,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,chlordiazepoxide,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers OTHER_DRUG sedative-hypnotics CNS depressants causing increased CNS depression .
254,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,sedative-hypnotics,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide OTHER_DRUG CNS depressants causing increased CNS depression .
255,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,CNS depressants,effect,DRUG acetaminophen caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
256,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,narcotic analgesic,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
257,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,alcohol,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics OTHER_DRUG general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
258,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,anesthetics,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general OTHER_DRUG tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
259,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,tranquilizers,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics OTHER_DRUG chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
260,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,chlordiazepoxide,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers OTHER_DRUG sedative-hypnotics CNS depressants causing increased CNS depression .
261,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,sedative-hypnotics,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide OTHER_DRUG CNS depressants causing increased CNS depression .
262,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,CNS depressants,effect,Butalbital DRUG caffeine may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
263,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,narcotic analgesic,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
264,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,alcohol,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics OTHER_DRUG general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
265,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,anesthetics,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general OTHER_DRUG tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
266,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,tranquilizers,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics OTHER_DRUG chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
267,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,chlordiazepoxide,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers OTHER_DRUG sedative-hypnotics CNS depressants causing increased CNS depression .
268,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,sedative-hypnotics,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide OTHER_DRUG CNS depressants causing increased CNS depression .
269,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,CNS depressants,effect,Butalbital acetaminophen DRUG may enhance effects of: narcotic analgesics alcohol general anesthetics tranquilizers chlordiazepoxide sedative-hypnotics CNS depressants causing increased CNS depression .
270,"CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.",Sonata,ethanol,effect,CNS-Active Drugs Ethanol: DRUG 10 mg potentiated CNS-impairing effects OTHER_DRUG 0 . 75 g/kg balance testing reaction time 1 hour OTHER_DRUG administration digit symbol substitution test (DSST) symbol copying test variability component divided attention test 2 . 5 hours OTHER_DRUG administration .
271,Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,imipramine,effect,Imipramine: Coadministration single doses DRUG 20 mg OTHER_DRUG 75 mg produced additive effects decreased alertness impaired psychomotor performance 2 4 hours administration .
272,Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.,Sonata,thioridazine,effect,Thioridazine: Coadministration single doses DRUG 20 mg OTHER_DRUG 50 mg produced additive effects decreased alertness impaired psychomotor performance 2 4 hours administration .
273,"Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.",zaleplon,promethazine,mechanism,Promethazine: Coadministration single dose DRUG OTHER_DRUG (10 25 mg respectively) resulted 15% decrease maximal plasma concentrations DRUG change area plasma concentration-time curve .
274,"Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.",rifampin,zaleplon,mechanism,Multiple-dose administration potent CYP3A4 inducer DRUG (600 mg every 24 hours q24h 14 days) however reduced OTHER_DRUG Cmax AUC approximately 80% .
275,"Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.",zaleplon,erythromycin,mechanism,Coadministration single oral doses DRUG OTHER_DRUG (10 mg 800 mg respectively) strong selective CYP3A4 inhibitor produced 34% increase zaleplons maximal plasma concentrations 20% increase area plasma concentration-time curve .
276,Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.,ketoconazole,zaleplon,mechanism,Other strong selective CYP3A4 inhibitors DRUG also expected increase exposure OTHER_DRUG .
277,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.",Cimetidine,zaleplon,mechanism,Drugs That Inhibit Both Aldehyde Oxidase CYP3A4 Cimetidine: DRUG inhibits aldehyde oxidase (in vitro) CYP3A4 (in vitro vivo) primary secondary enzymes respectively responsible OTHER_DRUG metabolism .
278,Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.,Sonata,cimetidine,mechanism,Concomitant administration DRUG (10 mg) OTHER_DRUG (800 mg) produced 85% increase mean Cmax AUC zaleplon .
279,"A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.",INSPRA,ketoconazole,mechanism,A pharmacokinetic study evaluating administration single dose DRUG 100 mg OTHER_DRUG 200 mg BID potent inhibitor CYP3A4 pathway showed 1 . 7-fold increase Cmax eplerenone 5 . 4-fold increase AUC eplerenone .
280,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,erythromycin,mechanism,Administration DRUG CYP3A4 inhibitors (e . g . OTHER_DRUG 500 mg BID verapamil 240 mg QD saquinavir 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax DRUG ranging 1 . 4- 1 . 6- fold AUC 2 . 0- 2 . 9- fold .
281,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,verapamil,mechanism,Administration DRUG CYP3A4 inhibitors (e . g . erythromycin 500 mg BID OTHER_DRUG 240 mg QD saquinavir 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax DRUG ranging 1 . 4- 1 . 6- fold AUC 2 . 0- 2 . 9- fold .
282,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,saquinavir,mechanism,Administration DRUG CYP3A4 inhibitors (e . g . erythromycin 500 mg BID verapamil 240 mg QD OTHER_DRUG 1200 mg TID fluconazole 200 mg QD) resulted increases Cmax DRUG ranging 1 . 4- 1 . 6- fold AUC 2 . 0- 2 . 9- fold .
283,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,fluconazole,mechanism,Administration DRUG CYP3A4 inhibitors (e . g . erythromycin 500 mg BID verapamil 240 mg QD saquinavir 1200 mg TID OTHER_DRUG 200 mg QD) resulted increases Cmax DRUG ranging 1 . 4- 1 . 6- fold AUC 2 . 0- 2 . 9- fold .
284,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,ACE inhibitors,effect,ACE Inhibitors Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies patients hypertension addition DRUG 50 100 mg ACE inhibitors angiotensin II receptor antagonists increased mean serum potassium slightly (about 0 . 09-0 . 13 mEq/L) .
285,"ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).",INSPRA,angiotensin II receptor antagonists,effect,ACE Inhibitors Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies patients hypertension addition DRUG 50 100 mg ACE inhibitors angiotensin II receptor antagonists increased mean serum potassium slightly (about 0 . 09-0 . 13 mEq/L) .
286,In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.,INSPRA,enalapril,effect,In study diabetics microalbuminuria DRUG 200 mg combined ACE inhibitor OTHER_DRUG 10 mg increased frequency hyperkalemia (serum potassium 5 . 5 mEq/L) 17% OTHER_DRUG alone 38% .
287,Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.,INSPRA,lithium,advise,Serum OTHER_DRUG levels monitored frequently DRUG administered concomitantly OTHER_DRUG .
288,The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.,potassium-sparing antihypertensives,NSAIDs,effect,The administration potassium-sparing antihypertensives OTHER_DRUG shown reduce antihypertensive effect patients result severe hyperkalemia patients impaired renal function .
289,"Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.",INSPRA,NSAIDs,advise,Therefore DRUG OTHER_DRUG used concomitantly patients observed determine whether desired effect blood pressure obtained .
290,Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.,Aminoglutethimide,corticosteroids,effect,Aminoglutethimide: DRUG may diminish adrenal suppression OTHER_DRUG .
291,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,amphotericin B,advise,Amphotericin B injection potassium-depleting agents: When DRUG administered concomitantly potassium-depleting agents (e . g . amphotericin B diuretics) patients observed closely development hypokalemia .
292,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,diuretics,advise,Amphotericin B injection potassium-depleting agents: When DRUG administered concomitantly potassium-depleting agents (e . g . amphotericin B diuretics) patients observed closely development hypokalemia .
293,"In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.",amphotericin B,hydrocortisone,effect,In addition cases reported concomitant use amphotericin B OTHER_DRUG followed cardiac enlargement congestive heart failure .
294,Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.,Macrolide antibiotics,corticosteroid,mechanism,Antibiotics: Macrolide antibiotics reported cause significant decrease OTHER_DRUG clearance .
295,Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.,anticholinesterase agents,corticosteroids,effect,Anticholinesterases: Concomitant use anticholinesterase agents OTHER_DRUG may produce severe weakness patients myasthenia gravis .
296,"If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.",anticholinesterase agents,corticosteroid,advise,If possible anticholinesterase agents withdrawn least 24 hours initiating OTHER_DRUG therapy .
297,"Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.",corticosteroids,warfarin,effect,Anticoagulants oral: Co-administration DRUG OTHER_DRUG usually results inhibition response OTHER_DRUG although conflicting reports .
298,"Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.",corticosteroids,antidiabetic agents,effect,Antidiabetics: Because DRUG may increase blood glucose concentrations dosage adjustments antidiabetic agents may required .
299,Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.,Cholestyramine,corticosteroids,mechanism,Cholestyramine: DRUG may increase clearance OTHER_DRUG .
300,Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.,cyclosporine,corticosteroids,effect,Cyclosporine: Increased activity DRUG OTHER_DRUG may occur two used concurrently .
301,"Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.",Ephedrine,corticosteroids,mechanism,Ephedrine: DRUG may enhance metabolic clearance OTHER_DRUG resulting decreased blood levels lessened physiologic activity thus requiring increase corticosteroid dosage .
302,"Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.",Estrogens,corticosteroids,mechanism,DRUG including oral contraceptives: DRUG may decrease hepatic metabolism certain OTHER_DRUG thereby increasing effect .
303,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",barbiturates,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e . g . DRUG phenytoin carbamazepine rifampin) may enhance metabolism OTHER_DRUG require dosage corticosteroid increased .
304,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",phenytoin,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e . g . barbiturates DRUG carbamazepine rifampin) may enhance metabolism OTHER_DRUG require dosage corticosteroid increased .
305,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",carbamazepine,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e . g . barbiturates phenytoin DRUG rifampin) may enhance metabolism OTHER_DRUG require dosage corticosteroid increased .
306,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",rifampin,corticosteroids,mechanism,Hepatic Enzyme Inducers Inhibitors Substrates: Drugs induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e . g . barbiturates phenytoin carbamazepine rifampin) may enhance metabolism OTHER_DRUG require dosage corticosteroid increased .
307,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",ketoconazole,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e . g . DRUG macrolide antibiotics erythromycin) potential result increased plasma concentrations OTHER_DRUG .
308,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",macrolide antibiotics,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e . g . ketoconazole macrolide antibiotics erythromycin) potential result increased plasma concentrations OTHER_DRUG .
309,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",erythromycin,corticosteroids,mechanism,Drugs inhibit CYP 3A4 (e . g . ketoconazole macrolide antibiotics erythromycin) potential result increased plasma concentrations OTHER_DRUG .
310,"Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.",Ketoconazole,corticosteroids,mechanism,Ketoconazole: DRUG reported decrease metabolism certain OTHER_DRUG 60% leading increased risk corticosteroid side effects .
311,"In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.",ketoconazole,corticosteroid,effect,In addition DRUG alone inhibit adrenal OTHER_DRUG synthesis may cause adrenal insufficiency OTHER_DRUG withdrawal .
312,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,aspirin,corticosteroids,effect,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use DRUG (or nonsteroidal antiinflammatory agents) OTHER_DRUG increases risk gastrointestinal side effects .
313,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.,nonsteroidal antiinflammatory agents,corticosteroids,effect,Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use aspirin (or nonsteroidal antiinflammatory agents) OTHER_DRUG increases risk gastrointestinal side effects .
314,Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.,Aspirin,corticosteroids,advise,DRUG used cautiously conjunction OTHER_DRUG hypoprothrombinemia .
315,The clearance of salicylates may be increased with concurrent use of corticosteroids.,salicylates,corticosteroids,mechanism,The clearance DRUG may increased concurrent use OTHER_DRUG .
316,"Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.",phenytoin,dexamethasone,mechanism,Phenytoin: In post-marketing experience reports increases decreases DRUG levels OTHER_DRUG co-administration leading alterations seizure control .
317,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,live vaccines,effect,Vaccines: Patients DRUG therapy may exhibit diminished response toxoids live inactivated vaccines due inhibition antibody response .
318,Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.,corticosteroid,inactivated vaccines,effect,Vaccines: Patients DRUG therapy may exhibit diminished response toxoids live inactivated vaccines due inhibition antibody response .
319,Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.,Corticosteroids,live attenuated vaccines,effect,DRUG may also potentiate replication organisms contained live attenuated vaccines .
320,Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.,vaccines,corticosteroid,advise,Routine administration DRUG toxoids deferred OTHER_DRUG therapy discontinued possible .
321,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,CENTRAL NERVOUS SYSTEM DEPRESSANTS,effect,THE POTENTIATING ACTION OF DRUG MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS NON-NARCOTIC ANALGESICS AND BARBITURATES .
322,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NARCOTICS,effect,THE POTENTIATING ACTION OF DRUG MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS OTHER_DRUG NON-NARCOTIC ANALGESICS AND BARBITURATES .
323,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,NON-NARCOTIC ANALGESICS,effect,THE POTENTIATING ACTION OF DRUG MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS NON-NARCOTIC ANALGESICS AND BARBITURATES .
324,"THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.",HYDROXYZINE,BARBITURATES,effect,THE POTENTIATING ACTION OF DRUG MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS NON-NARCOTIC ANALGESICS AND OTHER_DRUG .
325,Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.,central nervous system depressants,hydroxyzine,advise,Therefore central nervous system depressants administered concomitantly OTHER_DRUG dosage reduced .
326,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",Amantadine,clidinium,effect,DRUG tricyclic antidepressants MAOIs may increase anticholinergic effect OTHER_DRUG .
327,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",tricyclic antidepressants,clidinium,effect,Amantadine tricyclic antidepressants MAOIs may increase anticholinergic effect OTHER_DRUG .
328,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",MAOIs,clidinium,effect,Amantadine tricyclic antidepressants DRUG may increase anticholinergic effect OTHER_DRUG .
329,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,phenothiazines,effect,DRUG may decrease effect OTHER_DRUG levodopa ketoconazole .
330,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,levodopa,effect,DRUG may decrease effect phenothiazines OTHER_DRUG ketoconazole .
331,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,ketoconazole,effect,DRUG may decrease effect phenothiazines levodopa OTHER_DRUG .
332,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent administration DRUG OTHER_DRUG may result elevated serum levels DRUG .
333,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,In diabetic patients metabolic effects DRUG may decrease blood glucose therefore OTHER_DRUG requirements .
334,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,anticonvulsant,mechanism,Anticonvulsants: In pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long-term OTHER_DRUG therapy (eg phenytoin carbamazepine phenobarbital) healthy volunteers .
335,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenytoin,mechanism,Anticonvulsants: In pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long-term anticonvulsant therapy (eg OTHER_DRUG carbamazepine phenobarbital) healthy volunteers .
336,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,carbamazepine,mechanism,Anticonvulsants: In pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long-term anticonvulsant therapy (eg phenytoin OTHER_DRUG phenobarbital) healthy volunteers .
337,"Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.",felodipine,phenobarbital,mechanism,Anticonvulsants: In pharmacokinetic study maximum plasma concentrations DRUG considerably lower epileptic patients long-term anticonvulsant therapy (eg phenytoin carbamazepine phenobarbital) healthy volunteers .
338,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",NSAIDs,aspirin,advise,Aspirin: As DRUG concomitant administration Ponstel OTHER_DRUG generally recommended potential increased adverse effects .
339,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",Ponstel,aspirin,advise,Aspirin: As NSAIDs concomitant administration DRUG OTHER_DRUG generally recommended potential increased adverse effects .
340,Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.,NSAIDs,methotrexate,mechanism,Methotrexate: DRUG reported competitively inhibit OTHER_DRUG accumulation rabbit kidney slices .
341,Caution should be used when NSAIDs are administered concomitantly with methotrexate.,NSAIDs,methotrexate,advise,Caution used DRUG administered concomitantly OTHER_DRUG .
342,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.,NSAIDs,ACE inhibitors,effect,ACE inhibitors: Reports suggest DRUG may diminish antihypertensive effect ACE inhibitors .
343,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This interaction given consideration patients taking DRUG concomitantly ACE inhibitors .
344,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post-marketing observations shown DRUG reduce natriuretic effect OTHER_DRUG thiazides patients .
345,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post-marketing observations shown DRUG reduce natriuretic effect furosemide OTHER_DRUG patients .
346,"During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.",Ponstel,furosemide,advise,During concomitant therapy DRUG OTHER_DRUG patient observed closely signs renal failure well assure diuretic efficacy .
347,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: DRUG produced elevation plasma OTHER_DRUG levels reduction renal OTHER_DRUG clearance .
348,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: DRUG produced elevation plasma OTHER_DRUG levels reduction renal OTHER_DRUG clearance .
349,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,advise,Thus DRUG OTHER_DRUG administered concurrently subjects observed carefully signs OTHER_DRUG toxicity .
350,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.",warfarin,NSAIDs,effect,Warfarin: The effects DRUG OTHER_DRUG GI bleeding synergistic users drugs together risk serious GI bleeding higher users either drug alone .
351,"Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.",magnesium hydroxide,mefenamic acid,mechanism,Antacids: In single dose study (n=6) ingestion antacid containing 1 . 7-gram magnesium hydroxide 500-mg mefenamic acid increased Cmax AUC mefenamic acid 125% 36% respectively . A number compounds inhibitors CYP2C9 including fluconazole lovastatin trimethoprim .
352,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,warfarin,effect,Oral Anticoagulants: In normal volunteers concomitant administration DRUG OTHER_DRUG acenocoumarol phenprocoumon resulted prolongation prothrombin time .
353,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,acenocoumarol,effect,Oral Anticoagulants: In normal volunteers concomitant administration DRUG warfarin OTHER_DRUG phenprocoumon resulted prolongation prothrombin time .
354,"Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.",diflunisal,phenprocoumon,effect,Oral Anticoagulants: In normal volunteers concomitant administration DRUG warfarin acenocoumarol OTHER_DRUG resulted prolongation prothrombin time .
355,This may occur because diflunisal competitively displaces coumarins from protein binding sites.,diflunisal,coumarins,mechanism,This may occur DRUG competitively displaces OTHER_DRUG protein binding sites .
356,"Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.",diflunisal,anticoagulants,advise,Accordingly DRUG administered oral OTHER_DRUG prothrombin time closely monitored several days concomitant drug administration .
357,"Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.",diflunisal,hydrochlorothiazide,mechanism,Hydrochlorothiazide: In normal volunteers concomitant administration DRUG OTHER_DRUG resulted significantly increased plasma levels OTHER_DRUG .
358,Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.,Diflunisal,hydrochlorothiazide,effect,DRUG decreased hyperuricemic effect OTHER_DRUG .
359,Diflunisal decreased the hyperuricemic effect of furosemide.,Diflunisal,furosemide,effect,DRUG decreased hyperuricemic effect OTHER_DRUG .
360,Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.,antacids,diflunisal,mechanism,Antacids: Concomitant administration DRUG may reduce plasma levels OTHER_DRUG .
361,"Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.",diflunisal,acetaminophen,mechanism,Acetaminophen: In normal volunteers concomitant administration DRUG OTHER_DRUG resulted approximate 50% increase plasma levels OTHER_DRUG .
362,"Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.",diflunisal,acetaminophen,advise,Since OTHER_DRUG high doses associated hepatotoxicity concomitant administration DRUG OTHER_DRUG used cautiously careful monitoring patients .
363,"Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.",diflunisal,acetaminophen,effect,Concomitant administration DRUG OTHER_DRUG dogs rats approximately 2 times recommended maximum human therapeutic dose (40 52 mg/kg/day diflunisal/acetaminophen) resulted greater gastrointestinal toxicity either drug administered alone .
364,Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.,diflunisal,methotrexate,advise,Methotrexate: Caution used DRUG administered concomitantly OTHER_DRUG .
365,Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,Nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,Nonsteroidal anti-inflammatory drugs reported decrease tubular secretion OTHER_DRUG potentiate toxicity .
366,"Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",nonsteroial anti-inflammatory drugs,cyclosporine,mechanism,Cyclosporine: Administration nonsteroial anti-inflammatory drugs concomitantly OTHER_DRUG associated increase cyclosporine-induced toxicity possibly due decreased synthesis renal prostacyclin .
367,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,DRUG used caution patients taking OTHER_DRUG renal function carefully monitored .
368,Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.,diflunisal,indomethacin,mechanism,Nonsteroidal Anti-Inflammatory Drugs: The administration DRUG normal volunteers receiving OTHER_DRUG decreased renal clearance significantly increased plasma levels OTHER_DRUG .
369,In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.,indomethacin,diflunisal,effect,In patients combined use DRUG OTHER_DRUG associated fatal gastrointestinal hemorrhage .
370,"Therefore, indomethacin and diflunisal should not be used concomitantly.",indomethacin,diflunisal,advise,Therefore DRUG OTHER_DRUG used concomitantly .
371,"The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",diflunisal,NSAIDs,effect,The concomitant use DRUG tablets OTHER_DRUG recommended due increased possibility gastrointestinal toxicity little increase efficacy .
372,"Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.",diflunisal,aspirin,mechanism,Aspirin: In normal volunteers small decrease DRUG levels observed multiple doses DRUG OTHER_DRUG administered concomitantly .
373,Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.,diflunisal,sulindac,mechanism,Sulindac: The concomitant administration DRUG OTHER_DRUG normal volunteers resulted lowering plasma levels active OTHER_DRUG sulfide metabolite approximately one-third .
374,"Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.",diflunisal,naproxen,mechanism,Naproxen: The concomitant administration DRUG OTHER_DRUG normal volunteers effect plasma levels OTHER_DRUG significantly decreased urinary excretion OTHER_DRUG glucuronide metabolite .
375,Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.,Lincomycin,neuromuscular blocking agents,effect,DRUG shown neuromuscular blocking properties may enhance action neuromuscular blocking agents .
376,Antagonism between lincomycin and erythromycin in vitro has been demonstrated.,lincomycin,erythromycin,effect,Antagonism DRUG OTHER_DRUG vitro demonstrated .
377,Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.,amantadine,central nervous system stimulants,advise,Careful observation required DRUG administered concurrently central nervous system stimulants .
378,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",Zarontin,antiepileptic drugs,int,Since DRUG (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg ethosuximide may elevate phenytoin serum levels valproic acid reported increase decrease ethosuximide levels) .
379,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,antiepileptic drugs,int,Since Zarontin (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg DRUG may elevate phenytoin serum levels valproic acid reported increase decrease DRUG levels) .
380,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",ethosuximide,phenytoin,mechanism,Since Zarontin (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg DRUG may elevate OTHER_DRUG serum levels valproic acid reported increase decrease DRUG levels) .
381,"Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).",valproic acid,ethosuximide,mechanism,Since Zarontin (ethosuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg OTHER_DRUG may elevate phenytoin serum levels valproic acid reported increase decrease OTHER_DRUG levels) .
382,Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.,NIMBEX,succinylcholine,effect,Administration 0 . 1-mg/kg (2 x ED95) DRUG 10% 95% recovery following intubating dose OTHER_DRUG (1 mg/kg) produced 95% neuromuscular block .
383,The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.,NIMBEX,succinylcholine,effect,The time onset maximum block following DRUG approximately 2 minutes faster prior administration OTHER_DRUG .
384,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.,succinylcholine,NIMBEX,effect,Infusion requirements OTHER_DRUG patients administered DRUG prior infusions OTHER_DRUG comparable slightly greater DRUG administered .
385,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane administered nitrous oxide/oxygen achieve 1 . 25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses OTHER_DRUG decrease required infusion rate OTHER_DRUG .
386,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane administered nitrous oxide/oxygen achieve 1 . 25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses OTHER_DRUG decrease required infusion rate OTHER_DRUG .
387,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane DRUG administered nitrous oxide/oxygen achieve 1 . 25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses OTHER_DRUG decrease required infusion rate OTHER_DRUG .
388,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane DRUG administered nitrous oxide/oxygen achieve 1 . 25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses OTHER_DRUG decrease required infusion rate OTHER_DRUG .
389,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane enflurane administered nitrous oxide/oxygen achieve 1 . 25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses OTHER_DRUG decrease required infusion rate OTHER_DRUG .
390,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane enflurane administered nitrous oxide/oxygen achieve 1 . 25 MAC [Minimum Alveolar Concentration] may prolong clinically effective duration action initial maintenance doses OTHER_DRUG decrease required infusion rate OTHER_DRUG .
391,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",enflurane,NIMBEX,advise,In long surgical procedures DRUG isoflurane anesthesia less frequent maintenance dosing lower maintenance doses reduced infusion rates OTHER_DRUG may necessary .
392,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",isoflurane,NIMBEX,advise,In long surgical procedures enflurane DRUG anesthesia less frequent maintenance dosing lower maintenance doses reduced infusion rates OTHER_DRUG may necessary .
393,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,NIMBEX,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents OTHER_DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
394,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,antibiotics,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain OTHER_DRUG (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
395,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,aminoglycosides,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . OTHER_DRUG tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
396,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,tetracyclines,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides OTHER_DRUG bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
397,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,bacitracin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines OTHER_DRUG polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
398,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,polymyxins,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin OTHER_DRUG lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
399,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lincomycin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins OTHER_DRUG clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
400,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,clindamycin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin OTHER_DRUG colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
401,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,colistin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin OTHER_DRUG sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
402,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,sodium colistemethate,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
403,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,magnesium,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) OTHER_DRUG salts lithium local anesthetics procainamide quinidine .
404,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lithium,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts OTHER_DRUG local anesthetics procainamide quinidine .
405,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,anesthetics,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local OTHER_DRUG procainamide quinidine .
406,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,procainamide,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics OTHER_DRUG quinidine .
407,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,quinidine,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents NIMBEX include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide OTHER_DRUG .
408,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,antibiotics,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain OTHER_DRUG (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
409,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,aminoglycosides,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . OTHER_DRUG tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
410,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,tetracyclines,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides OTHER_DRUG bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
411,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,bacitracin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines OTHER_DRUG polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
412,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,polymyxins,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin OTHER_DRUG lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
413,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lincomycin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins OTHER_DRUG clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
414,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,clindamycin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin OTHER_DRUG colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
415,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,colistin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin OTHER_DRUG sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
416,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,sodium colistemethate,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide quinidine .
417,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,magnesium,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) OTHER_DRUG salts lithium local anesthetics procainamide quinidine .
418,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lithium,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts OTHER_DRUG local anesthetics procainamide quinidine .
419,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,anesthetics,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local OTHER_DRUG procainamide quinidine .
420,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,procainamide,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics OTHER_DRUG quinidine .
421,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,quinidine,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistemethate) magnesium salts lithium local anesthetics procainamide OTHER_DRUG .
422,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,phenytoin,effect,Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered OTHER_DRUG carbamazepine .
423,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,carbamazepine,effect,Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin OTHER_DRUG .
424,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",phenytoin,NIMBEX,effect,While effects chronic DRUG carbamazepine therapy action OTHER_DRUG unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher .
425,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",carbamazepine,NIMBEX,effect,While effects chronic phenytoin DRUG therapy action OTHER_DRUG unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher .
426,Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.,Starlix,tolbutamide,mechanism,DRUG potential inhibitor CYP2C9 isoenzyme vivo indicated ability inhibit vitro metabolism OTHER_DRUG .
427,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,Starlix,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
428,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",nonsteroidal anti-inflammatory agents,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs .
429,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,Starlix,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
430,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",NSAIDs,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs .
431,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,Starlix,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) DRUG monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
432,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",salicylates,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) DRUG monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs .
433,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,Starlix,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
434,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",monoamine oxidase inhibitors,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs .
435,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,Starlix,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
436,"Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.",non-selective beta-adrenergic-blocking agents,antidiabetic drugs,effect,Certain drugs including nonsteroidal anti-inflammatory agents (NSAIDs) salicylates monoamine oxidase inhibitors non-selective beta-adrenergic-blocking agents may potentiate hypoglycemic action Starlix oral antidiabetic drugs .
437,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,Starlix,effect,Certain drugs including DRUG corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
438,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thiazides,antidiabetic drugs,effect,Certain drugs including DRUG corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action Starlix oral antidiabetic drugs .
439,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,Starlix,effect,Certain drugs including thiazides DRUG thyroid products sympathomimetics may reduce hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
440,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",corticosteroids,antidiabetic drugs,effect,Certain drugs including thiazides DRUG thyroid products sympathomimetics may reduce hypoglycemic action Starlix oral antidiabetic drugs .
441,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,Starlix,effect,Certain drugs including thiazides corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
442,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",thyroid products,antidiabetic drugs,effect,Certain drugs including thiazides corticosteroids thyroid products sympathomimetics may reduce hypoglycemic action Starlix oral antidiabetic drugs .
443,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,Starlix,effect,Certain drugs including thiazides corticosteroids thyroid products DRUG may reduce hypoglycemic action OTHER_DRUG oral antidiabetic drugs .
444,"Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.",sympathomimetics,antidiabetic drugs,effect,Certain drugs including thiazides corticosteroids thyroid products DRUG may reduce hypoglycemic action Starlix oral antidiabetic drugs .
445,Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.,dexamethasone,albendazole,mechanism,Dexamethasone: Steady-state trough concentrations OTHER_DRUG sulfoxide 56% higher 8 mg DRUG coadministered dose OTHER_DRUG (15 mg/kg/day) eight neurocysticercosis patients .
446,"Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",praziquantel,albendazole sulfoxide,mechanism,Praziquantel: In fed state DRUG (40 mg/kg) increased mean maximum plasma concentration area curve albendazole sulfoxide 50% healthy subjects (n=10) compared separate group subjects (n=6) given albendazole alone .
447,Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).,Albendazole sulfoxide,cimetidine,mechanism,Cimetidine: Albendazole sulfoxide concentrations bile cystic fluid increased (about 2-fold) hydatid cyst patients treated OTHER_DRUG (10 mg/kg/day) (n=7) compared albendazole (20 mg/kg/day) alone (n=12) .
448,"Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.",duloxetine,fluvoxamine,mechanism,Inhibitors CYP1A2: Concomitant use DRUG OTHER_DRUG inhibitor CYP1A2 results approximately 6-fold increase AUC 2 . 5-fold increase Cmax DRUG .
449,"Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.",Paroxetine,duloxetine,mechanism,DRUG (20 mg QD) increased concentration OTHER_DRUG (40 mg QD) 60% greater degrees inhibition expected higher doses DRUG .
450,"When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.",duloxetine,desipramine,mechanism,When DRUG administered (at dose 60 mg BID) conjunction single 50-mg dose OTHER_DRUG CYP2D6 substrate AUC OTHER_DRUG increased 3-fold .
451,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,antidepressants,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain OTHER_DRUG (tricyclic OTHER_DRUG [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
452,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,tricyclic antidepressants,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
453,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,TCAs,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
454,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,nortriptyline,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] OTHER_DRUG amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
455,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,amitriptyline,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline OTHER_DRUG imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
456,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,imipramine,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
457,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,phenothiazines,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) OTHER_DRUG Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
458,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,Type 1C antiarrhythmics,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
459,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,propafenone,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . OTHER_DRUG flecainide) approached caution .
460,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,flecainide,advise,Therefore co-administration DRUG drugs extensively metabolized isozyme narrow therapeutic index including certain antidepressants (tricyclic antidepressants [TCAs] nortriptyline amitriptyline imipramine) phenothiazines Type 1C antiarrhythmics (e . g . propafenone flecainide) approached caution .
461,Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.,TCA,Duloxetine,advise,Plasma DRUG concentrations may need monitored dose DRUG may need reduced DRUG co-administered OTHER_DRUG .
462,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.",Duloxetine,thioridazine,advise,Because risk serious ventricular arrhythmias sudden death potentially associated elevated plasma levels OTHER_DRUG DRUG OTHER_DRUG co-administered .
463,Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.,naproxen sodium,Neurontin,mechanism,Naproxen: Coadministration (N=18) naproxen sodium capsules (250 mg) OTHER_DRUG (125 mg) appears increase amount gabapentin absorbed 12% 15% .
464,Hydrocodone increases gabapentin AUC values by 14%.,Hydrocodone,gabapentin,mechanism,DRUG increases OTHER_DRUG AUC values 14% .
465,"Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.",morphine,Neurontin,mechanism,Morphine: A literature article reported 60-mg controlled-release DRUG capsule administered 2 hours prior 600-mg OTHER_DRUG capsule (N=12) mean gabapentin AUC increased 44% compared gabapentin administered without DRUG .
466,Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.,cimetidine,gabapentin,mechanism,Cimetidine: In presence DRUG 300 mg QID (N=12) mean apparent oral clearance OTHER_DRUG fell 14% creatinine clearance fell 10% .
467,"Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.",cimetidine,gabapentin,mechanism,Thus DRUG appeared alter renal excretion OTHER_DRUG creatinine endogenous marker renal function .
468,This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.,gabapentin,cimetidine,mechanism,This small decrease excretion DRUG OTHER_DRUG expected clinical importance .
469,The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;,norethindrone,gabapentin,mechanism,The Cmax DRUG 13% higher coadministered gabapentin;
470,Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.,Maalox,gabapentin,mechanism,Antacid (Maalox ): DRUG reduced bioavailability OTHER_DRUG (N=16) 20% .
471,This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.,gabapentin,Maalox,mechanism,This decrease bioavailability 5% DRUG administered 2 hours OTHER_DRUG .
472,It is recommended that gabapentin be taken at least 2 hours following Maalox administration.,gabapentin,Maalox,advise,It recommended DRUG taken least 2 hours following OTHER_DRUG administration .
473,"Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).",Zalcitabine,ZDV,effect,DRUG also significant effect intracellular phosphorylation OTHER_DRUG shown vitro peripheral blood mononuclear cells two cell lines (U937 Molt-4) .
474,"Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.",lamivudine,zalcitabine,effect,Lamivudine: In vitro studies peripheral blood mononuclear cells U937 Molt-4 cells revealed DRUG significantly inhibited OTHER_DRUG phosphorylation dose dependent manner .
475,Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);,Zalcitabine,lamivudine,effect,DRUG inhibited OTHER_DRUG phosphorylation high concentration ratios (10 100);
476,"These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.",zalcitabine,lamivudine,effect,These vitro studies suggest concomitant administration DRUG OTHER_DRUG humans may result sub-therapeutic concentrations active phosphorylated DRUG may lead decreased antiretroviral effect DRUG .
477,Concomitant use of zalcitabine and lamivudine is not recommended.,zalcitabine,lamivudine,advise,Concomitant use DRUG OTHER_DRUG recommended .
478,Concomitant use of HIVID with didanosine is not recommended.,HIVID,didanosine,advise,Concomitant use DRUG OTHER_DRUG recommended .
479,Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.,pentamidine,HIVID,effect,Death due fulminant pancreatitis possibly related intravenous DRUG OTHER_DRUG reported .
480,"If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.",pentamidine,HIVID,advise,If intravenous DRUG required treat Pneumocystis carinii pneumonia treatment OTHER_DRUG interrupted .
481,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,HIVID,effect,DRUG Foscarnet Aminoglycosides: Drugs DRUG foscarnet aminoglycosides may increase risk developing peripheral neuropathy HIVID-associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure) .
482,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",amphotericin,zalcitabine,mechanism,DRUG Foscarnet Aminoglycosides: Drugs DRUG foscarnet aminoglycosides may increase risk developing peripheral neuropathy HIVID-associated adverse events interfering renal clearance OTHER_DRUG (thereby raising systemic exposure) .
483,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,HIVID,effect,Amphotericin DRUG Aminoglycosides: Drugs amphotericin DRUG aminoglycosides may increase risk developing peripheral neuropathy HIVID-associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure) .
484,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",foscarnet,zalcitabine,mechanism,Amphotericin DRUG Aminoglycosides: Drugs amphotericin DRUG aminoglycosides may increase risk developing peripheral neuropathy HIVID-associated adverse events interfering renal clearance OTHER_DRUG (thereby raising systemic exposure) .
485,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,HIVID,effect,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet DRUG may increase risk developing peripheral neuropathy HIVID-associated adverse events interfering renal clearance zalcitabine (thereby raising systemic exposure) .
486,"Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).",aminoglycosides,zalcitabine,mechanism,Amphotericin Foscarnet Aminoglycosides: Drugs amphotericin foscarnet DRUG may increase risk developing peripheral neuropathy HIVID-associated adverse events interfering renal clearance OTHER_DRUG (thereby raising systemic exposure) .
487,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",probenecid,zalcitabine,mechanism,DRUG Cimetidine: Concomitant administration DRUG cimetidine decreases elimination OTHER_DRUG likely inhibition renal tubular secretion OTHER_DRUG .
488,"Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.",cimetidine,zalcitabine,mechanism,Probenecid Cimetidine: Concomitant administration probenecid DRUG decreases elimination OTHER_DRUG likely inhibition renal tubular secretion OTHER_DRUG .
489,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,magnesium,advise,The clinical significance reduction known hence DRUG recommended ingested simultaneously magnesium/aluminum-containing antacids .
490,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,aluminum,advise,The clinical significance reduction known hence DRUG recommended ingested simultaneously magnesium/aluminum-containing antacids .
491,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,antacids,advise,The clinical significance reduction known hence DRUG recommended ingested simultaneously magnesium/aluminum-containing OTHER_DRUG .
492,Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.,zalcitabine,metoclopramide,mechanism,Metoclopramide: Bioavailability mildly reduced (approximately 10%) DRUG OTHER_DRUG coadministered .
493,Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.,Doxorubicin,zalcitabine,effect,Doxorubicin: DRUG caused decrease OTHER_DRUG phosphorylation ( 50% inhibition total phosphate formation) U937/Molt 4 cells .
494,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",Gastrointestinal acidifying agents,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine glutamic acid HCl ascorbic acid fruit juices etc . ) lower absorption OTHER_DRUG .
495,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",guanethidine,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine glutamic acid HCl ascorbic acid fruit juices etc . ) lower absorption OTHER_DRUG .
496,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",reserpine,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine DRUG glutamic acid HCl ascorbic acid fruit juices etc . ) lower absorption OTHER_DRUG .
497,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",glutamic acid HCl,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine glutamic acid HCl ascorbic acid fruit juices etc . ) lower absorption OTHER_DRUG .
498,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",ascorbic acid,amphetamines,mechanism,Acidifying agents: Gastrointestinal acidifying agents (guanethidine reserpine glutamic acid HCl ascorbic acid fruit juices etc . ) lower absorption OTHER_DRUG .
499,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",Urinary acidifying agents,amphetamine,mechanism,Urinary acidifying agents (ammonium chloride sodium acid phosphate etc . ) increase concentration ionized species OTHER_DRUG molecule thereby increasing urinary excretion .
500,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,Urinary acidifying agents (ammonium chloride sodium acid phosphate etc . ) increase concentration ionized species OTHER_DRUG molecule thereby increasing urinary excretion .
501,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,Urinary acidifying agents (ammonium chloride sodium acid phosphate etc . ) increase concentration ionized species OTHER_DRUG molecule thereby increasing urinary excretion .
502,Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic blockers: Adrenergic blockers inhibited OTHER_DRUG .
503,"Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.",sodium bicarbonate,amphetamines,mechanism,Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate etc . ) increase absorption OTHER_DRUG .
504,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",acetazolamide,amphetamine,mechanism,Urinary alkalinizing agents (acetazolamide thiazides) increase concentration non-ionized species OTHER_DRUG molecule thereby decreasing urinary excretion .
505,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",thiazides,amphetamine,mechanism,Urinary alkalinizing agents (acetazolamide thiazides) increase concentration non-ionized species OTHER_DRUG molecule thereby decreasing urinary excretion .
506,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,tricyclic,effect,Antidepressants tricyclic: DRUG may enhance activity OTHER_DRUG sympathomimetic agents;
507,"Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,Antidepressants tricyclic: DRUG may enhance activity tricyclic sympathomimetic agents;
508,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,DRUG OTHER_DRUG protriptyline possibly tricyclics cause striking sustained increases concentration DRUG brain;
509,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,DRUG desipramine OTHER_DRUG possibly tricyclics cause striking sustained increases concentration DRUG brain;
510,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,DRUG desipramine protriptyline possibly OTHER_DRUG cause striking sustained increases concentration DRUG brain;
511,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,MAO inhibitors: MAOI antidepressants well metabolite furazolidone slow OTHER_DRUG metabolism .
512,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,MAO inhibitors: MAOI antidepressants well metabolite DRUG slow OTHER_DRUG metabolism .
513,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines: DRUG may counteract sedative effect OTHER_DRUG .
514,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives: DRUG may antagonize hypotensive effects OTHER_DRUG .
515,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,Chlorpromazine: DRUG blocks dopamine norepinephrine reuptake thus inhibiting central stimulant effects OTHER_DRUG used treat amphetamine poisoning .
516,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide: DRUG may delay intestinal absorption OTHER_DRUG .
517,"Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,Haloperidol: DRUG blocks dopamine norepinephrine reuptake thus inhibiting central stimulant effects OTHER_DRUG .
518,Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium carbonate: The stimulatory effects DRUG may inhibited lithium carbonate .
519,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine: DRUG potentiate analgesic effect OTHER_DRUG .
520,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.",amphetamines,acidifying agents,mechanism,Methenamine therapy: Urinary excretion DRUG increased efficacy reduced acidifying agents used methenamine therapy .
521,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine: DRUG enhance adrenergic effect OTHER_DRUG .
522,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital: DRUG may delay intestinal absorption phenobarbital;
523,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin: DRUG may delay intestinal absorption phenytoin;
524,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,Propoxyphene: In cases DRUG overdosage OTHER_DRUG CNS stimulation potentiated fatal convulsions occur .
525,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum alkaloids: DRUG inhibit hypotensive effect veratrum alkaloids .
526,Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.,Amphetamines,corticosteroid,,Drug/Laboratory Test Interactions: DRUG cause significant elevation plasma OTHER_DRUG levels .
527,Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.,erythromycin,loratadine,mechanism,Plasma concentrations (AUC 0-24 hrs) DRUG decreased 15% coadministration OTHER_DRUG relative observed DRUG alone .
528,"In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.",AED,oxcarbazepine,mechanism,In addition several DRUG cytochrome P450 inducers decrease plasma concentrations OTHER_DRUG MHD .
529,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.",phenytoin,Trileptal,mechanism,1- nc denotes mean change less 10% 2- Pediatrics 3- Mean increase adults high OTHER_DRUG doses In vivo plasma levels DRUG increased 40% OTHER_DRUG given doses 1200 mg/day .
530,"Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.",Trileptal,phenytoin,advise,Therefore using doses DRUG greater 1200 mg/day adjunctive therapy decrease dose OTHER_DRUG may required .
531,"The increase of phenobarbital level, however, is small (15%) when given with Trileptal.",phenobarbital,Trileptal,mechanism,The increase DRUG level however small (15%) given OTHER_DRUG .
532,"Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).",Trileptal,contraceptive,mechanism,Hormonal contraceptives Co-administration DRUG oral OTHER_DRUG shown influence plasma concentrations two hormonal components ethinylestradiol (EE) levonorgestrel (LNG) .
533,"Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.",Trileptal,hormonal contraceptives,effect,Therefore concurrent use DRUG hormonal contraceptives may render contraceptives less effective .
534,"Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].",Trileptal,felodipine,mechanism,Calcium Antagonists: After repeated co-administration DRUG AUC OTHER_DRUG lowered 28% [90% CI: 20-33] .
535,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.,thiazide diuretics,dihydrotachysterol,effect,Administration thiazide diuretics hypoparathyroid patients concurrently treated OTHER_DRUG may cause hypercalcemia .
536,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,alcohol,effect,- DRUG may enhance CNS depressive effects OTHER_DRUG barbiturates sedatives
537,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,barbiturates,effect,- DRUG may enhance CNS depressive effects alcohol OTHER_DRUG sedatives
538,"- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives",Lofexidine,sedatives,effect,- DRUG may enhance CNS depressive effects alcohol barbiturates OTHER_DRUG
539,- Lofexidine may enhance the effects of anti-hypertensive drug therapy,Lofexidine,anti-hypertensive drug,effect,- DRUG may enhance effects anti-hypertensive drug therapy
540,- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.,tricyclic antidepressants,lofexidine,effect,- Concomitant use tricyclic antidepressants may reduce efficacy OTHER_DRUG .
541,"Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.",cefditoren pivoxil,antacids,advise,Although clinical significance known recommended cefditoren pivoxil taken concomitantly OTHER_DRUG .
542,"H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",famotidine,cefditoren pivoxil,mechanism,H2-Receptor Antagonists: Co-administration single dose intravenously administered DRUG (20 mg) reduced oral absorption single 400 mg dose cefditoren pivoxil administered following meal evidenced 27% decrease mean Cmax 22% decrease mean AUC .
543,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",b-lactam antibiotics,cefditoren pivoxil,mechanism,Probenecid: As b-lactam antibiotics co-administration probenecid cefditoren pivoxil resulted increase plasma exposure cefditoren 49% increase mean Cmax 122% increase mean AUC 53% increase half-life .
544,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",probenecid,cefditoren pivoxil,mechanism,Probenecid: As b-lactam antibiotics co-administration DRUG cefditoren pivoxil resulted increase plasma exposure cefditoren 49% increase mean Cmax 122% increase mean AUC 53% increase half-life .
545,Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.,Ocupress,beta-adrenergic blocking agent,advise,DRUG used caution patients receiving beta-adrenergic blocking agent orally potential additive effects systemic beta-blockade .
546,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.",beta-blocker,reserpine,advise,Close observation patient recommended DRUG administered patients receiving catecholamine-depleting drugs OTHER_DRUG possible additive effects production hypotension and/or marked bradycardia may produce vertigo syncope postural hypotension .
547,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",calcium channel blockers,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
548,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",dapsone,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers DRUG disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
549,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",disopyramide,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone DRUG quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
550,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide DRUG amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
551,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",amiodarone,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine DRUG quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
552,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",quinidine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone DRUG warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
553,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",warfarin,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine DRUG tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
554,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",tacrolimus,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin DRUG cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
555,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",cyclosporine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus DRUG ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
556,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",ergot derivatives,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
557,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",pimozide,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives DRUG carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
558,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",carbamazepine,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide DRUG fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
559,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",fentanyl,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine DRUG alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
560,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alfentanyl,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl DRUG alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
561,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",alprazolam,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl DRUG triazolam) may elevated plasma concentrations coadministered saquinavir;
562,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;",triazolam,saquinavir,mechanism,Although specific studies performed coadministration drugs mainly metabolized CYP3A4 (eg calcium channel blockers dapsone disopyramide quinine amiodarone quinidine warfarin tacrolimus cyclosporine ergot derivatives pimozide carbamazepine fentanyl alfentanyl alprazolam triazolam) may elevated plasma concentrations coadministered saquinavir;
563,"Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.",INVIRASE,ritonavir,advise,Since DRUG coadministered OTHER_DRUG OTHER_DRUG label reviewed additional drugs coadministered .
564,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenobarbital,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg DRUG phenytoin dexamethasone carbamazepine) may result decreased plasma levels OTHER_DRUG .
565,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",phenytoin,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital DRUG dexamethasone carbamazepine) may result decreased plasma levels OTHER_DRUG .
566,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",dexamethasone,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital phenytoin DRUG carbamazepine) may result decreased plasma levels OTHER_DRUG .
567,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.",carbamazepine,saquinavir,mechanism,Coadministration compounds potent inducers CYP3A4 (eg phenobarbital phenytoin dexamethasone carbamazepine) may result decreased plasma levels OTHER_DRUG .
568,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,antibiotics,effect,In vitro mixing DRUG beta-lactamtype OTHER_DRUG (penicillins cephalosporins) may result significant mutual inactivation .
569,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,penicillins,effect,In vitro mixing DRUG beta-lactamtype antibiotics (penicillins cephalosporins) may result significant mutual inactivation .
570,In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.,aminoglycoside,cephalosporins,effect,In vitro mixing DRUG beta-lactamtype antibiotics (penicillins cephalosporins) may result significant mutual inactivation .
571,"Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.",aminoglycoside,penicillin,mechanism,Even DRUG penicillin-type drug administered separately different routes reduction DRUG serum half-life serum levels reported patients impaired renal function patients normal renal function .
572,Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.,acitretin,ethanol,mechanism,Ethanol:Clinical evidence shown etretinate formed concurrent ingestion DRUG OTHER_DRUG .
573,"Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",acitretin,glibenclamide,effect,Glibenclamide: In study 7 healthy male volunteers DRUG treatment potentiated blood glucose lowering effect OTHER_DRUG (a sulfonylurea similar chlorpropamide) 3 7 subjects .
574,"However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.",acitretin,progestin,effect,However established DRUG interferes contraceptive effect microdosed OTHER_DRUG minipill preparations .
575,Microdosed minipill progestin preparations are not recommended for use with Soriatane.,progestin,Soriatane,advise,Microdosed minipill DRUG preparations recommended use OTHER_DRUG .
576,Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.,methotrexate,etretinate,effect,Methotrexate: An increased risk hepatitis reported result combined use DRUG OTHER_DRUG .
577,"Consequently, the combination of methotrexate with acitretin is also contraindicated.",methotrexate,acitretin,advise,Consequently combination DRUG OTHER_DRUG also contraindicated .
578,"Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.",acitretin,phenytoin,mechanism,Phenytoin: If DRUG given concurrently OTHER_DRUG protein binding OTHER_DRUG may reduced .
579,"Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.",acitretin,tetracyclines,effect,Tetracyclines: Since DRUG OTHER_DRUG cause increased intracranial pressure combined use contraindicated .
580,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,vitamin A,acitretin,advise,Vitamin A oral retinoids: Concomitant administration vitamin A and/or oral retinoids OTHER_DRUG must avoided risk hypervitaminosis A .
581,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,retinoids,acitretin,advise,Vitamin A oral retinoids: Concomitant administration vitamin A and/or oral DRUG OTHER_DRUG must avoided risk hypervitaminosis A .
582,Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.,Cerubidine,doxorubicin,effect,Use DRUG patient previously received OTHER_DRUG increases risk cardiotoxicity .
583,Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.,Cerubidine,doxorubicin,advise,DRUG used patients previously received recommended maximum cumulative doses OTHER_DRUG DRUG .
584,Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.,Cyclophosphamide,Cerubidine,effect,DRUG used concurrently OTHER_DRUG may also result increased cardiotoxicity .
585,"However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).",Argatroban,warfarin,effect,However concomitant use DRUG OTHER_DRUG (5-7 . 5 mg initial oral dose followed 2 . 5-6 mg/day orally 6-10 days) results prolongation prothrombin time (PT) International Normalized Ratio (INR) .
586,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,antiplatelet agents,effect,Co-administration: Concomitant use DRUG antiplatelet agents thrombolytics anticoagulants may increase risk bleeding .
587,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,thrombolytics,effect,Co-administration: Concomitant use DRUG antiplatelet agents OTHER_DRUG anticoagulants may increase risk bleeding .
588,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,anticoagulants,effect,Co-administration: Concomitant use DRUG antiplatelet agents thrombolytics OTHER_DRUG may increase risk bleeding .
589,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE inhibitors: Reports suggest DRUG may diminish antihypertensive effect Angiotensin Converting Enzyme (ACE) inhibitors .
590,"In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.",VIOXX,benazepril,effect,In patients mild moderate hypertension administration 25 mg daily DRUG ACE inhibitor OTHER_DRUG 10 40 mg 4 weeks associated average increase mean arterial pressure 3 mm Hg compared ACE inhibitor alone .
591,This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.,VIOXX,ACE inhibitors,advise,This interaction given consideration patients taking DRUG concomitantly ACE inhibitors .
592,"Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.",aspirin,VIOXX,effect,Aspirin: Concomitant administration low-dose DRUG OTHER_DRUG may result increased rate GI ulceration complications compared use OTHER_DRUG alone .
593,"Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.",cimetidine,rofecoxib,mechanism,Cimetidine: Co-administration high doses DRUG [800 mg twice daily] increased Cmax OTHER_DRUG 21% AUC0-120hr 23% t1/2 15% .
594,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post-marketing observations shown DRUG reduce natriuretic effect OTHER_DRUG thiazides patients .
595,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post-marketing observations shown DRUG reduce natriuretic effect furosemide OTHER_DRUG patients .
596,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: DRUG produced elevation plasma OTHER_DRUG levels reduction renal OTHER_DRUG clearance .
597,"Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",VIOXX,lithium,advise,Thus DRUG OTHER_DRUG administered concurrently subjects observed carefully signs OTHER_DRUG toxicity .
598,"At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.",VIOXX,methotrexate,mechanism,At higher recommended doses DRUG 75 mg administered daily 10 days increased plasma concentrations 23% measured AUC0-24hr patients receiving OTHER_DRUG 7 . 5 15 mg/week rheumatoid arthritis .
599,"At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).",methotrexate,rofecoxib,mechanism,At 24 hours postdose similar proportion patients treated DRUG alone (94%) subsequently treated DRUG co-administered 75 mg OTHER_DRUG (88%) DRUG plasma concentrations measurable limit (5 ng/mL) .
600,Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.,VIOXX,methotrexate,advise,Standard monitoring methotrexate-related toxicity continued DRUG OTHER_DRUG administered concomitantly .
601,"Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.",VIOXX,rifampin,mechanism,Rifampin: Co-administration DRUG OTHER_DRUG 600 mg daily potent inducer hepatic metabolism produced approximate 50% decrease rofecoxib plasma concentrations .
602,"Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.",VIOXX,theophylline,mechanism,OTHER_DRUG DRUG 12 . 5 25 50 mg administered daily 7 days increased plasma OTHER_DRUG concentrations (AUC(0- )) 38 60% healthy subjects administered single 300-mg dose OTHER_DRUG .
603,Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.,VIOXX,theophylline,advise,Adequate monitoring OTHER_DRUG plasma concentrations considered therapy DRUG initiated changed patients receiving OTHER_DRUG .
604,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.",VIOXX,warfarin,advise,Warfarin: Anticoagulant activity monitored particularly first days initiating changing DRUG therapy patients receiving OTHER_DRUG similar agents since patients increased risk bleeding complications .
605,"In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.",warfarin,rofecoxib,effect,In single multiple dose studies healthy subjects receiving DRUG OTHER_DRUG prothrombin time (measured INR) increased approximately 8% 11% .
606,"In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.",VIOXX,warfarin,effect,In post-marketing experience bleeding events reported predominantly elderly association increases prothrombin time patients receiving DRUG concurrently OTHER_DRUG .
607,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,phenothiazines,advise,DRUG administered concurrently D2-antagonists OTHER_DRUG butyrophenones thioxanthines metoclopramide .
608,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,butyrophenones,advise,DRUG administered concurrently D2-antagonists phenothiazines OTHER_DRUG thioxanthines metoclopramide .
609,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,thioxanthines,advise,DRUG administered concurrently D2-antagonists phenothiazines butyrophenones OTHER_DRUG metoclopramide .
610,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,metoclopramide,advise,DRUG administered concurrently D2-antagonists phenothiazines butyrophenones thioxanthines OTHER_DRUG .
611,"When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.",lansoprazole,theophylline,mechanism,When DRUG administered concomitantly OTHER_DRUG (CYP1A2 CYP3A) minor increase (10%) clearance OTHER_DRUG seen .
612,"Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.",theophylline,lansoprazole,advise,Nonetheless individual patients may require additional titration DRUG dosage OTHER_DRUG started stopped ensure clinically effective blood levels .
613,"In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.",proton pump inhibitors,sucralfate,mechanism,In single-dose crossover study examining lansoprazole 30 mg omeprazole 20 mg administered alone concomitantly OTHER_DRUG 1 gram absorption proton pump inhibitors delayed bioavailability reduced 17% 16% respectively administered concomitantly OTHER_DRUG .
614,"Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.",proton pump inhibitors,sucralfate,advise,Therefore proton pump inhibitors taken least 30 minutes prior OTHER_DRUG .
615,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ketoconazole,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e . g . OTHER_DRUG ampicillin esters iron salts digoxin) .
616,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,ampicillin,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e . g . ketoconazole OTHER_DRUG esters iron salts digoxin) .
617,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,iron,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e . g . ketoconazole ampicillin esters OTHER_DRUG salts digoxin) .
618,"therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).",lansoprazole,digoxin,mechanism,therefore theoretically possible DRUG may interfere absorption drugs gastric pH important determinant bioavailability (e . g . ketoconazole ampicillin esters iron salts digoxin) .
619,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,Phenurone,advise,Considerable caution exercised DRUG administered concurrently OTHER_DRUG (phenacemide) since paranoid symptoms reported therapy combination .
620,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,phenacemide,advise,Considerable caution exercised DRUG administered concurrently Phenurone (phenacemide) since paranoid symptoms reported therapy combination .
621,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,phenytoin,int,A two-way interaction hydantoin antiepileptic OTHER_DRUG coumarin anticoagulants suggested .
622,"A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.",hydantoin antiepileptic,coumarin anticoagulant,int,A two-way interaction hydantoin antiepileptic phenytoin coumarin anticoagulants suggested .
623,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin,mechanism,Presumably DRUG acts stimulator OTHER_DRUG metabolism reported cause decreased serum levels OTHER_DRUG anticoagulants increased prothrombin-proconvertin concentrations .
624,"Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.",phenytoin,coumarin anticoagulants,mechanism,Presumably DRUG acts stimulator coumarin metabolism reported cause decreased serum levels coumarin anticoagulants increased prothrombin-proconvertin concentrations .
625,"Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.",coumarin anticoagulants,phenytoin,mechanism,Conversely coumarin anticoagulants reported increase serum levels prolong serum half-life OTHER_DRUG inhibiting metabolism .
626,Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.,PEGANONE,coumarin anticoagulants,advise,Caution therefore advised administering DRUG patients receiving coumarin anticoagulants .
627,Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.,warfarin-type anticoagulant,griseofulvin,advise,Patients warfarin-type anticoagulant therapy may require dosage adjustment anticoagulant OTHER_DRUG therapy .
628,Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.,barbiturates,griseofulvin,effect,Concomitant use DRUG usually depresses OTHER_DRUG activity may necessitate raising dosage .
629,The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.,griseofulvin,contraceptives,effect,The concomitant administration DRUG reported reduce efficacy oral OTHER_DRUG increase incidence breakthrough bleeding .
630,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acetaminophen,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . OTHER_DRUG acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
631,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acyclovir,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen OTHER_DRUG angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
632,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,angiotensin-converting enzyme inhibitors,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
633,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,aminosalicylic acid,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
634,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,barbiturates,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid OTHER_DRUG benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
635,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,benzodiazepines,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates OTHER_DRUG bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
636,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,bumetanide,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines OTHER_DRUG clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
637,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,clofibrate,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide OTHER_DRUG methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
638,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,methotrexate,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate OTHER_DRUG famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
639,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,famotidine,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate OTHER_DRUG furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
640,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,furosemide,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine OTHER_DRUG nonsteroidal anti-inflammatory agents theophylline zidovudine) .
641,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,nonsteroidal anti-inflammatory,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
642,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,theophylline,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents OTHER_DRUG zidovudine) .
643,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,zidovudine,mechanism,DRUG : DRUG known interact metabolism renal tubular excretion many drugs (e . g . acetaminophen acyclovir angiotensin-converting enzyme inhibitors aminosalicylic acid barbiturates benzodiazepines bumetanide clofibrate methotrexate famotidine furosemide nonsteroidal anti-inflammatory agents theophylline zidovudine) .
644,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.,Zidovudine,probenecid,advise,DRUG either temporarily discontinued decreased 50% coadministered OTHER_DRUG day VISTIDE infusion .
645,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,aminoglycosides,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous OTHER_DRUG (e . g . tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents] contraindicated .
646,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,tobramycin,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . OTHER_DRUG gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents] contraindicated .
647,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,gentamicin,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . tobramycin OTHER_DRUG amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents] contraindicated .
648,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amikacin,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents] contraindicated .
649,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amphotericin B,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents] contraindicated .
650,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,foscarnet,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . tobramycin gentamicin amikacin) amphotericin B OTHER_DRUG intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents] contraindicated .
651,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,pentamidine,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous OTHER_DRUG vancomycin non-steroidal anti-inflammatory agents] contraindicated .
652,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,vancomycin,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine OTHER_DRUG non-steroidal anti-inflammatory agents] contraindicated .
653,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,non-steroidal anti-inflammatory agents,advise,Nephrotoxic agents : Concomitant administration DRUG agents nephrotoxic potential [e . g . intravenous aminoglycosides (e . g . tobramycin gentamicin amikacin) amphotericin B foscarnet intravenous pentamidine vancomycin non-steroidal anti-inflammatory agents] contraindicated .
654,"However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.",UROXATRAL,alpha-blockers,advise,However interactions may expected DRUG NOT used combination OTHER_DRUG .
655,Dimenhydrinate may decrease emetic response to apomorphine.,Dimenhydrinate,apomorphine,effect,DRUG may decrease emetic response OTHER_DRUG .
656,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin D analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: DRUG reported reduce intestinal absorption fat soluble vitamins;
657,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,Phenytoin/Phenobarbital: The coadministration DRUG phenobarbital affect plasma concentrations vitamin D may reduce endogenous plasma levels calcitriol/ergocalcitriol accelerating metabolism .
658,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,Phenytoin/Phenobarbital: The coadministration phenytoin DRUG affect plasma concentrations vitamin D may reduce endogenous plasma levels calcitriol/ergocalcitriol accelerating metabolism .
659,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some reports shown concomitant administration DRUG vitamin D causes hypercalcemia .
660,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: Vitamin D dosage must determined care patients undergoing treatment OTHER_DRUG hypercalcemia patients may precipitate cardiac arrhythmias .
661,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: DRUG may inhibit synthetic catabolic enzymes vitamin D .
662,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,Corticosteroids: A relationship functional antagonism exists vitamin D analogues promote calcium absorption OTHER_DRUG inhibit calcium absorption .
663,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,Magnesium: Magnesium-containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D patients chronic renal dialysis .
664,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,Magnesium: Magnesium-containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D patients chronic renal dialysis .
665,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,ERGAMISOL,alcohol,effect,DRUG (levamisole hydrochloride) reported produce ANTABUSE-like side effects given concomitantly OTHER_DRUG .
666,ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.,levamisole hydrochloride,alcohol,effect,ERGAMISOL (levamisole hydrochloride) reported produce ANTABUSE-like side effects given concomitantly OTHER_DRUG .
667,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.",levamisole,warfarin sodium,advise,Because reports prolongation prothrombin time beyond therapeutic range patients taking concurrent DRUG warfarin sodium suggested prothrombin time monitored carefully dose warfarin sodium coumarin-like drugs adjusted accordingly patients taking drugs .
668,Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.,azathioprine,allopurinol,mechanism,Use Allopurinol: The principal pathway detoxification DRUG inhibited OTHER_DRUG .
669,"Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.",azathioprine,allopurinol,advise,Patients receiving DRUG OTHER_DRUG concomitantly dose reduction DRUG approximately 1/3 1/4 usual dose .
670,Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.,angiotensin converting enzyme inhibitors,azathioprine,effect,Use Angiotensln Converting Enzyme Inhibitors: The use angiotensin converting enzyme inhibitors control hypertension patients OTHER_DRUG reported induce severe leukopenia .
671,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",psychotropic medications,LEXAPRO,advise,Alcohol - Although OTHER_DRUG potentiate cognitive motor effects alcohol clinical trial psychotropic medications use alcohol patients taking OTHER_DRUG recommended .
672,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",alcohol,LEXAPRO,advise,DRUG - Although OTHER_DRUG potentiate cognitive motor effects DRUG clinical trial psychotropic medications use DRUG patients taking OTHER_DRUG recommended .
673,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,NSAID,effect,Epidemiological studies case-control cohort design demonstrated association use psychotropic drugs interfere serotonin reuptake occurrence upper gastrointestinal bleeding also shown concurrent use OTHER_DRUG aspirin potentiated risk bleeding .
674,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.,psychotropic drugs,aspirin,effect,Epidemiological studies case-control cohort design demonstrated association use psychotropic drugs interfere serotonin reuptake occurrence upper gastrointestinal bleeding also shown concurrent use NSAID OTHER_DRUG potentiated risk bleeding .
675,"Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.",citalopram,cimetidine,mechanism,OTHER_DRUG - In subjects received 21 days 40 mg/day racemic DRUG combined administration 400 mg/day OTHER_DRUG 8 days resulted increase DRUG AUC Cmax 43% 39% respectively .
676,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",lithium,escitalopram,effect,Because DRUG may enhance serotonergic effects OTHER_DRUG caution exercised LEXAPRO DRUG coadministered .
677,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",LEXAPRO,lithium,advise,Because OTHER_DRUG may enhance serotonergic effects escitalopram caution exercised DRUG OTHER_DRUG coadministered .
678,"Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.",pimozide,citalopram,effect,DRUG Celexa - In controlled study single dose DRUG 2 mg co-administered racemic OTHER_DRUG 40 mg given daily 11 days associated mean increase QTc values approximately 10 msec compared DRUG given alone .
679,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",selective serotonin reuptake inhibitor,sumatriptan,effect,OTHER_DRUG - There rare postmarketing reports describing patients weakness hyperreflexia incoordination following use selective serotonin reuptake inhibitor (SSRI) OTHER_DRUG .
680,"Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.",SSRI,sumatriptan,effect,OTHER_DRUG - There rare postmarketing reports describing patients weakness hyperreflexia incoordination following use selective serotonin reuptake inhibitor (SSRI) OTHER_DRUG .
681,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,SSRI,advise,If concomitant treatment DRUG OTHER_DRUG (e . g . fluoxetine fluvoxamine paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised .
682,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluoxetine,advise,If concomitant treatment DRUG SSRI (e . g . OTHER_DRUG fluvoxamine paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised .
683,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluvoxamine,advise,If concomitant treatment DRUG SSRI (e . g . fluoxetine OTHER_DRUG paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised .
684,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,paroxetine,advise,If concomitant treatment DRUG SSRI (e . g . fluoxetine fluvoxamine OTHER_DRUG sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised .
685,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,sertraline,advise,If concomitant treatment DRUG SSRI (e . g . fluoxetine fluvoxamine paroxetine OTHER_DRUG citalopram escitalopram) clinically warranted appropriate observation patient advised .
686,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,citalopram,advise,If concomitant treatment DRUG SSRI (e . g . fluoxetine fluvoxamine paroxetine sertraline OTHER_DRUG escitalopram) clinically warranted appropriate observation patient advised .
687,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,escitalopram,advise,If concomitant treatment DRUG SSRI (e . g . fluoxetine fluvoxamine paroxetine sertraline citalopram escitalopram) clinically warranted appropriate observation patient advised .
688,"Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.",carbamazepine,escitalopram,mechanism,Although trough citalopram plasma levels unaffected given enzyme-inducing properties DRUG possibility DRUG might increase clearance OTHER_DRUG considered two drugs coadministered .
689,"Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.",citalopram,ketoconazole,mechanism,OTHER_DRUG - Combined administration racemic DRUG (40 mg) OTHER_DRUG (200 mg) decreased Cmax AUC OTHER_DRUG 21% 10% respectively significantly affect pharmacokinetics DRUG .
690,"However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.",escitalopram,desipramine,mechanism,However limited vivo data suggesting modest CYP2D6 inhibitory effect DRUG . . coadministration DRUG (20 mg/day 21 days) tricyclic antidepressant OTHER_DRUG (single dose 50 mg) substrate CYP2D6 resulted 40% increase Cmax 100% increase AUC OTHER_DRUG .
691,Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).,LEXAPRO,metoprolol,mechanism,OTHER_DRUG - Administration 20 mg/day DRUG 21 days healthy volunteers resulted 50% increase Cmax 82% increase AUC beta-adrenergic blocker OTHER_DRUG (given single dose 100 mg) .
692,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,citalopram,advise,Concomitant Administration Racemic OTHER_DRUG OTHER_DRUG - Since DRUG active isomer racemic OTHER_DRUG (Celexa) two agents coadministered .
693,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,Celexa,advise,Concomitant Administration Racemic Citalopram Citalopram - Since DRUG active isomer racemic citalopram (Celexa) two agents coadministered .
694,"However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.",EXTRANEAL,insulin,advise,However appropriate monitoring blood glucose performed initiating DRUG diabetic patients OTHER_DRUG dosage adjusted needed .
695,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,hypotensive drugs,effect,The hypotensive effect sodium nitroprusside augmented hypotensive drugs including ganglionic blocking agents negative inotropic agents inhaled anesthetics .
696,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,ganglionic blocking agents,effect,The hypotensive effect sodium nitroprusside augmented hypotensive drugs including ganglionic blocking agents negative inotropic agents inhaled anesthetics .
697,"The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.",sodium nitroprusside,anesthetics,effect,The hypotensive effect sodium nitroprusside augmented hypotensive drugs including ganglionic blocking agents negative inotropic agents inhaled OTHER_DRUG .
698,CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.,eszopiclone,ethanol,effect,CNS-Active Drugs OTHER_DRUG An additive effect psychomotor performance seen coadministration DRUG OTHER_DRUG 0 . 70 g/kg 4 hours OTHER_DRUG administration .
699,Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.,eszopiclone,olanzapine,effect,Olanzapine: Coadministration DRUG 3 mg OTHER_DRUG 10 mg produced decrease DSST scores .
700,"The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.",eszopiclone,ketoconazole,mechanism,The AUC DRUG increased 2 . 2-fold coadministration OTHER_DRUG potent inhibitor CYP3A4 400 mg daily 5 days .
701,"Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.",zopiclone,rifampicin,mechanism,Drugs That Induce CYP3A4 (Rifampicin) Racemic DRUG exposure decreased 80% concomitant useof OTHER_DRUG potent inducer CYP3A4 .
702,Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.,sympathomimetic agents,FORADIL,effect,Concomitant administration sympathomimetic agents may potentiate undesirable effects OTHER_DRUG .
703,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,monoamine oxidase inhibitors,advise,Monoamine Oxidase Inhibitors Tricyclic Antidepressants: DRUG administered extreme caution patients treated monoamine oxidase inhibitors tricyclic antidepressants action formoterol cardiovascular system may potentiated agents .
704,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,tricyclic antidepressants,advise,Monoamine Oxidase Inhibitors Tricyclic Antidepressants: DRUG administered extreme caution patients treated monoamine oxidase inhibitors tricyclic antidepressants action formoterol cardiovascular system may potentiated agents .
705,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",xanthine derivatives,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives steroids diuretics may potentiate possible hypokalemic effect beta2-agonists .
706,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",steroids,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives DRUG diuretics may potentiate possible hypokalemic effect beta2-agonists .
707,"Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.",diuretics,beta2-agonists.,effect,Corticosteroids Methylxanthines Diuretics: Concomitant treatment xanthine derivatives steroids DRUG may potentiate possible hypokalemic effect beta2-agonists .
708,"During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.",TAMBOCOR,digoxin,mechanism,During administration multiple oral doses DRUG healthy subjects stabilized maintenance dose OTHER_DRUG 13%-19% increase plasma OTHER_DRUG levels occurred six hours postdose .
709,"In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.",TAMBOCOR,propranolol,mechanism,In study involving healthy subjects receiving DRUG OTHER_DRUG concurrently plasma flecainide levels increased 20% OTHER_DRUG levels increased 30% compared control values .
710,The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.,TAMBOCOR,propranolol,effect,The effects concomitant administration DRUG OTHER_DRUG PR interval less additive .
711,"Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.",beta blockers,flecainide,effect,Nevertheless possibility additive negative inotropic effects beta blockers OTHER_DRUG recognized .
712,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenytoin,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( DRUG phenobarbital carbamazepine ) indicate 30% increase rate OTHER_DRUG elimination .
713,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",phenobarbital,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( phenytoin DRUG carbamazepine ) indicate 30% increase rate OTHER_DRUG elimination .
714,"Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.",carbamazepine,flecainide,mechanism,Limited data patients receiving known enzyme inducers ( phenytoin phenobarbital DRUG ) indicate 30% increase rate OTHER_DRUG elimination .
715,"In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.",cimetidine,flecainide,mechanism,In healthy subjects receiving DRUG (1 gm daily) one week plasma OTHER_DRUG levels increased 30% half-life increased 10% .
716,"When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.",amiodarone,flecainide,mechanism,When DRUG added OTHER_DRUG therapy plasma OTHER_DRUG levels may increase two-fold patients OTHER_DRUG dosage reduced .
717,"Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;",quinidine,flecainide,mechanism,Drugs inhibit cytochrome P450IID6 DRUG might increase plasma concentrations OTHER_DRUG patients chronic OTHER_DRUG therapy;
718,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",disopyramide,TAMBOCOR,advise,Because drugs negative inotropic properties effects coadministration OTHER_DRUG unknown neither DRUG verapamil administered concurrently OTHER_DRUG unless judgment physician benefits combination outweigh risks .
719,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",verapamil,TAMBOCOR,advise,Because drugs negative inotropic properties effects coadministration OTHER_DRUG unknown neither disopyramide DRUG administered concurrently OTHER_DRUG unless judgment physician benefits combination outweigh risks .
720,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",D.H.E. 45,peripheral vasoconstrictors,effect,Vasoconstrictors: D . H . E . 45 (dihydroergotamine mesylate) Injection USP used peripheral vasoconstrictors combination may cause synergistic elevation blood pressure .
721,"Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.",dihydroergotamine mesylate,peripheral vasoconstrictors,effect,Vasoconstrictors: D . H . E . 45 (dihydroergotamine mesylate) Injection USP used peripheral vasoconstrictors combination may cause synergistic elevation blood pressure .
722,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,D.H.E. 45,effect,Sumatriptan: DRUG reported cause coronary artery vasospasm effect could additive D . H . E . 45 (dihydroergotamine mesylate) Injection USP .
723,"Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.",Sumatriptan,dihydroergotamine mesylate,effect,Sumatriptan: DRUG reported cause coronary artery vasospasm effect could additive D . H . E . 45 (dihydroergotamine mesylate) Injection USP .
724,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,D.H.E. 45,advise,DRUG D . H . E . 45 (dihydroergotamine mesylate) Injection USP taken within 24 hours . .
725,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,dihydroergotamine mesylate,advise,DRUG D . H . E . 45 (dihydroergotamine mesylate) Injection USP taken within 24 hours . .
726,"Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.",propranolol,ergotamine,effect,Beta Blockers: Although results clinical study indicate safe problem associated administration D . H . E . 45 (dihydroergotamine mesylate) Injection USP subjects already receiving DRUG reports DRUG may potentiate vasoconstrictive action OTHER_DRUG blocking vasodilating property epinephrine .
727,"Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.",Nicotine,ergot,effect,Nicotine: DRUG may provoke vasoconstriction patients predisposing greater ischemic response OTHER_DRUG therapy .
728,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",ergot alkaloid class,macrolide class,mechanism,Macrolide Antibiotics (e . g . erythromycin troleandomycin): Agents ergot alkaloid class D . H . E . 45 (dihydroergotamine mesylate) Injection USP member shown interact antibiotics macrolide class resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction .
729,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",D.H.E. 45,macrolide class,mechanism,Macrolide Antibiotics (e . g . erythromycin troleandomycin): Agents ergot alkaloid class D . H . E . 45 (dihydroergotamine mesylate) Injection USP member shown interact antibiotics macrolide class resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction .
730,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",dihydroergotamine mesylate,macrolide class,mechanism,Macrolide Antibiotics (e . g . erythromycin troleandomycin): Agents ergot alkaloid class D . H . E . 45 (dihydroergotamine mesylate) Injection USP member shown interact antibiotics macrolide class resulting increased plasma levels unchanged alkaloids peripheral vasoconstriction .
731,Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.,ergotamine,antibiotics,effect,Vasospastic reactions reported therapeutic doses ergotamine-containing drugs co-administered OTHER_DRUG .
732,"SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.",5-HT1 agonists,SSRIs,effect,SSRIs: Weakness hyperreflexia incoordination reported rarely 5-HT1 agonists co-administered OTHER_DRUG (e . g .
733,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).",Kineret,etanercept,effect,In study patients active RA treated 24 weeks concurrent DRUG OTHER_DRUG therapy 7% rate serious infections observed higher observed OTHER_DRUG alone (0%) .
734,Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).,Kineret,etanercept,effect,Two percent patients treated concurrently DRUG OTHER_DRUG developed neutropenia (ANC 1 x 109/L) .
735,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antiarrhythmics,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
736,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,amiodarone,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: OTHER_DRUG quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
737,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,quinidine,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone OTHER_DRUG Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
738,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antihistamines,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
739,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,astemizole,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: OTHER_DRUG terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
740,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,terfenadine,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole OTHER_DRUG Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
741,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,ergot derivatives,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
742,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antimycobacterial agents,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: cisapride
743,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,rifampin,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: OTHER_DRUG Benzodiazepines midazolam triazolam GI motility agents: cisapride
744,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Benzodiazepines,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin OTHER_DRUG midazolam triazolam GI motility agents: cisapride
745,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,midazolam,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines OTHER_DRUG triazolam GI motility agents: cisapride
746,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,triazolam,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam OTHER_DRUG GI motility agents: cisapride
747,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,cisapride,advise,Drugs That Should Not Be Coadministered With DRUG Antiarrhythmics: amiodarone quinidine Antihistamines: astemizole terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam triazolam GI motility agents: OTHER_DRUG
748,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,Antimycobacterial agents,advise,Drugs Which Require Dose Reduction When Coadminstered With DRUG Antimycobacterial agents: rifabutin
749,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,rifabutin,advise,Drugs Which Require Dose Reduction When Coadminstered With DRUG Antimycobacterial agents: OTHER_DRUG
750,"therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.",VIRACEPT,terfenadine,advise,therefore DRUG administered concurrently OTHER_DRUG potential serious and/or life-threatening cardiac arrhythmias .
751,"Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.",VIRACEPT,astemizole,advise,Because similar interaction likely DRUG also administered concurrently OTHER_DRUG .
752,Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.,indinavir,VIRACEPT,mechanism,Indinavir: Coadministration DRUG OTHER_DRUG resulted 83% increase nelfinavir plasma AUC 51% increase DRUG plasma A . C .
753,Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.,ritonavir,VIRACEPT,mechanism,Ritonavir: Coadministration DRUG OTHER_DRUG resulted 152% increase nelfinavir plasma AUC little change DRUG plasma A . C .
754,Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.,saquinavir,VIRACEPT,mechanism,Saquinavir: Coadministration DRUG (using experimental soft-gelatin capsule formulation DRUG 1200mg) OTHER_DRUG resulted 18% increase nelfinavir plasma AUC 4-fold increase DRUG plasma A . C .
755,Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.,ketoconazole,VIRACEPT,mechanism,Ketoconazole: Coadministration DRUG OTHER_DRUG resulted 35% increase nelfinavir plasma A . C .
756,"therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.",nelfinavir,didanosine,advise,therefore DRUG administered (with food) one hour two hours OTHER_DRUG .
757,A dose adjustment is not needed when zidovudine is administered with VIRACEPT.,zidovudine,VIRACEPT,advise,A dose adjustment needed DRUG administered OTHER_DRUG .
758,Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.,rifabutin,VIRACEPT,mechanism,Rifabutin: Coadministration DRUG OTHER_DRUG resulted 32% decrease nelfinavir plasma AUC 207% increase DRUG plasma A . C .
759,It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.,rifabutin,VIRACEPT,advise,It recommended dose DRUG reduced one-half usual dose administered OTHER_DRUG .
760,Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.,rifampin,VIRACEPT,mechanism,Rifampin: Coadministration DRUG OTHER_DRUG resulted 82% decrease nelfinavir plasma A . C .
761,VIRACEPT and rifampin should not be coadministered.,VIRACEPT,rifampin,advise,DRUG OTHER_DRUG coadministered .
762,Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.,VIRACEPT,OVCON-35,mechanism,Ethinyl Estradiol Norethindrone: Coadministration DRUG OTHER_DRUG resulted 47% decrease ethinyl estradiol 18% decrease norethindrone plasma concentrations .
763,Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.,rauwolfia alkaloid,MAO inhibitors,effect,Taking rauwolfia alkaloid taking within 2 weeks taking MAO inhibitors may increase risk central nervous system depression may cause severe high blood pressure reaction .
764,Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.,ELSPAR,methotrexate,effect,Tissue culture animal studies indicate DRUG diminish abolish effect OTHER_DRUG malignant cells . 14 This effect OTHER_DRUG activity persists long plasma asparagine levels suppressed .
765,"These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.",methotrexate,ELSPAR,advise,These results would seem dictate clinical use DRUG OTHER_DRUG period following OTHER_DRUG therapy plasma asparagine levels normal .
766,"Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.",MONUROL,metoclopramide,mechanism,Metoclopramide: When coadministered DRUG OTHER_DRUG drug increases gastrointestinal motility lowers serum concentration urinary excretion fosfomycin .
767,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,acetaminophen,int,DRUG may interact following medications: OTHER_DRUG (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
768,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tylenol,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
769,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antibiotics,int,DRUG may interact following medications: acetaminophen (Tylenol) OTHER_DRUG ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
770,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,ampicillin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics OTHER_DRUG tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
771,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,tetracycline,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin OTHER_DRUG anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
772,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,anticonvulsants,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline OTHER_DRUG (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
773,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Dilantin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
774,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Phenobarbital,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin OTHER_DRUG Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
775,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Tegretol,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital OTHER_DRUG Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
776,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Trileptal,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol OTHER_DRUG Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
777,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Topamax,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal OTHER_DRUG Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
778,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Felbatol,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
779,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,antifungals,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) OTHER_DRUG (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
780,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Gris-PEG,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
781,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Nizoral,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG OTHER_DRUG Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
782,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sporanox,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
783,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,atorvastatin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) OTHER_DRUG (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
784,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Lipitor,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
785,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,clofibrate,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) OTHER_DRUG (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
786,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Atromid-S,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
787,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,cyclosporine,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) OTHER_DRUG (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
788,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Neoral,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
789,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Sandimmune,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
790,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,protease inhibitors,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
791,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Agenerase,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
792,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Crixivan,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase OTHER_DRUG Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
793,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Fortovase,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan OTHER_DRUG Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
794,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Invirase,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase OTHER_DRUG Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
795,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kaletra,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase OTHER_DRUG Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
796,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Norvir,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra OTHER_DRUG Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
797,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Viracept,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
798,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,morphine,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) OTHER_DRUG (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
799,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Astramorph,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
800,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Kadian,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph OTHER_DRUG MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
801,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,MS Contin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
802,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,phenylbutazone,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) OTHER_DRUG prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
803,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,prednisolone,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone OTHER_DRUG (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
804,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Prelone,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
805,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifadin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) OTHER_DRUG (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
806,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,rifampin,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
807,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,temazepam,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort OTHER_DRUG theophylline (Theo-Dur) vitamin C .
808,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,theophylline,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam OTHER_DRUG (Theo-Dur) vitamin C .
809,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,Theo-Dur,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
810,"Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.",Etonogestrel,vitamin C,int,DRUG may interact following medications: acetaminophen (Tylenol) antibiotics ampicillin tetracycline anticonvulsants (Dilantin Phenobarbital Tegretol Trileptal Topamax Felbatol) antifungals (Gris-PEG Nizoral Sporanox) atorvastatin (Lipitor) clofibrate (Atromid-S) cyclosporine (Neoral Sandimmune) HIV drugs classified protease inhibitors (Agenerase Crixivan Fortovase Invirase Kaletra Norvir Viracept) morphine (Astramorph Kadian MS Contin) phenylbutazone prednisolone (Prelone) rifadin (rifampin) St . Johns wort temazepam theophylline (Theo-Dur) vitamin C .
811,"For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.",vitamin K antagonists,nilutamide,advise,For example vitamin K antagonists administered concomitantly OTHER_DRUG prothrombin time carefully monitored necessary dosage vitamin K antagonists reduced .
812,Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.,L-glutamine,human growth hormone,mechanism,Human growth hormone - Concomitant use DRUG human growth hormone may enhance nutrient absorption severe short bowel syndrome .
813,Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.,L-glutamine,indomethacin,effect,OTHER_DRUG - Concomitant use DRUG OTHER_DRUG may ameliorate increased intestinal permeability caused OTHER_DRUG .
814,Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.,methotrexate,L-glutamine,effect,DRUG - There one report DRUG may decrease possible effectiveness supplemental OTHER_DRUG chemotherapy-induced mucositis .
815,"In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.",methotrexate,L-glutamine,effect,In another report nine patients breast cancer reported decreased symptoms methotrexate-related toxicity given supplemental OTHER_DRUG dose 0 . 5 gram/kilogram/day .
816,"Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.",L-glutamine,paclitaxel,effect,OTHER_DRUG - In one report DRUG dose 10 grams three times daily given 24 hours receiving OTHER_DRUG appeared prevent development myalgia arthralgia adverse reactions OTHER_DRUG .
817,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,ketoconazole,mechanism,However co administration fexofenadine hydrochloride either OTHER_DRUG erythromycin led increased plasma concentrations fexofenadine .
818,"However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.",fexofenadine hydrochloride,erythromycin,mechanism,However co administration fexofenadine hydrochloride either ketoconazole OTHER_DRUG led increased plasma concentrations fexofenadine .
819,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,ketoconazole,fexofenadine,mechanism,These studies indicate DRUG erythromycin co-administration enhances OTHER_DRUG gastrointestinal absorption .
820,These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.,erythromycin,fexofenadine,mechanism,These studies indicate ketoconazole DRUG co-administration enhances OTHER_DRUG gastrointestinal absorption .
821,"This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.",ketoconazole,fexofenadine,mechanism,This observed increase bioavailability OTHER_DRUG may due transport-related effects p-glycoprotein . vivo animal studies also suggest addition enhancing absorption DRUG decreases OTHER_DRUG gastrointestinal secretion erythromycin may also decrease biliary excretion .
822,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,aluminum,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes OTHER_DRUG magnesium containing antacid (Maalox ) decreased fexofenadine AUC 41% cmax 43% .
823,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,magnesium,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes aluminum OTHER_DRUG containing antacid (Maalox ) decreased fexofenadine AUC 41% cmax 43% .
824,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,antacid,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes aluminum magnesium containing OTHER_DRUG (Maalox ) decreased fexofenadine AUC 41% cmax 43% .
825,Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.,fexofenadine hydrochloride,Maalox,mechanism,Drug Interactions Antacids Administration 120 mg fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes aluminum magnesium containing antacid (Maalox ) decreased fexofenadine AUC 41% cmax 43% .
826,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,aluminum,advise,DRUG taken closely time OTHER_DRUG magnesium containing antacids .
827,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,magnesium,advise,DRUG taken closely time aluminum OTHER_DRUG containing antacids .
828,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",narcotic analgesic,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
829,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",anesthetics,DILAUDID,effect,Patients receiving narcotic analgesics general DRUG phenothiazines tranquilizers sedative-hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
830,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",phenothiazines,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics DRUG tranquilizers sedative-hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
831,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tranquilizers,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines DRUG sedative-hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
832,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",sedative-hypnotics,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers DRUG tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
833,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",tricyclic antidepressants,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
834,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",CNS depressants,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
835,"Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.",alcohol,DILAUDID,effect,Patients receiving narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics tricyclic antidepressants CNS depressants (including alcohol) concomitantly OTHER_DRUG may exhibit additive CNS depression .
836,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,aspirin,advise,Before taking DRUG tell doctor taking following medicines: - OTHER_DRUG another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
837,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salicylate,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another OTHER_DRUG magnesium/choline OTHER_DRUG (Trilisate) salsalate (Disalcid others) choline OTHER_DRUG (Arthropan) magnesium OTHER_DRUG (Magan) bismuth subsalicylate (Pepto-Bismol);
838,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium/choline salicylate,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
839,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Trilisate,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
840,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salsalate,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) OTHER_DRUG (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
841,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Disalcid,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
842,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,choline salicylate,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
843,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Arthropan,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
844,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium salicylate,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
845,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Magan,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
846,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,bismuth subsalicylate,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
847,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Pepto-Bismol,advise,Before taking DRUG tell doctor taking following medicines: - aspirin another salicylate magnesium/choline salicylate (Trilisate) salsalate (Disalcid others) choline salicylate (Arthropan) magnesium salicylate (Magan) bismuth subsalicylate (Pepto-Bismol);
848,HEMABATE may augment the activity of other oxytocic agents.,HEMABATE,oxytocic agents,effect,DRUG may augment activity oxytocic agents .
849,"Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.",Furosemide,aminoglycoside antibiotics,effect,DRUG may increase ototoxic potential aminoglycoside antibiotics especially presence impaired renal function .
850,Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.,Furosemide,ethacrynic acid,advise,DRUG used concomitantly ethacrynic acid possibility ototoxicity .
851,"Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.",salicylates,furosemide,effect,Patients receiving high doses DRUG concomitantly OTHER_DRUG rheumatic disease may experience salicylate toxicity lower doses competitive renal excretory sites .
852,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,tubocurarine,effect,DRUG tendency antagonize skeletal muscle relaxing effect OTHER_DRUG may potentiate action succinylcholine .
853,Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.,Furosemide,succinylcholine,effect,DRUG tendency antagonize skeletal muscle relaxing effect tubocurarine may potentiate action OTHER_DRUG .
854,Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally given OTHER_DRUG reduce lithiums renal clearance add high risk DRUG toxicity .
855,Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.,Furosemide,antihypertensive drugs,effect,DRUG may add potentiate therapeutic effect antihypertensive drugs .
856,Furosemide may decrease arterial responsiveness to norepinephrine.,Furosemide,norepinephrine,effect,DRUG may decrease arterial responsiveness OTHER_DRUG .
857,Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.,sucralfate,furosemide,effect,Tablets Simultaneous administration DRUG OTHER_DRUG tablets may reduce natriuretic antihypertensive effects OTHER_DRUG .
858,The intake of furosemide and sucralfate should be separated by at least two hours.,furosemide,sucralfate,advise,The intake DRUG OTHER_DRUG separated least two hours .
859,"Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.",furosemide,acetylsalicylic acid,effect,Tablets Injection Oral Solution One study six subjects demonstrated combination DRUG acetylsalicylic acid temporarily reduced creatinine clearance patients chronic renal insufficiency .
860,"There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.",furosemide,NSAIDs,effect,There case reports patients developed increased BUN serum creatinine serum potassium levels weight gain DRUG used conjunction OTHER_DRUG .
861,Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.,indomethacin,furosemide,effect,Literature reports indicate coadministration DRUG may reduce natriuretic antihypertensive effects OTHER_DRUG patients inhibiting prostaglandin synthesis .
862,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.,indomethacin,furosemide,advise,Patients receiving DRUG OTHER_DRUG observed closely determine desired diuretic and/or antihypertensive effect OTHER_DRUG achieved .
863,Warfarin: Meclofenamate sodium enhances the effect of warfarin.,Warfarin,Meclofenamate sodium,effect,Warfarin: Meclofenamate sodium enhances effect DRUG .
864,"Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.",meclofenamate sodium,warfarin,advise,Therefore meclofenamate sodium given patient receiving OTHER_DRUG dosage OTHER_DRUG reduced prevent excessive prolongation prothrombin time .
865,"Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.",aspirin,meclofenamate sodium,mechanism,Aspirin: Concurrent administration DRUG may lower meclofenamate sodium plasma levels possibly competing protein-binding sites .
866,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent administration DRUG OTHER_DRUG may result elevated serum levels DRUG .
867,"In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.",androgens,insulin,effect,In diabetic patients metabolic effects DRUG may decrease blood glucose therefore OTHER_DRUG requirements .
868,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",Chloramphenicol,penicillins,effect,Bacteriostatic Antibiotics: DRUG erythromycins sulfonamides tetracyclines may interfere bactericidal effect OTHER_DRUG .
869,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",erythromycins,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol DRUG sulfonamides tetracyclines may interfere bactericidal effect OTHER_DRUG .
870,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",sulfonamides,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol erythromycins DRUG tetracyclines may interfere bactericidal effect OTHER_DRUG .
871,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",tetracyclines,penicillins,effect,Bacteriostatic Antibiotics: Chloramphenicol erythromycins sulfonamides DRUG may interfere bactericidal effect OTHER_DRUG .
872,Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.,Probenecid,ampicillin,mechanism,Probenecid: May decrease renal tubular secretion OTHER_DRUG resulting increased blood levels and/or OTHER_DRUG toxicity .
873,"Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.",bepridil hydrochloride,digoxin,mechanism,Digoxin: In controlled studies healthy volunteers bepridil hydrochloride either effect (one study) associated modest increases 30% (two studies) steady-state serum OTHER_DRUG concentrations .
874,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,Anti-arrhythmics,bepridil hydrochloride,effect,DRUG tricyclic anti-depressants could exaggerate prolongation QT interval observed bepridil hydrochloride .
875,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,tricyclic anti-depressants,bepridil hydrochloride,effect,Anti-arrhythmics tricyclic anti-depressants could exaggerate prolongation QT interval observed bepridil hydrochloride .
876,Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.,Cardiac glycosides,bepridil hydrochloride,effect,Cardiac glycosides could exaggerate depression AV nodal conduction observed bepridil hydrochloride .
877,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,DRUG bacteriostatic antibiotic may antagonize bactericidal effect OTHER_DRUG concurrent use drugs avoided .
878,"Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary",hydroxyurea,uricosuric medication,effect,Since DRUG may raise serum uric acid level dosage adjustment uricosuric medication may necessary
879,Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.,probenecid,penciclovir,mechanism,Concurrent use DRUG drugs significantly eliminated active renal tubular secretion may result increased plasma concentrations OTHER_DRUG .
880,Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.,aminoglycoside antibiotics,cephalosporin antibiotics,effect,Nephrotoxicity reported following concomitant administration aminoglycoside antibiotics cephalosporin antibiotics .
881,Concomitant administration of probenecid doubled the AUC for cefprozil.,probenecid,cefprozil,mechanism,Concomitant administration DRUG doubled AUC OTHER_DRUG .
882,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",Diphenoxylate HCl,MAO inhibitors,int,Diphenoxylate HCl atropine sulfate may interact MAO inhibitors In studies male rats diphenoxylate hydrochloride found inhibit hepatic microsomal enzyme system dose 2 mg/kg/day .
883,"Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.",atropine sulfate,MAO inhibitors,int,Diphenoxylate HCl atropine sulfate may interact MAO inhibitors In studies male rats diphenoxylate hydrochloride found inhibit hepatic microsomal enzyme system dose 2 mg/kg/day .
884,"Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.",Exjade,aluminum,advise,Although deferasirox lower affinity OTHER_DRUG iron DRUG taken aluminum-containing antacid preparations .
885,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenylbutazone,mechanism,DRUG resin may delay reduce absorption concomitant oral medication OTHER_DRUG warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis .
886,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,warfarin,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone OTHER_DRUG thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis .
887,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thiazide diuretics,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis .
888,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,propranolol,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) OTHER_DRUG (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis .
889,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,tetracycline,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well OTHER_DRUG penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis .
890,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,penicillin G,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins digitalis .
891,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenobarbital,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G OTHER_DRUG thyroid thyroxine preparations estrogens progestins digitalis .
892,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thyroxine,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid OTHER_DRUG preparations estrogens progestins digitalis .
893,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,estrogens,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations OTHER_DRUG progestins digitalis .
894,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,progestins,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens OTHER_DRUG digitalis .
895,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,digitalis,mechanism,DRUG resin may delay reduce absorption concomitant oral medication phenylbutazone warfarin thiazide diuretics (acidic) propranolol (basic) well tetracycline penicillin G phenobarbital thyroid thyroxine preparations estrogens progestins OTHER_DRUG .
896,"Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.",cholestyramine,digitalis,mechanism,DRUG resin may interfere pharmacokinetics drugs undergo enterohepatic circulation The discontinuance DRUG resin could pose hazard health potentially toxic drug OTHER_DRUG filtrated maintenance level patient taking DRUG resin .
897,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,Acetazolamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: OTHER_DRUG azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
898,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,azole antifungals,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
899,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,cimetidine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals OTHER_DRUG clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
900,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,clarithromycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
901,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,dalfopristin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) OTHER_DRUG danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
902,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,danazol,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin OTHER_DRUG delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
903,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,delavirdine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol OTHER_DRUG diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
904,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,diltiazem,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine OTHER_DRUG erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
905,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,erythromycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
906,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluoxetine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) OTHER_DRUG fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
907,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluvoxamine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine OTHER_DRUG grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
908,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,isoniazid,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice OTHER_DRUG itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
909,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,itraconazole,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid OTHER_DRUG ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
910,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,ketoconazole,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole OTHER_DRUG loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
911,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,loratadine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole OTHER_DRUG nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
912,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nefazodone,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine OTHER_DRUG niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
913,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,niacinamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone OTHER_DRUG nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
914,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nicotinamide,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide OTHER_DRUG protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
915,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,protease inhibitors,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
916,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,propoxyphene,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors OTHER_DRUG quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
917,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinine,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene OTHER_DRUG quinupristin troleandomycin valproate(1) verapamil zileuton .
918,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinupristin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine OTHER_DRUG troleandomycin valproate(1) verapamil zileuton .
919,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,troleandomycin,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin OTHER_DRUG valproate(1) verapamil zileuton .
920,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,valproate,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil zileuton .
921,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,verapamil,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) OTHER_DRUG zileuton .
922,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,zileuton,mechanism,Agents CYP3A4 inhibitors found expected increase plasma levels DRUG following: Acetazolamide azole antifungals cimetidine clarithromycin(1) dalfopristin danazol delavirdine diltiazem erythromycin(1) fluoxetine fluvoxamine grapefruit juice isoniazid itraconazole ketoconazole loratadine nefazodone niacinamide nicotinamide protease inhibitors propoxyphene quinine quinupristin troleandomycin valproate(1) verapamil OTHER_DRUG .
923,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Cisplatin,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: OTHER_DRUG doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
924,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,doxorubicin HCL,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
925,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,felbamate,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL OTHER_DRUG rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
926,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,rifampin,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL felbamate OTHER_DRUG phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
927,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,phenobarbital,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL felbamate rifampin OTHER_DRUG Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
928,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Phenytoin,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
929,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,primidone,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) OTHER_DRUG methsuximide theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
930,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,methsuximide,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone OTHER_DRUG theophylline Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
931,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,theophylline,mechanism,Agents CYP inducers found expected decrease plasma levels DRUG following: Cisplatin doxorubicin HCL felbamate rifampin phenobarbital Phenytoin(2) primidone methsuximide OTHER_DRUG Thus patient titrated stable dosage DRUG begins course treatment one CYP3A4 inducers reasonable expect dose increase DRUG may necessary .
932,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Acetaminophen,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: OTHER_DRUG alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
933,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,alprazolam,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen OTHER_DRUG amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
934,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,amitriptyline,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam OTHER_DRUG bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
935,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,bupropion,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline OTHER_DRUG buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
936,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,buspirone,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion OTHER_DRUG citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
937,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,citalopram,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone OTHER_DRUG clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
938,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clobazam,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram OTHER_DRUG clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
939,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clonazepam,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam OTHER_DRUG clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
940,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clozapine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam OTHER_DRUG cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
941,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,cyclosporin,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine OTHER_DRUG delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
942,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,delavirdine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin OTHER_DRUG desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
943,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,desipramine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine OTHER_DRUG diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
944,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,diazepam,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine OTHER_DRUG dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
945,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,dicumarol,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam OTHER_DRUG doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
946,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,doxycycline,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol OTHER_DRUG ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
947,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ethosuximide,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline OTHER_DRUG felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
948,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felbamate,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide OTHER_DRUG felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
949,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felodipine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate OTHER_DRUG glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
950,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,glucocorticoids,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine OTHER_DRUG haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
951,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,haloperidol,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids OTHER_DRUG itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
952,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,itraconazole,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol OTHER_DRUG lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
953,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lamotrigine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole OTHER_DRUG levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
954,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,levothyroxine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine OTHER_DRUG lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
955,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lorazepam,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine OTHER_DRUG methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
956,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,methadone,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam OTHER_DRUG midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
957,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,midazolam,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone OTHER_DRUG mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
958,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,mirtazapine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam OTHER_DRUG nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
959,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,nortriptyline,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine OTHER_DRUG olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
960,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,olanzapine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline OTHER_DRUG oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
961,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,contraceptives,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
962,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,oxcarbazepine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) OTHER_DRUG Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
963,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Phenytoin,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
964,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,praziquantel,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) OTHER_DRUG protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
965,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,protease inhibitors,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
966,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,quetiapine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors OTHER_DRUG risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
967,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,risperidone,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine OTHER_DRUG theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
968,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,theophylline,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone OTHER_DRUG topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
969,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,topiramate,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline OTHER_DRUG tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
970,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tiagabine,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate OTHER_DRUG tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
971,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tramadol,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine OTHER_DRUG triazolam valproate warfarin(5) ziprasidone zonisamide .
972,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,triazolam,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol OTHER_DRUG valproate warfarin(5) ziprasidone zonisamide .
973,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,valproate,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam OTHER_DRUG warfarin(5) ziprasidone zonisamide .
974,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,warfarin,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone zonisamide .
975,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ziprasidone,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) OTHER_DRUG zonisamide .
976,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,zonisamide,mechanism,Agents found expected decreased plasma levels presence DRUG due induction CYP enzymes following: Acetaminophen alprazolam amitriptyline bupropion buspirone citalopram clobazam clonazepam clozapine cyclosporin delavirdine desipramine diazepam dicumarol doxycycline ethosuximide felbamate felodipine glucocorticoids haloperidol itraconazole lamotrigine levothyroxine lorazepam methadone midazolam mirtazapine nortriptyline olanzapine oral contraceptives(3) oxcarbazepine Phenytoin(4) praziquantel protease inhibitors quetiapine risperidone theophylline topiramate tiagabine tramadol triazolam valproate warfarin(5) ziprasidone OTHER_DRUG .
977,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Clomipramine HCl,mechanism,Agents Increased Levels Presence Carbamazepine: DRUG increases plasma levels following agents: Clomipramine HCl Phenytoin(6) primidone Thus patient titrated stable dosage one agents category begins course treatment DRUG reasonable expect dose decrease concomitant agent may necessary .
978,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Phenytoin,mechanism,Agents Increased Levels Presence Carbamazepine: DRUG increases plasma levels following agents: Clomipramine HCl Phenytoin(6) primidone Thus patient titrated stable dosage one agents category begins course treatment DRUG reasonable expect dose decrease concomitant agent may necessary .
979,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,primidone,mechanism,Agents Increased Levels Presence Carbamazepine: DRUG increases plasma levels following agents: Clomipramine HCl Phenytoin(6) OTHER_DRUG Thus patient titrated stable dosage one agents category begins course treatment DRUG reasonable expect dose decrease concomitant agent may necessary .
980,Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.,carbamazepine,lithium,effect,Pharmacological/Pharmacodynamic Interactions DRUG Concomitant administration DRUG OTHER_DRUG may increase risk neurotoxic side effects .
981,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",anti-malarial drugs,carbamazepine,effect,Additionally anti-malarial drugs chloroquine mefloquine may antagonize activity OTHER_DRUG .
982,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",chloroquine,carbamazepine,effect,Additionally anti-malarial drugs DRUG mefloquine may antagonize activity OTHER_DRUG .
983,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",mefloquine,carbamazepine,effect,Additionally anti-malarial drugs chloroquine DRUG may antagonize activity OTHER_DRUG .
984,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,centrally acting drugs,advise,Because primary CNS effect caution used DRUG taken centrally acting drugs alcohol .
985,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,alcohol,advise,Because primary CNS effect caution used DRUG taken centrally acting drugs OTHER_DRUG .
986,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,monoamine oxidase inhibitors,effect,In patients receiving another serotonin reuptake inhibitor drug combination monoamine oxidase inhibitors (MAOI) reports serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability possible rapid fluctuations vital signs mental status changes include extreme agitation progressing delirium coma .
987,"In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.",serotonin reuptake inhibitor drug,MAOI,effect,In patients receiving another serotonin reuptake inhibitor drug combination monoamine oxidase inhibitors (MAOI) reports serious sometimes fatal reactions including hyperthermia rigidity myoclonus autonomic instability possible rapid fluctuations vital signs mental status changes include extreme agitation progressing delirium coma .
988,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOIs,advise,Therefore recommended DRUG Tablets used combination OTHER_DRUG within 14 days discontinuing treatment MAOI .
989,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOI,advise,Therefore recommended DRUG Tablets used combination MAOIs within 14 days discontinuing treatment OTHER_DRUG .
990,"After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.",Fluvoxamine,MAOI,advise,After stopping DRUG Tablets least 2 weeks allowed starting OTHER_DRUG .
991,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",Terfenadine,ketoconazole,mechanism,DRUG astemizole cisapride metabolized cytochrome P450IIIA4 isozyme demonstrated OTHER_DRUG potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug .
992,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",astemizole,ketoconazole,mechanism,Terfenadine DRUG cisapride metabolized cytochrome P450IIIA4 isozyme demonstrated OTHER_DRUG potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug .
993,"Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.",cisapride,ketoconazole,mechanism,Terfenadine astemizole DRUG metabolized cytochrome P450IIIA4 isozyme demonstrated OTHER_DRUG potent inhibitor IIIA4 blocks metabolism drugs resulting increased plasma concentrations parent drug .
994,"Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.",fluvoxamine,alprazolam,int,Although definitively demonstrated DRUG potent IIIA4 inhibitor likely given substantial interaction DRUG OTHER_DRUG .
995,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,terbinafine,advise,Consequently recommended DRUG used combination either OTHER_DRUG astemizole cisapride .
996,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,astemizole,advise,Consequently recommended DRUG used combination either terbinafine OTHER_DRUG cisapride .
997,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,cisapride,advise,Consequently recommended DRUG used combination either terbinafine astemizole OTHER_DRUG .
998,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",Benzodiazepines,fluvoxamine,mechanism,Other Potentially Important Drug Interactions: Benzodiazepines: DRUG metabolized hepatic oxidation (e . g . alprazolam midazolam triazolam elc . ) used caution clearance drugs likely reduced OTHER_DRUG .
999,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",alprazolam,fluvoxamine,mechanism,Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e . g . DRUG midazolam triazolam elc . ) used caution clearance drugs likely reduced OTHER_DRUG .
1000,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",midazolam,fluvoxamine,mechanism,Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e . g . alprazolam DRUG triazolam elc . ) used caution clearance drugs likely reduced OTHER_DRUG .
1001,"Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.",triazolam,fluvoxamine,mechanism,Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized hepatic oxidation (e . g . alprazolam midazolam DRUG elc . ) used caution clearance drugs likely reduced OTHER_DRUG .
1002,"Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;",fluvoxamine maleate,alprazolam,mechanism,Alprazolam: When fluvoxamine maleate (100 mg qd) OTHER_DRUG (1 mg q . . co-administered steady state plasma concentration pharmacokinetics parameters (AUC Cmax T1/2) OTHER_DRUG approximately twice observed OTHER_DRUG administered alone;
1003,"This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.",alprazolam,Fluvoxamine,advise,This interaction investigated using higher doses OTHER_DRUG may pronounced 300 mg daily dose co-administered particularly since OTHER_DRUG exhibits non-linear pharmacokinetics dosage range 100-300 mg . If DRUG co-administered OTHER_DRUG Tablets initial DRUG dosage least halved titration lowest effective dose recommended .
1004,Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.,Fluvoxamine,diazepam,advise,Diazepam: The co-administration DRUG Tablets OTHER_DRUG generally advisable .
1005,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,diazepam,mechanism,Because DRUG reduces clearance OTHER_DRUG active metabolite N-desmethyldiazepam strong likelihood substantial accumulation species chronic co-administration .
1006,"Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.",fluvoxamine,N-desmethyldiazepam,mechanism,Because DRUG reduces clearance diazepam active metabolite OTHER_DRUG strong likelihood substantial accumulation species chronic co-administration .
1007,Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.,fluvoxamine,diazepam,advise,Evidence supporting conclusion inadvisable co-administer DRUG OTHER_DRUG derived study healthy volunteers taking 150 mg/day DRUG administered single oral dose 10 mg OTHER_DRUG .
1008,"Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.",alprazolam,fluvoxamine,effect,Moreover noted DRUG effect OTHER_DRUG may even pronounced administered higher doses .
1009,"Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.",diazepam,fluvoxamine,advise,Accordingly DRUG OTHER_DRUG ordinarily co-administered .
1010,"Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.",theophylline,fluvoxamine maleate,advise,Therefore DRUG co-administered fluvoxamine maleate dose reduced one third usual daily maintenance dose plasma concentrations DRUG monitored .
1011,"Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.",fluvoxamine maleate,warfarin,mechanism,Warfarin: When fluvoxamine maleate (50 mg tid) administered concomitantly OTHER_DRUG two weeks OTHER_DRUG plasma concentrations increased 98% prothrombin times prolonged .
1012,Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.,anticoagulants,Fluvoxamine,advise,Thus patients receiving oral DRUG OTHER_DRUG Tablets prothrombin time monitored anticoagulant dose adjusted accordingly .
1013,"Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).",nitazoxanide,warfarin,mechanism,Therefore caution used administering DRUG concurrently highly plasma protein-bound drugs narrow therapeutic indices competition binding sites may occur (e . g . warfarin) .
1014,"Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agent,effect,Catecholamine-depleting drugs (eg reserpine) may additive effect given beta-blocking agents .
1015,Calcium channel blockers may also have an additive effect when given with TENORMIN .,Calcium channel blockers,TENORMIN,effect,Calcium channel blockers may also additive effect given OTHER_DRUG .
1016,Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.,Beta blockers,clonidine,effect,Beta blockers may exacerbate rebound hypertension follow withdrawal OTHER_DRUG .
1017,"If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.",beta blocker,clonidine,advise,If two drugs coadministered beta blocker withdrawn several days gradual withdrawal OTHER_DRUG .
1018,"If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.",beta blockers,clonidine,advise,If replacing OTHER_DRUG beta-blocker therapy introduction beta blockers delayed several days OTHER_DRUG administration stopped .
1019,"Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.",indomethacin,beta blockers,effect,Concomitant use prostaglandin synthase inhibiting drugs eg DRUG may decrease hypotensive effects beta blockers .
1020,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,aspirin,int,Interactions may occur DRUG supplements OTHER_DRUG non-steroidal anti-inflammatory drugs herbs garlic (Allium sativum) ginkgo (Ginkgo biloba) .
1021,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,non-steroidal anti-inflammatory drugs,int,Interactions may occur DRUG supplements aspirin non-steroidal anti-inflammatory drugs herbs garlic (Allium sativum) ginkgo (Ginkgo biloba) .
1022,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,ginkgo,int,Interactions may occur DRUG supplements aspirin non-steroidal anti-inflammatory drugs herbs garlic (Allium sativum) OTHER_DRUG (Ginkgo biloba) .
1023,Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).,EPA,Ginkgo biloba,int,Interactions may occur DRUG supplements aspirin non-steroidal anti-inflammatory drugs herbs garlic (Allium sativum) ginkgo (Ginkgo biloba) .
1024,"When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.",amphotericin B,Antineoplastic agents,effect,When administered concurrently following drugs may interact amphotericin B: Antineoplastic agents: may enhance potential renal toxicity bronchospasm hypotension .
1025,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticosteroids,amphotericin B,effect,DRUG Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia may predispose patient cardiac dysfunction .
1026,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticotropin,amphotericin B,effect,Corticosteroids DRUG (ACTH): may potentiate amphotericin B- induced hypokalemia may predispose patient cardiac dysfunction .
1027,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,ACTH,amphotericin B,effect,Corticosteroids Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia may predispose patient cardiac dysfunction .
1028,Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.,amphotericin B,digitalis,effect,OTHER_DRUG glycosides: amphotericin B-induced hypokalemia may potentiate OTHER_DRUG toxicity .
1029,"Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.",amphotericin B,flucytosine,effect,Flucytosine: synergistic relationship amphotericin B reported concomitant use may increase toxicity OTHER_DRUG possibly increasing cellular uptake and/or impairing renal excretion .
1030,"Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.",imidazoles,amphotericin B,effect,DRUG (e . g . ketoconazole miconazole clotrimazole fluconazole etc . ): vitro animal studies combination amphotericin B DRUG suggest DRUG may induce fungal resistance amphotericin B .
1031,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,skeletal muscle relaxants,effect,Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance curariform effect skeletal muscle relaxants (e . g . tubocurarine) .
1032,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,tubocurarine,effect,Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance curariform effect skeletal muscle relaxants (e . g . tubocurarine) .
1033,Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.,amphotericin B,leukocyte transfusions,effect,Leukocyte transfusions: acute pulmonary toxicity reported patients receiving intravenous amphotericin B leukocyte transfusions .
1034,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,iron,mechanism,The absorption DRUG may affected simultaneous administration indigestion remedies OTHER_DRUG zinc supplements .
1035,"The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.",lymecycline,zinc,mechanism,The absorption DRUG may affected simultaneous administration indigestion remedies iron OTHER_DRUG supplements .
1036,Oral contraceptives may be less effective while you are taking lymecycline.,contraceptives,lymecycline,effect,Oral DRUG may less effective taking OTHER_DRUG .
1037,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,diuretics,effect,Additional reductions blood pressure may occur DRUG administered OTHER_DRUG antihypertensive agents vasodilators .
1038,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,antihypertensive agents,effect,Additional reductions blood pressure may occur DRUG administered diuretics antihypertensive agents vasodilators .
1039,"Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.",FLOLAN,vasodilators,effect,Additional reductions blood pressure may occur DRUG administered diuretics antihypertensive agents OTHER_DRUG .
1040,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",antiplatelet agents,FLOLAN,effect,When antiplatelet agents anticoagulants used concomitantly potential OTHER_DRUG increase risk bleeding .
1041,"When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.",anticoagulants,FLOLAN,effect,When antiplatelet agents DRUG used concomitantly potential OTHER_DRUG increase risk bleeding .
1042,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,FLOLAN,mechanism,In clinical trials OTHER_DRUG used digoxin diuretics anticoagulants oral vasodilators supplemental oxygen . In pharmacokinetic substudy patients congestive heart failure receiving DRUG digoxin therapy OTHER_DRUG initiated apparent oral clearance values DRUG (n = 23) digoxin (n = 30) decreased 13% 15% respectively second day therapy returned baseline values day 87 .
1043,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,FLOLAN,mechanism,In clinical trials OTHER_DRUG used DRUG diuretics anticoagulants oral vasodilators supplemental oxygen . In pharmacokinetic substudy patients congestive heart failure receiving furosemide DRUG therapy OTHER_DRUG initiated apparent oral clearance values furosemide (n = 23) DRUG (n = 30) decreased 13% 15% respectively second day therapy returned baseline values day 87 .
1044,"However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.",digoxin,FLOLAN,mechanism,However patients DRUG may show elevations DRUG concentrations initiation therapy OTHER_DRUG may clinically significant patients prone DRUG toxicity .
1045,Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.,L-arginine,cyclosporin,effect,Cyclosporine - DRUG may counteract antinaturetic effect OTHER_DRUG .
1046,Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.,L-arginine,ibuprofen,mechanism,OTHER_DRUG - DRUG may increase absorption OTHER_DRUG taken concomitantly .
1047,Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.,L-arginine,nitrates,effect,Organic OTHER_DRUG - DRUG supplements theoretically may potentiate effects organic OTHER_DRUG taken concomitantly .
1048,"Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.",L-arginine,sildenafil citrate,effect,Sildenafil citrate - Theoretically DRUG supplements taken concomitantly sildenafil citrate may potentiate effects drug .
1049,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergotamine,AXERT,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours avoided .
1050,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergot-type medications,AXERT,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours avoided .
1051,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",dihydroergotamine,AXERT,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like DRUG methysergide) OTHER_DRUG within 24 hours avoided .
1052,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",methysergide,AXERT,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours avoided .
1053,Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.,moclobemide,almotriptan,mechanism,Monoamine Oxidase Inhibitors: Coadministration DRUG resulted 27% decrease OTHER_DRUG clearance increase Cmax approximately 6% .
1054,Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.,5-HT1B/1D agonists,AXERT,advise,Other 5-HT1B/1D Agonists Concomitant use 5-HT1B/1D agonists within 24 hours treatment OTHER_DRUG contraindicated .
1055,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): DRUG (e . g . fluoxetine fluvoxamine paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
1056,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e . g . DRUG fluvoxamine paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
1057,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e . g . fluoxetine DRUG paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
1058,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e . g . fluoxetine fluvoxamine DRUG sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
1059,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e . g . fluoxetine fluvoxamine paroxetine sertraline) rarely reported cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
1060,"If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.",AXERT,SSRI,advise,If concomitant treatment DRUG OTHER_DRUG clinically warranted appropriate observation patient advised .
1061,Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.,almotriptan,verapamil,mechanism,Verapamil: Coadministration DRUG OTHER_DRUG resulted 24% increase plasma concentrations DRUG .
1062,Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.,almotriptan,ketoconazole,mechanism,Coadministration DRUG potent CYP3A4 inhibitor OTHER_DRUG (400 mg q . . 3 days) resulted approximately 60% increase area plasma concentration-time curve maximal plasma concentrations DRUG .
1063,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",itraconazole,almotriptan,advise,Although interaction OTHER_DRUG potent CYP3A4 inhibitors (e . g . DRUG ritonavir erythromycin) studied increased exposures OTHER_DRUG may expected OTHER_DRUG used concomitantly medications .
1064,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",ritonavir,almotriptan,advise,Although interaction OTHER_DRUG potent CYP3A4 inhibitors (e . g . itraconazole DRUG erythromycin) studied increased exposures OTHER_DRUG may expected OTHER_DRUG used concomitantly medications .
1065,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",erythromycin,almotriptan,advise,Although interaction OTHER_DRUG potent CYP3A4 inhibitors (e . g . itraconazole ritonavir erythromycin) studied increased exposures OTHER_DRUG may expected OTHER_DRUG used concomitantly medications .
1066,Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.,Lamivudine,zalcitabine,effect,DRUG OTHER_DRUG may inhibit intracellular phosphorylation one another .
1067,"Therefore, use of lamivudine in combination with zalcitabine is not recommended",lamivudine,zalcitabine,advise,Therefore use DRUG combination OTHER_DRUG recommended
1068,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenobarbital,effect,Folic acid large amounts may counteract antiepileptic effect OTHER_DRUG phenytoin primidone increase frequency seizures susceptible pediatric patients .
1069,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,phenytoin,effect,Folic acid large amounts may counteract antiepileptic effect phenobarbital OTHER_DRUG primidone increase frequency seizures susceptible pediatric patients .
1070,"Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.",Folic acid,primidone,effect,Folic acid large amounts may counteract antiepileptic effect phenobarbital phenytoin OTHER_DRUG increase frequency seizures susceptible pediatric patients .
1071,"However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.",leucovorin,methotrexate,effect,However high doses DRUG may reduce efficacy intrathecally administered OTHER_DRUG .
1072,Leucovorin may enhance the toxicity of 5-fluorouracil.,Leucovorin,5-fluorouracil,effect,DRUG may enhance toxicity OTHER_DRUG .
1073,"The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.",Ketoconazole,terfenadine,mechanism,The following drug interactions identified involving NIZORAL Tablets drugs metabolized cytochrome P450 3A4 enzyme system: DRUG tablets inhibit metabolism OTHER_DRUG resulting increased plasma concentration OTHER_DRUG delay elimination acid metabolite .
1074,"Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.",ketoconazole,astemizole,effect,Pharmacokinetic data indicate oral DRUG inhibits metabolism OTHER_DRUG resulting elevated plasma levels OTHER_DRUG active metabolite desmethylastemizole may prolong QT intervals .
1075,Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.,astemizole,ketoconazole,advise,Coadministration DRUG OTHER_DRUG tablets therefore contraindicated .
1076,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.,ketoconazole,cisapride,mechanism,Human pharmacokinetics data indicate oral DRUG potently inhibits metabolism OTHER_DRUG resulting mean eight-fold increase AUC OTHER_DRUG .
1077,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data suggest coadministration oral DRUG OTHER_DRUG result prolongation QT interval ECG .
1078,Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.,ketoconazole,cisapride,advise,Therefore concomitant administration DRUG tablets OTHER_DRUG contraindicated .
1079,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,cyclosporine,mechanism,DRUG tablets may alter metabolism OTHER_DRUG tacrolimus methylprednisolone resulting elevated plasma concentrations latter drugs .
1080,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,tacrolimus,mechanism,DRUG tablets may alter metabolism cyclosporine OTHER_DRUG methylprednisolone resulting elevated plasma concentrations latter drugs .
1081,"Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.",Ketoconazole,methylprednisolone,mechanism,DRUG tablets may alter metabolism cyclosporine tacrolimus OTHER_DRUG resulting elevated plasma concentrations latter drugs .
1082,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,midazolam,mechanism,Coadministration DRUG Tablets OTHER_DRUG triazolam resulted elevated plasma concentrations latter two drugs .
1083,Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,NIZORAL,triazolam,mechanism,Coadministration DRUG Tablets midazolam OTHER_DRUG resulted elevated plasma concentrations latter two drugs .
1084,"It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.",digoxin,ketoconazole,advise,It therefore advisable monitor DRUG concentrations patients receiving OTHER_DRUG .
1085,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",imidazole compounds,coumarin,effect,When taken orally imidazole compounds like ketoconazole may enhance anticoagulant effect coumarin-like drugs .
1086,"When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.",ketoconazole,coumarin,effect,When taken orally imidazole compounds like DRUG may enhance anticoagulant effect coumarin-like drugs .
1087,"In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.",imidazole drugs,coumarin drugs,advise,In simultaneous treatment imidazole drugs coumarin drugs anticoagulant effect carefully titrated monitored .
1088,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.",miconazole,hypoglycemic agents,effect,Because severe hypoglycemia reported patients concomitantly receiving oral DRUG (an imidazole) oral hypoglycemic agents potential interaction involving latter agents used concomitantly ketoconazole tablets (an imidazole) ruled .
1089,Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.,ketoconazole,phenytoin,mechanism,Concomitant administration DRUG tablets OTHER_DRUG may alter metabolism one drugs .
1090,It is suggested to monitor both ketoconazole and phenytoin.,ketoconazole,phenytoin,advise,It suggested monitor DRUG OTHER_DRUG .
1091,Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.,rifampin,ketoconazole,mechanism,Concomitant administration DRUG OTHER_DRUG tablets reduces blood levels latter .
1092,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,INH,ketoconazole,mechanism,DRUG (Isoniazid) also reported affect OTHER_DRUG concentrations adversely .
1093,INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.,Isoniazid,ketoconazole,mechanism,INH (Isoniazid) also reported affect OTHER_DRUG concentrations adversely .
1094,"After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.",ketoconazole,loratadine,mechanism,After coadministration 200 mg oral DRUG twice daily one 20 mg dose OTHER_DRUG 11 subjects AUC Cmax OTHER_DRUG averaged 302% ( 142 S . D . ) 251% ( 68 S . D . ) respectively obtained co-treatment placebo .
1095,"Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.",cephalosporins,aminoglycosides,effect,Although occurrence reported Cefizox nephrotoxicity reported following concomitant administration DRUG OTHER_DRUG .
1096,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroids,mechanism,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance OTHER_DRUG may require increases corticosteroid dose achieve desired response .
1097,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroid,advise,Drugs induce hepatic enzymes DRUG phenytoin rifampin may increase clearance corticosteroids may require increases OTHER_DRUG dose achieve desired response .
1098,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance OTHER_DRUG may require increases corticosteroid dose achieve desired response .
1099,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroid,advise,Drugs induce hepatic enzymes phenobarbital DRUG rifampin may increase clearance corticosteroids may require increases OTHER_DRUG dose achieve desired response .
1100,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance OTHER_DRUG may require increases corticosteroid dose achieve desired response .
1101,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroid,advise,Drugs induce hepatic enzymes phenobarbital phenytoin DRUG may increase clearance corticosteroids may require increases OTHER_DRUG dose achieve desired response .
1102,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,troleandomycin,corticosteroids,mechanism,Drugs DRUG ketoconazole may inhibit metabolism OTHER_DRUG thus decrease clearance .
1103,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,ketoconazole,corticosteroids,mechanism,Drugs troleandomycin DRUG may inhibit metabolism OTHER_DRUG thus decrease clearance .
1104,Corticosteroids may increase the clearance of chronic high dose aspirin.,Corticosteroids,aspirin,effect,DRUG may increase clearance chronic high dose OTHER_DRUG .
1105,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.,salicylate,corticosteroid,effect,This could lead decreased DRUG serum levels increase risk DRUG toxicity OTHER_DRUG withdrawn .
1106,Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.,Aspirin,cortico-steroids,advise,DRUG used cautiously conjunction OTHER_DRUG patients suffering hypopro-thrombinemia .
1107,The effect of corticosteroids on oral anticoagulants is variable.,corticosteroids,anticoagulants,effect,The effect DRUG oral OTHER_DRUG variable .
1108,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.,anticoagulants,corticosteroids,effect,There reports enhanced well diminished effects DRUG given concurrently OTHER_DRUG .
1109,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,aminoglycosides,advise,Co-administration DRUG OTHER_DRUG agents interfering neuromuscular transmission (e . g . curare-like compounds) performed caution effect toxin may potentiated .
1110,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,curare-like compounds,advise,Co-administration DRUG aminoglycosides agents interfering neuromuscular transmission (e . g . curare-like compounds) performed caution effect toxin may potentiated .
1111,Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.,botulinum toxin,botulinum toxin,effect,Excessive neuromuscular weakness may exacerbated administration another botulinum toxin prior resolution effects previously administered botulinum toxin .
1112,Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.,Fluvoxamine,alosetron,mechanism,DRUG increased mean OTHER_DRUG plasma concentrations (AUC) approximately 6-fold prolonged half-life approximately 3-fold .
1113,Concomitant administration of alosetron and fluvoxamine is contraindicated.,alosetron,fluvoxamine,advise,Concomitant administration DRUG OTHER_DRUG contraindicated .
1114,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,quinolone antibiotics,advise,Concomitant administration DRUG moderate CYP1A2 inhibitors including quinolone antibiotics cimetidine evaluated avoided unless clinically necessary similar potential drug interactions .
1115,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,cimetidine,advise,Concomitant administration DRUG moderate CYP1A2 inhibitors including quinolone antibiotics OTHER_DRUG evaluated avoided unless clinically necessary similar potential drug interactions .
1116,Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.,Ketoconazole,alosetron,mechanism,DRUG increased mean OTHER_DRUG plasma concentrations (AUC) 29% .
1117,Caution should be used when alosetron and ketoconazole are administered concomitantly.,alosetron,ketoconazole,advise,Caution used DRUG OTHER_DRUG administered concomitantly .
1118,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,clarithromycin,advise,Coadministration DRUG strong CYP3A4 inhibitors OTHER_DRUG telithromycin protease inhibitors voriconazole itraconazole evaluated undertaken caution similar potential drug interactions .
1119,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,telithromycin,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin OTHER_DRUG protease inhibitors voriconazole itraconazole evaluated undertaken caution similar potential drug interactions .
1120,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,protease inhibitors,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors voriconazole itraconazole evaluated undertaken caution similar potential drug interactions .
1121,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,voriconazole,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors OTHER_DRUG itraconazole evaluated undertaken caution similar potential drug interactions .
1122,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,itraconazole,advise,Coadministration DRUG strong CYP3A4 inhibitors clarithromycin telithromycin protease inhibitors voriconazole OTHER_DRUG evaluated undertaken caution similar potential drug interactions .
1123,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,isoniazid,effect,Although studied DRUG inhibition N-acetyltransferase may clinically relevant consequences drugs OTHER_DRUG procainamide hydralazine .
1124,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,procainamide,effect,Although studied DRUG inhibition N-acetyltransferase may clinically relevant consequences drugs isoniazid OTHER_DRUG hydralazine .
1125,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,hydralazine,effect,Although studied DRUG inhibition N-acetyltransferase may clinically relevant consequences drugs isoniazid procainamide OTHER_DRUG .
1126,Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.,Dipyridamole,adenosine,mechanism,Adenosine: DRUG reported increase plasma levels cardiovascular effects OTHER_DRUG .
1127,"Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.",Dipyridamole,cholinesterase inhibitors,effect,Cholinesterase Inhibitors: DRUG may counteract anticholinesterase effect cholinesterase inhibitors thereby potentially aggravating myasthenia gravis .
1128,"Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.",ipratropium bromide,anticholinergic medications,effect,Anticholinergic agents: Although ipratropium bromide minimally absorbed systemic circulation potential additive interaction concomitantly used anticholinergic medications .
1129,Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.,ATROVENT,anticholinergic,advise,Caution therefore advised coadministration DRUG Inhalation Aerosol anticholinergic-containing drugs .
1130,"An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.",lithium,HALDOL,effect,An encephalopathic syndrome (characterized weakness lethargy fever tremulousness confusion extrapyramidal symptoms leukocytosis elevated serum enzymes BUN FBS) followed irreversible brain damage occurred patients treated DRUG plus OTHER_DRUG .
1131,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,CNS depressants,effect,As antipsychotic agents noted HALDOL may capable potentiating CNS depressants anesthetics opiates alcohol .
1132,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,anesthetics,effect,As antipsychotic agents noted HALDOL may capable potentiating CNS depressants OTHER_DRUG opiates alcohol .
1133,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,opiates,effect,As antipsychotic agents noted HALDOL may capable potentiating CNS depressants anesthetics OTHER_DRUG alcohol .
1134,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",antipsychotic agents,alcohol,effect,As antipsychotic agents noted HALDOL may capable potentiating CNS depressants anesthetics opiates OTHER_DRUG .
1135,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,CNS depressants,effect,As antipsychotic agents noted DRUG may capable potentiating CNS depressants anesthetics opiates alcohol .
1136,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,anesthetics,effect,As antipsychotic agents noted DRUG may capable potentiating CNS depressants OTHER_DRUG opiates alcohol .
1137,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,opiates,effect,As antipsychotic agents noted DRUG may capable potentiating CNS depressants anesthetics OTHER_DRUG alcohol .
1138,"As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.",HALDOL,alcohol,effect,As antipsychotic agents noted DRUG may capable potentiating CNS depressants anesthetics opiates OTHER_DRUG .
1139,"In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.",haloperidol,rifampin,mechanism,In study 12 schizophrenic patients coadministered oral DRUG OTHER_DRUG plasma DRUG levels decreased mean 70% mean scores Brief Psychiatric Rating Scale increased baseline .
1140,"In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.",rifampin,haloperidol,mechanism,In 5 schizophrenic patients treated oral OTHER_DRUG DRUG discontinuation DRUG produced mean 3 . 3-fold increase OTHER_DRUG concentrations .
1141,"Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.",rifampin,haloperidol,advise,Thus careful monitoring clinical status warranted DRUG administered discontinued haloperidol-treated patients .
1142,apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.,diphenidol,apomorphine,effect,OTHER_DRUG - prior ingestion DRUG may decrease emetic response OTHER_DRUG treatment poisoning .
1143,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",doxazosin,cimetidine,mechanism,In placebo-controlled trial normal volunteers administration single 1 mg dose DRUG day 1 four-day regimen oral OTHER_DRUG (400 mg twice daily) resulted 10% increase mean AUC DRUG (p=0 . 006) slight statistically significant increase mean Cmax mean half-life DRUG .
1144,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors prolong intensify anticholinergic effects OTHER_DRUG .
1145,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,alcohol,effect,DRUG may additive effects OTHER_DRUG CNS depressants . g . hypnotics sedatives tranquilizers antianxiety agents .
1146,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,CNS depressants,effect,DRUG may additive effects alcohol CNS depressants . g . hypnotics sedatives tranquilizers antianxiety agents .
1147,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,hypnotics,effect,DRUG may additive effects alcohol CNS depressants . g . OTHER_DRUG sedatives tranquilizers antianxiety agents .
1148,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,sedatives,effect,DRUG may additive effects alcohol CNS depressants . g . hypnotics OTHER_DRUG tranquilizers antianxiety agents .
1149,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,tranquilizers,effect,DRUG may additive effects alcohol CNS depressants . g . hypnotics sedatives OTHER_DRUG antianxiety agents .
1150,"Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.",Antihistamines,antianxiety agents,effect,DRUG may additive effects alcohol CNS depressants . g . hypnotics sedatives tranquilizers antianxiety agents .
1151,The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.,cromolyn sodium,isoproterenol,effect,The addition 540 mg/kg/day cromolyn sodium (approximately 340 times maximum recommended daily inhalation dose adults mg/m2 basis) 2 . 7 mg/kg/day OTHER_DRUG (approximately 7 times maximum recommended daily inhalation dose adults mg/m2 basis) appears increased incidence resorptions malformations .
1152,Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.,naltrexone,Acamprosate,mechanism,Co-administration DRUG OTHER_DRUG produced 25% increase AUC 33% increase Cmax OTHER_DRUG .
1153,"Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.",Acamprosate,antidepressants,effect,Patients taking DRUG concomitantly OTHER_DRUG commonly reported weight gain weight loss compared patients taking either medication alone .
1154,All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.,vasopressors,monoamine oxidase (MAO) inhibitors,advise,All DRUG used cautiously patients taking monoamine oxidase (MAO) inhibitors .
1155,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,sympathomimetic drugs,advise,DRUG administered concomitantly sympathomimetic drugs (such isoproterenol) possible additive effects increased toxicity .
1156,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,isoproterenol,advise,DRUG administered concomitantly sympathomimetic drugs (such isoproterenol) possible additive effects increased toxicity .
1157,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,cyclopropane,effect,Administration DRUG patients receiving OTHER_DRUG halogenated hydrocarbon general anesthetics halothane sensitize myocardium may induce cardiac arrhythmia . .
1158,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halogenated hydrocarbon general anesthetics,effect,Administration DRUG patients receiving cyclopropane halogenated hydrocarbon general anesthetics halothane sensitize myocardium may induce cardiac arrhythmia . .
1159,"Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..",epinephrine,halothane,effect,Administration DRUG patients receiving cyclopropane halogenated hydrocarbon general anesthetics OTHER_DRUG sensitize myocardium may induce cardiac arrhythmia . .
1160,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,digitalis,advise,DRUG also used cautiously drugs (e . g . OTHER_DRUG glycosides) sensitize myocardium actions sympathomimetic drugs .
1161,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,glycosides,advise,DRUG also used cautiously drugs (e . g . digitalis glycosides) sensitize myocardium actions sympathomimetic drugs .
1162,Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.,Diuretic agents,epinephrine,effect,Diuretic agents may decrease vascular response pressor drugs OTHER_DRUG .
1163,Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.,Epinephrine,guanethidine,effect,DRUG may antagonize neuron blockade produced OTHER_DRUG resulting decreased antihypertensive effect requiring increased dosage latter .
1164,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.",CANCIDAS,tacrolimus,mechanism,DRUG reduced blood AUC0-12 OTHER_DRUG approximately 20% peak blood concentration (Cmax) 16% 12-hour blood concentration (C12hr) 26% healthy subjects OTHER_DRUG (2 doses 0 . 1 mg/kg 12 hours apart) administered 10th day DRUG 70 mg daily compared results control period OTHER_DRUG administered alone .
1165,"In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.",cyclosporine,caspofungin,mechanism,In two clinical studies DRUG (one 4 mg/kg dose two 3 mg/kg doses) increased AUC OTHER_DRUG approximately 35% .
1166,There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.,CANCIDAS,cyclosporine,effect,There transient increases liver ALT AST DRUG OTHER_DRUG co-administered .
1167,A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.,rifampin,caspofungin,mechanism,A drug-drug interaction study DRUG healthy volunteers shown 30% decrease OTHER_DRUG trough concentrations .
1168,Patients on rifampin should receive 70 mg of CANCIDAS daily.,rifampin,CANCIDAS,advise,Patients DRUG receive 70 mg OTHER_DRUG daily .
1169,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",efavirenz,CANCIDAS,mechanism,In addition results regression analyses patient pharmacokinetic data suggest co-administration inducers drug clearance (efavirenz nevirapine phenytoin dexamethasone carbamazepine) OTHER_DRUG may result clinically meaningful reductions caspofungin concentrations .
1170,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",nevirapine,CANCIDAS,mechanism,In addition results regression analyses patient pharmacokinetic data suggest co-administration inducers drug clearance (efavirenz DRUG phenytoin dexamethasone carbamazepine) OTHER_DRUG may result clinically meaningful reductions caspofungin concentrations .
1171,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",phenytoin,CANCIDAS,mechanism,In addition results regression analyses patient pharmacokinetic data suggest co-administration inducers drug clearance (efavirenz nevirapine DRUG dexamethasone carbamazepine) OTHER_DRUG may result clinically meaningful reductions caspofungin concentrations .
1172,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",dexamethasone,CANCIDAS,mechanism,In addition results regression analyses patient pharmacokinetic data suggest co-administration inducers drug clearance (efavirenz nevirapine phenytoin DRUG carbamazepine) OTHER_DRUG may result clinically meaningful reductions caspofungin concentrations .
1173,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",carbamazepine,CANCIDAS,mechanism,In addition results regression analyses patient pharmacokinetic data suggest co-administration inducers drug clearance (efavirenz nevirapine phenytoin dexamethasone carbamazepine) OTHER_DRUG may result clinically meaningful reductions caspofungin concentrations .
1174,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,efavirenz,advise,When DRUG co-administered inducers drug clearance OTHER_DRUG nevirapine phenytoin dexamethasone carbamazepine use daily dose 70 mg DRUG considered
1175,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,nevirapine,advise,When DRUG co-administered inducers drug clearance efavirenz OTHER_DRUG phenytoin dexamethasone carbamazepine use daily dose 70 mg DRUG considered
1176,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,phenytoin,advise,When DRUG co-administered inducers drug clearance efavirenz nevirapine OTHER_DRUG dexamethasone carbamazepine use daily dose 70 mg DRUG considered
1177,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,dexamethasone,advise,When DRUG co-administered inducers drug clearance efavirenz nevirapine phenytoin OTHER_DRUG carbamazepine use daily dose 70 mg DRUG considered
1178,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,carbamazepine,advise,When DRUG co-administered inducers drug clearance efavirenz nevirapine phenytoin dexamethasone OTHER_DRUG use daily dose 70 mg DRUG considered
1179,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased nephrotoxicity reported following concomitant administration DRUG aminoglycoside antibiotics .
1180,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,DRUG may accentuate electrolyte loss associated OTHER_DRUG therapy .
1181,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,barbiturates,effect,Tablets: The DRUG including lorazepam produce CNS-depressant effects administered medications OTHER_DRUG alcohol .
1182,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",benzodiazepines,alcohol,effect,Tablets: The DRUG including lorazepam produce CNS-depressant effects administered medications barbiturates OTHER_DRUG .
1183,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,barbiturates,effect,Tablets: The benzodiazepines including DRUG produce CNS-depressant effects administered medications OTHER_DRUG alcohol .
1184,"Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.",lorazepam,alcohol,effect,Tablets: The benzodiazepines including DRUG produce CNS-depressant effects administered medications barbiturates OTHER_DRUG .
1185,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,ethyl alcohol,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants . When scopolamine used concomitantly injectable DRUG increased incidence sedation hallucinations irrational behavior observed .
1186,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,phenothiazines,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol OTHER_DRUG barbiturates MAO inhibitors antidepressants . When scopolamine used concomitantly injectable DRUG increased incidence sedation hallucinations irrational behavior observed .
1187,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,barbiturates,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines OTHER_DRUG MAO inhibitors antidepressants . When scopolamine used concomitantly injectable DRUG increased incidence sedation hallucinations irrational behavior observed .
1188,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,MAO inhibitors,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants . When scopolamine used concomitantly injectable DRUG increased incidence sedation hallucinations irrational behavior observed .
1189,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",Lorazepam,antidepressants,effect,Injection: DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors OTHER_DRUG . When scopolamine used concomitantly injectable DRUG increased incidence sedation hallucinations irrational behavior observed .
1190,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,ethyl alcohol,effect,Injection: Lorazepam injection like injectable DRUG produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants . When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed .
1191,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,phenothiazines,effect,Injection: Lorazepam injection like injectable DRUG produces depression central nervous system administered ethyl alcohol OTHER_DRUG barbiturates MAO inhibitors antidepressants . When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed .
1192,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,barbiturates,effect,Injection: Lorazepam injection like injectable DRUG produces depression central nervous system administered ethyl alcohol phenothiazines OTHER_DRUG MAO inhibitors antidepressants . When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed .
1193,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,MAO inhibitors,effect,Injection: Lorazepam injection like injectable DRUG produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants . When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed .
1194,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",benzodiazepines,antidepressants,effect,Injection: Lorazepam injection like injectable DRUG produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors OTHER_DRUG . When scopolamine used concomitantly injectable lorazepam increased incidence sedation hallucinations irrational behavior observed .
1195,"Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.",scopolamine,lorazepam,effect,Injection: OTHER_DRUG injection like injectable benzodiazepines produces depression central nervous system administered ethyl alcohol phenothiazines barbiturates MAO inhibitors antidepressants . When DRUG used concomitantly injectable OTHER_DRUG increased incidence sedation hallucinations irrational behavior observed .
1196,(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.,Femara,tamoxifen,mechanism,(See CLINICAL PHARMACOLOGY) Coadministration DRUG OTHER_DRUG 20 mg daily resulted reduction letrozole plasma levels 38% average .
1197,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,narcotic analgesics,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics CNS depressants (including alcohol) additive depressant effects .
1198,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,anesthetics,effect,DRUG combination narcotic analgesics general OTHER_DRUG phenothiazines tranquilizers sedative-hypnotics CNS depressants (including alcohol) additive depressant effects .
1199,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,phenothiazines,effect,DRUG combination narcotic analgesics general anesthetics OTHER_DRUG tranquilizers sedative-hypnotics CNS depressants (including alcohol) additive depressant effects .
1200,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,tranquilizers,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines OTHER_DRUG sedative-hypnotics CNS depressants (including alcohol) additive depressant effects .
1201,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,sedative-hypnotics,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines tranquilizers OTHER_DRUG CNS depressants (including alcohol) additive depressant effects .
1202,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,CNS depressants,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics CNS depressants (including alcohol) additive depressant effects .
1203,"Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.",Codeine,alcohol,effect,DRUG combination narcotic analgesics general anesthetics phenothiazines tranquilizers sedative-hypnotics CNS depressants (including alcohol) additive depressant effects .
1204,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,Antabuse,advise,DRUG administered caution patients receiving OTHER_DRUG (disulfiram Wyeth-Ayerst Laboratories) .
1205,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,disulfiram,advise,DRUG administered caution patients receiving Antabuse (disulfiram Wyeth-Ayerst Laboratories) .
1206,"In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.",MAO inhibitor,disulfiram,effect,In single study rats given high intraperitoneal doses MAO inhibitor plus OTHER_DRUG experienced severe toxicity including convulsions death .
1207,Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.,Isocarboxazid,psychotropic agents,advise,Concomitant use DRUG psychotropic agents generally recommended possible potentiating effects .
1208,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,anesthetics,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration DRUG OTHER_DRUG sedatives hypnotics opioids likely lead enhancement effects .
1209,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,sedatives,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration DRUG anesthetics OTHER_DRUG hypnotics opioids likely lead enhancement effects .
1210,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,hypnotics,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration DRUG anesthetics sedatives OTHER_DRUG opioids likely lead enhancement effects .
1211,"Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.",PRECEDEX,opioids,effect,Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration DRUG anesthetics sedatives hypnotics OTHER_DRUG likely lead enhancement effects .
1212,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,anesthetic,advise,However due possible pharmacodynamic interactions co-administered DRUG reduction dosage DRUG concomitant OTHER_DRUG sedative hypnotic opioid may required .
1213,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,sedative,advise,However due possible pharmacodynamic interactions co-administered DRUG reduction dosage DRUG concomitant anesthetic OTHER_DRUG hypnotic opioid may required .
1214,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,hypnotic,advise,However due possible pharmacodynamic interactions co-administered DRUG reduction dosage DRUG concomitant anesthetic sedative OTHER_DRUG opioid may required .
1215,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,opioid,advise,However due possible pharmacodynamic interactions co-administered DRUG reduction dosage DRUG concomitant anesthetic sedative hypnotic OTHER_DRUG may required .
1216,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,Digoxin,Adenocard,effect,DRUG verapamil use may rarely associated ventricular fibrillation combined OTHER_DRUG .
1217,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,verapamil,Adenocard,effect,Digoxin DRUG use may rarely associated ventricular fibrillation combined OTHER_DRUG .
1218,The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.,Adenocard,digitalis,effect,The use DRUG patients receiving OTHER_DRUG may rarely associated ventricular fibrillation .
1219,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,methylxanthines,effect,The effects DRUG antagonized OTHER_DRUG caffeine theophylline .
1220,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,caffeine,effect,The effects DRUG antagonized methylxanthines OTHER_DRUG theophylline .
1221,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,theophylline,effect,The effects DRUG antagonized methylxanthines caffeine OTHER_DRUG .
1222,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,In presence DRUG larger doses OTHER_DRUG may required OTHER_DRUG may effective .
1223,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,In presence DRUG larger doses OTHER_DRUG may required OTHER_DRUG may effective .
1224,Adenosine effects are potentiated by dipyridamole.,Adenosine,dipyridamole,effect,DRUG effects potentiated OTHER_DRUG .
1225,"Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.",adenosine,dipyridamole,effect,Thus smaller doses DRUG may effective presence OTHER_DRUG .
1226,"As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.",adenosine,carbamazepine,effect,As primary effect DRUG decrease conduction A-V node higher degrees heart block may produced presence OTHER_DRUG .
1227,"Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).",cimetidine,isradipine,mechanism,Cimetidine: In study healthy volunteers one-week course DRUG 400 mg b . . . single 5 mg dose OTHER_DRUG sixth day showed increase OTHER_DRUG mean peak plasma concentrations (36%) significant increase area curve (50%) .
1228,If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.,isradipine,cimetidine,advise,If DRUG therapy initiated patient currently receiving OTHER_DRUG careful monitoring adverse reactions advised downward dose adjustment may required .
1229,"Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.",rifampicin,isradipine,mechanism,Rifampicin: In study healthy volunteers six-day course DRUG 600 mg/day followed single 5 mg dose OTHER_DRUG resulted reduction OTHER_DRUG levels detectable limits .
1230,"If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.",rifampicin,isradipine,mechanism,If DRUG therapy required OTHER_DRUG concentrations therapeutic effects likely markedly reduced abolished consequence increased metabolism higher clearance OTHER_DRUG .
1231,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,beta blocker,effect,DRUG Anesthesia: Severe hypotension reported DRUG anesthesia concomitant use beta blocker calcium channel blocker .
1232,Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.,fentanyl,calcium channel blocker,effect,DRUG Anesthesia: Severe hypotension reported DRUG anesthesia concomitant use beta blocker calcium channel blocker .
1233,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",phenobarbital,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg DRUG rifampin rifabutin) would expected increase clearance OTHER_DRUG resulting lowered plasma concentrations .
1234,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifampin,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg phenobarbital DRUG rifabutin) would expected increase clearance OTHER_DRUG resulting lowered plasma concentrations .
1235,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifabutin,efavirenz,mechanism,Drugs induce CYP3A4 activity (eg phenobarbital rifampin rifabutin) would expected increase clearance OTHER_DRUG resulting lowered plasma concentrations .
1236,"In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.",SUSTIVA,clarithromycin,effect,In uninfected volunteers 46% developed rash receiving DRUG OTHER_DRUG .
1237,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.,indinavir,SUSTIVA,mechanism,Increasing DRUG dose 1000 mg every 8 hours compensate increased DRUG metabolism due OTHER_DRUG .
1238,"When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.",indinavir,SUSTIVA,mechanism,When DRUG increased dose (1000 mg every 8 hours) given OTHER_DRUG (600 mg daily) DRUG AUC Cmin decreased average 33-46% 39-57% respectively compared DRUG (800 mg every 8 hours) given alone .
1239,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,lopinavir,SUSTIVA,advise,A dose increase lopinavir/ritonavir 533/133 mg (4 capsules 6 . 5 mL) twice daily taken food recommended used combination OTHER_DRUG .
1240,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,ritonavir,SUSTIVA,advise,A dose increase lopinavir/ritonavir 533/133 mg (4 capsules 6 . 5 mL) twice daily taken food recommended used combination OTHER_DRUG .
1241,"Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.",efavirenz,contraceptives,advise,Because potential interaction DRUG oral OTHER_DRUG fully characterized reliable method barrier contraception used addition oral OTHER_DRUG .
1242,Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.,SUSTIVA,ritonavir,advise,Monitoring liver enzymes recommended DRUG used combination OTHER_DRUG .
1243,Potential for reduction in anticonvulsant and/or efavirenz plasma levels;,anticonvulsant,efavirenz,mechanism,Potential reduction DRUG and/or OTHER_DRUG plasma levels;
1244,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,itraconazole,mechanism,DRUG potential decrease plasma concentrations OTHER_DRUG ketoconazole .
1245,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,ketoconazole,mechanism,DRUG potential decrease plasma concentrations itraconazole OTHER_DRUG .
1246,"Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.",Indinavir,amprenavir,mechanism,DRUG steady-state Cmax A . C . Cmin decreased 22% 38% 27% respectively concomitant OTHER_DRUG .
1247,"Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.",Saquinavir,amprenavir,mechanism,DRUG steady-state Cmax A . C . Cmin increased 21% decreased 19% decreased 48% respectively concomitant OTHER_DRUG .
1248,"Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.",Nelfinavir,amprenavir,mechanism,DRUG steady-state Cmax A . C . Cmin increased 12% 15% 14% respectively concomitant OTHER_DRUG .
1249,Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.,amprenavir,methadone,effect,Methadone: Coadministration DRUG OTHER_DRUG decrease plasma levels OTHER_DRUG .
1250,"Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.",amprenavir,methadone,mechanism,Coadministration DRUG OTHER_DRUG compared non-matched historicalcontrol group resulted 30% 27% 25% decrease serum DRUG AUC Cmax andCmin respectively .
1251,"Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",Amprenavir,ritonavir,effect,Laboratory Tests: The combination DRUG low-dose OTHER_DRUG associated elevations cholesterol triglycerides SGOT (AST) SGPT (ALT) patients .
1252,Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.,Amprenavir,ritonavir,advise,Appropriate laboratory testing considered prior initiating combination therapy DRUG OTHER_DRUG periodic intervals clinical signs symptoms hyperlipidemia elevated liver function tests occur therapy .
1253,Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.,Corticotropin,diuretic,effect,DRUG may accentuate electrolyte loss associated OTHER_DRUG therapy .
1254,"Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.",nifedipine,beta-blocking agents,effect,Beta-adrenergic Blocking Agents: Experience 1400 patients non-comparative clinical trial shown concomitant administration DRUG beta-blocking agents usually well tolerated occasional literature reports suggesting combination may increase likelihood congestive heart failure severe hypotension exacerbation angina .
1255,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,int,Digitalis: Immediate Release Capsules: Since isolated reports patients elevated DRUG levels possible interaction DRUG OTHER_DRUG recommended DRUG levels monitored initiating adjusting discontinuing OTHER_DRUG avoid possible over- under-digitalization .
1256,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,Digitalis: Immediate Release Capsules: Since isolated reports patients elevated DRUG levels possible interaction DRUG OTHER_DRUG recommended DRUG levels monitored initiating adjusting discontinuing OTHER_DRUG avoid possible over- under-digitalization .
1257,Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.,digoxin,digoxin,mechanism,Extended Release Tablets: Administration nifedipine DRUG increased DRUG levels 9 12 normal volunteers .
1258,"Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,Since isolated reports patients elevated DRUG levels recommended DRUG levels monitored initiating adjusting discontinuing OTHER_DRUG avoid possible over- under-digitalization .
1259,Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).,quinidine,nifedipine,mechanism,Quinidine: Immediate Release Capsules: There rare reports interaction DRUG OTHER_DRUG (with decreased plasma level quinidine) .
1260,Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.,coumarin anticoagulants,nifedipine,effect,Coumarin Anticoagulants: There rare reports increased prothrombin time patients taking coumarin anticoagulants OTHER_DRUG administered .
1261,Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.,cimetidine,nifedipine,mechanism,Cimetidine: A study 6 healthy volunteers shown significant increase peak OTHER_DRUG plasma levels (80%) area-under-the-curve (74%) 1 week course DRUG 1000 mg per day OTHER_DRUG 40 mg per day .
1262,"If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.",nifedipine,cimetidine,advise,If DRUG therapy initiated patient currently receiving OTHER_DRUG cautious titration advised .
1263,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin D analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: DRUG reported reduce intestinal absorption fat soluble vitamins;
1264,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some reports shown concomitant administration DRUG vitamin D causes hypercalcemia .
1265,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: Vitamin D dosage must determined care patients undergoing treatment OTHER_DRUG hypercalcemia patients may precipitate cardiac arrhythmias .
1266,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: DRUG may inhibit synthetic catabolic enzymes vitamin D .
1267,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D,corticosteroids,effect,Corticosteroids: A relationship functional antagonism exists vitamin D analogues promote calcium absorption OTHER_DRUG inhibit calcium absorption .
1268,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,effect,Magnesium: Magnesium-containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D patients chronic renal dialysis .
1269,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,effect,Magnesium: Magnesium-containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D patients chronic renal dialysis .
1270,"In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.",diflunisal,indomethacin,mechanism,In normal volunteers receiving OTHER_DRUG administration DRUG decreased renal clearance significantly increased plasma levels OTHER_DRUG .
1271,"In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.",INDOCIN,diflunisal,effect,In patients combined use DRUG OTHER_DRUG associated fatal gastrointestinal hemorrhage .
1272,"Therefore, diflunisal and INDOCIN should not be used concomitantly.",diflunisal,INDOCIN,advise,Therefore DRUG OTHER_DRUG used concomitantly .
1273,"In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.",aspirin,indomethacin,mechanism,In study normal volunteers found chronic concurrent administration 3 . 6 g DRUG per day decreases OTHER_DRUG blood levels approximately 20% .
1274,"The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",INDOCIN,NSAIDs,advise,The concomitant use DRUG OTHER_DRUG recommended due increased possibility gastrointestinal toxicity little increase efficacy .
1275,"However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.",INDOCIN,anticoagulant,advise,However additional drug including DRUG added treatment patients OTHER_DRUG therapy patients observed alterations prothrombin time .
1276,"In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.",anticoagulants,INDOCIN,effect,In post-marketing experience bleeding reported patients concomitant treatment DRUG OTHER_DRUG .
1277,Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.,INDOCIN,anticoagulants,advise,Caution exercised DRUG OTHER_DRUG administered concomitantly .
1278,"When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.",INDOCIN,probenecid,mechanism,When DRUG given patients receiving OTHER_DRUG plasma levels indomethacin likely increased .
1279,Caution should be used if INDOCIN is administered simultaneously with methotrexate.,INDOCIN,methotrexate,advise,Caution used DRUG administered simultaneously OTHER_DRUG .
1280,INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,INDOCIN,methotrexate,mechanism,DRUG reported decrease tubular secretion OTHER_DRUG potentiate toxicity .
1281,"Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",non-steroidal anti-inflammatory drugs,cyclosporine,effect,Administration non-steroidal anti-inflammatory drugs concomitantly OTHER_DRUG associated increase cyclosporine-induced toxicity possibly due decreased synthesis renal prostacyclin .
1282,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,DRUG used caution patients taking OTHER_DRUG renal function carefully monitored .
1283,Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.,INDOCIN,lithium,mechanism,Capsules DRUG 50 mg . . . produced clinically relevant elevation plasma OTHER_DRUG reduction renal OTHER_DRUG clearance psychiatric patients normal subjects steady state plasma OTHER_DRUG concentrations .
1284,"As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.",INDOCIN,lithium,advise,As consequence DRUG OTHER_DRUG given concomitantly patient carefully observed signs OTHER_DRUG toxicity .
1285,INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.,INDOCIN,digoxin,mechanism,DRUG given concomitantly OTHER_DRUG reported increase serum concentration prolong half-life OTHER_DRUG .
1286,"Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.",INDOCIN,digoxin,advise,Therefore DRUG OTHER_DRUG used concomitantly serum OTHER_DRUG levels closely monitored .
1287,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,loop diuretics,effect,In patients administration DRUG reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
1288,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,potassium-sparing diuretics,effect,In patients administration DRUG reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
1289,"In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.",INDOCIN,thiazide diuretics,effect,In patients administration DRUG reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
1290,It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.,triamterene,INDOCIN,effect,It reported addition DRUG maintenance schedule OTHER_DRUG resulted reversible acute renal failure two four healthy volunteers .
1291,INDOCIN and triamterene should not be administered together.,INDOCIN,triamterene,advise,DRUG OTHER_DRUG administered together .
1292,The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.,INDOCIN,potassium-sparing diuretics,effect,The potential effects DRUG potassium-sparing diuretics potassium kinetics renal function considered agents administered concurrently .
1293,"Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.",diuretics,INDOCIN,effect,Most effects concerning DRUG attributed least part mechanisms involving inhibition prostaglandin synthesis OTHER_DRUG .
1294,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,non-steroidal antiinflammatory drugs,effect,Blunting antihypertensive effect beta-adrenoceptor blocking agents non-steroidal antiinflammatory drugs including INDOCIN reported .
1295,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.,beta-adrenoceptor blocking agents,INDOCIN,effect,Blunting antihypertensive effect beta-adrenoceptor blocking agents non-steroidal antiinflammatory drugs including OTHER_DRUG reported .
1296,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,captopril,effect,DRUG reduce antihypertensive effects OTHER_DRUG losartan .
1297,INDOCIN can reduce the antihypertensive effects of captopril and losartan.,INDOCIN,losartan,effect,DRUG reduce antihypertensive effects captopril OTHER_DRUG .
1298,"Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).",tamoxifen,anastrozole,advise,Based clinical pharmacokinetic results ATAC trial DRUG administered OTHER_DRUG (see CLINICAL PHARMACOLOGY Drug Interactions CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment Breast Cancer Postmenopausal Women subsections) .
1299,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.,anastrozole,tamoxifen,mechanism,Co-administration DRUG OTHER_DRUG resulted reduction DRUG plasma levels 27% compared achieved DRUG alone .
1300,Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.,Estrogen,ARIMIDEX,advise,Estrogen-containing therapies used OTHER_DRUG may diminish pharmacologic action .
1301,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",ciclesonide,ketoconazole,mechanism,In another drug interaction study co-administration orally inhaled DRUG oral OTHER_DRUG potent inhibitor cytochrome P450 3A4 increased exposure (AUC) des-ciclesonide approximately 3 . 6-fold steady state levels DRUG remained unchanged .
1302,"Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.",ketoconazole,ciclesonide,advise,Therefore DRUG administered caution intranasal OTHER_DRUG .
1303,"Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.",doxylamine,CNS depressant drugs,effect,Potential drug interactions DRUG include increased sedation DRUG combined CNS depressant drugs .
1304,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,heparin,effect,DRUG may partially counteract anticoagulation effects OTHER_DRUG warfarin .
1305,Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.,Antihistamines,warfarin,effect,DRUG may partially counteract anticoagulation effects heparin OTHER_DRUG .
1306,Doxylamine may enhance the effects of epinephrine.,Doxylamine,epinephrine,effect,DRUG may enhance effects OTHER_DRUG .
1307,The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.,NSAIDs,ACE inhibitors,effect,The use DRUG patients receiving ACE inhibitors may potentiate renal disease states .
1308,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,Concomitant administration DRUG OTHER_DRUG recommended DRUG displaced binding sites concomitant administration OTHER_DRUG resulting lower plasma concentrations peak plasma levels .
1309,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,Concomitant administration DRUG OTHER_DRUG recommended DRUG displaced binding sites concomitant administration OTHER_DRUG resulting lower plasma concentrations peak plasma levels .
1310,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,propranolol,effect,DRUG NSAIDs reduce antihypertensive effect OTHER_DRUG beta-blockers .
1311,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,Naproxen,beta-blockers,effect,DRUG NSAIDs reduce antihypertensive effect propranolol OTHER_DRUG .
1312,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,propranolol,effect,Naproxen DRUG reduce antihypertensive effect OTHER_DRUG beta-blockers .
1313,Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.,NSAIDs,beta-blockers,effect,Naproxen DRUG reduce antihypertensive effect propranolol OTHER_DRUG .
1314,Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.,Probenecid,naproxen,mechanism,DRUG given concurrently increases OTHER_DRUG anion plasma levels extends plasma half-life significantly .
1315,Caution should be used if naproxen is administered concomitantly with methotrexate.,naproxen,methotrexate,advise,Caution used DRUG administered concomitantly OTHER_DRUG .
1316,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",Naproxen,methotrexate,mechanism,DRUG DRUG sodium NSAIDs reported reduce tubular secretion OTHER_DRUG animal model possibly increasing toxicity OTHER_DRUG .
1317,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",naproxen sodium,methotrexate,mechanism,Naproxen naproxen sodium NSAIDs reported reduce tubular secretion OTHER_DRUG animal model possibly increasing toxicity OTHER_DRUG .
1318,"Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.",NSAIDs,methotrexate,mechanism,Naproxen naproxen sodium DRUG reported reduce tubular secretion OTHER_DRUG animal model possibly increasing toxicity OTHER_DRUG .
1319,"If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.",CEFOTAN,aminoglycoside,effect,If DRUG OTHER_DRUG used concomitantly renal function carefully monitored nephrotoxicity may potentiated .
1320,Colchicine is inhibited by acidifying agents.,Colchicine,acidifying agents,mechanism,DRUG inhibited acidifying agents .
1321,The action of colchicine is potentiated by alkalinizing agents.,colchicine,alkalinizing agents,mechanism,The action DRUG potentiated alkalinizing agents .
1322,Colchicine may increase sensitivity to the CNS depressants.,Colchicine,CNS depressants,effect,DRUG may increase sensitivity CNS depressants .
1323,Response to sympathomimetic agents may be enhanced by colchicine.,sympathomimetic agents,colchicine,effect,Response sympathomimetic agents may enhanced OTHER_DRUG .
1324,"Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.",Anagrelide,aspirin,effect,DRUG alone effect platelet aggregation slightly enhance inhibition platelet aggregation OTHER_DRUG .
1325,"It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.",fluvoxamine,anagrelide,mechanism,It known CYP1A2 inhibited several medicinal products including DRUG medicinal products could theoretically adversely influence clearance OTHER_DRUG .
1326,Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.,Anagrelide,theophylline,mechanism,DRUG demonstrates limited inhibitory activity towards CYP1A2 may present theoretical potential interaction coadministered medicinal products sharing clearance mechanism . g . OTHER_DRUG .
1327,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",milrinone,anagrelide,effect,The effects medicinal products similar properties inotropes DRUG enoximone amrinone olprinone cilostazol may exacerbated OTHER_DRUG .
1328,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",enoximone,anagrelide,effect,The effects medicinal products similar properties inotropes milrinone DRUG amrinone olprinone cilostazol may exacerbated OTHER_DRUG .
1329,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",amrinone,anagrelide,effect,The effects medicinal products similar properties inotropes milrinone enoximone DRUG olprinone cilostazol may exacerbated OTHER_DRUG .
1330,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",olprinone,anagrelide,effect,The effects medicinal products similar properties inotropes milrinone enoximone amrinone DRUG cilostazol may exacerbated OTHER_DRUG .
1331,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",cilostazol,anagrelide,effect,The effects medicinal products similar properties inotropes milrinone enoximone amrinone olprinone DRUG may exacerbated OTHER_DRUG .
1332,"There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.",sucralfate,anagrelide,mechanism,There single case report suggests DRUG may interfere OTHER_DRUG absorption .
1333,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,non-depolarising muscle relaxant,effect,DRUG augments action non-depolarising muscle relaxants muscle relaxant effects aminoglycosides .
1334,FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.,FLUOTHANE,aminoglycosides,effect,DRUG augments action non-depolarising muscle relaxants muscle relaxant effects OTHER_DRUG .
1335,FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.,FLUOTHANE,tubocurarine,effect,DRUG may augment hypotension caused ganglionic-blocking effect OTHER_DRUG .
1336,Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.,adrenaline,FLUOTHANE,advise,Caution exercised administration DRUG patients anaesthetised OTHER_DRUG arrhythmias may precipitated .
1337,"Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects",Accutane,vitamin A,effect,Vitamin A: Because relationship DRUG vitamin A patients advised taking vitamin supplements containing vitamin A avoid additive toxic effects
1338,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,advise,Tetracyclines: Concomitant treatment DRUG OTHER_DRUG avoided DRUG use associated number cases pseudotumor cerebri (benign intracranial hypertension) involved concomitant use OTHER_DRUG
1339,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,effect,Tetracyclines: Concomitant treatment DRUG OTHER_DRUG avoided DRUG use associated number cases pseudotumor cerebri (benign intracranial hypertension) involved concomitant use OTHER_DRUG
1340,Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.,progesterone,Accutane,effect,Micro-dosed DRUG Preparations: Micro-dosed DRUG preparations (minipills contain estrogen) may inadequate method contraception OTHER_DRUG therapy .
1341,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking,effect,Catecholamine-depleting drugs (e . g . reserpine) may additive effect given OTHER_DRUG agents .
1342,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blockers,clonidine,advise,Should decided discontinue therapy patients receiving DRUG OTHER_DRUG concurrently beta-blocker discontinued slowly several days gradual withdrawal OTHER_DRUG .
1343,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blocker,clonidine,advise,Should decided discontinue therapy patients receiving beta-blockers OTHER_DRUG concurrently DRUG discontinued slowly several days gradual withdrawal OTHER_DRUG .
1344,"Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.",calcium antagonists,beta-adrenergic blocking agents,advise,Literature reports suggest oral calcium antagonists may used combination beta-adrenergic blocking agents heart function normal avoided patients impaired cardiac function .
1345,"Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.",beta-adrenergic blocking agents,calcium antagonist,effect,Hypotension AV conduction disturbances left ventricular failure reported patients receiving beta-adrenergic blocking agents oral calcium antagonist added treatment regimen .
1346,"Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",beta-blockers,epinephrine,effect,Risk Anaphylactic Reaction: Although known patients DRUG may refractory OTHER_DRUG treatment anaphylactic shock DRUG addition interfere modulation allergic reaction lead increased severity and/or frequency attacks .
1347,The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.,guanfacine,CNS-depressant drug,effect,The potential increased sedation DRUG given CNS-depressant drug appreciated .
1348,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenobarbital,mechanism,The administration DRUG concomitantly known microsomal enzyme inducer (phenobarbital phenytoin) two patients renal impairment reportedly resulted significant reductions elimination half-life plasma concentration .
1349,The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.,guanfacine,phenytoin,mechanism,The administration DRUG concomitantly known microsomal enzyme inducer (phenobarbital phenytoin) two patients renal impairment reportedly resulted significant reductions elimination half-life plasma concentration .
1350,TCAs decrease the hypotensive effect of guanfacine.,TCAs,guanfacine,effect,DRUG decrease hypotensive effect OTHER_DRUG .
1351,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",Noncardioselective beta-blockers,guanfacine,effect,Noncardioselective beta-blockers (nadololporpranololtimolol) may exacerbate rebound hypertension OTHER_DRUG withdrawn .
1352,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",nadolol,guanfacine,effect,Noncardioselective beta-blockers (nadololporpranololtimolol) may exacerbate rebound hypertension OTHER_DRUG withdrawn .
1353,"Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.",timolol,guanfacine,effect,Noncardioselective beta-blockers (nadololporpranololtimolol) may exacerbate rebound hypertension OTHER_DRUG withdrawn .
1354,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,however 150 mg DRUG q12h 3 days increased OTHER_DRUG C max 23% OTHER_DRUG AUC 16% .
1355,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,however 150 mg DRUG q12h 3 days increased OTHER_DRUG C max 23% OTHER_DRUG AUC 16% .
1356,FLEXERIL may have life-threatening interactions with MAO inhibitors.,FLEXERIL,MAO inhibitors,int,DRUG may life-threatening interactions MAO inhibitors .
1357,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,alcohol,effect,DRUG may enhance effects OTHER_DRUG barbiturates CNS depressants .
1358,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,barbiturates,effect,DRUG may enhance effects alcohol OTHER_DRUG CNS depressants .
1359,"FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.",FLEXERIL,CNS depressants,effect,DRUG may enhance effects alcohol barbiturates CNS depressants .
1360,Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.,Tricyclic antidepressants,guanethidine,effect,Tricyclic antidepressants may block antihypertensive action OTHER_DRUG similarly acting compounds .
1361,Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol,Tricyclic antidepressants,tramadol,effect,Tricyclic antidepressants may enhance seizure risk patients taking OTHER_DRUG
1362,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,Urinary acidifying agents These agents (ammonium chloride sodium acid phosphate etc . ) increase concentration ionized species OTHER_DRUG molecule thereby increasing urinary excretion .
1363,"Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,Urinary acidifying agents These agents (ammonium chloride sodium acid phosphate etc . ) increase concentration ionized species OTHER_DRUG molecule thereby increasing urinary excretion .
1364,Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.,Adrenergic blockers,amphetamines,effect,Adrenergic blockers Adrenergic blockers inhibited OTHER_DRUG .
1365,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,tricyclic antidepressants,effect,Antidepressants tricyclic DRUG may enhance activity tricyclic antidepressants sympathomimetic agents;
1366,"Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;",Amphetamines,sympathomimetic agents,effect,Antidepressants tricyclic DRUG may enhance activity tricyclic antidepressants sympathomimetic agents;
1367,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,DRUG OTHER_DRUG protriptyline possibly tricyclics cause striking sustained increases concentration DRUG brain;
1368,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,DRUG desipramine OTHER_DRUG possibly tricyclics cause striking sustained increases concentration DRUG brain;
1369,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,DRUG desipramine protriptyline possibly OTHER_DRUG cause striking sustained increases concentration DRUG brain;
1370,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,MAO inhibitors MAOI antidepressants well metabolite furazolidone slow OTHER_DRUG metabolism .
1371,"MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,MAO inhibitors MAOI antidepressants well metabolite DRUG slow OTHER_DRUG metabolism .
1372,Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.,Amphetamines,antihistamines,effect,Antihistamines: DRUG may counteract sedative effect OTHER_DRUG .
1373,Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.,Amphetamines,antihypertensives,effect,Antihypertensives: DRUG may antagonize hypotensive effects OTHER_DRUG .
1374,"Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.",Chlorpromazine,amphetamines,effect,Chlorpromazine: DRUG blocks dopamine norepinephrine receptors thus inhibiting central stimulant effects OTHER_DRUG used treat amphetamine poisoning .
1375,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide: DRUG may delay intestinal absorption OTHER_DRUG .
1376,"Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.",Haloperidol,amphetamines,effect,Haloperidol: DRUG blocks dopamine receptors thus inhibiting central stimulant effects OTHER_DRUG .
1377,Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.,amphetamines,lithium carbonate,effect,Lithium carbonate: The anorectic stimulatory effects DRUG may inhibited lithium carbonate .
1378,Meperidine: Amphetamines potentiate the analgesic effect of meperidine.,Amphetamines,meperidine,effect,Meperidine: DRUG potentiate analgesic effect OTHER_DRUG .
1379,"Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.",amphetamines,methenamine,mechanism,OTHER_DRUG therapy Urinary excretion DRUG increased efficacy reduced acidifying agents used OTHER_DRUG therapy .
1380,Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.,Amphetamines,norepinephrine,effect,Norepinephrine: DRUG enhance adrenergic effect OTHER_DRUG .
1381,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital: DRUG may delay intestinal absorption phenobarbital;
1382,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin: DRUG may delay intestinal absorption phenytoin;
1383,"Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.",propoxyphene,amphetamine,effect,Propoxyphene: In cases DRUG overdosage OTHER_DRUG CNS stimulation potentiated fatal convulsions occur .
1384,Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.,Amphetamines,veratrum alkaloids,effect,Veratrum alkaloids: DRUG inhibit hypotensive effect veratrum alkaloids .
1385,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",Intestinal adsorbents,Acarbose,mechanism,Intestinal adsorbents (e . g . charcoal) digestive enzyme preparations containing carbohydrate-splitting enzymes (e . g . amylase pancreatin) may reduce effect OTHER_DRUG taken concomitantly .
1386,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",charcoal,Acarbose,mechanism,Intestinal adsorbents (e . g . charcoal) digestive enzyme preparations containing carbohydrate-splitting enzymes (e . g . amylase pancreatin) may reduce effect OTHER_DRUG taken concomitantly .
1387,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",amylase,Acarbose,mechanism,Intestinal adsorbents (e . g . charcoal) digestive enzyme preparations containing carbohydrate-splitting enzymes (e . g . DRUG pancreatin) may reduce effect OTHER_DRUG taken concomitantly .
1388,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",pancreatin,Acarbose,mechanism,Intestinal adsorbents (e . g . charcoal) digestive enzyme preparations containing carbohydrate-splitting enzymes (e . g . amylase pancreatin) may reduce effect OTHER_DRUG taken concomitantly .
1389,"Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.",Acarbose,digoxin,mechanism,DRUG shown change bioavailabillty OTHER_DRUG co-administered may require OTHER_DRUG dose adjustment .
1390,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",metformin,Acarbose,mechanism,However peak plasma level DRUG reduced approximately 20% taking OTHER_DRUG due slight delay absorption DRUG .
1391,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",Acarbose,metformin,mechanism,However peak plasma level OTHER_DRUG reduced approximately 20% taking DRUG due slight delay absorption OTHER_DRUG .
1392,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,carbachol,effect,DRUG may interfere anti-glaucoma action OTHER_DRUG pilocarpine;
1393,Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;,Cyclopentolate,pilocarpine,effect,DRUG may interfere anti-glaucoma action carbachol pilocarpine;
1394,A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.,amiodarone,indinavir,mechanism,A case report one patient taking DRUG 200 mg OTHER_DRUG 800 mg three times day resulted increases DRUG concentrations 0 . 9 mg/L 1 . 3 mg/L .
1395,Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.,amiodarone,protease inhibitor,advise,Monitoring DRUG toxicity serial measurement DRUG serum concentration concomitant protease inhibitor therapy considered .
1396,Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.,Histamine H2 antagonists,Cimetidine,mechanism,Histamine H2 antagonists: OTHER_DRUG inhibits CYP3A4 increase serum amiodarone levels .
1397,"On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.",amiodarone,digitalis,advise,On administration oral DRUG need OTHER_DRUG therapy reviewed dose reduced approximately 50% discontinued .
1398,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",Nafazodone,Xanax,advise,DRUG fluvoxamine cimetidine (consider OTHER_DRUG dose reduction) .
1399,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",fluvoxamine,Xanax,advise,Nafazodone DRUG cimetidine (consider OTHER_DRUG dose reduction) .
1400,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",cimetidine,Xanax,advise,Nafazodone fluvoxamine DRUG (consider OTHER_DRUG dose reduction) .
1401,Concomitant use of calcium supplements and L-lysine may increase calcium absorption,calcium,L-lysine,mechanism,Concomitant use DRUG supplements OTHER_DRUG may increase DRUG absorption
1402,Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.,sympathomimetic amines,monoamine oxidase inhibitors,effect,Hypertensive crises resulted sympathomimetic amines used concomitantly within14 days following use monoamine oxidase inhibitors .
1403,DIDREX should not be used concomitantly with other CNS stimulants.,DIDREX,CNS stimulants,advise,DRUG used concomitantly CNS stimulants .
1404,Amphetamines may decrease the hypotensive effect of antihypertensives.,Amphetamines,antihypertensives,effect,DRUG may decrease hypotensive effect OTHER_DRUG .
1405,Amphetamines may enhance the effects of tricyclic antidepressants.,Amphetamines,tricyclic antidepressants,effect,DRUG may enhance effects tricyclic antidepressants .
1406,Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.,Urinary acidifying,amphetamines,mechanism,Urinary acidifying agents decrease blood levels increase excretion OTHER_DRUG .
1407,"In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.",labetalol HCl,tricyclic antidepressants,effect,In one survey 2 . 3% patients taking labetalol HCl combination tricyclic antidepressants experienced tremor compared 0 . 7% reported occur labetalol HCl alone .
1408,Cimetidine has been shown to increase the bioavailability of labetalol HCl.,Cimetidine,labetalol HCl,mechanism,DRUG shown increase bioavailability labetalol HCl .
1409,Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.,halothane,labetalol HCl,effect,Synergism shown DRUG anesthesia intravenously administered labetalol HCl .
1410,"During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.",labetalol HCl,halothane,effect,During controlled hypotensive anesthesia using labetalol HCl association OTHER_DRUG high concentrations (3% above) OTHER_DRUG used degree hypotension increased possibility large reduction cardiac output increase central venous pressure .
1411,Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.,Labetalol HCl,nitroglycerin,effect,Labetalol HCl blunts reflex tachycardia produced OTHER_DRUG without preventing hypotensive effect .
1412,"If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.",labetalol HCl,nitroglycerin,effect,If labetalol HCl used OTHER_DRUG patients angina pectoris additional antihypertensive effects may occur .
1413,Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.,labetalol,calcium antagonist,advise,Care taken DRUG used concomitantly calcium antagonists verapamil type .
1414,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,The administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1415,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,The administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1416,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,The administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1417,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,The administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1418,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,DRUG butyrophenones may reduce reverse pressor effect OTHER_DRUG .
1419,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines DRUG may reduce reverse pressor effect OTHER_DRUG .
1420,Apraclonidine should not be used in patients receiving MAO inhibitors..,Apraclonidine,MAO inhibitors,advise,DRUG used patients receiving MAO inhibitors . .
1421,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,CNS depressants,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies DRUG 0 . 5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics) considered .
1422,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,alcohol,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies DRUG 0 . 5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics) considered .
1423,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,barbiturates,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies DRUG 0 . 5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol OTHER_DRUG opiates sedatives anesthetics) considered .
1424,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,opiates,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies DRUG 0 . 5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates OTHER_DRUG sedatives anesthetics) considered .
1425,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,sedatives,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies DRUG 0 . 5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates OTHER_DRUG anesthetics) considered .
1426,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,anesthetics,advise,Although specific drug interactions topical glaucoma drugs systemic medications identified clinical studies DRUG 0 . 5% Ophthalmic Solution possibility additive potentiating effect CNS depressants (alcohol barbiturates opiates sedatives anesthetics) considered .
1427,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.,Tricyclic antidepressants,clonidine,effect,Tricyclic antidepressants reported blunt hypotensive effect systemic OTHER_DRUG .
1428,An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.,clonidine,neuroleptic,effect,An additive hypotensive effect reported combination systemic DRUG OTHER_DRUG therapy .
1429,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,beta-blockers,advise,Since DRUG may reduce pulse blood pressure caution using drugs OTHER_DRUG (ophthalmic systemic) antihypertensives cardiac glycosides advised .
1430,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,antihypertensives,advise,Since DRUG may reduce pulse blood pressure caution using drugs beta-blockers (ophthalmic systemic) OTHER_DRUG cardiac glycosides advised .
1431,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,cardiac glycosides,advise,Since DRUG may reduce pulse blood pressure caution using drugs beta-blockers (ophthalmic systemic) antihypertensives cardiac glycosides advised .
1432,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip,anticoagulants of the coumarin type,effect,When DRUG DRUG retard used time medicines substances following interactions must taken account: - DRUG DRUG retard may enhance action anticoagulants coumarin type .
1433,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip retard,anticoagulants of the coumarin type,effect,When Bezalip Bezalip retard used time medicines substances following interactions must taken account: - Bezalip Bezalip retard may enhance action anticoagulants coumarin type .
1434,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,For reason dose DRUG reduced 30 - 50% start treatment OTHER_DRUG OTHER_DRUG retard titrated according blood clotting parameters
1435,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,For reason dose DRUG reduced 30 - 50% start treatment OTHER_DRUG OTHER_DRUG retard titrated according blood clotting parameters
1436,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip,effect,- The action DRUG insulin may enhanced OTHER_DRUG OTHER_DRUG retard .
1437,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,sulphonylureas,Bezalip retard,effect,- The action DRUG insulin may enhanced Bezalip Bezalip retard .
1438,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip,effect,- The action sulphonylureas DRUG may enhanced OTHER_DRUG OTHER_DRUG retard .
1439,- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.,insulin,Bezalip retard,effect,- The action sulphonylureas DRUG may enhanced Bezalip Bezalip retard .
1440,"- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.",immuno-suppressant,bezafibrate,effect,- In isolated cases pronounced though reversible impairment renal function (accompanied corresponding increase serum creatinine level) reported organ transplant patients receiving DRUG therapy concomitant OTHER_DRUG .
1441,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,anion-exchange resins,advise,- When DRUG DRUG retard used concurrently anion-exchange resins (e . g . cholestryramine) interval least 2 hours maintained two medicines since absorption DRUG DRUG retard impaired
1442,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,cholestryramine,advise,- When DRUG DRUG retard used concurrently anion-exchange resins (e . g . cholestryramine) interval least 2 hours maintained two medicines since absorption DRUG DRUG retard impaired
1443,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,anion-exchange resins,advise,- When Bezalip Bezalip retard used concurrently anion-exchange resins (e . g . cholestryramine) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1444,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,cholestryramine,advise,- When Bezalip Bezalip retard used concurrently anion-exchange resins (e . g . cholestryramine) interval least 2 hours maintained two medicines since absorption Bezalip Bezalip retard impaired
1445,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip,advise,- Perhexiline hydrogen maleate MAO-inhibitors (with hepatotoxic potential) must administered together OTHER_DRUG OTHER_DRUG retard .
1446,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,Perhexiline hydrogen maleate,Bezalip retard,advise,- Perhexiline hydrogen maleate MAO-inhibitors (with hepatotoxic potential) must administered together Bezalip Bezalip retard .
1447,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip,advise,- Perhexiline hydrogen maleate DRUG (with hepatotoxic potential) must administered together OTHER_DRUG OTHER_DRUG retard .
1448,- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.,MAO-inhibitors,Bezalip retard,advise,- Perhexiline hydrogen maleate DRUG (with hepatotoxic potential) must administered together Bezalip Bezalip retard .
1449,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitric oxide donor compounds,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds including sodium nitroprusside nitroglycerin may additive effect OTHER_DRUG risk developing methemoglobinemia .
1450,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",sodium nitroprusside,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds including sodium nitroprusside nitroglycerin may additive effect OTHER_DRUG risk developing methemoglobinemia .
1451,"Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.",nitroglycerin,INOmax,effect,Although study data evaluate possibility nitric oxide donor compounds including sodium nitroprusside DRUG may additive effect OTHER_DRUG risk developing methemoglobinemia .
1452,Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.,ketoconazole,budesonide,mechanism,Concomitant oral administration DRUG (a known inhibitor CYP3A4 activity liver intestinal mucosa) caused eight-fold increase systemic exposure oral OTHER_DRUG .
1453,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ketoconazole,budesonide,advise,If treatment inhibitors CYP3A4 activity (such DRUG intraconazole ritonavir indinavir saquinavir erythromycin etc . ) indicated reduction OTHER_DRUG dose considered .
1454,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",intraconazole,budesonide,advise,If treatment inhibitors CYP3A4 activity (such ketoconazole DRUG ritonavir indinavir saquinavir erythromycin etc . ) indicated reduction OTHER_DRUG dose considered .
1455,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ritonavir,budesonide,advise,If treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole DRUG indinavir saquinavir erythromycin etc . ) indicated reduction OTHER_DRUG dose considered .
1456,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",indinavir,budesonide,advise,If treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir DRUG saquinavir erythromycin etc . ) indicated reduction OTHER_DRUG dose considered .
1457,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",saquinavir,budesonide,advise,If treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir indinavir DRUG erythromycin etc . ) indicated reduction OTHER_DRUG dose considered .
1458,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",erythromycin,budesonide,advise,If treatment inhibitors CYP3A4 activity (such ketoconazole intraconazole ritonavir indinavir saquinavir DRUG etc . ) indicated reduction OTHER_DRUG dose considered .
1459,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,warfarin-type anticoagulants,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1460,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,phenytoin,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants OTHER_DRUG propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1461,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,propranolol,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin OTHER_DRUG nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1462,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,nifedipine,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol OTHER_DRUG chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1463,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,chlordiazepoxide,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol nifedipine OTHER_DRUG diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1464,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,diazepam,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide OTHER_DRUG certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1465,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,tricyclic antidepressants,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1466,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,lidocaine,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants OTHER_DRUG theophylline metronidazole thereby delaying elimination increasing blood levels drugs .
1467,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,theophylline,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine OTHER_DRUG metronidazole thereby delaying elimination increasing blood levels drugs .
1468,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,metronidazole,mechanism,DRUG apparently effect certain microsomal enzyme systems reported reduce hepatic metabolism warfarin-type anticoagulants phenytoin propranolol nifedipine chlordiazepoxide diazepam certain tricyclic antidepressants lidocaine theophylline OTHER_DRUG thereby delaying elimination increasing blood levels drugs .
1469,"therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.",anticoagulant,Tagamet,advise,therefore close monitoring prothrombin time recommended adjustment DRUG dose may necessary OTHER_DRUG administered concomitantly .
1470,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,theophylline,mechanism,However crossover study healthy subjects receiving either DRUG 300 mg q . . . 800 mg . . concomitantly 300 mg b . . . dosage OTHER_DRUG (Theo-Dur Key Pharmaceuticals Inc . ) demonstrated less alteration steady-state OTHER_DRUG peak serum levels 800 mg . . regimen particularly subjects aged 54 years older .
1471,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,Theo-Dur,mechanism,However crossover study healthy subjects receiving either DRUG 300 mg q . . . 800 mg . . concomitantly 300 mg b . . . dosage theophylline (Theo-Dur Key Pharmaceuticals Inc . ) demonstrated less alteration steady-state theophylline peak serum levels 800 mg . . regimen particularly subjects aged 54 years older .
1472,"Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.",ELLENCE,calcium channel blockers,advise,Concomitant use DRUG cardioactive compounds could cause heart failure (e . g . calcium channel blockers) requires close monitoring cardiac function throughout treatment .
1473,Cimetidine increased the AUC of epirubicin by 50%.,Cimetidine,epirubicin,mechanism,DRUG increased AUC OTHER_DRUG 50% .
1474,Cimetidine treatment should be stopped during treatment with ELLENCE.,Cimetidine,ELLENCE,advise,DRUG treatment stopped treatment OTHER_DRUG .
1475,MAO inhibitors prolong and intensify the effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors prolong intensify effects OTHER_DRUG .
1476,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,alcohol,effect,Concomitant use DRUG OTHER_DRUG tricyclic antidepressants barbiturates central nervous system depressants may additive effect .
1477,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,tricyclic antidepressants,effect,Concomitant use DRUG alcohol tricyclic antidepressants barbiturates central nervous system depressants may additive effect .
1478,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,barbiturates,effect,Concomitant use DRUG alcohol tricyclic antidepressants OTHER_DRUG central nervous system depressants may additive effect .
1479,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,central nervous system depressants,effect,Concomitant use DRUG alcohol tricyclic antidepressants barbiturates central nervous system depressants may additive effect .
1480,"When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.",sympathomimetic drugs,monoamine oxidase inhibitors,effect,When sympathomimetic drugs given patients receiving monoamine oxidase inhibitors hypertensive reactions including hypertensive crises may occur .
1481,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",methyldopa,sympathomimetics,effect,The antihypertensive effects DRUG mecamylamine reserpine veratrum alkaloids may reduced OTHER_DRUG .
1482,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",mecamylamine,sympathomimetics,effect,The antihypertensive effects methyldopa DRUG reserpine veratrum alkaloids may reduced OTHER_DRUG .
1483,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",reserpine,sympathomimetics,effect,The antihypertensive effects methyldopa mecamylamine DRUG veratrum alkaloids may reduced OTHER_DRUG .
1484,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",veratrum alkaloids,sympathomimetics,effect,The antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids may reduced OTHER_DRUG .
1485,Beta-adrenergic blocking agents may also interact with sympathomimetics.,Beta-adrenergic blocking agents,sympathomimetics,int,Beta-adrenergic blocking agents may also interact OTHER_DRUG .
1486,Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.,pseudoephedrine,digitalis,effect,Increased ectopic pacemaker activity occur DRUG used concomitantly OTHER_DRUG .
1487,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",Antacids,pseudoephedrine,mechanism,DRUG increase rate absorption OTHER_DRUG kaolin decreases .
1488,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",pseudoephedrine,kaolin,mechanism,Antacids increase rate absorption DRUG OTHER_DRUG decreases .
1489,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,int,DRUG interact OTHER_DRUG CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1490,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,int,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1491,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,int,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) OTHER_DRUG medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1492,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,int,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1493,"In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).",TAXOL,cisplatin,effect,In Phase I trial using escalating doses DRUG (110-200 mg/m2) OTHER_DRUG (50 75 mg/m2) given sequential infusions myelosuppression profound DRUG given OTHER_DRUG alternate sequence (ie DRUG cisplatin) .
1494,Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.,TAXOL,cisplatin,mechanism,Pharmacokinetic data patients demonstrated decrease paclitaxel clearance approximately 33% DRUG administered following OTHER_DRUG .
1495,Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.,paclitaxel,doxorubicin,mechanism,Reports literature suggest plasma levels OTHER_DRUG (and active metabolite doxorubicinol) may increased DRUG OTHER_DRUG used combination .
1496,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",cyclosporin,TAXOL,advise,Hypersensitivity Reactions: Patients history severe hypersensitivity reactions products containing Cremophor EL (eg DRUG injection concentrate teniposide injection concentrate) treated OTHER_DRUG .
1497,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",teniposide,TAXOL,advise,Hypersensitivity Reactions: Patients history severe hypersensitivity reactions products containing Cremophor EL (eg cyclosporin injection concentrate DRUG injection concentrate) treated OTHER_DRUG .
1498,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1499,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,azoles,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents OTHER_DRUG drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1500,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound OTHER_DRUG sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1501,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound salicylates OTHER_DRUG chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1502,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound salicylates sulfonamides OTHER_DRUG probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1503,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol OTHER_DRUG coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1504,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid OTHER_DRUG monoamine oxidase inhibitors beta adrenergic blocking agents .
1505,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1506,"Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,Immediate Extended Release Tablets The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents azoles drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
1507,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,int,A potential interaction oral DRUG oral hypoglycemic agents leading severe hypoglycemia reported .
1508,The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.,fluconazole,glipizide,int,The effect concomitant administration DRUG OTHER_DRUG demonstrated placebo-controlled crossover study normal volunteers .
1509,The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).,glipizide,fluconazole,mechanism,The mean percentage increase DRUG AUC OTHER_DRUG administration 56 . 9% (range: 35 81) .
1510,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",barbiturates,contraceptives,effect,Interactions may occur following: adrenocorticoids (cortisone-like medicine) anticoagulants (blood thinners) carbamazepine corticotropin (barbiturates may decrease effects medicines) central nervous system (CNS) depressants (using medicines DRUG may result increased CNS depressant effects) divalproex sodium valproic acid (using medicines DRUG may change amount either medicine need take) oral OTHER_DRUG containing estrogens (barbiturates may decrease effectiveness oral OTHER_DRUG may need change different type birth control) .
1511,ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,OTHER_DRUG Reports suggest DRUG may diminish antihypertensive effect OTHER_DRUG .
1512,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.,NSAIDs,ACE-inhibitors,advise,This interaction given consideration patients taking DRUG concomitantly OTHER_DRUG .
1513,"Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.",Lodine,aspirin,mechanism,Aspirin: When DRUG administered OTHER_DRUG protein binding reduced although clearance free etodolac altered .
1514,"however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.",Lodine,aspirin,advise,however NSAIDs concomitant administration DRUG OTHER_DRUG generally recommended potential increased adverse effects .
1515,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,cyclosporine,mechanism,OTHER_DRUG Digoxin Methotrexate DRUG like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels OTHER_DRUG digoxin methotrexate increased toxicity .
1516,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,digoxin,mechanism,Cyclosporine OTHER_DRUG Methotrexate DRUG like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine OTHER_DRUG methotrexate increased toxicity .
1517,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",Lodine,methotrexate,mechanism,Cyclosporine Digoxin OTHER_DRUG DRUG like NSAIDs effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin OTHER_DRUG increased toxicity .
1518,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,cyclosporine,mechanism,OTHER_DRUG Digoxin Methotrexate Lodine like DRUG effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels OTHER_DRUG digoxin methotrexate increased toxicity .
1519,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,digoxin,mechanism,Cyclosporine OTHER_DRUG Methotrexate Lodine like DRUG effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine OTHER_DRUG methotrexate increased toxicity .
1520,"Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.",NSAIDs,methotrexate,mechanism,Cyclosporine Digoxin OTHER_DRUG Lodine like DRUG effects renal prostaglandins may cause changes elimination drugs leading elevated serum levels cyclosporine digoxin OTHER_DRUG increased toxicity .
1521,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,furosemide,effect,Nevertheless clinical studies well postmarketing observations shown DRUG reduce natriuretic effect OTHER_DRUG thiazides patients .
1522,"Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.",Lodine,thiazides,effect,Nevertheless clinical studies well postmarketing observations shown DRUG reduce natriuretic effect furosemide OTHER_DRUG patients .
1523,Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.,NSAIDs,lithium,mechanism,Lithium: DRUG produced elevation plasma OTHER_DRUG levels reduction renal OTHER_DRUG clearance .
1524,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,effect,Thus DRUG OTHER_DRUG administered concurrently subjects observed carefully signs OTHER_DRUG toxicity .
1525,Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.,Phenylbutazone,etodolac,mechanism,Phenylbutazone: DRUG causes increase (by 80%) free fraction OTHER_DRUG .
1526,"Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.",etodolac,phenylbutazone,advise,Although vivo studies done see DRUG clearance changed coadministration OTHER_DRUG recommended coadministered .
1527,"Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.",warfarin,NSAIDs,effect,Warfarin: The effects DRUG OTHER_DRUG GI bleeding synergistic users drugs together risk serious GI bleeding higher users either drug alone .
1528,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,Lodine,mechanism,Short-term pharmacokinetic studies demonstrated concomitant administration DRUG OTHER_DRUG (etodolac capsules tablets) results reduced protein binding DRUG change clearance free DRUG .
1529,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.",warfarin,etodolac,mechanism,Short-term pharmacokinetic studies demonstrated concomitant administration DRUG Lodine (etodolac capsules tablets) results reduced protein binding DRUG change clearance free DRUG .
1530,"However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.",etodolac,warfarin,effect,However caution exercised spontaneous reports prolonged prothrombin times without bleeding etodolac-treated patients receiving concomitant OTHER_DRUG therapy .
1531,"In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.",aspirin,nizatidine,mechanism,In patients given high doses (3900 mg) DRUG daily increases serum salicylate levels seen OTHER_DRUG 150 mg b . . . administered concurrently .
1532,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,CNS depressants,effect,Additive CNS depression may occur DRUG administered concomitantly CNS depressants including barbiturates tranquilizers alcohol .
1533,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,barbiturates,effect,Additive CNS depression may occur DRUG administered concomitantly CNS depressants including OTHER_DRUG tranquilizers alcohol .
1534,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,tranquilizers,effect,Additive CNS depression may occur DRUG administered concomitantly CNS depressants including barbiturates OTHER_DRUG alcohol .
1535,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,alcohol,effect,Additive CNS depression may occur DRUG administered concomitantly CNS depressants including barbiturates tranquilizers OTHER_DRUG .
1536,Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.,antihistamines,CNS depressant drugs,advise,Patients receiving DRUG advised concurrent use CNS depressant drugs .
1537,Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.,Monoamine oxidase (MAO) inhibitors,antihistamines,effect,Monoamine oxidase (MAO) inhibitors prolong intensify anticholinergic effects OTHER_DRUG .
1538,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,sympathomimetic,effect,Administration DRUG patients receiving OTHER_DRUG monoamine oxidase inhibiting drugs may result additive pressor effect .
1539,Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .,doxapram,monoamine oxidase inhibiting drugs,effect,Administration DRUG patients receiving sympathomimetic monoamine oxidase inhibiting drugs may result additive pressor effect .
1540,"In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.",doxapram,muscle relaxant drugs,effect,In patients received muscle relaxants DRUG may temporarily mask residual effects muscle relaxant drugs .
1541,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,ERGOMAR,triacetyloleandomycin,mechanism,The effects DRUG may potentiated OTHER_DRUG inhibits metabolism ergotamine .
1542,The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.,triacetyloleandomycin,ergotamine,mechanism,The effects ERGOMAR may potentiated DRUG inhibits metabolism OTHER_DRUG .
1543,The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.,ERGOMAR,vasoconstrictor drugs,effect,The pressor effects DRUG vasoconstrictor drugs combine cause dangerous hypertension .
1544,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",xanthine bronchodilators,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators (e . g . theophylline) ephedrine sympathomimetic bronchodilators reported .
1545,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",theophylline,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators (e . g . theophylline) ephedrine sympathomimetic bronchodilators reported .
1546,"Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.",ephedrine,sympathomimetic bronchodilators,effect,Synergism xanthine bronchodilators (e . g . theophylline) DRUG sympathomimetic bronchodilators reported .
1547,"Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .",dyphylline,probenecid,mechanism,Concurrent administration DRUG OTHER_DRUG competes tubular secretion shown increase plasma half-life DRUG .
1548,"However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.",carbonic anhydrase inhibitors,salicylate,int,However patients treated oral carbonic anhydrase inhibitors rare instances drug interactions occurred high-dose OTHER_DRUG therapy .
1549,Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.,levetiracetam,AEDs,mechanism,Effect OTHER_DRUG Pediatric Patients There 22% increase apparent total body clearance DRUG co-administered enzyme-inducing OTHER_DRUG .
1550,"When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.",probenecid,ertapenem,mechanism,When OTHER_DRUG co-administered DRUG (500 mg p . . every 6 hours) DRUG competes active tubular secretion reduces renal clearance OTHER_DRUG .
1551,"Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.",ertapenem,probenecid,mechanism,Based total DRUG concentrations OTHER_DRUG increased AUC 25% reduced plasma renal clearances 20% 35% respectively .
1552,"Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.",probenecid,ertapenem,advise,Because small effect half-life coadministration DRUG extend half-life OTHER_DRUG recommended .
1553,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",ketoconazole,bexarotene,mechanism,On basis metabolism OTHER_DRUG cytochrome P450 3A4 DRUG itraconazole erythromycin gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma OTHER_DRUG concentrations .
1554,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",itraconazole,bexarotene,mechanism,On basis metabolism OTHER_DRUG cytochrome P450 3A4 ketoconazole DRUG erythromycin gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma OTHER_DRUG concentrations .
1555,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",erythromycin,bexarotene,mechanism,On basis metabolism OTHER_DRUG cytochrome P450 3A4 ketoconazole itraconazole DRUG gemfibrozil grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma OTHER_DRUG concentrations .
1556,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",gemfibrozil,bexarotene,mechanism,On basis metabolism OTHER_DRUG cytochrome P450 3A4 ketoconazole itraconazole erythromycin DRUG grapefruit juice inhibitors cytochrome P450 3A4 would expected lead increase plasma OTHER_DRUG concentrations .
1557,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",rifampin,bexarotene,mechanism,Furthermore DRUG phenytoin phenobarbital inducers cytochrome P450 3A4 may cause reduction plasma OTHER_DRUG concentrations .
1558,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenytoin,bexarotene,mechanism,Furthermore rifampin DRUG phenobarbital inducers cytochrome P450 3A4 may cause reduction plasma OTHER_DRUG concentrations .
1559,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenobarbital,bexarotene,mechanism,Furthermore rifampin phenytoin DRUG inducers cytochrome P450 3A4 may cause reduction plasma OTHER_DRUG concentrations .
1560,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.",Targretin,gemfibrozil,mechanism,Concomitant administration DRUG capsules OTHER_DRUG resulted substantial increases plasma concentrations bexarotene probably least partially related cytochrome P450 3A4 inhibition OTHER_DRUG .
1561,Concomitant administration of gemfibrozil with Targretin capsules is not recommended.,gemfibrozil,Targretin,advise,Concomitant administration DRUG OTHER_DRUG capsules recommended .
1562,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,effect,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered OTHER_DRUG concomitant use DRUG drugs 5HT3 antagonist class (including example OTHER_DRUG granisetron dolasetron palonosetron alosetron) contraindicated .
1563,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,5HT3 antagonist class,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron palonosetron alosetron) contraindicated .
1564,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered OTHER_DRUG concomitant use DRUG drugs 5HT3 antagonist class (including example OTHER_DRUG granisetron dolasetron palonosetron alosetron) contraindicated .
1565,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,granisetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron OTHER_DRUG dolasetron palonosetron alosetron) contraindicated .
1566,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,dolasetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron granisetron OTHER_DRUG palonosetron alosetron) contraindicated .
1567,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,palonosetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron OTHER_DRUG alosetron) contraindicated .
1568,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,alosetron,advise,5HT3 Antagonists: Based reports profound hypotension loss consciousness DRUG administered ondansetron concomitant use DRUG drugs 5HT3 antagonist class (including example ondansetron granisetron dolasetron palonosetron alosetron) contraindicated .
1569,"Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.",antihypertensive medications,vasodilators,effect,Antihypertensive Medications Vasodilators: The following adverse events experienced commonly patients receiving concomitant antihypertensive medications OTHER_DRUG (n = 94) compared patients receiving concomitant drugs (n = 456): hypotension 10% vs 4% myocardial infarction 3% vs 1% serious pneumonia 5% vs 3% serious falls 9% vs 3% bone joint injuries 6% vs 2% .
1570,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",dopamine antagonists,metoclopramide,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) OTHER_DRUG may diminish effectiveness APOKYN .
1571,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",phenothiazines,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) metoclopramide may diminish effectiveness OTHER_DRUG .
1572,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",butyrophenones,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines DRUG thioxanthenes) metoclopramide may diminish effectiveness OTHER_DRUG .
1573,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",thioxanthenes,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) metoclopramide may diminish effectiveness OTHER_DRUG .
1574,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",metoclopramide,APOKYN,effect,Dopamine Antagonists: Since apomorphine dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) DRUG may diminish effectiveness OTHER_DRUG .
1575,"Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.",neuroleptics,dopamine agonists,advise,Patients major psychotic disorders treated DRUG treated dopamine agonists potential benefits outweigh risks .
1576,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,The administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1577,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,The administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1578,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,The administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1579,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,The administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants may produce severe prolonged hypertension .
1580,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,DRUG butyrophenones may reduce reverse pressor effect OTHER_DRUG .
1581,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines DRUG may reduce reverse pressor effect OTHER_DRUG .
1582,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,centrally acting drugs,advise,Drug-Drug Interactions Given primary CNS effects aripiprazole caution used DRUG taken combination centrally acting drugs alcohol .
1583,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,alcohol,advise,Drug-Drug Interactions Given primary CNS effects aripiprazole caution used DRUG taken combination centrally acting drugs OTHER_DRUG .
1584,"1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.",aripiprazole,antihypertensive agents,effect,1- adrenergic receptor antagonism DRUG potential enhance effect certain antihypertensive agents .
1585,"Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.",carbamazepine,aripiprazole,mechanism,Agents induce CYP3A4 (eg carbamazepine) could cause increase OTHER_DRUG clearance lower blood levels .
1586,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",ketoconazole,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine fluoxetine paroxetine) inhibit OTHER_DRUG elimination cause increased blood levels .
1587,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",quinidine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg DRUG fluoxetine paroxetine) inhibit OTHER_DRUG elimination cause increased blood levels .
1588,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",fluoxetine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine DRUG paroxetine) inhibit OTHER_DRUG elimination cause increased blood levels .
1589,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",paroxetine,aripiprazole,mechanism,Inhibitors CYP3A4 (eg ketoconazole) CYP2D6 (eg quinidine fluoxetine paroxetine) inhibit OTHER_DRUG elimination cause increased blood levels .
1590,"Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.",ketoconazole,aripiprazole,mechanism,Ketoconazole: Coadministration DRUG (200 mg/day 14 days) 15-mg single dose OTHER_DRUG increased AUC OTHER_DRUG active metabolite 63% 77% respectively .
1591,"When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.",ketoconazole,aripiprazole,advise,When concomitant administration DRUG OTHER_DRUG occurs OTHER_DRUG dose reduced one-half normal dose .
1592,"Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.",aripiprazole,quinidine,mechanism,Quinidine: Coadministration 10-mg single dose DRUG OTHER_DRUG (166 mg/day 13 days) potent inhibitor CYP2D6 increased AUC DRUG 112% decreased AUC active metabolite dehydroaripiprazole 35% .
1593,Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.,quinidine,aripiprazole,advise,OTHER_DRUG dose reduced one-half normal dose concomitant administration DRUG OTHER_DRUG occurs .
1594,"Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",carbamazepine,aripiprazole,mechanism,Carbamazepine: Coadministration DRUG (200 mg BID) potent CYP3A4 inducer OTHER_DRUG (30 mg QD) resulted approximate 70% decrease Cmax AUC values OTHER_DRUG active metabolite dehydro-aripiprazole .
1595,"When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.",carbamazepine,aripiprazole,advise,When DRUG added OTHER_DRUG therapy OTHER_DRUG dose doubled .
1596,"When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.",carbamazepine,aripiprazole,advise,When DRUG withdrawn combination therapy OTHER_DRUG dose reduced .
1597,"As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY",alcohol,ABILIFY,advise,As psychoactive medications patients advised avoid DRUG taking OTHER_DRUG
1598,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,effect,DRUG interact OTHER_DRUG CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1599,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,effect,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1600,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,effect,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) OTHER_DRUG medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1601,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,effect,DRUG interact alcohol CNS depressants (may potentiate CNS depressant effects either medications antihistamines) anticholinergics medications anticholinergic activity (anticholinergic effects may potentiated medications used concurrently antihistamines) monoamine oxidase (MAO) inhibitors (concurrent use antihistamines may prolong intensify anticholinergic CNS depressant effects antihistamines) .
1602,Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.,cholestyramine,vitamin K,mechanism,Cholestyramine-Concomitant intake DRUG vitamin K may reduce absorption vitamin K .
1603,Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.,colestipol,vitamin K,mechanism,Colestipol-Concomitant intake DRUG vitamin K may reduce absorption vitamin K .
1604,Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.,mineral oil,vitamin K,mechanism,Mineral Oil-Concomitant intake mineral oil vitamin K may reduce absorption vitamin K .
1605,Orlistat-Orlistat may decrease the absorption of vitamin K.,Orlistat,vitamin K,mechanism,Orlistat-Orlistat may decrease absorption vitamin K .
1606,Warfarin-Vitamin K can antagonize the effect of warfarin,Vitamin K,warfarin,effect,Warfarin-Vitamin K antagonize effect OTHER_DRUG
1607,A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.,nisoldipine,cimetidine 400 mg,mechanism,A 30 45% increase AUC Cmax DRUG observed concomitant administration cimetidine 400 mg twice daily .
1608,Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.,phenytoin,SULAR,mechanism,Coadministration DRUG 40 mg OTHER_DRUG tablets epileptic patients lowered nisoldipine plasma concentrations undetectable levels .
1609,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.,SULAR,phenytoin,advise,Coadministration DRUG OTHER_DRUG known CYP3A4 inducer avoided alternative antihypertensive therapy considered .
1610,Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.,Propranolol,nisoldipine,effect,DRUG attenuated heart rate increase following administration immediate release OTHER_DRUG .
1611,The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.,SULAR,atenolol,effect,The blood pressure effect DRUG tended greater patients OTHER_DRUG patients antihypertensive therapy .
1612,"Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.",Quinidine,nisoldipine,mechanism,DRUG 648 mg bid decreased bioavailability (AUC) OTHER_DRUG 26% peak concentration .
1613,"The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.",nisoldipine,quinidine,mechanism,The immediate release coat-core formulation DRUG increased plasma OTHER_DRUG concentrations 20% .
1614,"It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.",buspirone hydrochloride,MAO inhibitors,advise,It recommended buspirone hydrochloride used concomitantly MAO inhibitors Because effects concomitant administration buspirone HCl psychotropic drugs studied concomitant use buspirone HCl CNS-active drugs approached caution .
1615,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,trazodone hydrochloride,buspirone HCl,effect,There one report suggesting concomitant use trazodone hydrochloride (Desyrel) buspirone HCl may caused 3- 6-fold elevations SGPT (ALT) patients .
1616,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,Desyrel,buspirone HCl,effect,There one report suggesting concomitant use trazodone hydrochloride (Desyrel) buspirone HCl may caused 3- 6-fold elevations SGPT (ALT) patients .
1617,"In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.",buspirone HCl,haloperidol,mechanism,In study normal volunteers concomitant administration buspirone HCl OTHER_DRUG resulted increased serum OTHER_DRUG concentrations .
1618,"However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.",buspirone,warfarin,effect,However one report prolonged prothrombin time DRUG added regimen patient treated OTHER_DRUG .
1619,"In vitro, buspirone may displace less firmly bound drugs like digoxin.",buspirone,digoxin,mechanism,In vitro DRUG may displace less firmly bound drugs like OTHER_DRUG .
1620,Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.,L-phenylalanine,non-selective MAO inhibitors,effect,Concomitant use DRUG non-selective MAO inhibitors may cause hypertension .
1621,Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.,L-phenylalanine,selegiline,effect,OTHER_DRUG - DRUG selective MAO inhibitor OTHER_DRUG may synergistic antidepressant activity used concomitantly .
1622,Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.,Neuroleptic Drugs,L-phenylalanine,effect,Neuroleptic Drugs - OTHER_DRUG may potentiate tardive dyskinesia side reactions neuroleptic drugs used concomitantly .
1623,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,psychoactive drugs,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including alcohol barbiturates narcotic analgesics history psychiatric disorder (including manic-depressive illness schizophrenia) .
1624,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,CNS depressants,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including alcohol barbiturates narcotic analgesics history psychiatric disorder (including manic-depressive illness schizophrenia) .
1625,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,alcohol,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including OTHER_DRUG barbiturates narcotic analgesics history psychiatric disorder (including manic-depressive illness schizophrenia) .
1626,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,barbiturates,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including alcohol OTHER_DRUG narcotic analgesics history psychiatric disorder (including manic-depressive illness schizophrenia) .
1627,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,narcotic analgesics,advise,DRUG administered caution patients taking psychoactive drugs CNS depressants including alcohol barbiturates narcotic analgesics history psychiatric disorder (including manic-depressive illness schizophrenia) .
1628,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,diazepam,effect,DRUG shown additive CNS depressant effect given either OTHER_DRUG secobarbitone sodium alcohol codeine .
1629,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,secobarbitone sodium,effect,DRUG shown additive CNS depressant effect given either diazepam secobarbitone sodium alcohol codeine .
1630,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,alcohol,effect,DRUG shown additive CNS depressant effect given either diazepam secobarbitone sodium OTHER_DRUG codeine .
1631,"Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.",Nabilone,codeine,effect,DRUG shown additive CNS depressant effect given either diazepam secobarbitone sodium alcohol OTHER_DRUG .
1632,"Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.",warfarin,ketorolac tromethamine,mechanism,DRUG Digoxin Salicylate Heparin The vitro binding DRUG plasma proteins slightly reduced ketorolac tromethamine (99 . 5% control vs 99 . 3%) ketorolac plasma concentrations reach 5 to10 g/mL .
1633,"In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.",salicylate,ketorolac,mechanism,In vitro studies indicate therapeutic concentrations DRUG (300 g/mL) binding OTHER_DRUG reduced approximately 99 . 2% 97 . 5% representing potential twofold increase unbound OTHER_DRUG plasma levels .
1634,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.",TORADOL,anticoagulants,advise,Although results indicate significant interaction DRUG warfarin heparin administration DRUG patients taking OTHER_DRUG done extremely cautiously patients closely monitored .
1635,Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).,TORADOL,furosemide,effect,Furosemide: DRUG IV/IM reduced diuretic response OTHER_DRUG normovolemic healthy subjects approximately 20% (mean sodium urinary output decreased 17%) .
1636,Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.,TORADOL,probenecid,mechanism,Probenecid: Concomitant administration DRUG ORAL OTHER_DRUG resulted decreased clearance ketorolac significant increases ketorolac plasma levels (total AUC increased approximately threefold 5 . 4 17 . 8 g/h/mL) terminal half-life increased approximately twofold 6 . 6 15 . 1 hours .
1637,"Therefore, concomitant use of TORADOL and probenecid is contraindicated.",TORADOL,probenecid,advise,Therefore concomitant use DRUG OTHER_DRUG contraindicated .
1638,"The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.",lithium,TORADOL,mechanism,The effect OTHER_DRUG plasma DRUG studied cases increased DRUG plasma levels OTHER_DRUG therapy reported .
1639,"Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.",methotrexate,NSAIDs,mechanism,Methotrexate: Concomitant administration DRUG OTHER_DRUG reported reduce clearance DRUG enhancing toxicity DRUG .
1640,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,antiepileptic drugs,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use DRUG antiepileptic drugs (phenytoin carbamazepine) .
1641,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,phenytoin,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use DRUG antiepileptic drugs (phenytoin carbamazepine) .
1642,"Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).",TORADOL,carbamazepine,effect,Antiepileptic Drugs: Sporadic cases seizures reported concomitant use DRUG antiepileptic drugs (phenytoin carbamazepine) .
1643,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,psychoactive drugs,effect,Psychoactive Drugs: Hallucinations reported DRUG used patients taking psychoactive drugs (fluoxetine thiothixene alprazolam) .
1644,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,fluoxetine,effect,Psychoactive Drugs: Hallucinations reported DRUG used patients taking psychoactive drugs (fluoxetine thiothixene alprazolam) .
1645,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,thiothixene,effect,Psychoactive Drugs: Hallucinations reported DRUG used patients taking psychoactive drugs (fluoxetine OTHER_DRUG alprazolam) .
1646,"Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).",TORADOL,alprazolam,effect,Psychoactive Drugs: Hallucinations reported DRUG used patients taking psychoactive drugs (fluoxetine thiothixene alprazolam) .
1647,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,ACE inhibitors,mechanism,DRUG Reversible increases serum DRUG concentrations toxicity reported concomitant administration DRUG ACE inhibitors angiotensin II receptor antagonists .
1648,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,angiotensin II receptor antagonists,mechanism,DRUG Reversible increases serum DRUG concentrations toxicity reported concomitant administration DRUG ACE inhibitors angiotensin II receptor antagonists .
1649,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.",lithium,ATACAND,mechanism,An increase serum DRUG concentration reported concomitant administration DRUG OTHER_DRUG careful monitoring serum DRUG levels recommended concomitant use .
1650,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,alcohol,int,DRUG may interact OTHER_DRUG blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications .
1651,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,blood thinner,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications .
1652,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,decongestant drugs,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications .
1653,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,lithium,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs OTHER_DRUG norepinephrine NSAIDs like Aleve Ibuprofen high blood pressure medications .
1654,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,norepinephrine,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium OTHER_DRUG NSAIDs like Aleve Ibuprofen high blood pressure medications .
1655,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,NSAIDs,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine OTHER_DRUG like Aleve Ibuprofen high blood pressure medications .
1656,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Aleve,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like OTHER_DRUG Ibuprofen high blood pressure medications .
1657,"Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.",Benzthiazide,Ibuprofen,int,DRUG may interact alcohol blood thinners decongestant drugs (allergy cold sinus medicines) diabetic drugs lithium norepinephrine NSAIDs like Aleve OTHER_DRUG high blood pressure medications .
1658,"The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.",alcohol,bromocriptine mesylate,effect,The risk using bromocriptine mesylate combination drugs systematically evaluated DRUG may potentiate side effects bromocriptine mesylate .
1659,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,dopamine antagonists,int,Bromocriptine mesylate may interact dopamine antagonists butyrophenones certain agents .
1660,"Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.",Bromocriptine mesylate,butyrophenones,int,Bromocriptine mesylate may interact dopamine antagonists OTHER_DRUG certain agents .
1661,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,phenothiazines,effect,Compounds categories result decreased efficacy bromocriptine mesylate: OTHER_DRUG haloperidol metoclopramide pimozide .
1662,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,haloperidol,effect,Compounds categories result decreased efficacy bromocriptine mesylate: phenothiazines OTHER_DRUG metoclopramide pimozide .
1663,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,metoclopramide,effect,Compounds categories result decreased efficacy bromocriptine mesylate: phenothiazines haloperidol OTHER_DRUG pimozide .
1664,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,pimozide,effect,Compounds categories result decreased efficacy bromocriptine mesylate: phenothiazines haloperidol metoclopramide OTHER_DRUG .
1665,Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.,bromocriptine mesylate,ergot alkaloids,advise,Concomitant use bromocriptine mesylate ergot alkaloids recommended .
1666,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,coumarin-derivative anticoagulants,effect,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding reported patients taking DRUG concomitantly coumarin-derivative anticoagulants warfarin phenprocoumon .
1667,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,phenprocoumon,effect,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding reported patients taking DRUG concomitantly coumarin-derivative anticoagulants warfarin OTHER_DRUG .
1668,Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).,coumarin-derivative anticoagulants,capecitabine,advise,Patients taking coumarin-derivative anticoagulants concomitantly OTHER_DRUG monitored regularly alterations coagulation parameters (PT INR) .
1669,Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.,5-fluorouracil,leucovorin,mechanism,Leucovorin: The concentration DRUG increased toxicity may enhanced OTHER_DRUG .
1670,"Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.",leucovorin,fluorouracil,effect,Deaths severe enterocolitis diarrhea dehydration reported elderly patients receiving weekly DRUG OTHER_DRUG .
1671,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",Iodine,Carbimazole,effect,DRUG DRUG excess may decrease effect OTHER_DRUG DRUG deficiency increase effect OTHER_DRUG .
1672,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",iodine,Carbimazole,effect,DRUG DRUG excess may decrease effect OTHER_DRUG DRUG deficiency increase effect OTHER_DRUG .
1673,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digoxin,antithyroid agents,mechanism,Serum concentration DRUG digitoxin may increase patients take antithyroid agents .
1674,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digitoxin,antithyroid agents,mechanism,Serum concentration digoxin DRUG may increase patients take antithyroid agents .
1675,"Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.",Antithyroid agents,sodium iodide I131,effect,Antithyroid agents may decrease thyroidal uptake sodium iodide I131 rebound uptake may occur 5 days sudden withdrawal Carbimazole .
1676,"Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.",buprenorphine,benzodiazepines,int,Based anecdotal reports may interaction DRUG OTHER_DRUG .
1677,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.,buprenorphine,benzodiazepines,effect,There number reports post-marketing experience coma death associated concomitant intravenous misuse DRUG OTHER_DRUG addicts .
1678,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBUTEX,benzodiazepines,advise,DRUG SUBOXONE prescribed caution patients OTHER_DRUG drugs act central nervous system regardless whether drugs taken advice physician taken drugs abuse .
1679,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBOXONE,benzodiazepines,advise,SUBUTEX DRUG prescribed caution patients OTHER_DRUG drugs act central nervous system regardless whether drugs taken advice physician taken drugs abuse .
1680,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBOXONE,advise,Patients warned potential danger intravenous self-administration DRUG treatment OTHER_DRUG SUBUTEX .
1681,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBUTEX,advise,Patients warned potential danger intravenous self-administration DRUG treatment SUBOXONE OTHER_DRUG .
1682,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,cimetidine,mechanism,Blood levels hydrodolasetron increased 24% DRUG coadministered OTHER_DRUG (nonselective inhibitor cytochrome P-450) 7 days decreased 28% coadministration rifampin (potent inducer cytochrome P-450) 7 days .
1683,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,rifampin,mechanism,Blood levels hydrodolasetron increased 24% DRUG coadministered cimetidine (nonselective inhibitor cytochrome P-450) 7 days decreased 28% coadministration OTHER_DRUG (potent inducer cytochrome P-450) 7 days .
1684,Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.,dolasetron mesylate,atenolol,mechanism,Clearance hydrodolasetron decreased 27% dolasetron mesylate administered intravenously concomitantly OTHER_DRUG .
1685,Chlorprothixene may increase the plasma-level of concomitantly given lithium.,Chlorprothixene,lithium,mechanism,DRUG may increase plasma-level concomitantly given OTHER_DRUG .
1686,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,advise,If DRUG given concomitantly OTHER_DRUG opioid dose reduced (by approx . 50%) DRUG amplifies therapeutic actions side-effects OTHER_DRUG massively .
1687,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,effect,If DRUG given concomitantly OTHER_DRUG opioid dose reduced (by approx . 50%) DRUG amplifies therapeutic actions side-effects OTHER_DRUG massively .
1688,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,tramadol,advise,Avoid concomitant use DRUG OTHER_DRUG (Ultram) .
1689,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,Ultram,advise,Avoid concomitant use DRUG tramadol (Ultram) .
1690,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,benzodiazepines,effect,Consider additive sedative effects confusional states emerge DRUG given OTHER_DRUG barbituates .
1691,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,barbituates,effect,Consider additive sedative effects confusional states emerge DRUG given benzodiazepines OTHER_DRUG .
1692,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,anticholinergic drugs,advise,Exert particular caution combining DRUG anticholinergic drugs (tricyclic antidepressants antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma .
1693,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,tricyclic antidepressants,advise,Exert particular caution combining DRUG anticholinergic drugs (tricyclic antidepressants antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma .
1694,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,antiparkinsonian agents,advise,Exert particular caution combining DRUG anticholinergic drugs (tricyclic antidepressants antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma .
1695,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,antiepileptic drugs,mechanism,Use Conjunction Other Antiepileptic Drugs: The addition DRUG antiepileptic drugs (AEDs) affects steady-state plasma concentrations AEDs .
1696,Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.,Felbatol,AEDs,mechanism,Use Conjunction Other Antiepileptic Drugs: The addition DRUG antiepileptic drugs (AEDs) affects steady-state plasma concentrations OTHER_DRUG .
1697,Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.,Felbatol,phenytoin,mechanism,Specific Effects DRUG Other Antiepileptic Drugs Phenytoin: DRUG causes increase steady-state OTHER_DRUG plasma concentrations .
1698,Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.,felbamate,phenytoin,mechanism,Increasing DRUG dose 1800 mg/day six subjects increased steady-state OTHER_DRUG Cmin 25 7 micrograms/mL .
1699,"In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.",felbamate,phenytoin,advise,In order maintain OTHER_DRUG levels limit adverse experiences achieve DRUG dose 3600 mg/day OTHER_DRUG dose reduction approximately 40% necessary eight 10 subjects .
1700,Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.,Felbatol,carbamazepine,mechanism,Carbamazepine: DRUG causes decrease steady-state OTHER_DRUG plasma concentrations increase steady-state OTHER_DRUG epoxide plasma concentration .
1701,"The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.",carbamazepine,felbamate,mechanism,The DRUG steady-state Cmin decreased 31% 5 1 micrograms/mL OTHER_DRUG (3000 mg/day divided three doses) coadministered .
1702,Valproate: Felbatol  causes an increase in steady-state valproate concentrations.,Felbatol,valproate,mechanism,Valproate: DRUG causes increase steady-state OTHER_DRUG concentrations .
1703,Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.,felbamate,valproate,mechanism,Increasing DRUG dose 2400 mg/day increased steadystate OTHER_DRUG Cmin 96 25 micrograms/mL .
1704,"Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.",felbamate,phenobarbital,mechanism,Phenobarbital: Coadministration DRUG OTHER_DRUG causes increase OTHER_DRUG plasma concentrations In 12 otherwise healthy male volunteers ingesting OTHER_DRUG steady-state trough (Cmin) OTHER_DRUG concentration 14 . 2 micrograms/mL .
1705,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,Felbatol,mechanism,Effects Other Antiepileptic Drugs OTHER_DRUG Phenytoin: DRUG causes approximate doubling clearance OTHER_DRUG (felbamate) steady state therefore addition DRUG causes approximate 45% decrease steady-state trough concentrations OTHER_DRUG compared dose OTHER_DRUG given monotherapy .
1706,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Phenytoin,felbamate,mechanism,Effects Other Antiepileptic Drugs Felbatol Phenytoin: DRUG causes approximate doubling clearance Felbatol (felbamate) steady state therefore addition DRUG causes approximate 45% decrease steady-state trough concentrations Felbatol compared dose Felbatol given monotherapy .
1707,"Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",phenytoin,Felbatol,mechanism,Effects Other Antiepileptic Drugs OTHER_DRUG Phenytoin: DRUG causes approximate doubling clearance OTHER_DRUG (felbamate) steady state therefore addition DRUG causes approximate 45% decrease steady-state trough concentrations OTHER_DRUG compared dose OTHER_DRUG given monotherapy .
1708,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",Carbamazepine,Felbatol,mechanism,Carbamazepine: DRUG causes approximate 50% increase clearance OTHER_DRUG steady state therefore addition DRUG results approximate 40% decrease steady-state trough concentrations OTHER_DRUG compared dose OTHER_DRUG given monotherapy .
1709,"Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.",carbamazepine,Felbatol,mechanism,Carbamazepine: DRUG causes approximate 50% increase clearance OTHER_DRUG steady state therefore addition DRUG results approximate 40% decrease steady-state trough concentrations OTHER_DRUG compared dose OTHER_DRUG given monotherapy .
1710,Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.,phenobarbital,felbamate,mechanism,Phenobarbital: It appears DRUG may reduce plasma OTHER_DRUG concentrations .
1711,"Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.",Felbamate,gestodene,mechanism,DRUG treatment resulted 42% decrease OTHER_DRUG AUC 0-24 clinically relevant effect observed pharmacokinetic parameters ethinyl estradiol .
1712,Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.,Chirocaine,anesthetics,advise,DRUG used caution patients receiving local OTHER_DRUG agents structurally related amide-type local OTHER_DRUG since toxic effects drugs could additive .
1713,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenytoin,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such OTHER_DRUG phenobarbital rifampin) CYP3A4 inhibitors (azole antimycotics . g . ketoconazole;
1714,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,phenobarbital,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such phenytoin OTHER_DRUG rifampin) CYP3A4 inhibitors (azole antimycotics . g . ketoconazole;
1715,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,rifampin,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such phenytoin phenobarbital rifampin) CYP3A4 inhibitors (azole antimycotics . g . ketoconazole;
1716,"Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;",levobupivacaine,ketoconazole,mechanism,Although clinical studies conducted likely metabolism DRUG may affected known CYP3A4 inducers (such phenytoin phenobarbital rifampin) CYP3A4 inhibitors (azole antimycotics . g . ketoconazole;
1717,Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.,Nicotinic acid,ganglionic blocking agents,effect,Interactions Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate effects ganglionic blocking agents vasoactive drugs resulting postural hypotension .
1718,Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.,aspirin,nicotinic acid,mechanism,Aspirin: Concomitant DRUG may decrease metabolic clearance nicotinic acid .
1719,Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.,irbesartan,aliskiren,mechanism,Co-administration DRUG reduced OTHER_DRUG Cmax 50% multiple dosing .
1720,Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.,atorvastatin,aliskiren,mechanism,Co-administration DRUG resulted 50% increase OTHER_DRUG Cmax AUC multiple dosing .
1721,Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.,ketoconazole,aliskiren,mechanism,Ketoconazole: Co-administration 200 mg twice-daily DRUG OTHER_DRUG resulted approximate 80% increase plasma levels OTHER_DRUG .
1722,"Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.",aliskiren,furosemide,mechanism,Furosemide: When DRUG co-administered OTHER_DRUG AUC Cmax OTHER_DRUG reduced 30% 50% respectively .
1723,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,phenothiazines,effect,The response DRUG may blunted OTHER_DRUG dopamine antagonists cause rise prolactin .
1724,The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.,Factrel,dopamine antagonists,effect,The response DRUG may blunted phenothiazines dopamine antagonists cause rise prolactin .
1725,"Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.",diuretics,Lotensin,effect,Diuretics: Patients DRUG especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy OTHER_DRUG .
1726,The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.,diuretic,Lotensin,advise,The possibility hypotensive effects OTHER_DRUG minimized either discontinuing DRUG increasing salt intake prior initiation treatment OTHER_DRUG .
1727,Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.,Potassium-Sparing Diuretics,thiazide diuretics,effect,Potassium Supplements Potassium-Sparing Diuretics Lotensin attenuate potassium loss caused thiazide diuretics .
1728,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.,ACE inhibitors,lithium,mechanism,Lithium: Increased serum OTHER_DRUG levels symptoms OTHER_DRUG toxicity reported patients receiving ACE inhibitors therapy OTHER_DRUG .
1729,"If a diuretic is also used, the risk of lithium toxicity may be increased.",diuretic,lithium,effect,If DRUG also used risk OTHER_DRUG toxicity may increased .
1730,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",Benazepril,beta-adrenergic blockers,effect,DRUG like ACE inhibitors less additive effects beta-adrenergic blockers presumably drugs lower blood pressure inhibiting parts renin-angiotensin system
1731,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",ACE inhibitors,beta-adrenergic blockers,effect,Benazepril like ACE inhibitors less additive effects beta-adrenergic blockers presumably drugs lower blood pressure inhibiting parts renin-angiotensin system
1732,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,Geocillin,probenecid,mechanism,DRUG (carbenicillin indanyl sodium) blood levels may increased prolonged concurrent administration OTHER_DRUG .
1733,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,carbenicillin indanyl sodium,probenecid,mechanism,Geocillin (carbenicillin indanyl sodium) blood levels may increased prolonged concurrent administration OTHER_DRUG .
1734,Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.,aspirin,valdecoxib,effect,Aspirin: Concomitant administration DRUG OTHER_DRUG may result increased risk GI ulceration complications compared OTHER_DRUG alone .
1735,ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.,NSAIDs,ACE-inhibitors,effect,ACE-inhibitors:Reports suggest DRUG may diminish antihypertensive effect OTHER_DRUG .
1736,This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.,BEXTRA,ACE-inhibitors,advise,This interaction given consideration patients taking DRUG concomitantly OTHER_DRUG .
1737,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post-marketing observations shown DRUG reduce natriuretic effect OTHER_DRUG thiazides patients .
1738,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post-marketing observations shown DRUG reduce natriuretic effect furosemide OTHER_DRUG patients .
1739,Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).,valdecoxib,phenytoin,mechanism,Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) DRUG (40 mg BID 12 days) decreased 27% co-administered multiple doses (300 mg QD 12 days) OTHER_DRUG (a CYP 3A4 inducer) .
1740,Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.,valdecoxib,phenytoin,advise,Patients already stabilized DRUG closely monitored loss symptom control OTHER_DRUG coadministration .
1741,"Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.",valdecoxib,dextromethorphan,mechanism,Coadministration DRUG (40 mg BID 7 days) resulted significant increase OTHER_DRUG plasma levels suggesting doses DRUG weak inhibitor 2D6 .
1742,Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.,dextromethorphan,valdecoxib,mechanism,Even DRUG plasma concentrations presence high doses OTHER_DRUG almost 5-fold lower seen CYP 2D6 poor metabolizers suggesting dose adjustment necessary .
1743,Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.,Valdecoxib,lithium,mechanism,Lithium: DRUG 40 mg BID 7 days produced significant decreases OTHER_DRUG serum clearance (25%) renal clearance (30%) 34% higher serum exposure compared OTHER_DRUG alone .
1744,Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.,BEXTRA,lithium,advise,OTHER_DRUG serum concentrations monitored closely initiating changing therapy DRUG patients receiving OTHER_DRUG .
1745,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,R-warfarin,mechanism,DRUG caused statistically significant increase plasma exposures OTHER_DRUG S-warfarin (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) warfarin .
1746,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,S-warfarin,mechanism,DRUG caused statistically significant increase plasma exposures R-warfarin OTHER_DRUG (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) warfarin .
1747,"Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.",Valdecoxib,warfarin,effect,DRUG caused statistically significant increase plasma exposures R-warfarin S-warfarin (12% 15% respectively) pharmacodynamic effects (prothrombin time measured INR) OTHER_DRUG .
1748,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.",BEXTRA,warfarin,advise,Anticoagulant therapy monitored particularly first weeks initiating therapy DRUG patients receiving OTHER_DRUG similar agents .
1749,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,ketoconazole,mechanism,Concomitant single dose administration DRUG 20 mg multiple doses OTHER_DRUG fluconazole produced significant increase exposure DRUG .
1750,Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.,valdecoxib,fluconazole,mechanism,Concomitant single dose administration DRUG 20 mg multiple doses ketoconazole OTHER_DRUG produced significant increase exposure DRUG .
1751,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,fluconazole,mechanism,Plasma exposure (AUC) DRUG increased 62% coadministered OTHER_DRUG 38% coadministered ketoconazole .
1752,Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.,valdecoxib,ketoconazole,mechanism,Plasma exposure (AUC) DRUG increased 62% coadministered fluconazole 38% coadministered OTHER_DRUG .
1753,Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.,valdecoxib,glyburide,mechanism,Coadministration DRUG (40 mg BID (day 1) 40 mg QD (days 2-7)) OTHER_DRUG (10 mg OTHER_DRUG BID) resulted 21% increase OTHER_DRUG AUC0-12 16% increase OTHER_DRUG Cmax leading 16% decrease glucose AUC0-24 .
1754,"Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.",glyburide,valdecoxib,advise,Because changes glucose concentrations OTHER_DRUG coadministration within normal variability individual glucose concentrations near 70 mg/dL dose adjustment DRUG (5 mg QD 10 mg BID) OTHER_DRUG coadministration (up 40 mg QD) indicated .
1755,Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.,valdecoxib,omeprazole,mechanism,Coadministration DRUG increased exposure OTHER_DRUG (AUC) 46% .
1756,"Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.",valdecoxib,Ortho-Novum,mechanism,Coadministration DRUG OTHER_DRUG 1/35 increased exposure norethindrone ethinyl estradiol 20% 34% respectively .
1757,These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.,contraceptive,valdecoxib,advise,These increased exposures norethindrone ethinyl estradiol taken consideration selecting oral DRUG women taking OTHER_DRUG .
1758,"Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.",diazepam,valdecoxib,mechanism,Plasma exposure DRUG (10 mg BID) increased 28% following administration OTHER_DRUG (40 mg BID) 12 days plasma exposure OTHER_DRUG (40 mg BID) substantially increased following administration DRUG (10 mg BID) 12 days .
1759,"Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.",valdecoxib,diazepam,effect,Although magnitude changes OTHER_DRUG plasma exposure coadministered DRUG sufficient warrant dosage adjustments patients may experience enhanced sedative side effects caused increased exposure OTHER_DRUG circumstance .
1760,"Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.",Clozapine,alcohol,effect,Given primary CNS effects DRUG caution advised using concomitantly CNS-active drugs OTHER_DRUG .
1761,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,benzodiazepine,advise,Although established interaction DRUG benzodiazepines psychotropics caution advised DRUG initiated patients taking OTHER_DRUG psychotropic drug .
1762,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,psychotropic drug,advise,Although established interaction DRUG benzodiazepines psychotropics caution advised DRUG initiated patients taking benzodiazepine psychotropic drug .
1763,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,antihypertensive drugs,effect,DRUG may potentiate hypotensive effects antihypertensive drugs anticholinergic effects atropine-type drugs .
1764,Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.,Clozapine,atropine,effect,DRUG may potentiate hypotensive effects antihypertensive drugs anticholinergic effects atropine-type drugs .
1765,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",Phenytoin,Clozapine,mechanism,DRUG nicotine rifampin may decrease OTHER_DRUG plasma levels resulting decrease effectiveness previously effective OTHER_DRUG dose .
1766,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",nicotine,Clozapine,mechanism,Phenytoin DRUG rifampin may decrease OTHER_DRUG plasma levels resulting decrease effectiveness previously effective OTHER_DRUG dose .
1767,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",rifampin,Clozapine,mechanism,Phenytoin nicotine DRUG may decrease OTHER_DRUG plasma levels resulting decrease effectiveness previously effective OTHER_DRUG dose .
1768,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",Cimetidine,Clozapine,mechanism,DRUG caffeine erythromycin may increase plasma levels OTHER_DRUG potentially resulting adverse effects .
1769,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",caffeine,Clozapine,mechanism,Cimetidine DRUG erythromycin may increase plasma levels OTHER_DRUG potentially resulting adverse effects .
1770,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",erythromycin,Clozapine,mechanism,Cimetidine caffeine DRUG may increase plasma levels OTHER_DRUG potentially resulting adverse effects .
1771,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",Clozapine,carbamazepine,advise,Although concomitant use DRUG OTHER_DRUG recommended noted discontinuation concomitant OTHER_DRUG administration may result increase DRUG plasma levels .
1772,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",carbamazepine,Clozapine,mechanism,Although concomitant use OTHER_DRUG DRUG recommended noted discontinuation concomitant DRUG administration may result increase OTHER_DRUG plasma levels .
1773,Paroxetine produced only minor changes in the levels of clozapine and its metabolites.,Paroxetine,clozapine,mechanism,DRUG produced minor changes levels OTHER_DRUG metabolites .
1774,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,paroxetine,mechanism,However published reports describe modest elevations (less two-fold) DRUG metabolite concentrations DRUG taken OTHER_DRUG fluoxetine sertraline .
1775,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,fluoxetine,mechanism,However published reports describe modest elevations (less two-fold) DRUG metabolite concentrations DRUG taken paroxetine OTHER_DRUG sertraline .
1776,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,sertraline,mechanism,However published reports describe modest elevations (less two-fold) DRUG metabolite concentrations DRUG taken paroxetine fluoxetine OTHER_DRUG .
1777,"Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.",Clozapine,fluvoxamine,advise,Therefore combined treatment approached caution patients monitored closely DRUG combined drugs particularly OTHER_DRUG .
1778,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,antidepressants,advise,Therefore co-administration DRUG drugs metabolized isozyme including OTHER_DRUG phenothiazines carbamazepine Type 1C antiarrhythmics (e . g . propafenone flecainide encainide) inhibit enzyme (e . g . quinidine) approached caution .
1779,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,phenothiazines,advise,Therefore co-administration DRUG drugs metabolized isozyme including antidepressants OTHER_DRUG carbamazepine Type 1C antiarrhythmics (e . g . propafenone flecainide encainide) inhibit enzyme (e . g . quinidine) approached caution .
1780,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,carbamazepine,advise,Therefore co-administration DRUG drugs metabolized isozyme including antidepressants phenothiazines OTHER_DRUG Type 1C antiarrhythmics (e . g . propafenone flecainide encainide) inhibit enzyme (e . g . quinidine) approached caution .
1781,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,Type 1C antiarrhythmics,advise,Therefore co-administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e . g . propafenone flecainide encainide) inhibit enzyme (e . g . quinidine) approached caution .
1782,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,propafenone,advise,Therefore co-administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e . g . OTHER_DRUG flecainide encainide) inhibit enzyme (e . g . quinidine) approached caution .
1783,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,flecainide,advise,Therefore co-administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e . g . propafenone OTHER_DRUG encainide) inhibit enzyme (e . g . quinidine) approached caution .
1784,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,encainide,advise,Therefore co-administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e . g . propafenone flecainide encainide) inhibit enzyme (e . g . quinidine) approached caution .
1785,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,quinidine,advise,Therefore co-administration DRUG drugs metabolized isozyme including antidepressants phenothiazines carbamazepine Type 1C antiarrhythmics (e . g . propafenone flecainide encainide) inhibit enzyme (e . g . quinidine) approached caution .
1786,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",quinolones,caffeine,mechanism,Some DRUG including ciprofloxacin also shown interfere metabolism OTHER_DRUG .
1787,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",ciprofloxacin,caffeine,mechanism,Some quinolones including DRUG also shown interfere metabolism OTHER_DRUG .
1788,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",quinolones,cyclosporine,effect,Some DRUG including ciprofloxacin associated transient elevations serum creatinine patients receiving OTHER_DRUG concomitantly .
1789,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",ciprofloxacin,cyclosporine,effect,Some quinolones including DRUG associated transient elevations serum creatinine patients receiving OTHER_DRUG concomitantly .
1790,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,sulfonylurea,effect,Glyburide: The concomitant administration DRUG OTHER_DRUG glyburide rare occasions resulted severe hypoglycemia .
1791,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,glyburide,effect,Glyburide: The concomitant administration DRUG sulfonylurea OTHER_DRUG rare occasions resulted severe hypoglycemia .
1792,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.",methotrexate,ciprofloxacin,mechanism,DRUG Renal tubular transport DRUG may inhibited concomitant administration OTHER_DRUG potentially leading increased plasma levels DRUG .
1793,"Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.",methotrexate,ciprofloxacin,advise,Therefore patients DRUG therapy carefully monitored concomitant OTHER_DRUG therapy indicated .
1794,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,magnesium,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products OTHER_DRUG aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1795,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,aluminum,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products magnesium OTHER_DRUG antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1796,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,antacids,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products magnesium aluminum OTHER_DRUG sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1797,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,sucralfate,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products magnesium aluminum antacids OTHER_DRUG VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1798,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,VIDEX,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products magnesium aluminum antacids sucralfate OTHER_DRUG chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1799,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,calcium,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing OTHER_DRUG iron zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1800,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,iron,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium OTHER_DRUG zinc may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1801,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,zinc,mechanism,Multivalent Cation-Containing Products: Concurrent administration DRUG including ciprofloxacin multivalent cation-containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron OTHER_DRUG may substantially decrease absorption ciprofloxacin resulting serum urine levels considerably lower desired .
1802,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,magnesium,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products OTHER_DRUG aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1803,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,aluminum,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium OTHER_DRUG antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1804,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,antacids,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium aluminum OTHER_DRUG sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1805,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,sucralfate,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium aluminum antacids OTHER_DRUG VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1806,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,VIDEX,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium aluminum antacids sucralfate OTHER_DRUG chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1807,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,calcium,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing OTHER_DRUG iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1808,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,iron,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium OTHER_DRUG zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1809,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,zinc,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron OTHER_DRUG may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1810,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,ciprofloxacin,mechanism,Multivalent Cation-Containing Products: Concurrent administration quinolone including DRUG multivalent cation-containing products magnesium aluminum antacids sucralfate VIDEX chewable/buffered tablets pediatric powder products containing calcium iron zinc may substantially decrease absorption DRUG resulting serum urine levels considerably lower desired .
1811,"This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.",ciprofloxacin,antacids,advise,This time window different oral formulations DRUG usually administered 2 hours 6 hours OTHER_DRUG .
1812,Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.,phenytoin,ciprofloxacin,mechanism,Phenytoin: Altered serum levels DRUG (increased decreased) reported patients receiving concomitant OTHER_DRUG .
1813,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid: DRUG interferes renal tubular secretion OTHER_DRUG produces increase level OTHER_DRUG serum .
1814,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid: DRUG interferes renal tubular secretion OTHER_DRUG produces increase level OTHER_DRUG serum .
1815,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",quinolones,theophylline,mechanism,Theophylline: As DRUG concurrent administration ciprofloxacin OTHER_DRUG may lead elevated serum concentrations OTHER_DRUG prolongation elimination half-life .
1816,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",ciprofloxacin,theophylline,mechanism,Theophylline: As quinolones concurrent administration DRUG OTHER_DRUG may lead elevated serum concentrations OTHER_DRUG prolongation elimination half-life .
1817,Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.,Quinolones,warfarin,effect,Warfarin: DRUG reported enhance effects oral anticoagulant OTHER_DRUG derivatives .
1818,"Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.",Bismuth subsalicylate,enoxacin,mechanism,Bismuth: Bismuth subsalicylate given concomitantly OTHER_DRUG 60 minutes following OTHER_DRUG administration decreased OTHER_DRUG bioavailability approximately 25% .
1819,"Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.",enoxacin,bismuth subsalicylate,advise,Thus concomitant administration DRUG bismuth subsalicylate avoided .
1820,Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Caffeine: DRUG potent inhibitor cytochrome P-450 isozymes responsible metabolism OTHER_DRUG .
1821,"In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.",enoxacin,caffeine,mechanism,In multiple-dose study DRUG caused dose-related increase mean elimination half-life OTHER_DRUG thereby decreasing clearance OTHER_DRUG 80% leading five-fold increase AUC half-life OTHER_DRUG .
1822,Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.,caffeine,enoxacin,mechanism,Trough plasma OTHER_DRUG levels also 20% higher DRUG OTHER_DRUG administered concomitantly .
1823,Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.,caffeine,enoxacin,effect,Caffeine-related adverse effects occurred patients consuming DRUG therapy OTHER_DRUG .
1824,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine: Elevated serum levels DRUG reported concomitant use DRUG members quinolone class .
1825,Digoxin: Enoxacin may raise serum digoxin levels in some individuals.,Enoxacin,digoxin,mechanism,Digoxin: DRUG may raise serum OTHER_DRUG levels individuals .
1826,"If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.",enoxacin,digoxin,effect,If signs symptoms suggestive OTHER_DRUG toxicity occur DRUG OTHER_DRUG given concomitantly physicians advised obtain serum OTHER_DRUG levels adjust OTHER_DRUG doses appropriately .
1827,Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.,enoxacin,fenbufen,effect,Non-steroidal anti-inflammatory agents: Seizures reported patients taking DRUG concomitantly nonsteroidal anti-inflammatory drug OTHER_DRUG .
1828,or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.,zinc,quinolone,mechanism,multivitamins containing DRUG may substantially interfere drug absorption result insufficient plasma tissue OTHER_DRUG concentrations .
1829,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,aluminum hydroxide,enoxacin,mechanism,Antacids containing aluminum hydroxide magnesium hydroxide reduce oral absorption OTHER_DRUG 75% .
1830,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,magnesium hydroxide,enoxacin,mechanism,Antacids containing aluminum hydroxide magnesium hydroxide reduce oral absorption OTHER_DRUG 75% .
1831,The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.,enoxacin,ranitidine,mechanism,The oral bioavailability DRUG reduced 60% coadministration OTHER_DRUG .
1832,Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Theophylline: DRUG potent inhibitor cytochrome P-450 isozymes responsible metabolism OTHER_DRUG .
1833,Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.,Enoxacin,theophylline,mechanism,DRUG interferes metabolism OTHER_DRUG resulting 42% 74% dose-related decrease OTHER_DRUG clearance subsequent 260% 350% increase serum OTHER_DRUG levels .
1834,Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.,theophylline,enoxacin,effect,Theophylline-related adverse effects occurred patients DRUG OTHER_DRUG coadministered .
1835,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",Quinolones,R-warfarin,mechanism,Warfarin: DRUG including enoxacin decrease clearance OTHER_DRUG less active isomer racemic warfarin .
1836,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",enoxacin,R-warfarin,mechanism,Warfarin: Quinolones including DRUG decrease clearance OTHER_DRUG less active isomer racemic warfarin .
1837,"Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.",warfarin,enoxacin,advise,Nevertheless prothrombin time suitable coagulation test monitored DRUG derivatives OTHER_DRUG given concomitantly .
1838,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",calcium,Ibandronate,mechanism,Products containing DRUG multivalent cations (such aluminum magnesium iron) likely interfere absorption OTHER_DRUG .
1839,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",aluminum,Ibandronate,mechanism,Products containing calcium multivalent cations (such DRUG magnesium iron) likely interfere absorption OTHER_DRUG .
1840,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",magnesium,Ibandronate,mechanism,Products containing calcium multivalent cations (such aluminum DRUG iron) likely interfere absorption OTHER_DRUG .
1841,"Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.",iron,Ibandronate,mechanism,Products containing calcium multivalent cations (such aluminum magnesium iron) likely interfere absorption OTHER_DRUG .
1842,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,antacids,advise,DRUG taken least 60 minutes oral medications containing multivalent cations (including OTHER_DRUG supplements vitamins) .
1843,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,vitamins,advise,DRUG taken least 60 minutes oral medications containing multivalent cations (including antacids supplements vitamins) .
1844,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",aspirin,Ibandronate,advise,However since DRUG NSAIDs bisphosphonates associated gastrointestinal irritation caution exercised concomitant use DRUG NSAIDs OTHER_DRUG .
1845,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",NSAIDs,Ibandronate,advise,However since aspirin DRUG bisphosphonates associated gastrointestinal irritation caution exercised concomitant use aspirin DRUG OTHER_DRUG .
1846,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,azathioprine,mechanism,Total body clearance DRUG reduced average 22% 51% OTHER_DRUG mycophenolate mofetil respectively added regimen consisting cyclosporine USP (MODIFIED) corticosteroids .
1847,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,mycophenolate mofetil,mechanism,Total body clearance DRUG reduced average 22% 51% azathioprine mycophenolate mofetil respectively added regimen consisting cyclosporine USP (MODIFIED) corticosteroids .
1848,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,central nervous system depressants,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1849,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,alcohol,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg OTHER_DRUG sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1850,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,sedatives,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol OTHER_DRUG hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1851,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,hypnotics,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives OTHER_DRUG opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1852,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,opioids,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics OTHER_DRUG general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1853,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,anesthetics,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general OTHER_DRUG barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1854,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,barbiturates,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics OTHER_DRUG tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1855,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tricyclic antidepressants,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1856,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,phenothiazines,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants OTHER_DRUG tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1857,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,tranquilizers,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines OTHER_DRUG skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1858,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,skeletal muscle relaxants,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1859,"Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.",Levo-Dromoran,antihistamines,effect,Interactions Other CNS Agents: Concurrent use DRUG central nervous system depressants (eg alcohol sedatives hypnotics opioids general anesthetics barbiturates tricyclic antidepressants phenothiazines tranquilizers skeletal muscle relaxants antihistamines) may result additive central nervous system depressant effects .
1860,"Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.",Levo-Dromoran,MAO inhibitors,advise,Although interaction MAO inhibitors DRUG observed recommended use MAO inhibitors .
1861,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",Agonist/antagonist analgesics,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine buprenorphine) NOT administered patient received receiving course therapy pure agonist opioid analgesic OTHER_DRUG .
1862,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pentazocine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg DRUG nalbuphine butorphanol dezocine buprenorphine) NOT administered patient received receiving course therapy pure agonist opioid analgesic OTHER_DRUG .
1863,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",nalbuphine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine DRUG butorphanol dezocine buprenorphine) NOT administered patient received receiving course therapy pure agonist opioid analgesic OTHER_DRUG .
1864,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",butorphanol,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine DRUG dezocine buprenorphine) NOT administered patient received receiving course therapy pure agonist opioid analgesic OTHER_DRUG .
1865,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",dezocine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol DRUG buprenorphine) NOT administered patient received receiving course therapy pure agonist opioid analgesic OTHER_DRUG .
1866,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",buprenorphine,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine buprenorphine) NOT administered patient received receiving course therapy pure agonist opioid analgesic OTHER_DRUG .
1867,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pure agonist opioid analgesic,Levo-Dromoran,advise,Interactions Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg pentazocine nalbuphine butorphanol dezocine buprenorphine) NOT administered patient received receiving course therapy pure agonist opioid analgesic OTHER_DRUG .
1868,Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.,cinacalcet,amitriptyline,mechanism,Amitriptyline: Concurrent administration 25 mg 100 mg DRUG 50 mg OTHER_DRUG increased OTHER_DRUG exposure nortriptyline (active metabolite) exposure approximately 20% CYP2D6 extensive metabolizers .
1869,"Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.",ketoconazole,cinacalcet,mechanism,Co-administration DRUG strong inhibitor CYP3A4 increased OTHER_DRUG exposure following single 90 mg dose Sensipar 2 . 3 fold .
1870,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,ketoconazole,advise,Dose adjustment DRUG may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e . g . OTHER_DRUG erythromycin itraconazole;
1871,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,erythromycin,advise,Dose adjustment DRUG may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e . g . ketoconazole OTHER_DRUG itraconazole;
1872,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,itraconazole,advise,Dose adjustment DRUG may required PTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor (e . g . ketoconazole erythromycin itraconazole;
1873,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",alcohol,ethchlorvynol,effect,Other depressasnts DRUG barbiturates MAOIs may enhance CNS depression administered OTHER_DRUG .
1874,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",barbiturates,ethchlorvynol,effect,Other depressasnts alcohol DRUG MAOIs may enhance CNS depression administered OTHER_DRUG .
1875,"Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.",MAOIs,ethchlorvynol,effect,Other depressasnts alcohol barbiturates DRUG may enhance CNS depression administered OTHER_DRUG .
1876,"In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.",cerivastatin sodium,cholestyramine,mechanism,In first study concomitant administration 0 . 2 mg cerivastatin sodium 12 g OTHER_DRUG resulted decreases 22% AUC 40% Cmax compared dosing cerivastatin sodium alone .
1877,"However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.",cholestyramine,cerivastatin sodium,mechanism,However second study administration 12 g DRUG 1 hour evening meal 0 . 3 mg cerivastatin sodium approximately 4 hours evening meal resulted decrease cerivastatin AUC less 8% decrease Cmax 30% compared dosing cerivastatin sodium alone .
1878,"ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.",cerivastatin,erythromycin,mechanism,ERYTHROMYCIN: In hypercholesterolemic patients steady-state DRUG AUC Cmax increased approximately 50% 24% respectively 10 days co-administration OTHER_DRUG known inhibitor cytochrome P450 3A4 .
1879,Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).,allopurinol,VIDEX,mechanism,Allopurinol: The AUC didanosine increased 4-fold DRUG 300 mg/day coadministered single 200-mg dose OTHER_DRUG two patients renal impairment (CLcr=15 18 mL/min) .
1880,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,antacids,VIDEX,effect,Antacids: Concomitant administration DRUG containing magnesium aluminum OTHER_DRUG Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components .
1881,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,magnesium,VIDEX,effect,Antacids: Concomitant administration antacids containing DRUG aluminum OTHER_DRUG Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components .
1882,Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.,aluminum,VIDEX,effect,Antacids: Concomitant administration antacids containing magnesium DRUG OTHER_DRUG Chewable/Dispersible Buffered Tablets Pediatric Powder Oral Solution may potentiate adverse events associated antacid components .
1883,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,ketoconazole,VIDEX,advise,Drugs Whose Absorption Can Be Affected Level Acidity Stomach: Drugs DRUG itraconazole administered least 2 hours prior dosing OTHER_DRUG .
1884,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,itraconazole,VIDEX,advise,Drugs Whose Absorption Can Be Affected Level Acidity Stomach: Drugs ketoconazole DRUG administered least 2 hours prior dosing OTHER_DRUG .
1885,Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).,VIDEX,ganciclovir,mechanism,Ganciclovir: Administration DRUG 2 hours prior concurrent oral OTHER_DRUG associated 111 (114)% increase steady-state AUC didanosine (n = 12) .
1886,"A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).",VIDEX,ganciclovir,mechanism,A 21 (17)% decrease steady-state AUC OTHER_DRUG observed DRUG administered 2 hours prior OTHER_DRUG two drugs administered simultaneously (n = 12) .
1887,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",VIDEX,ciprofloxacin,advise,Quinolone Antibiotics: DRUG administered least 2 hours 6 hours dosing OTHER_DRUG plasma concentrations OTHER_DRUG decreased administered antacids containing magnesium calcium aluminum .
1888,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,magnesium,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing DRUG plasma concentrations DRUG decreased administered antacids containing OTHER_DRUG calcium aluminum .
1889,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,calcium,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing DRUG plasma concentrations DRUG decreased administered antacids containing magnesium OTHER_DRUG aluminum .
1890,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,aluminum,mechanism,Quinolone Antibiotics: VIDEX administered least 2 hours 6 hours dosing DRUG plasma concentrations DRUG decreased administered antacids containing magnesium calcium OTHER_DRUG .
1891,"In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.",ciprofloxacin,VIDEX,mechanism,In eight HIV-infected patients steady-state AUC DRUG decreased average 26% (95% CI = 14% 37%) DRUG administered 2 hours prior marketed chewable/dispersible tablet formulation OTHER_DRUG .
1892,The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.,ciprofloxacin,didanosine,mechanism,The AUC DRUG decreased average 15-fold 12 healthy subjects given DRUG didanosine-placebo tablets concurrently .
1893,"In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.",ciprofloxacin,didanosine,mechanism,In single subject given one dose DRUG 2 hours dose didanosine-placebo tablets greater 50% reduction AUC DRUG observed .
1894,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,magnesium,mechanism,Plasma concentrations quinolone antibiotics decreased administered antacids containing OTHER_DRUG calcium aluminum .
1895,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,calcium,mechanism,Plasma concentrations quinolone antibiotics decreased administered antacids containing magnesium OTHER_DRUG aluminum .
1896,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,aluminum,mechanism,Plasma concentrations quinolone antibiotics decreased administered antacids containing magnesium calcium OTHER_DRUG .
1897,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,delavirdine,VIDEX,mechanism,Interactions Other Antiretroviral Drugs: Significant decreases AUC DRUG (20%) indinavir (84%) occurred following simultaneous administration agents OTHER_DRUG .
1898,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,indinavir,VIDEX,mechanism,Interactions Other Antiretroviral Drugs: Significant decreases AUC delavirdine (20%) DRUG (84%) occurred following simultaneous administration agents OTHER_DRUG .
1899,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",delavirdine,VIDEX,advise,To avoid interaction DRUG indinavir given 1 hour prior dosing OTHER_DRUG .
1900,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",indinavir,VIDEX,advise,To avoid interaction delavirdine DRUG given 1 hour prior dosing OTHER_DRUG .
1901,The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.,SSRI,TCA,effect,The extent SSRI-TCA interactions may pose clinical problems depend degree inhibition pharmacokinetics DRUG involved .
1902,"Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.",TCAs,SSRIs,advise,Nevertheless caution indicated coadministration DRUG OTHER_DRUG also switching one class .
1903,"Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.",amitriptyline HCl,anticholinergic,effect,Hyperpyrexia reported amitriptyline HCl administered OTHER_DRUG agents neuroleptic drugs particularly hot weather .
1904,Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.,tricyclic antidepressants,anticholinergic,effect,Paralytic ileus may occur patients taking tricyclic antidepressants combination anticholinergic-type drugs .
1905,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.",Cimetidine,tricyclic antidepressants,mechanism,DRUG reported reduce hepatic metabolism certain tricyclic antidepressants thereby delaying elimination increasing steady-state concentrations drugs .
1906,Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.,tricyclic antidepressants,cimetidine,effect,Clinically significant effects reported tricyclic antidepressants used concomitantly OTHER_DRUG .
1907,"Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.",tricyclic antidepressants,cimetidine,mechanism,Increases plasma levels tricyclic antidepressants frequency severity side effects particularly anticholinergic reported OTHER_DRUG added drug regimen .
1908,Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.,tricyclic antidepressants,cimetidine,mechanism,Discontinuation OTHER_DRUG well-controlled patients receiving tricyclic antidepressants OTHER_DRUG may decrease plasma levels efficacy antidepressants .
1909,Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.,ethchlorvynol,amitriptyline HCl,effect,Transient delirium reported patients treated one gram DRUG 75 - 150 mg amitriptyline HCl .
1910,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,beta-blockers,Tiazac,effect,Pharmacologic studies indicate may additive effects prolonging AV conduction using DRUG digitalis concomitantly OTHER_DRUG .
1911,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.,digitalis,Tiazac,effect,Pharmacologic studies indicate may additive effects prolonging AV conduction using beta-blockers DRUG concomitantly OTHER_DRUG .
1912,Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.,diltiazem hydrochloride,propranolol,mechanism,Administration diltiazem hydrochloride concomitantly OTHER_DRUG five normal volunteers resulted increased OTHER_DRUG levels subjects bioavailability OTHER_DRUG increased approximately 50% .
1913,"In vitro, propranolol appears to be displaced from its binding sites by diltiazem.",propranolol,diltiazem,mechanism,In vitro DRUG appears displaced binding sites OTHER_DRUG .
1914,A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.,cimetidine,diltiazem,mechanism,A study six healthy volunteers shown significant increase peak OTHER_DRUG plasma levels (58%) AUC (53%) 1-week course DRUG 1200 mg/day single dose OTHER_DRUG 60mg .
1915,"The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.",cimetidine,diltiazem,mechanism,The effect may mediated cimetidines known inhibition hepatic cytochrome P-450 enzyme system responsible first-pass metabolism OTHER_DRUG .
1916,Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.,diltiazem,cimetidine,advise,Patients currently receiving DRUG therapy carefully monitored change pharmacological effect initiating discontinuing therapy OTHER_DRUG .
1917,Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.,diltiazem hydrochloride,digoxin,mechanism,Administration diltiazem hydrochloride OTHER_DRUG 24 healthy male subjects increased plasma OTHER_DRUG concentrations approximately 20% .
1918,"Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.",digoxin,diltiazem hydrochloride,advise,Since conflicting results regarding effect DRUG levels recommended DRUG levels monitored initiating adjusting discontinuing diltiazem hydrochloride therapy avoid possible over- under-digitalization .
1919,"The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.",anesthetics,calcium channel blockers,effect,The depression cardiac contractility conductivity automaticity well vascular dilation associated DRUG may potentiated calcium channel blockers .
1920,"When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.",anesthetics,calcium channel blockers,advise,When used concomitantly DRUG calcium channel blockers titrated carefully .
1921,A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.,diltiazem,cyclosporine,int,A pharmacokinetic interaction DRUG OTHER_DRUG observed studies involving renal cardiac transplant patients .
1922,"In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.",cyclosporine,diltiazem,mechanism,In renal cardiac transplant recipients reduction DRUG dose ranging 15% 48% necessary maintain DRUG trough concentrations similar seen prior addition OTHER_DRUG .
1923,"If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.",cyclosporine,diltiazem,advise,If agents administered concurrently DRUG concentrations monitored especially OTHER_DRUG therapy initiated adjusted discontinued .
1924,"Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.",diltiazem,carbamazepine,mechanism,Concomitant administration DRUG OTHER_DRUG reported result elevated serum levels OTHER_DRUG (40% 72% increase) resulting toxicity cases .
1925,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,midazolam,mechanism,Studies showed DRUG increased AUC OTHER_DRUG triazolam 3-4 fold Cmax 2-fold compared placebo .
1926,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,triazolam,mechanism,Studies showed DRUG increased AUC midazolam OTHER_DRUG 3-4 fold Cmax 2-fold compared placebo .
1927,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,midazolam,diltiazem,mechanism,The elimination half life DRUG triazolam also increased (1 . 5-2 . 5 fold) coadministration OTHER_DRUG .
1928,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,triazolam,diltiazem,mechanism,The elimination half life midazolam DRUG also increased (1 . 5-2 . 5 fold) coadministration OTHER_DRUG .
1929,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,midazolam,effect,These pharmacokinetic effects seen DRUG coadministration result increased clinical effects (e . g . prolonged sodation)of OTHER_DRUG triazolam .
1930,"These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.",diltiazem,triazolam,effect,These pharmacokinetic effects seen DRUG coadministration result increased clinical effects (e . g . prolonged sodation)of midazolam OTHER_DRUG .
1931,"In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;",diltiazem,lovastatin,mechanism,In ten-subject study coadministration DRUG (120 mg bid) OTHER_DRUG resulted 3-4 times increase mean OTHER_DRUG AUC Cmax vs . OTHER_DRUG alone;
1932,Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.,rifampin,diltiazem,mechanism,Coadministration DRUG OTHER_DRUG lowered OTHER_DRUG plasma concentrations undetectable levels .
1933,"Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.",diltiazem,rifampin,advise,Coadministration DRUG OTHER_DRUG known CYP3A4 inducer avoided possible alternative therapy considered .
1934,Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.,CRIXIVAN,atazanavir,advise,Combinations drugs studied coadministration DRUG OTHER_DRUG recommended .
1935,Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.,CRIXIVAN,delavirdine,advise,Dose reduction DRUG 600 mg every 8 hours considered taking OTHER_DRUG 400 mg three times day .
1936,Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.,Indinavir,didanosine,advise,DRUG OTHER_DRUG formulations containing buffer administered least one hour apart empty stomach .
1937,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.,indinavir,efavirenz,mechanism,Increasing DRUG dose 1000 mg every 8 hours compensate increased DRUG metabolism due OTHER_DRUG .
1938,Indinavir concentrations may be decreased in the presence of nevirapine.,Indinavir,nevirapine,mechanism,DRUG concentrations may decreased presence OTHER_DRUG .
1939,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.,indinavir,ritonavir,effect,Preliminary clinical data suggest incidence nephrolithiasis higher patients receiving DRUG combination OTHER_DRUG receiving CRIXIVAN 800 mg q8h .
1940,Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.,antiarrhythmics,CRIXIVAN,advise,Caution warranted therapeutic concentration monitoring recommended DRUG coadministered OTHER_DRUG .
1941,CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.,CRIXIVAN,indinavir,effect,DRUG may effective due decreased OTHER_DRUG concentrations patients taking agents concomitantly .
1942,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",atorvastatin,CRIXIVAN,advise,Use lowest possible dose DRUG careful monitoring consider HMG-CoA reductase inhibitors primarily metabolized CYP3A4 pravastatin fluvastatin rosuvastatin combination OTHER_DRUG .
1943,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",HMG-CoA reductase inhibitors,CRIXIVAN,advise,Use lowest possible dose atorvastatin careful monitoring consider HMG-CoA reductase inhibitors primarily metabolized CYP3A4 pravastatin fluvastatin rosuvastatin combination OTHER_DRUG .
1944,Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.,CRIXIVAN,itraconazole,advise,Dose reduction DRUG 600 mg every 8 hours recommended administering OTHER_DRUG concurrently .
1945,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.,rifabutin,CRIXIVAN,advise,Dose reduction DRUG half standard dose dose increase OTHER_DRUG 1000 mg (three 333-mg capsules) every 8 hours recommended DRUG OTHER_DRUG coadministered .
1946,Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.,Sildenafil,indinavir,advise,DRUG dose exceed maximum 25 mg 48- hour period patients receiving concomitant OTHER_DRUG therapy .
1947,Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.,Tadalafil,indinavir,advise,DRUG dose exceed maximum 10 mg 72- hour period patients receiving concomitant OTHER_DRUG therapy .
1948,Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.,Vardenafil,indinavir,advise,DRUG dose exceed maximum 2 . 5 mg 24-hour period patients receiving concomitant OTHER_DRUG therapy .
1949,"Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",digoxin,conivaptan,mechanism,Digoxin: Coadministration DRUG P-glycoprotein substrate oral OTHER_DRUG resulted reduction clearance increase DRUG Cmax AUC values .
1950,"Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.",digoxin,VAPRISOL,mechanism,Therefore DRUG administered OTHER_DRUG clinician alert possibility increases DRUG levels .
1951,There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.,etidronate,warfarin,effect,There isolated reports patients experiencing increases prothrombin times DRUG added OTHER_DRUG therapy .
1952,Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.,escitalopram,non-selective MAO inhibitor,advise,Wait 5 weeks stopping DRUG starting non-selective MAO inhibitor .
1953,Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.,MAO inhibitor,escitalopram,advise,Wait 2 weeks stopping MAO inhibitor starting OTHER_DRUG .
1954,Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.,Erythromycin,theophylline,effect,DRUG use patients receiving high doses OTHER_DRUG may associated increase serum OTHER_DRUG levels potential OTHER_DRUG toxicity .
1955,"In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.",theophylline,erythromycin,advise,In case DRUG toxicity and/or elevated serum DRUG levels dose DRUG reduced patient receiving concomitant OTHER_DRUG therapy .
1956,Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Concomitant administration DRUG OTHER_DRUG reported result elevated OTHER_DRUG serum levels .
1957,There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,There reports increased anticoagulant effects DRUG oral OTHER_DRUG used concomitantly .
1958,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Concurrent use DRUG OTHER_DRUG dihydroergotamine associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia .
1959,Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Concurrent use DRUG ergotamine OTHER_DRUG associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia .
1960,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,triazolam,mechanism,DRUG reported decrease clearance OTHER_DRUG midazolam thus may increase pharmacologic effect benzodiazepines .
1961,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,midazolam,mechanism,DRUG reported decrease clearance triazolam OTHER_DRUG thus may increase pharmacologic effect benzodiazepines .
1962,Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.,Erythromycin,benzodiazepines,effect,DRUG reported decrease clearance triazolam midazolam thus may increase pharmacologic effect OTHER_DRUG .
1963,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,carbamazepine,int,There reports interactions DRUG OTHER_DRUG cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole .
1964,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cyclosporine,int,There reports interactions DRUG carbamazepine OTHER_DRUG tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole .
1965,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,tacrolimus,int,There reports interactions DRUG carbamazepine cyclosporine OTHER_DRUG hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole .
1966,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,hexobarbital,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus OTHER_DRUG phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole .
1967,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,phenytoin,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital OTHER_DRUG alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole .
1968,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,alfentanil,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin OTHER_DRUG cisapride disopyramide lovastatin bromocriptine valproate terfenadine astemizole .
1969,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,cisapride,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil OTHER_DRUG disopyramide lovastatin bromocriptine valproate terfenadine astemizole .
1970,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,disopyramide,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride OTHER_DRUG lovastatin bromocriptine valproate terfenadine astemizole .
1971,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,lovastatin,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide OTHER_DRUG bromocriptine valproate terfenadine astemizole .
1972,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,bromocriptine,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin OTHER_DRUG valproate terfenadine astemizole .
1973,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,valproate,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine OTHER_DRUG terfenadine astemizole .
1974,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,terfenadine,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate OTHER_DRUG astemizole .
1975,"There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.",erythromycin,astemizole,int,There reports interactions DRUG carbamazepine cyclosporine tacrolimus hexobarbital phenytoin alfentanil cisapride disopyramide lovastatin bromocriptine valproate terfenadine OTHER_DRUG .
1976,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,terfenadine,mechanism,DRUG reported significantly alter metabolism nonsedating antihistamines OTHER_DRUG astemizole taken concomitantly .
1977,Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.,Erythromycin,astemizole,mechanism,DRUG reported significantly alter metabolism nonsedating antihistamines terfenadine OTHER_DRUG taken concomitantly .
1978,"In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.",terfenadine,erythromycin,effect,In addition deaths reported rarely concomitant administration DRUG OTHER_DRUG .
1979,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",erythromycin,cisapride,effect,There postmarketing reports drug interactions DRUG coadministered OTHER_DRUG resulting QT prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation torsades de pointes like due inhibition hepatic metabolism OTHER_DRUG DRUG .
1980,"There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.",cisapride,erythromycin,mechanism,There postmarketing reports drug interactions OTHER_DRUG coadministered DRUG resulting QT prolongation cardiac arrythmias ventricular tachycardia ventricular fibrulation torsades de pointes like due inhibition hepatic metabolism DRUG OTHER_DRUG .
1981,Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;,lovastatin,erythromycin,advise,Patients receiving concomitant DRUG OTHER_DRUG carefully monitored;
1982,"Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,Because DRUG shown depress plasma prothrombin activity patients OTHER_DRUG therapy may require downward adjustment OTHER_DRUG dosage .
1983,"Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.",tetracycline class,penicillins,effect,Since bacteriostatic drugs tetracycline class antibiotics may interfere bactericidal action OTHER_DRUG advisable administer drugs concomitantly .
1984,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent use DRUG oral OTHER_DRUG may render oral OTHER_DRUG less effective .
1985,Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.,warfarin,flutamide,effect,Increases prothrombin time noted patients receiving long- term DRUG therapy OTHER_DRUG initiated .
1986,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.",EULEXIN,warfarin,advise,Therefore close monitoring prothrombin time recommended adjustment anticoagulant dose may necessary DRUG Capsules administered concomitantly OTHER_DRUG .
1987,"in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.",terfenadine,dirithromycin,mechanism,one man C max DRUG 8 . 1 ng/mL DRUG alone 7 . 2 ng/mL DRUG plus OTHER_DRUG .
1988,The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.,terfenadine,dirithromycin,effect,The mean QT c interval (msec) 369 DRUG alone 367 DRUG plus OTHER_DRUG .
1989,"Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.",erythromycin,terfenadine,int,Thus interaction observed DRUG OTHER_DRUG expected dirithromycin .
1990,"Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.",terfenadine,macrolide antibiotics,effect,Serious cardiac dysrhythmias resulting death occurred patients receiving DRUG concomitantly macrolide antibiotics .
1991,"In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.",macrolides,terfenadine,advise,In addition DRUG contraindicated patients receiving OTHER_DRUG therapy pre-existing cardiac abnormalities (arrhythmia bradycardia QT c interval prolongation ischemic heart disease congestive heart failure etc . ) electrolyte disturbances .
1992,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,antacids,mechanism,OTHER_DRUG H 2 receptor antagonists: When DRUG administered immediately following OTHER_DRUG H 2 -receptor antagonists absorption DRUG slightly enhanced .
1993,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,H 2 -receptor antagonists,mechanism,Antacids H 2 receptor antagonists: When DRUG administered immediately following antacids H 2 -receptor antagonists absorption DRUG slightly enhanced .
1994,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,mechanism,Triazolam: DRUG reported decrease clearance OTHER_DRUG thus may increase pharmacologic effect OTHER_DRUG .
1995,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,effect,Triazolam: DRUG reported decrease clearance OTHER_DRUG thus may increase pharmacologic effect OTHER_DRUG .
1996,Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Digoxin: Concomitant administration DRUG OTHER_DRUG reported result elevated OTHER_DRUG serum levels .
1997,Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.,erythromycin,anticoagulants,effect,Anticoagulants: There reports increased anticoagulant effects DRUG oral OTHER_DRUG used concomitantly .
1998,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,ergotamine,effect,Ergotamine: Concurrent use DRUG OTHER_DRUG dihydroergotamine associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia .
1999,Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.,erythromycin,dihydroergotamine,effect,Ergotamine: Concurrent use DRUG ergotamine OTHER_DRUG associated patients acute ergot toxicity characterized severe peripheral vasospasm dysesthesia .
2000,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,cyclosporine,int,Other drugs Drug interactions reported concomitant administration DRUG medications including OTHER_DRUG hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin .
2001,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,hexobarbital,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine OTHER_DRUG carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin .
2002,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,carbamazepine,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital OTHER_DRUG alfentanil disopyramide phenytoin bromocriptine valproate astemizole lovastatin .
2003,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,alfentanil,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine OTHER_DRUG disopyramide phenytoin bromocriptine valproate astemizole lovastatin .
2004,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,disopyramide,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil OTHER_DRUG phenytoin bromocriptine valproate astemizole lovastatin .
2005,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,phenytoin,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide OTHER_DRUG bromocriptine valproate astemizole lovastatin .
2006,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,bromocriptine,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin OTHER_DRUG valproate astemizole lovastatin .
2007,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,valproate,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine OTHER_DRUG astemizole lovastatin .
2008,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,astemizole,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate OTHER_DRUG lovastatin .
2009,"Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.",erythromycin,lovastatin,int,Other drugs Drug interactions reported concomitant administration DRUG medications including cyclosporine hexobarbital carbamazepine alfentanil disopyramide phenytoin bromocriptine valproate astemizole OTHER_DRUG .
2010,"The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.",REVIA,disulfiram,effect,The safety efficacy concomitant use DRUG OTHER_DRUG unknown concomitant use two potentially hepatotoxic medications ordinarily recommended unless probable benefits outweigh known risks .
2011,Lethargy and somnolence have been reported following doses of REVIA and thioridazine.,REVIA,thioridazine,effect,Lethargy somnolence reported following doses DRUG OTHER_DRUG .
2012,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid,effect,Patients taking DRUG may benefit OTHER_DRUG containing medicines cough cold preparations antidiarrheal preparations OTHER_DRUG analgesics .
2013,"Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.",REVIA,opioid analgesics,effect,Patients taking DRUG may benefit opioid containing medicines cough cold preparations antidiarrheal preparations opioid analgesics .
2014,"In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.",REVIA,opioid,effect,In emergency situation OTHER_DRUG analgesia must administered patient receiving DRUG amount OTHER_DRUG required may greater usual resulting respiratory depression may deeper prolonged .
2015,Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.,hydrochlorothiazide,anionic exchange resins,mechanism,Cholestyramine colestipol resins: Absorption DRUG impaired presence anionic exchange resins .
2016,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",cholestyramine,hydrochlorothiazide,mechanism,Single doses either DRUG colestipol resins bind OTHER_DRUG reduce absorption gastrointestinal tract 85 43 percent respectively .
2017,"Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.",colestipol,hydrochlorothiazide,mechanism,Single doses either cholestyramine DRUG resins bind OTHER_DRUG reduce absorption gastrointestinal tract 85 43 percent respectively .
2018,Lithium: generally should not be given with diuretics.,Lithium,diuretics,advise,Lithium: generally given OTHER_DRUG .
2019,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic agents reduce renal clearance OTHER_DRUG add high risk OTHER_DRUG toxicity .
2020,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,effect,Diuretic agents reduce renal clearance OTHER_DRUG add high risk OTHER_DRUG toxicity .
2021,Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.,lithium,Hydrochlorothiazide,advise,Refer package insert DRUG preparations use preparations OTHER_DRUG .
2022,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,Non-steroidal Anti-inflammatory Drugs: In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2023,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,Non-steroidal Anti-inflammatory Drugs: In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2024,"Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,Non-steroidal Anti-inflammatory Drugs: In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2025,"Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",Hydrochlorothiazide,non-steroidal anti-inflammatory agents,advise,Therefore DRUG non-steroidal anti-inflammatory agents used concomitantly patient observed closely determine desired effect diuretic obtained .
2026,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased nephrotoxicity reported following concomitant administration DRUG aminoglycoside antibiotics .
2027,Sulfacetamide preparations are incompatible with silver preparations.,Sulfacetamide,silver,int,DRUG preparations incompatible OTHER_DRUG preparations .
2028,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,vasodilators,effect,However DRUG potential increase hypotensive effect OTHER_DRUG antihypertensive agents .
2029,"However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.",iloprost,antihypertensive agents,effect,However DRUG potential increase hypotensive effect vasodilators antihypertensive agents .
2030,"Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.",iloprost,anticoagulants,effect,Since DRUG inhibits platelet function potential increased risk bleeding particularly patients maintained OTHER_DRUG .
2031,RAPTIVA should not be used with other immunosuppressive drugs.,RAPTIVA,immunosuppressive drugs,advise,DRUG used immunosuppressive drugs .
2032,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",Acellular vaccines,RAPTIVA,advise,Acellular live live-attenuated vaccines administered OTHER_DRUG treatment .
2033,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live vaccines,RAPTIVA,advise,Acellular live live-attenuated vaccines administered OTHER_DRUG treatment .
2034,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live-attenuated vaccines,RAPTIVA,advise,Acellular live live-attenuated vaccines administered OTHER_DRUG treatment .
2035,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,fat-soluble vitamins,mechanism,Mineral oil interferes absorption fat-soluble vitamins including vitamin D preparations .
2036,"Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.",Mineral oil,vitamin D preparations,mechanism,Mineral oil interferes absorption fat-soluble vitamins including vitamin D preparations .
2037,Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.,thiazide diuretics,ergocalciferol,effect,Administration thiazide diuretics hypoparathyroid patients concurrently treated OTHER_DRUG may cause hypercalcemia .
2038,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,loop diuretics,advise,DRUG administered concomitantly potent loop diuretics furosemide ethacrynic acid potential ototoxicity enhanced combination .
2039,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,furosemide,advise,DRUG administered concomitantly potent loop diuretics OTHER_DRUG ethacrynic acid potential ototoxicity enhanced combination .
2040,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,ethacrynic acid,advise,DRUG administered concomitantly potent loop diuretics furosemide ethacrynic acid potential ototoxicity enhanced combination .
2041,"When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.",amiloride,angiotensin-converting enzyme inhibitor,effect,When DRUG HCl administered concomitantly angiotensin-converting enzyme inhibitor risk hyperkalemia may increased .
2042,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally given OTHER_DRUG reduce renal clearance add high risk DRUG toxicity .
2043,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2044,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2045,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2046,"Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",MIDAMOR,non-steroidal anti-inflammatory agents,advise,Therefore DRUG non-steroidal anti-inflammatory agents used concomitantly patient observed closely determine desired effect diuretic obtained .
2047,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,potassium-sparing diuretics,effect,Since DRUG potassium-sparing diuretics including MIDAMOR may associated increased serum potassium levels potential effects potassium kinetics renal function considered agents administered concurrently .
2048,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,MIDAMOR,effect,Since DRUG potassium-sparing diuretics including OTHER_DRUG may associated increased serum potassium levels potential effects potassium kinetics renal function considered agents administered concurrently .
2049,"- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.",bumetanide,aminoglycoside antibiotics,advise,- Drugs ototoxic potential: Especially presence impaired renal function use parenterally administered DRUG patients aminoglycoside antibiotics also given avoided except life-threatening conditions .
2050,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,- Lithium: DRUG generally given OTHER_DRUG (such bumetanide) reduce renal clearance add high risk DRUG toxicity .
2051,- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,bumetanide,advise,- Lithium: DRUG generally given diuretics (such bumetanide) reduce renal clearance add high risk DRUG toxicity .
2052,- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.,probenecid,bumetanide,effect,- Probenecid: Pretreatment DRUG reduces natriuresis hyperreninemia produced OTHER_DRUG .
2053,This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.,probenecid,bumetanide,mechanism,This antagonistic effect DRUG OTHER_DRUG natriuresis due direct action sodium excretion probably secondary inhibitory effect renal tubular secretion OTHER_DRUG .
2054,"Thus, probenecid should not be administered concurrently with bumetanide.",probenecid,bumetanide,advise,Thus DRUG administered concurrently OTHER_DRUG .
2055,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,mechanism,- Indomethacin: DRUG blunts increases urine volume sodium excretion seen OTHER_DRUG treatment inhibits bumetanide-induced increase plasma renin activity .
2056,- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.,Indomethacin,bumetanide,effect,- Indomethacin: DRUG blunts increases urine volume sodium excretion seen OTHER_DRUG treatment inhibits bumetanide-induced increase plasma renin activity .
2057,"- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.",Bumetanide,antihypertensive drugs,effect,- Antihypertensives: DRUG may potentiate effect various antihypertensive drugs necessitating reduction dosage drugs .
2058,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,nonsteroidal anti-inflammatory agents,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
2059,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,salicylates,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound OTHER_DRUG sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
2060,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,sulfonamides,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound salicylates OTHER_DRUG chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
2061,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,chloramphenicol,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound salicylates sulfonamides OTHER_DRUG probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
2062,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,probenecid,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol OTHER_DRUG coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
2063,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,coumarins,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid OTHER_DRUG monoamine oxidase inhibitors beta adrenergic blocking agents .
2064,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,monoamine oxidase inhibitors,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
2065,"The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.",sulfonylureas,beta adrenergic blocking agents,effect,The hypoglycemic action DRUG may potentiated certain drugs including nonsteroidal anti-inflammatory agents drugs highly protein bound salicylates sulfonamides chloramphenicol probenecid coumarins monoamine oxidase inhibitors beta adrenergic blocking agents .
2066,"A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.",glyburide,ciprofloxacin,int,A possible interaction DRUG OTHER_DRUG fluoroquinolone antibiotic reported resulting potentiation hypoglycemic action DRUG .
2067,A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.,miconazole,hypoglycemic agents,effect,A potential interaction oral DRUG oral hypoglycemic agents leading severe hypoglycemia reported .
2068,"Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.",anticoagulants,chlordiazepoxide,effect,Although clinical studies established cause effect relationship physicians aware variable effects blood coagulation reported rarely patients receiving oral DRUG OTHER_DRUG .
2069,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,amikacin,advise,DRUG administered concomitantly OTHER_DRUG ciprofloxacin gentamicin netilmicin tobramycin .
2070,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,ciprofloxacin,advise,DRUG administered concomitantly amikacin OTHER_DRUG gentamicin netilmicin tobramycin .
2071,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,gentamicin,advise,DRUG administered concomitantly amikacin ciprofloxacin OTHER_DRUG netilmicin tobramycin .
2072,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,netilmicin,advise,DRUG administered concomitantly amikacin ciprofloxacin gentamicin OTHER_DRUG tobramycin .
2073,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,tobramycin,advise,DRUG administered concomitantly amikacin ciprofloxacin gentamicin netilmicin OTHER_DRUG .
2074,"Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.",vitamin B12,folic acid,int,Medications interfere folate utilization including: anticonvulsant medications (such phenytoin primidone) metformin (sometimes prescribed control blood sugar type 2 diabetes) sulfasalazine (used control inflammation associated Crohns disease ulcerative colitis) triamterene (a diuretic) Methotrexate There concern interaction vitamin B12 folic acid .
2075,"Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.",magnesium trisilicate,nitrofurantoin,mechanism,Antacids containing magnesium trisilicate administered concomitantly OTHER_DRUG reduce rate extent absorption .
2076,The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.,nitrofurantoin,magnesium trisilicate,mechanism,The mechanism interaction probably adsorption DRUG onto surface magnesium trisilicate .
2077,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",Uricosuric drugs,nitrofurantoin,mechanism,Uricosuric drugs probenecid sulfinpyrazone inhibit renal tubular secretion OTHER_DRUG .
2078,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",probenecid,nitrofurantoin,mechanism,Uricosuric drugs DRUG sulfinpyrazone inhibit renal tubular secretion OTHER_DRUG .
2079,"Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.",sulfinpyrazone,nitrofurantoin,mechanism,Uricosuric drugs probenecid DRUG inhibit renal tubular secretion OTHER_DRUG .
2080,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",aminoglycosides,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e . g . DRUG indomethacin) myelotoxic (e . g . cytotoxic chemotherapy) cardiotoxic (e . g . doxorubicin) hepatotoxic (e . g . methotrexate asparaginase) effects OTHER_DRUG may increase toxicity organ systems .
2081,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",indomethacin,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e . g . aminoglycosides indomethacin) myelotoxic (e . g . cytotoxic chemotherapy) cardiotoxic (e . g . doxorubicin) hepatotoxic (e . g . methotrexate asparaginase) effects OTHER_DRUG may increase toxicity organ systems .
2082,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",cytotoxic,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e . g . aminoglycosides indomethacin) myelotoxic (e . g . DRUG chemotherapy) cardiotoxic (e . g . doxorubicin) hepatotoxic (e . g . methotrexate asparaginase) effects OTHER_DRUG may increase toxicity organ systems .
2083,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",doxorubicin,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e . g . aminoglycosides indomethacin) myelotoxic (e . g . cytotoxic chemotherapy) cardiotoxic (e . g . doxorubicin) hepatotoxic (e . g . methotrexate asparaginase) effects OTHER_DRUG may increase toxicity organ systems .
2084,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",methotrexate,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e . g . aminoglycosides indomethacin) myelotoxic (e . g . cytotoxic chemotherapy) cardiotoxic (e . g . doxorubicin) hepatotoxic (e . g . DRUG asparaginase) effects OTHER_DRUG may increase toxicity organ systems .
2085,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",asparaginase,PROLEUKIN,effect,Concurrent administration drugs possessing nephrotoxic (e . g . aminoglycosides indomethacin) myelotoxic (e . g . cytotoxic chemotherapy) cardiotoxic (e . g . doxorubicin) hepatotoxic (e . g . methotrexate asparaginase) effects OTHER_DRUG may increase toxicity organ systems .
2086,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,antineoplastic agents,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose DRUG antineoplastic agents specifically dacarbazine cis-platinum tamoxifen interferon-alfa .
2087,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,dacarbazine,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose DRUG antineoplastic agents specifically OTHER_DRUG cis-platinum tamoxifen interferon-alfa .
2088,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,cis-platinum,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose DRUG antineoplastic agents specifically dacarbazine OTHER_DRUG tamoxifen interferon-alfa .
2089,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,tamoxifen,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose DRUG antineoplastic agents specifically dacarbazine cis-platinum OTHER_DRUG interferon-alfa .
2090,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,interferon-alfa,effect,Hypersensitivity reactions reported patients receiving combination regimens containing sequential high dose DRUG antineoplastic agents specifically dacarbazine cis-platinum tamoxifen OTHER_DRUG .
2091,"Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.",PROLEUKIN,interferon-alfa,effect,Myocardial injury including myocardial infarction myocarditis ventricular hypokinesia severe rhabdomyolysis appear increased patients receiving DRUG OTHER_DRUG concurrently .
2092,"Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.",interferon-alfa,PROLEUKIN,effect,Exacerbation initial presentation number autoimmune inflammatory disorders observed following concurrent use DRUG OTHER_DRUG including crescentic IgA glomerulonephritis oculo-bulbar myasthenia gravis inflammatory arthritis thyroiditis bullous pemphigoid Stevens-Johnson syndrome .
2093,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",glucocorticoids,PROLEUKIN,effect,Although DRUG shown reduce PROLEUKIN-induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents OTHER_DRUG may reduce antitumor effectiveness OTHER_DRUG thus avoided . 12 Beta-blockers antihypertensives may potentiate hypotension seen OTHER_DRUG .
2094,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",Beta-blockers,PROLEUKIN,effect,Although glucocorticoids shown reduce PROLEUKIN-induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents OTHER_DRUG may reduce antitumor effectiveness OTHER_DRUG thus avoided . 12 DRUG antihypertensives may potentiate hypotension seen OTHER_DRUG .
2095,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",antihypertensives,PROLEUKIN,effect,Although glucocorticoids shown reduce PROLEUKIN-induced side effects including fever renal insufficiency hyperbilirubinemia confusion dyspnea concomitant administration agents OTHER_DRUG may reduce antitumor effectiveness OTHER_DRUG thus avoided . 12 Beta-blockers DRUG may potentiate hypotension seen OTHER_DRUG .
2096,"Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.",interleukin-2,radiographic iodinated contrast media,effect,Delayed Adverse Reactions Iodinated Contrast Media: A review literature revealed 12 . 6% (range 11-28%) 501 patients treated various DRUG containing regimens subsequently administered radiographic iodinated contrast media experienced acute atypical adverse reactions .
2097,"Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.",Cevimeline,beta adrenergic antagonists,advise,DRUG administered caution patients taking beta adrenergic antagonists possibility conduction disturbances .
2098,PROSTIN E2 may augment the activity of other oxytocic drugs.,PROSTIN E2,oxytocic drugs,effect,PROSTIN E2 may augment activity oxytocic drugs .
2099,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,Interactions vitamin D analogues (Vitamin D2 Vitamin D3 Calcitriol Calcidiol): Cholestyramine: DRUG reported reduce intestinal absorption fat soluble vitamins;
2100,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,Phenytoin/Phenobarbital: The coadministration DRUG phenobarbital affect plasma concentrations vitamin D may reduce endogenous plasma levels calcitriol/ergocalcitriol accelerating metabolism .
2101,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,Phenytoin/Phenobarbital: The coadministration phenytoin DRUG affect plasma concentrations vitamin D may reduce endogenous plasma levels calcitriol/ergocalcitriol accelerating metabolism .
2102,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some reports shown concomitant administration DRUG vitamin D causes hypercalcemia .
2103,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,Digitalis: Vitamin D dosage must determined care patients undergoing treatment OTHER_DRUG hypercalcemia patients may precipitate cardiac arrhythmias .
2104,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole: DRUG may inhibit synthetic catabolic enzymes vitamin D .
2105,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,Corticosteroids: A relationship functional antagonism exists vitamin D analogues promote calcium absorption OTHER_DRUG inhibit calcium absorption .
2106,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,Magnesium: Magnesium-containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D patients chronic renal dialysis .
2107,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,Magnesium: Magnesium-containing preparations (eg antacids) may cause hypermagnesemia therefore taken therapy vitamin D patients chronic renal dialysis .
2108,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",cholestyramine,thiazide diuretics,effect,May interact following: DRUG colestipol (use thiazide diuretics may prevent diuretic working properly;
2109,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",colestipol,thiazide diuretics,effect,May interact following: cholestyramine DRUG (use thiazide diuretics may prevent diuretic working properly;
2110,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",CNS depressant drugs,INAPSINE,effect,Other CNS depressant drugs (e . g . barbiturates tranquilizers opioids general anesthetics) additive potentiating effects OTHER_DRUG .
2111,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",barbiturates,INAPSINE,effect,Other CNS depressant drugs (e . g . DRUG tranquilizers opioids general anesthetics) additive potentiating effects OTHER_DRUG .
2112,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",tranquilizers,INAPSINE,effect,Other CNS depressant drugs (e . g . barbiturates DRUG opioids general anesthetics) additive potentiating effects OTHER_DRUG .
2113,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",opioids,INAPSINE,effect,Other CNS depressant drugs (e . g . barbiturates tranquilizers DRUG general anesthetics) additive potentiating effects OTHER_DRUG .
2114,"Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.",anesthetics,INAPSINE,effect,Other CNS depressant drugs (e . g . barbiturates tranquilizers opioids general anesthetics) additive potentiating effects OTHER_DRUG .
2115,"Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.",INAPSINE,CNS depressant drugs,advise,Following administration DRUG dose CNS depressant drugs reduced .
2116,Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.,Isoproterenol hydrochloride,epinephrine,advise,Isoproterenol hydrochloride injection OTHER_DRUG administered simultaneously drugs direct cardiac stimulants combined effects may induce serious arrhythmias .
2117,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,anesthetics,advise,DRUG used caution potent inhalational OTHER_DRUG halothane employed potential sensitize myocardium effects sympathomimetic amines .
2118,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,halothane,advise,DRUG used caution potent inhalational anesthetics OTHER_DRUG employed potential sensitize myocardium effects sympathomimetic amines .
2119,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,phenytoin,effect,The effectiveness progestin-only pills reduced hepatic enzyme-inducing drugs anticonvulsants OTHER_DRUG carbamazepine barbiturates antituberculosis drug rifampin .
2120,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,carbamazepine,effect,The effectiveness progestin-only pills reduced hepatic enzyme-inducing drugs anticonvulsants phenytoin OTHER_DRUG barbiturates antituberculosis drug rifampin .
2121,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,barbiturates,effect,The effectiveness progestin-only pills reduced hepatic enzyme-inducing drugs anticonvulsants phenytoin carbamazepine OTHER_DRUG antituberculosis drug rifampin .
2122,"The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.",progestin,rifampin,effect,The effectiveness progestin-only pills reduced hepatic enzyme-inducing drugs anticonvulsants phenytoin carbamazepine barbiturates antituberculosis drug OTHER_DRUG .
2123,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,calcium carbonate,mechanism,Concomitant administration DRUG calcium carbonate cimetidine omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance .
2124,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,cimetidine,mechanism,Concomitant administration DRUG calcium carbonate OTHER_DRUG omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance .
2125,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,omeprazole,mechanism,Concomitant administration DRUG calcium carbonate cimetidine OTHER_DRUG estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance .
2126,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,estrogen,mechanism,Concomitant administration DRUG calcium carbonate cimetidine omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance .
2127,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,progesterone,mechanism,Concomitant administration DRUG calcium carbonate cimetidine omeprazole estrogen/progesterone oral contraceptive produced minor changes pharmacokinetics gemifloxacin considered without clinical significance .
2128,"Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.",FACTIVE,contraceptive,mechanism,Concomitant administration DRUG calcium carbonate cimetidine omeprazole estrogen/progesterone oral OTHER_DRUG produced minor changes pharmacokinetics gemifloxacin considered without clinical significance .
2129,Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.,FACTIVE,probenecid,mechanism,Concomitant administration DRUG OTHER_DRUG resulted 45% increase systemic exposure gemifloxacin .
2130,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolones,warfarin,effect,However DRUG reported enhance anticoagulant effects OTHER_DRUG derivatives patients prothrombin time suitable coagulation test closely monitored quinolone antimicrobial administered concomitantly OTHER_DRUG derivatives .
2131,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,However quinolones reported enhance anticoagulant effects OTHER_DRUG derivatives patients prothrombin time suitable coagulation test closely monitored quinolone antimicrobial administered concomitantly OTHER_DRUG derivatives .
2132,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,aluminum,mechanism,The absorption oral DRUG significantly reduced concomitant administration antacid containing OTHER_DRUG magnesium .
2133,The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.,gemifloxacin,magnesium,mechanism,The absorption oral DRUG significantly reduced concomitant administration antacid containing aluminum OTHER_DRUG .
2134,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Magnesium,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2135,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",aluminum,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2136,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",ferrous sulfate,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2137,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",iron,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2138,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",multivitamin preparations,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2139,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",zinc,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing DRUG metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2140,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Videx,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations DRUG (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2141,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",didanosine,FACTIVE,advise,Magnesium- and/or aluminum-containing antacids products containing ferrous sulfate (iron) multivitamin preparations containing zinc metal cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution taken within 3 hours 2 hours OTHER_DRUG .
2142,Sucralfate should not be taken within 2 hours of FACTIVE.,Sucralfate,FACTIVE,advise,DRUG taken within 2 hours OTHER_DRUG .
2143,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Steroids,edetate calcium disodium,effect,DRUG enhance renal toxicity edetate calcium disodium animals . 7 Edetate calcium disodium interferes action zinc insulin preparations chelating zinc . 7
2144,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Edetate calcium disodium,zinc insulin,mechanism,Steroids enhance renal toxicity edetate calcium disodium animals . 7 Edetate calcium disodium interferes action zinc insulin preparations chelating zinc . 7
2145,(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.),thiazide diuretics,digitalis,effect,(Concurrent use thiazide diuretics may enhance possibility OTHER_DRUG toxicity associated hypokalemia . )
2146,"for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;",hypoglycemic medications,thiazide diuretic,advise,adult-onset diabetics dosage adjustment hypoglycemic medications may necessary thiazide diuretic therapy;
2147,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,loop diuretics,effect,(In patients steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics .
2148,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,potassium sparing diuretics,effect,(In patients steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics .
2149,"(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.",steroidal anti-inflammatory agent,thiazide diuretics,effect,(In patients steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium sparing thiazide diuretics .
2150,"Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)",hydroflumethiazide,nonsteroidal anti-inflammatory agents,advise,Therefore DRUG nonsteroidal anti-inflammatory agents used concomitantly patient observed closely determine desired effect diuretic obtained . )
2151,(Thiazides may decrease arterial responsiveness to norepinephrine.,Thiazides,norepinephrine,effect,(Thiazides may decrease arterial responsiveness OTHER_DRUG .
2152,(Thiazide drugs may increase the responsiveness to tubocurarine.),Thiazide drugs,tubocurarine,effect,(Thiazide drugs may increase responsiveness OTHER_DRUG . )
2153,"Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.",HMG-CoA reductase inhibitors,Fentanyl,advise,Experience co-administration HMG-CoA reductase inhibitors OTHER_DRUG patients limitedthereforeconsideration given temporarily suspending use HMG-CoA reductase inhibitors patients receiving OTHER_DRUG .
2154,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,acetaminophen,effect,OTHER_DRUG methotrexate - DRUG may decrease hepatic toxicity OTHER_DRUG overdosage taking methotrexate .
2155,Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.,L-methionine,methotrexate,effect,Acetaminophen OTHER_DRUG - DRUG may decrease hepatic toxicity acetaminophen overdosage taking OTHER_DRUG .
2156,Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.,Methionine,gentamicin,effect,OTHER_DRUG - DRUG may protect ototoxic effects OTHER_DRUG .
2157,"Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.",BETAGAN,epinephrine,effect,Although DRUG used alone little effect pupil size mydriasis resulting concomitant therapy DRUG OTHER_DRUG may occur .
2158,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.",beta-blocker,reserpine,advise,Close observation patient recommended DRUG administered patients receiving catecholamine-depleting drugs OTHER_DRUG possible additive effects production hypotension and/or marked bradycardia may produce vertigo syncope postural hypotension .
2159,"Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.",beta-adrenergic blocking agents,calcium antagonists,advise,Patients receiving beta-adrenergic blocking agents along either oral intravenous calcium antagonists monitored possible atrioventricular conduction disturbances left ventricular failure hypotension .
2160,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,digitalis,effect,The concomitant use beta-adrenergic blocking agents OTHER_DRUG calcium antagonists may additive effects prolonging atrioventricular conduction time .
2161,The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.,beta-adrenergic blocking agents,calcium antagonist,effect,The concomitant use beta-adrenergic blocking agents digitalis calcium antagonists may additive effects prolonging atrioventricular conduction time .
2162,Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.,Phenothiazine-related compounds,beta-adrenergic blocking agents,mechanism,Phenothiazine-related compounds beta-adrenergic blocking agents may additive hypotensite effects due inhibition metabolism .
2163,International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.,warfarin,IRESSA,effect,International Normalized Ratio (INR) elevations and/or bleeding events reported patients taking DRUG OTHER_DRUG therapy .
2164,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg DRUG itraconazole) decrease OTHER_DRUG metabolism increase OTHER_DRUG plasma concentrations .
2165,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",ketoconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg DRUG itraconazole) decrease OTHER_DRUG metabolism increase OTHER_DRUG plasma concentrations .
2166,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole itraconazole) decrease OTHER_DRUG metabolism increase OTHER_DRUG plasma concentrations .
2167,"Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.",itraconazole,gefitinib,mechanism,Substances potent inhibitors CYP3A4 activity (eg ketoconazole itraconazole) decrease OTHER_DRUG metabolism increase OTHER_DRUG plasma concentrations .
2168,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,histamine H2-receptor antagonists,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2-receptor antagonists ranitidine cimetidine) may reduce plasma concentrations OTHER_DRUG therefore potentially may reduce efficacy .
2169,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,ranitidine,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2-receptor antagonists DRUG cimetidine) may reduce plasma concentrations OTHER_DRUG therefore potentially may reduce efficacy .
2170,Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.,cimetidine,IRESSA,mechanism,Drugs cause significant sustained elevation gastric pH (histamine H2-receptor antagonists ranitidine cimetidine) may reduce plasma concentrations OTHER_DRUG therefore potentially may reduce efficacy .
2171,"Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.",IRESSA,vinorelbine,effect,Phase II clinical trial data DRUG OTHER_DRUG used concomitantly indicate DRUG may exacerbate neutropenic effect OTHER_DRUG .
2172,"There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.",loxapine,lorazepam,effect,There rare reports significant respiratory depression stupor and/or hypotension concomitant use DRUG OTHER_DRUG .
2173,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,ketoconazole,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering DRUG inhibitors CYP3A4 family (e . g . OTHER_DRUG itraconazole erythromycin clarithromycin) .
2174,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,itraconazole,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering DRUG inhibitors CYP3A4 family (e . g . ketoconazole OTHER_DRUG erythromycin clarithromycin) .
2175,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,erythromycin,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering DRUG inhibitors CYP3A4 family (e . g . ketoconazole itraconazole OTHER_DRUG clarithromycin) .
2176,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,clarithromycin,advise,Drugs may alter imatinib plasma concentrations Drugs may increase imatinib plasma concentrations: Caution recommended administering DRUG inhibitors CYP3A4 family (e . g . ketoconazole itraconazole erythromycin clarithromycin) .
2177,There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).,Gleevec,ketoconazole,mechanism,There significant increase exposure imatinib DRUG coadministered OTHER_DRUG (CYP3A4 inhibitor) .
2178,"Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).",rifampin,Gleevec,mechanism,Pretreatment healthy volunteers multiple doses DRUG followed single dose OTHER_DRUG increased OTHER_DRUG oral-dose clearance 3 . 8-fold significantly (p 0 . 05) decreased mean cmax AUC(0-8) .
2179,"Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.",Gleevec,simvastatin,mechanism,Drugs may plasma concentration altered DRUG DRUG increases mean cmax AUC OTHER_DRUG (CYP3A4 substrate) 2- 3 . 5-fold respectively suggesting inhibition CYP3A4 DRUG .
2180,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,cyclosporine,advise,Particular caution recommended administering DRUG CYP3A4 substrates narrow therapeutic window (e . g . OTHER_DRUG pimozide) .
2181,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,pimozide,advise,Particular caution recommended administering DRUG CYP3A4 substrates narrow therapeutic window (e . g . cyclosporine pimozide) .
2182,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,benzodiazepines,mechanism,DRUG increase plasmaconcentration CYP3A4 metabolized drugs (e . g . triazolo-benzodiazepines dihydropyridine calcium channel blockers certain HMG-CoA reductase inhibitors etc . ) .
2183,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,dihydropyridine calcium channel blockers,mechanism,DRUG increase plasmaconcentration CYP3A4 metabolized drugs (e . g . triazolo-benzodiazepines dihydropyridine calcium channel blockers certain HMG-CoA reductase inhibitors etc . ) .
2184,"Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).",Gleevec,HMG-CoA reductase inhibitors,mechanism,DRUG increase plasmaconcentration CYP3A4 metabolized drugs (e . g . triazolo-benzodiazepines dihydropyridine calcium channel blockers certain HMG-CoA reductase inhibitors etc . ) .
2185,Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.,acetaminophen,Gleevec,mechanism,Systemic exposure DRUG expected increased coadministered OTHER_DRUG .
2186,A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.,FOSCAVIR,pentamidine,int,A possible drug interaction DRUG intravenous OTHER_DRUG described .
2187,Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;,FOSCAVIR,pentamidine,effect,Concomitant treatment four patients United Kingdom DRUG intravenous OTHER_DRUG may caused hypocalcemia;
2188,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,aminoglycosides,advise,Because foscarnets tendency cause renal impairment use DRUG avoided combination potentially nephrotoxic drugs OTHER_DRUG amphotericin B intravenous pentamidine unless potential benefits outweigh risks patient .
2189,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,amphotericin B,advise,Because foscarnets tendency cause renal impairment use DRUG avoided combination potentially nephrotoxic drugs aminoglycosides amphotericin B intravenous pentamidine unless potential benefits outweigh risks patient .
2190,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,pentamidine,advise,Because foscarnets tendency cause renal impairment use DRUG avoided combination potentially nephrotoxic drugs aminoglycosides amphotericin B intravenous OTHER_DRUG unless potential benefits outweigh risks patient .
2191,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergotamine,naratriptan,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours contraindicated .
2192,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergot-type medications,naratriptan,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours contraindicated .
2193,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",dihydroergotamine,naratriptan,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like DRUG methysergide) OTHER_DRUG within 24 hours contraindicated .
2194,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",methysergide,naratriptan,advise,Because theoretical basis effects may additive use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours contraindicated .
2195,"Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.",naratriptan,5-HT1 agonists,advise,Because vasospastic effects may additive coadministration DRUG 5-HT1 agonists within 24 hours recommended .
2196,"If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",naratriptan,SSRI,advise,If concomitant treatment DRUG OTHER_DRUG clinically warranted appropriate observation patient advised .
2197,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,fluconazole,int,Clinical studies DRUG identified potentially significant interactions OTHER_DRUG lithium .
2198,Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.,celecoxib,lithium,int,Clinical studies DRUG identified potentially significant interactions fluconazole OTHER_DRUG .
2199,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,furosemide,int,Experience nonsteroidal anti-inflammatory drugs (NSAIDs) suggests potential interactions OTHER_DRUG ACE inhibitors .
2200,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,nonsteroidal anti-inflammatory drugs,ACE inhibitors,int,Experience nonsteroidal anti-inflammatory drugs (NSAIDs) suggests potential interactions furosemide ACE inhibitors .
2201,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,furosemide,int,Experience nonsteroidal anti-inflammatory drugs (NSAIDs) suggests potential interactions OTHER_DRUG ACE inhibitors .
2202,Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.,NSAIDs,ACE inhibitors,int,Experience nonsteroidal anti-inflammatory drugs (NSAIDs) suggests potential interactions furosemide ACE inhibitors .
2203,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE inhibitors: Reports suggest DRUG may diminish antihypertensive effect Angiotensin Converting Enzyme (ACE) inhibitors .
2204,This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.,CELEBREX,ACE-inhibitors,advise,This interaction given consideration patients taking DRUG concomitantly OTHER_DRUG .
2205,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown DRUG reduce natriuretic effect OTHER_DRUG thiazides patients .
2206,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,Furosemide: Clinical studies well post marketing observations shown DRUG reduce natriuretic effect furosemide OTHER_DRUG patients .
2207,Aspirin: CELEBREX can be used with low dose aspirin.,CELEBREX,aspirin,advise,Aspirin: DRUG used low dose OTHER_DRUG .
2208,"However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.",aspirin,CELEBREX,effect,However concomitant administration DRUG OTHER_DRUG may result increased rate GI ulceration complications compared use OTHER_DRUG alone .
2209,Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.,fluconazole,celecoxib,mechanism,Fluconazole: Concomitant administration DRUG 200 mg QD resulted two-fold increase OTHER_DRUG plasma concentration .
2210,This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).,celecoxib,fluconazole,mechanism,This increase due inhibition DRUG metabolism via P450 2C9 OTHER_DRUG (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism) .
2211,CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.,CELEBREX,fluconazole,advise,DRUG introduced lowest recommended dose patients receiving OTHER_DRUG .
2212,"Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.",lithium,CELEBREX,mechanism,Lithium: In study conducted healthy subjects mean steady-state DRUG plasma levels increased approximately 17% subjects receiving DRUG 450 mg BID OTHER_DRUG 200 mg BID compared subjects receiving DRUG alone .
2213,Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.,lithium,CELEBREX,advise,Patients DRUG treatment closely monitored OTHER_DRUG introduced withdrawn .
2214,"However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.",CELEBREX,warfarin,advise,However caution used administering DRUG OTHER_DRUG since patients increased risk bleeding complications .
2215,Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.,L-histidine,medroxyprogesterone acetate,effect,Medroxyprogesterone Acetate - DRUG observed enhance (in tissue culture) effect medroxyprogesterone acetate reducing number human breast cancer cells S phase .
2216,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H1 blockers,effect,H1 H2 Blockers - Although reported DRUG via metabolism histamine might decrease efficacy H1 H2 blockers .
2217,"H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.",L-histidine,H2 blockers,effect,H1 H2 Blockers - Although reported DRUG via metabolism histamine might decrease efficacy H1 H2 blockers .
2218,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,theophylline,mechanism,However systemic administration DRUG shown elevate plasma concentrations OTHER_DRUG interfere metabolism caffeine enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly .
2219,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,caffeine,mechanism,However systemic administration DRUG shown elevate plasma concentrations theophylline interfere metabolism OTHER_DRUG enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly .
2220,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,warfarin,effect,However systemic administration DRUG shown elevate plasma concentrations theophylline interfere metabolism caffeine enhance effects oral anticoagulant OTHER_DRUG derivatives associated transient elevations serum creatinine patients receiving systemic cyclosporine concomitantly .
2221,"However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.",quinolones,cyclosporine,effect,However systemic administration DRUG shown elevate plasma concentrations theophylline interfere metabolism caffeine enhance effects oral anticoagulant warfarin derivatives associated transient elevations serum creatinine patients receiving systemic OTHER_DRUG concomitantly .
2222,Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.,Erythromycin,vardenafil,mechanism,DRUG (500 mg . . d) produced 4-fold increase OTHER_DRUG AUC 3-fold increase Cmax co-administered OTHER_DRUG 5 mg healthy volunteers .
2223,It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.,Vardenafil,erythromycin,advise,It recommended exceed single 5 mg dose DRUG 24-hour period used combination OTHER_DRUG .
2224,Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.,Ketoconazole,vardenafil,mechanism,DRUG (200 mg daily) produced 10-fold increase OTHER_DRUG AUC 4-fold increase Cmax co-administered OTHER_DRUG (5 mg) healthy volunteers .
2225,A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.,Vardenafil,ketoconazole,advise,A 5-mg DRUG dose exceeded used combination 200 mg daily OTHER_DRUG .
2226,"Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.",Vardenafil,ketoconazole,advise,Since higher doses OTHER_DRUG (400 mg daily) may result higher increases Cmax AUC single 2 . 5 mg dose DRUG exceeded 24-hour period used combination OTHER_DRUG 400 mg daily .
2227,"HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.",Indinavir,Vardenafil,mechanism,HIV Protease Inhibitors: DRUG (800 mg . . . ) co-administered OTHER_DRUG 10 mg resulted 16-fold increase OTHER_DRUG AUC 7-fold increase OTHER_DRUG Cmax 2-fold increase OTHER_DRUG half-life .
2228,It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.,Vardenafil,indinavir,advise,It recommended exceed single 2 . 5 mg DRUG dose 24-hour period used combination OTHER_DRUG .
2229,Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.,Ritonavir,Vardenafil,mechanism,DRUG (600 mg b . . . ) co-administered OTHER_DRUG 5 mg resulted 49-fold increase OTHER_DRUG AUC 13-fold increase OTHER_DRUG Cmax .
2230,"The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.",vardenafil,ritonavir,mechanism,The interaction consequence blocking hepatic metabolism DRUG OTHER_DRUG highly potent CYP3A4 inhibitor also inhibits CYP2C9 .
2231,Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.,Ritonavir,vardenafil,mechanism,DRUG significantly prolonged half-life OTHER_DRUG 26 hours .
2232,"Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.",Vardenafil,ritonavir,advise,Consequently recommended exceed single 2 . 5 mg DRUG dose 72-hour period used combination OTHER_DRUG .
2233,"In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.",nitrates,vardenafil,mechanism,In vivo studies: Nitrates: The blood pressure lowering effects sublingual DRUG (0 . 4 mg) taken 1 4 hours OTHER_DRUG increases heart rate taken 1 4 8 hours potentiated 20 mg dose OTHER_DRUG healthy middle-aged subjects .
2234,"Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.",Vardenafil,nitrates,advise,Potentiation hypotensive effects OTHER_DRUG patients ischemic heart disease evaluated concomitant use DRUG OTHER_DRUG contraindicated .
2235,"In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.",nifedipine,Vardenafil,effect,In patients whose hypertension controlled DRUG OTHER_DRUG 20 mg produced mean additional supine systolic/diastolic blood pressure reductions 6/5 mm Hg compared placebo .
2236,"Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.",Vardenafil,terazosin,effect,Alpha-blockers: When DRUG 10 20 mg given healthy volunteers either simultaneously 6 hours 10 mg dose OTHER_DRUG significant hypotension developed substantial number subjects .
2237,"With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,With simultaneous dosing DRUG 10 mg OTHER_DRUG 10 mg 6 8 subjects experienced standing systolic blood pressure less 85 mm Hg .
2238,"With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.",Vardenafil,terazosin,effect,With simultaneous dosing DRUG 20 mg OTHER_DRUG 10 mg 2 9 subjects experienced standing systolic blood pressure less 85 mm Hg .
2239,"When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.",Vardenafil,terazosin,effect,When DRUG dosing separated OTHER_DRUG 10 mg 6 hours 7 28 subjects received 20 mg DRUG experienced decrease standing systolic blood pressure 85 mm Hg .
2240,"In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.",Vardenafil,tamsulosin,effect,In similar study OTHER_DRUG healthy volunteers 1 24 subjects dosed DRUG 20 mg OTHER_DRUG 0 . 4 mg separated 6 hours experienced standing systolic blood pressure 85 mm Hg .
2241,Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.,Vardenafil,tamsulosin,effect,Two 16 subjects dosed simultaneously DRUG 10 mg OTHER_DRUG 0 . 4 mg experienced standing systolic blood pressure 85 mm Hg .
2242,"Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.",Vardenafil,alpha-blocker,advise,Based data DRUG used patients OTHER_DRUG therapy .
2243,"Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.",Vardenafil,ritonavir,mechanism,OTHER_DRUG indinavir: Upon concomitant administration 5 mg DRUG 600 mg BID OTHER_DRUG Cmax AUC OTHER_DRUG reduced approximately 20% .
2244,"Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.",Vardenafil,indinavir,mechanism,Upon administration 10 mg DRUG 800 mg TID OTHER_DRUG Cmax AUC OTHER_DRUG reduced 40% 30% respectively .
2245,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",b-lactam antibiotics,probenecid,mechanism,Probenecid: As b-lactam antibiotics renal excretion loracarbef inhibited OTHER_DRUG resulted approximate 80% increase AUC loracarbef .
2246,"Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.",loracarbef,probenecid,mechanism,Probenecid: As b-lactam antibiotics renal excretion DRUG inhibited OTHER_DRUG resulted approximate 80% increase AUC DRUG .
2247,Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.,anticoagulants,thyroid,advise,Patients stabilized oral DRUG found require OTHER_DRUG replacement therapy watched closely OTHER_DRUG started .
2248,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T4,mechanism,Cholestyramine: DRUG binds OTHER_DRUG T3 intestine thus impairing absorption thyroid hormones .
2249,"Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.",Cholestyramine,T3,mechanism,Cholestyramine: DRUG binds T4 OTHER_DRUG intestine thus impairing absorption thyroid hormones .
2250,"Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.",cholestyramine,thyroid hormones,advise,Therefore 4 5 hours elapse administration DRUG thyroid hormones .
2251,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.",levothyroxine,estrogens,mechanism,In patient nonfunctioning thyroid gland receiving thyroid replacement therapy free DRUG may decreased OTHER_DRUG started thus increasing thyroid requirements .
2252,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,estrogens,advise,Therefore patients without functioning DRUG gland DRUG replacement therapy may need increase DRUG dose OTHER_DRUG estrogen-containing oral contraceptives given .
2253,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,contraceptives,advise,Therefore patients without functioning DRUG gland DRUG replacement therapy may need increase DRUG dose estrogens estrogen-containing oral OTHER_DRUG given .
2254,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,imipramine,effect,Tricyclic Antidepressants: Use thyroid products OTHER_DRUG tricyclic antidepressants may increase receptor sensitivity enhance antidepressant activity transient cardiac arrhythmias observed .
2255,Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.,thyroid products,tricyclic antidepressants,effect,Tricyclic Antidepressants: Use thyroid products imipramine tricyclic antidepressants may increase receptor sensitivity enhance antidepressant activity transient cardiac arrhythmias observed .
2256,Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.,Thyroid preparations,digitalis,effect,Digitalis: Thyroid preparations may potentiate toxic effects OTHER_DRUG .
2257,"Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.",thyroid preparation,anesthetic,effect,Ketamine: When administered patients thyroid preparation parenteral OTHER_DRUG may cause hypertension tachycardia .
2258,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,epinephrine,effect,Vasopressors: DRUG increases adrenergic effect catecholamines OTHER_DRUG norepinephrine .
2259,Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.,Thyroxine,norepinephrine,effect,Vasopressors: DRUG increases adrenergic effect catecholamines epinephrine OTHER_DRUG .
2260,Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.,antacids,lactulose,mechanism,Results preliminary studies humans rats suggest nonabsorbable DRUG given concurrently OTHER_DRUG may inhibit desired lactulose-induced drop colonic pH .
2261,Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.,Digitalis,Bretylium Tosylate,effect,DRUG toxicity may aggravated initial release norepinephrine caused Bretylium Tosylate Injection .
2262,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,catecholamines,Bretylium Tosylate,effect,The pressor effects DRUG dopamine norepinephrine enhanced Bretylium Tosylate .
2263,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,dopamine,Bretylium Tosylate,effect,The pressor effects catecholamines DRUG norepinephrine enhanced Bretylium Tosylate .
2264,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,norepinephrine,Bretylium Tosylate,effect,The pressor effects catecholamines dopamine DRUG enhanced Bretylium Tosylate .
2265,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,muscle relaxants,effect,DRUG potentiates muscle relaxant effect muscle relaxants notably nondepolarizing muscle relaxants MAC (minimum alveolar concentration) reduced concomitant administration N 2O .
2266,"Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.",Isoflurane,nondepolarizing muscle relaxants,effect,DRUG potentiates muscle relaxant effect muscle relaxants notably nondepolarizing muscle relaxants MAC (minimum alveolar concentration) reduced concomitant administration N 2O .
2267,Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.,MAO inhibitors,dopamine HCl,advise,Patients treated MAO inhibitors within two three weeks prior administration dopamine HCl receive initial doses dopamine HCl greater one-tenth (1/10) usual dose .
2268,Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.,dopamine HCl,diuretic agents,effect,Concurrent administration low-dose dopamine HCl diuretic agents may produce additive potentiating effect urine flow .
2269,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,beta-adrenergic blocking agents,effect,Cardiac effects DRUG antagonized beta-adrenergic blocking agents propranolol metoprolol .
2270,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,propranolol,effect,Cardiac effects DRUG antagonized beta-adrenergic blocking agents OTHER_DRUG metoprolol .
2271,"Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.",dopamine,metoprolol,effect,Cardiac effects DRUG antagonized beta-adrenergic blocking agents propranolol OTHER_DRUG .
2272,The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.,dopamine HCl,alpha-adrenergic blocking agents,effect,The peripheral vasoconstriction caused high doses dopamine HCl antagonized alpha-adrenergic blocking agents .
2273,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,Butyrophenones,dopamine,effect,DRUG (such haloperidol) phenothiazines suppress dopaminergic renal mesenteric vasodilation induced low dose OTHER_DRUG infusion .
2274,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,haloperidol,dopamine,effect,Butyrophenones (such haloperidol) phenothiazines suppress dopaminergic renal mesenteric vasodilation induced low dose OTHER_DRUG infusion .
2275,Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.,phenothiazines,dopamine,effect,Butyrophenones (such haloperidol) DRUG suppress dopaminergic renal mesenteric vasodilation induced low dose OTHER_DRUG infusion .
2276,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,catecholamines,effect,DRUG halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered OTHER_DRUG dopamine .
2277,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",Cyclopropane,dopamine,effect,DRUG halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines OTHER_DRUG .
2278,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,catecholamines,effect,Cyclopropane halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered OTHER_DRUG dopamine .
2279,"Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.",halogenated hydrocarbon anesthetics,dopamine,effect,Cyclopropane halogenated hydrocarbon anesthetics increase cardiac autonomic irritability may sensitize myocardium action certain intravenously administered catecholamines OTHER_DRUG .
2280,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,cyclopropane,advise,Therefore EXTREME CAUTION exercised administering dopamine HCl patients receiving OTHER_DRUG halogenated hydrocarbon anesthetics .
2281,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,halogenated hydrocarbon anesthetics,advise,Therefore EXTREME CAUTION exercised administering dopamine HCl patients receiving cyclopropane halogenated hydrocarbon anesthetics .
2282,It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.,dopamine,propranolol,effect,It reported results studies animals indicate dopamine-induced ventricular arrhythmias anesthesia reversed OTHER_DRUG .
2283,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",vasopressor,oxytocic drugs,effect,The concomitant use vasopressors vasoconstricting agents (such ergonovine) oxytocic drugs may result severe hypertension .
2284,"The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.",ergonovine,oxytocic drugs,effect,The concomitant use vasopressors vasoconstricting agents (such ergonovine) oxytocic drugs may result severe hypertension .
2285,Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.,phenytoin,dopamine HCl,effect,Administration DRUG patients receiving dopamine HCl reported lead hypotension bradycardia .
2286,"It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.",dopamine HCl,phenytoin,advise,It suggested patients receiving dopamine HCl alternatives OTHER_DRUG used anticonvulsant therapy needed .
2287,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,narcotic analgesics,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2288,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,meperidine,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics OTHER_DRUG phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2289,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,phenothiazines,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics meperidine OTHER_DRUG antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2290,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antipsychotics,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics meperidine phenothiazines OTHER_DRUG tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2291,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,tricyclic antidepressants,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2292,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antiarrhythmics,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain OTHER_DRUG quinidine salts antihistamines .
2293,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,quinidine,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics OTHER_DRUG salts antihistamines .
2294,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antihistamines,effect,Drug Interactions: The central DRUG syndrome occur DRUG agents AKINETON administered concomitantly drugs secondary DRUG actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts OTHER_DRUG .
2295,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,narcotic analgesics,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2296,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,meperidine,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics OTHER_DRUG phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2297,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,phenothiazines,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics meperidine OTHER_DRUG antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2298,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antipsychotics,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics meperidine phenothiazines OTHER_DRUG tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2299,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,tricyclic antidepressants,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts antihistamines .
2300,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antiarrhythmics,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain OTHER_DRUG quinidine salts antihistamines .
2301,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,quinidine,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics OTHER_DRUG salts antihistamines .
2302,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antihistamines,effect,Drug Interactions: The central anticholinergic syndrome occur anticholinergic agents DRUG administered concomitantly drugs secondary anticholinergic actions . g . certain narcotic analgesics meperidine phenothiazines antipsychotics tricyclic antidepressants certain antiarrhythmics quinidine salts OTHER_DRUG .
2303,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ritonavir,mechanism,The concomitant use transdermal DRUG OTHER_DRUG potent 3A4 inhibitors ketoconazole itraconazole troleandomycin clarithromycin nelfinavir nefazadone may result increase DRUG plasma concentrations .
2304,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,ketoconazole,mechanism,The concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors OTHER_DRUG itraconazole troleandomycin clarithromycin nelfinavir nefazadone may result increase DRUG plasma concentrations .
2305,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,itraconazole,mechanism,The concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole OTHER_DRUG troleandomycin clarithromycin nelfinavir nefazadone may result increase DRUG plasma concentrations .
2306,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,troleandomycin,mechanism,The concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole itraconazole OTHER_DRUG clarithromycin nelfinavir nefazadone may result increase DRUG plasma concentrations .
2307,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,clarithromycin,mechanism,The concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole itraconazole troleandomycin OTHER_DRUG nelfinavir nefazadone may result increase DRUG plasma concentrations .
2308,"The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.",fentanyl,nelfinavir,mechanism,The concomitant use transdermal DRUG ritonavir potent 3A4 inhibitors ketoconazole itraconazole troleandomycin clarithromycin OTHER_DRUG nefazadone may result increase DRUG plasma concentrations .
2309,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",diltiazem,fentanyl,mechanism,The concomitant use CYP3A4 inhibitors DRUG erythromycin transdermal OTHER_DRUG may also result increase OTHER_DRUG plasma concentrations could increase prolong adverse drug effects may cause serious respiratory depression .
2310,"The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.",erythromycin,fentanyl,mechanism,The concomitant use CYP3A4 inhibitors diltiazem DRUG transdermal OTHER_DRUG may also result increase OTHER_DRUG plasma concentrations could increase prolong adverse drug effects may cause serious respiratory depression .
2311,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,central nervous system depressants,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2312,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,opioids,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited OTHER_DRUG sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2313,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,sedatives,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids OTHER_DRUG hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2314,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,hypnotics,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives OTHER_DRUG tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2315,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,tranquilizers,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics OTHER_DRUG (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2316,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,benzodiazepines,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2317,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,anesthetics,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general OTHER_DRUG phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2318,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,phenothiazines,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics OTHER_DRUG skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2319,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,skeletal muscle relaxants,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2320,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",DURAGESIC,alcohol,effect,Central Nervous System Depressants: The concomitant use DRUG (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants OTHER_DRUG may cause respiratory depression hypotension profound sedation potentially result coma death .
2321,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,central nervous system depressants,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2322,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,opioids,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited OTHER_DRUG sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2323,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,sedatives,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids OTHER_DRUG hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2324,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,hypnotics,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives OTHER_DRUG tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2325,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,tranquilizers,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics OTHER_DRUG (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2326,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,benzodiazepines,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2327,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,anesthetics,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general OTHER_DRUG phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2328,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,phenothiazines,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics OTHER_DRUG skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2329,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,skeletal muscle relaxants,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants alcohol may cause respiratory depression hypotension profound sedation potentially result coma death .
2330,"Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.",fentanyl,alcohol,effect,Central Nervous System Depressants: The concomitant use DURAGESIC (fentanyl transdermal system) central nervous system depressants including limited opioids sedatives hypnotics tranquilizers (e . g . benzodiazepines) general anesthetics phenothiazines skeletal muscle relaxants OTHER_DRUG may cause respiratory depression hypotension profound sedation potentially result coma death .
2331,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,DURAGESIC,MAOI,advise,MAO Inhibitors: DRUG recommended use patients received OTHER_DRUG within 14 days severe unpredictable potentiation MAO inhibitors reported opioid analgesics
2332,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,MAO inhibitors,opioid analgesics,advise,MAO Inhibitors: DURAGESIC recommended use patients received MAOI within 14 days severe unpredictable potentiation MAO inhibitors reported opioid analgesics
2333,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,coumarin anticoagulant,mechanism,In vitro studies shown DRUG displace coumarin anticoagulants warfarin protein-binding sites .
2334,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,warfarin,mechanism,In vitro studies shown DRUG displace coumarin anticoagulants OTHER_DRUG protein-binding sites .
2335,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,coumarin anticoagulants,advise,It recommended DRUG started patients already receiving coumarin anticoagulants prothrombin times closely monitored adjustment anticoagulant dose may necessary .
2336,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,anticoagulant,advise,It recommended DRUG started patients already receiving coumarin anticoagulants prothrombin times closely monitored adjustment OTHER_DRUG dose may necessary .
2337,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,tricyclic antidepressants,effect,The administration local anesthetic solutions containing epinephrine norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension .
2338,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,phenothiazines,effect,The administration local anesthetic solutions containing epinephrine norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants OTHER_DRUG may produce severe prolonged hypotension hypertension .
2339,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,monoamine oxidase inhibitors,effect,The administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension .
2340,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,tricyclic antidepressants,effect,The administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension .
2341,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,phenothiazines,effect,The administration local anesthetic solutions containing DRUG norepinephrine patients receiving monoamine oxidase inhibitors tricyclic antidepressants OTHER_DRUG may produce severe prolonged hypotension hypertension .
2342,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,The administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension .
2343,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,tricyclic antidepressants,effect,The administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants phenothiazines may produce severe prolonged hypotension hypertension .
2344,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,phenothiazines,effect,The administration local anesthetic solutions containing epinephrine DRUG patients receiving monoamine oxidase inhibitors tricyclic antidepressants OTHER_DRUG may produce severe prolonged hypotension hypertension .
2345,"Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.",vasopressor drugs,ergot-type oxytocic drugs,effect,Concurrent administration vasopressor drugs (for treatment hypotension related obstetric blocks) ergot-type oxytocic drugs may cause severe persistent hypertension cerebrovascular accidents .
2346,"Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.",chloroprocaine,sulfonamide drug,advise,Therefore DRUG used condition sulfonamide drug employed .
2347,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;",Anticholinergic agents,digoxin,mechanism,Anticholinergic agents may affect gastrointestinal absorption various drugs slowly dissolving dosage forms digoxin;
2348,"Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.",Anticholinergic drugs,metoclopramide,mechanism,Anticholinergic drugs may antagonize effects drugs alter gastrointestinal motility OTHER_DRUG .
2349,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.",antacids,anticholinergic agents,mechanism,Because DRUG may interfere absorption anticholinergic agents simultaneous use drugs avoided .
2350,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).",ENBREL,anakinra,effect,In study patients active RA treated 24 weeks concurrent DRUG OTHER_DRUG therapy 7% rate serious infections observed higher observed DRUG alone (0%) .
2351,Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).,ENBREL,anakinra,effect,Two percent patients treated concurrently DRUG OTHER_DRUG developed neutropenia (ANC 1 x 109/L) .
2352,"Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.",sulfasalazine,ENBREL,effect,Patients clinical study established therapy DRUG OTHER_DRUG added noted develop mild decrease mean neutrophil counts comparison groups treated either OTHER_DRUG CI DRUG alone .
2353,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,nabumetone,warfarin,advise,Caution exercised administering DRUG OTHER_DRUG since interactions seen NSAIDs .
2354,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,warfarin,NSAIDs,int,Caution exercised administering nabumetone DRUG since interactions seen OTHER_DRUG .
2355,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,central nervous system depressants,effect,Concurrent use DRUG central nervous system depressants (e . g . alcohol barbiturates tranquilizers antihistamines) may result increased central nervous system depressant effects .
2356,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,alcohol,effect,Concurrent use DRUG central nervous system depressants (e . g . OTHER_DRUG barbiturates tranquilizers antihistamines) may result increased central nervous system depressant effects .
2357,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,barbiturates,effect,Concurrent use DRUG central nervous system depressants (e . g . alcohol OTHER_DRUG tranquilizers antihistamines) may result increased central nervous system depressant effects .
2358,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,tranquilizers,effect,Concurrent use DRUG central nervous system depressants (e . g . alcohol barbiturates OTHER_DRUG antihistamines) may result increased central nervous system depressant effects .
2359,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,antihistamines,effect,Concurrent use DRUG central nervous system depressants (e . g . alcohol barbiturates tranquilizers antihistamines) may result increased central nervous system depressant effects .
2360,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.",STADOL NS,sumatriptan,mechanism,However another study healthy volunteers pharmacokinetics butorphanol significantly altered (29% decrease AUC 38% decrease Cmax) 1-mg dose STADOL NS administered 1 minute 20-mg dose OTHER_DRUG nasal spray .
2361,"When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.",STADOL NS,sumatriptan,mechanism,When STADOL NS administered 30 minutes OTHER_DRUG nasal spray AUC butorphanol increased 11% Cmax decreased 18% .
2362,"These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.",STADOL NS,sumatriptan,effect,These results suggest analgesic effect STADOL NS may diminished administered shortly OTHER_DRUG nasal spray 30 minutes reduction effect minimal .
2363,"It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.",butorphanol,erythromycin,advise,It known effects DRUG altered concomitant medications affect hepatic metabolism drugs (erythromycin etc . ) physicians alert possibility smaller initial dose longer intervals doses may needed .
2364,"Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.",STADOL NS,nasal vasoconstrictor,effect,Therefore slower onset anticipated STADOL NS administered concomitantly immediately following nasal vasoconstrictor .
2365,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalapril,effect,Hypotension: Patients Diuretic Therapy: Patients DRUG especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy OTHER_DRUG enalaprilat .
2366,"Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.",diuretics,enalaprilat,effect,Hypotension: Patients Diuretic Therapy: Patients DRUG especially diuretic therapy recently instituted may occasionally experience excessive reduction blood pressure initiation therapy enalapril OTHER_DRUG .
2367,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalapril,diuretic,effect,The possibility hypotensive effects DRUG enalaprilat minimized either discontinuing OTHER_DRUG increasing salt intake prior initiation treatment DRUG enalaprilat .
2368,The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.,enalaprilat,diuretic,effect,The possibility hypotensive effects enalapril DRUG minimized either discontinuing OTHER_DRUG increasing salt intake prior initiation treatment enalapril DRUG .
2369,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,Agents Causing Renin Release: The antihypertensive effect DRUG DRUG IV augmented antihypertensive agents cause renin release (e . g . diuretics) .
2370,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,Agents Causing Renin Release: The antihypertensive effect DRUG DRUG IV augmented antihypertensive agents cause renin release (e . g . diuretics) .
2371,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,antihypertensive agents,effect,Agents Causing Renin Release: The antihypertensive effect DRUG DRUG IV augmented antihypertensive agents cause renin release (e . g . diuretics) .
2372,"Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).",enalapril,diuretics,effect,Agents Causing Renin Release: The antihypertensive effect DRUG DRUG IV augmented antihypertensive agents cause renin release (e . g . diuretics) .
2373,"Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.",nonsteroidal anti-inflammatory drugs,enalapril,effect,Non-steroidal Anti-inflammatory Agents: In patients compromised renal function treated nonsteroidal anti-inflammatory drugs co-administration OTHER_DRUG may result deterioration renal function .
2374,"However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.",NSAIDs,ACE inhibitors,effect,However reports suggest DRUG may diminish antihypertensive effect ACE inhibitors .
2375,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This interaction given consideration patients taking DRUG concomitantly ACE inhibitors .
2376,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,Enalapril,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: DRUG DRUG IV attenuate potassium loss caused thiazide-type diuretics .
2377,Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.,enalapril,thiazide-type diuretics,effect,Agents Increasing Serum Potassium: DRUG DRUG IV attenuate potassium loss caused thiazide-type diuretics .
2378,"Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.",lithium,ACE inhibitors,effect,Lithium: DRUG toxicity reported patients receiving DRUG concomitantly drugs cause elimination sodium including ACE inhibitors .
2379,It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.,enalapril,lithium,advise,It recommended serum OTHER_DRUG levels monitored frequently DRUG administered concomitantly OTHER_DRUG .
2380,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,Colchicine,vitamin B12,mechanism,DRUG para-aminosalicylic acid heavy alcohol intake longer 2 weeks may produce malabsorption vitamin B12 .
2381,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,para-aminosalicylic acid,vitamin B12,mechanism,Colchicine para-aminosalicylic acid heavy alcohol intake longer 2 weeks may produce malabsorption vitamin B12 .
2382,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,alcohol,vitamin B12,mechanism,Colchicine para-aminosalicylic acid heavy DRUG intake longer 2 weeks may produce malabsorption vitamin B12 .
2383,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,probenecid,effect,Uricosuric Agents: DRUG may decrease effects OTHER_DRUG sulfinpyrazone phenylbutazone .
2384,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,sulfinpyrazone,effect,Uricosuric Agents: DRUG may decrease effects probenecid OTHER_DRUG phenylbutazone .
2385,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,phenylbutazone,effect,Uricosuric Agents: DRUG may decrease effects probenecid sulfinpyrazone OTHER_DRUG .
2386,Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.,Alcohol,aspirin,effect,Alcohol: Has synergistic effect OTHER_DRUG causing gastrointestinal bleeding .
2387,Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.,Corticosteroids,aspirin,effect,Corticosteroids: Concomitant administration OTHER_DRUG may increase risk gastrointestinal ulceration may reduce serum salicylate levels .
2388,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",Pyrazolone Derivatives,aspirin,effect,Pyrazolone Derivatives (phenylbutazone oxyphenbutazone possibly dipyrone): Concomitant administration OTHER_DRUG may increase risk gastrointestinal ulceration .
2389,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",phenylbutazone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone oxyphenbutazone possibly dipyrone): Concomitant administration OTHER_DRUG may increase risk gastrointestinal ulceration .
2390,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",oxyphenbutazone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone DRUG possibly dipyrone): Concomitant administration OTHER_DRUG may increase risk gastrointestinal ulceration .
2391,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",dipyrone,aspirin,effect,Pyrazolone Derivatives (phenylbutazone oxyphenbutazone possibly dipyrone): Concomitant administration OTHER_DRUG may increase risk gastrointestinal ulceration .
2392,Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.,Aspirin,nonsteroidal anti-inflammatory,advise,Nonsteroidal Antiinflammatory Agents: DRUG contraindicated patients hypersensitive nonsteroidal anti-inflammatory agents .
2393,Phenobarbital: Decreases aspirin effectiveness by enzyme induction.,Phenobarbital,aspirin,mechanism,Phenobarbital: Decreases OTHER_DRUG effectiveness enzyme induction .
2394,Phenytoin: Serum phenytoin levels may be increased by aspirin.,phenytoin,aspirin,effect,Phenytoin: Serum DRUG levels may increased OTHER_DRUG .
2395,Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.,Propranolol,aspirins,effect,Propranolol: May decrease OTHER_DRUG anti-inflammatory action competing receptors .
2396,"Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.",Aspirin,antacids,advise,Antacids: Enteric Coated DRUG given concurrently OTHER_DRUG since increase pH stomach may effect enteric coating tablets .
2397,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ketoconazole,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg OTHER_DRUG itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2398,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,itraconazole,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole OTHER_DRUG erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2399,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,erythromycin,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole OTHER_DRUG clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2400,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,clarithromycin,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin OTHER_DRUG ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2401,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ritonavir,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin OTHER_DRUG atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2402,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,atazanavir,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir OTHER_DRUG indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2403,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,indinavir,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir OTHER_DRUG nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2404,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nefazodone,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir OTHER_DRUG nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2405,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nelfinavir,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone OTHER_DRUG saquinavir telithromycin) may increase exposure dasatinib avoided .
2406,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,saquinavir,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir OTHER_DRUG telithromycin) may increase exposure dasatinib avoided .
2407,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,telithromycin,mechanism,Concomitant use DRUG drugs inhibit CYP3A4 (eg ketoconazole itraconazole erythromycin clarithromycin ritonavir atazanavir indinavir nefazodone nelfinavir saquinavir telithromycin) may increase exposure dasatinib avoided .
2408,Simultaneous administration of SPRYCEL with antacids should be avoided.,SPRYCEL,antacids,advise,Simultaneous administration DRUG OTHER_DRUG avoided .
2409,"If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.",antacid,SPRYCEL,advise,If DRUG therapy needed DRUG dose administered least 2 hours prior 2 hours dose OTHER_DRUG .
2410,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",H2 blockers,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long-term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg famotidine omeprazole) likely reduce OTHER_DRUG exposure .
2411,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",proton pump inhibitors,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long-term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg famotidine omeprazole) likely reduce OTHER_DRUG exposure .
2412,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",famotidine,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long-term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg DRUG omeprazole) likely reduce OTHER_DRUG exposure .
2413,"H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.",omeprazole,dasatinib,effect,H2 Blockers/Proton Pump Inhibitors: Long-term suppression gastric acid secretion H2 blockers proton pump inhibitors (eg famotidine omeprazole) likely reduce OTHER_DRUG exposure .
2414,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,H2 blockers,SPRYCEL,advise,The concomitant use H2 blockers proton pump inhibitors OTHER_DRUG recommended .
2415,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,proton pump inhibitors,SPRYCEL,advise,The concomitant use H2 blockers proton pump inhibitors OTHER_DRUG recommended .
2416,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,H2 blockers,SPRYCEL,advise,The use antacids considered place H2 blockers proton pump inhibitors patients receiving OTHER_DRUG therapy .
2417,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,proton pump inhibitors,SPRYCEL,advise,The use antacids considered place H2 blockers proton pump inhibitors patients receiving OTHER_DRUG therapy .
2418,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",alfentanil,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index DRUG astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2419,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",astemizole,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil DRUG terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2420,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",terfenadine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole DRUG cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2421,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cisapride,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine DRUG cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2422,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cyclosporine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride DRUG fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2423,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",fentanyl,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine DRUG pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2424,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",pimozide,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl DRUG quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2425,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",quinidine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide DRUG sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2426,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",sirolimus,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine DRUG tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2427,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",tacrolimus,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus DRUG ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2428,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergot alkaloids,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2429,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergotamine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2430,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",dihydroergotamine,SPRYCEL,advise,Therefore CYP3A4 substrates known narrow therapeutic index alfentanil astemizole terfenadine cisapride cyclosporine fentanyl pimozide quinidine sirolimus tacrolimus ergot alkaloids (ergotamine dihydroergotamine) administered caution patients receiving OTHER_DRUG .
2431,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",interferon beta-1a,TYSABRI,mechanism,After multiple dosing interferon beta-1a (AVONEX 30 mcg IM weekly) reduced OTHER_DRUG clearance approximately 30% .
2432,"After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.",AVONEX,TYSABRI,mechanism,After multiple dosing interferon beta-1a (AVONEX 30 mcg IM weekly) reduced OTHER_DRUG clearance approximately 30% .
2433,"Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.",terfenadine,Itraconazole,mechanism,Coadministration DRUG OTHER_DRUG led elevated plasma concentrations DRUG resulting rare instances life- threatening cardiac dysrhythmias one death .
2434,"Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.",ketoconazole,astemizole,mechanism,Another oral azole antifungal DRUG inhibits metabolism OTHER_DRUG resulting elevated plasma concentrations OTHER_DRUG active metabolite desmethylastermizole may prolong QT intervals .
2435,"In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.",itraconazole,astemizole,mechanism,In vitro data suggest DRUG compared ketoconazole less pronounced effect biotransformation system responsible metabolism OTHER_DRUG .
2436,"Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.",astemizole,itraconazole,advise,Based chemical resemblance OTHER_DRUG ketoconazole coadministration DRUG OTHER_DRUG contraindicated .
2437,Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.,ketoconazole,cisapride,mechanism,Human pharmacokinetics data indicate oral DRUG potently inhibits metabolism OTHER_DRUG resulting eight-fold increase mean AUC OTHER_DRUG .
2438,Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.,ketoconazole,cisapride,effect,Data suggest coadministration oral DRUG OTHER_DRUG result prolongation QT interval ECG .
2439,In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;,itraconazole,cisapride,mechanism,In vitro data suggest DRUG also markedly inhibits biotransformation system mainly responsible metabolism cisapride;
2440,therefore concomitant administration of Itraconazole with cisapride is contraindicated.,Itraconazole,cisapride,advise,therefore concomitant administration DRUG OTHER_DRUG contraindicated .
2441,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,midazolam,mechanism,Coadministration DRUG oral OTHER_DRUG triazolam resulted elevated plasma concentrations latter two drugs .
2442,Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.,Itraconazole,triazolam,mechanism,Coadministration DRUG oral midazolam OTHER_DRUG resulted elevated plasma concentrations latter two drugs .
2443,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,cyclosporine,mechanism,Coadministration DRUG OTHER_DRUG tacrolimus digoxin led increased plasma concentrations latter three drugs .
2444,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,tacrolimus,mechanism,Coadministration DRUG cyclosporine OTHER_DRUG digoxin led increased plasma concentrations latter three drugs .
2445,"Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.",Itraconazole,digoxin,mechanism,Coadministration DRUG cyclosporine tacrolimus OTHER_DRUG led increased plasma concentrations latter three drugs .
2446,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",Cyclosporine,Itraconazole,advise,DRUG tacrolimus digoxin concentrations monitored initiation OTHER_DRUG therapy frequently thereafter dose three drug products adjusted appropriately .
2447,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",tacrolimus,Itraconazole,advise,Cyclosporine DRUG digoxin concentrations monitored initiation OTHER_DRUG therapy frequently thereafter dose three drug products adjusted appropriately .
2448,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",digoxin,Itraconazole,advise,Cyclosporine tacrolimus DRUG concentrations monitored initiation OTHER_DRUG therapy frequently thereafter dose three drug products adjusted appropriately .
2449,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,immunosuppressive drugs,effect,Rhabdomyolysis observed patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) concomitantly immunosuppressive drugs including cyclosporine .
2450,Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.,HMG-CoA reductase inhibitors,cyclosporine,effect,Rhabdomyolysis observed patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) concomitantly immunosuppressive drugs including OTHER_DRUG .
2451,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,phenytoin,mechanism,When DRUG coadministered OTHER_DRUG rifampin H2antagonists reduced plasma concentrations DRUG reported .
2452,"When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.",Itraconazole,rifampin,mechanism,When DRUG coadministered phenytoin OTHER_DRUG H2antagonists reduced plasma concentrations DRUG reported .
2453,"Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;",Itraconazole,phenytoin,mechanism,Although studies conducted concomitant administration DRUG OTHER_DRUG may alter metabolism phenytoin;
2454,"therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.",phenytoin,Itraconazole,advise,therefore plasma concentrations DRUG also monitored given concurrently OTHER_DRUG .
2455,It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.,Itraconazole,coumarin,effect,It reported DRUG enhances anticoagulant effect coumarin-like drugs .
2456,"Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.",Itraconazole,coumarin,advise,Therefore prothrombin time carefully monitored patients receiving DRUG coumarin-like drugs simultaneously .
2457,Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.,azole antifungal agents,isoniazid,mechanism,Plasma concentrations azole antifungal agents reduced given concurrently OTHER_DRUG .
2458,Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.,Itraconazole,isoniazid,advise,DRUG plasma concentrations monitored DRUG OTHER_DRUG coadministered .
2459,Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.,azole antifungal agents,hypoglycemic agents,effect,Severe hypoglycemia reported patients concomitantly receiving azole antifungal agents oral hypoglycemic agents .
2460,Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.,Itraconazole,hypoglycemic agents,advise,Blood glucose concentrations carefully monitored DRUG oral hypoglycemic agents coadministered .
2461,Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.,Itraconazole,quinidine,effect,Tinnitus decreased hearing reported patients concomitantly receiving DRUG OTHER_DRUG .
2462,Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.,Itraconazole,dihydropyridine calcium channel blockers,effect,Edema reported patients concomitantly receiving DRUG dihydropyridine calcium channel blockers .
2463,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,DRUG bacteriostatic antibiotic may antagonize bactercidal effect OTHER_DRUG concurrent use drugs avoided .
2464,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",clarithromycin,cisapride,mechanism,Antibiotics: In vitro and/or vivo data show DRUG erythromycin troleandomycin markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2465,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",erythromycin,cisapride,mechanism,Antibiotics: In vitro and/or vivo data show clarithromycin DRUG troleandomycin markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2466,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",troleandomycin,cisapride,mechanism,Antibiotics: In vitro and/or vivo data show clarithromycin erythromycin DRUG markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2467,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",anticholinergic compounds,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds belladonna alkaloids dicyclomine would expected compromise beneficial effects OTHER_DRUG .
2468,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",belladonna alkaloids,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds belladonna alkaloids dicyclomine would expected compromise beneficial effects OTHER_DRUG .
2469,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",dicyclomine,cisapride,effect,Anticholinergics: Concurrent administration certain anticholinergic compounds belladonna alkaloids DRUG would expected compromise beneficial effects OTHER_DRUG .
2470,"It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.",cisapride,anticoagulant,advise,It advisable check coagulation time within first days start discontinuation DRUG therapy appropriate adjustment OTHER_DRUG dose necessary .
2471,"Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",nefazodone,cisapride,mechanism,Antidepressants: In vitro data indicate DRUG inhibits metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2472,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",fluconazole,cisapride,mechanism,Antifungals: In vitro and/or vivo data indicate DRUG itraconazole oral ketoconazole markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2473,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",itraconazole,cisapride,mechanism,Antifungals: In vitro and/or vivo data indicate fluconazole DRUG oral ketoconazole markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2474,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",ketoconazole,cisapride,mechanism,Antifungals: In vitro and/or vivo data indicate fluconazole itraconazole oral DRUG markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2475,"Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.",ketoconazole,cisapride,mechanism,Human pharmacokinetic data indicate oral DRUG markedly inhibits metabolism OTHER_DRUG resulting mean eight-fold increase AUC OTHER_DRUG .
2476,A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.,cisapride,ketoconazole,effect,A study 14 normal male female volunteers suggests coadministration DRUG OTHER_DRUG result prolongation QT interval ECG .
2477,"H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.",Cimetidine,cisapride,mechanism,H2 Receptor Antagonists: DRUG coadministration leads increased peak plasma concentration AUC OTHER_DRUG effect OTHER_DRUG absorption coadministered ranitidine .
2478,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,cimetidine,cisapride,mechanism,The gastrointestinal absorption DRUG ranitidine accelerated coadministered OTHER_DRUG .
2479,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,ranitidine,cisapride,mechanism,The gastrointestinal absorption cimetidine DRUG accelerated coadministered OTHER_DRUG .
2480,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,indinavir,cisapride,mechanism,Protease Inhibitors: In vitro data indicate DRUG ritonavir markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2481,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,ritonavir,cisapride,mechanism,Protease Inhibitors: In vitro data indicate indinavir DRUG markedly inhibit metabolism OTHER_DRUG result increase plasma OTHER_DRUG levels prolongation QT interval ECG .
2482,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,antiarrhythmics,advise,DRUG used concomitantly drugs known prolong QT interval: certain OTHER_DRUG including Class IA (such quinidine procainamide) Class III (such sotalol);
2483,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,quinidine,advise,DRUG used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such OTHER_DRUG procainamide) Class III (such sotalol);
2484,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,procainamide,advise,DRUG used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such quinidine procainamide) Class III (such sotalol);
2485,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,sotalol,advise,DRUG used concomitantly drugs known prolong QT interval: certain antiarrhythmics including Class IA (such quinidine procainamide) Class III (such sotalol);
2486,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,antidepressants,int,DRUG may interact OTHER_DRUG aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin .
2487,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,aspirin,int,DRUG may interact antidepressants OTHER_DRUG barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin .
2488,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,barbiturates,int,DRUG may interact antidepressants aspirin OTHER_DRUG bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin .
2489,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,bromocriptine,int,DRUG may interact antidepressants aspirin barbiturates OTHER_DRUG calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin .
2490,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,calcium,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine OTHER_DRUG supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin .
2491,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticosteroids,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements OTHER_DRUG corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen warfarin .
2492,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,corticotropin,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids OTHER_DRUG cyclosporine dantrolene nicotine somatropin tamoxifen warfarin .
2493,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,cyclosporine,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin OTHER_DRUG dantrolene nicotine somatropin tamoxifen warfarin .
2494,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,dantrolene,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine OTHER_DRUG nicotine somatropin tamoxifen warfarin .
2495,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,nicotine,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene OTHER_DRUG somatropin tamoxifen warfarin .
2496,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,somatropin,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine OTHER_DRUG tamoxifen warfarin .
2497,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,tamoxifen,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin OTHER_DRUG warfarin .
2498,"Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.",Chlorotrianisene,warfarin,int,DRUG may interact antidepressants aspirin barbiturates bromocriptine calcium supplements corticosteroids corticotropin cyclosporine dantrolene nicotine somatropin tamoxifen OTHER_DRUG .
2499,"In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.",central nervous system depressants,heroin,effect,In combination central nervous system depressants OTHER_DRUG may still kill even experienced users particularly tolerance drug reduced strength usual dose increased .
2500,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,central nervous system depressants,effect,Toxicology studies heroin-related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam (Valium) rising degree methadone .
2501,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,alcohol,effect,Toxicology studies heroin-related deaths reveal frequent involvement central nervous system depressants including OTHER_DRUG benzodiazepines diazepam (Valium) rising degree methadone .
2502,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,benzodiazepines,effect,Toxicology studies heroin-related deaths reveal frequent involvement central nervous system depressants including alcohol OTHER_DRUG diazepam (Valium) rising degree methadone .
2503,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,diazepam,effect,Toxicology studies heroin-related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines OTHER_DRUG (Valium) rising degree methadone .
2504,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,Valium,effect,Toxicology studies heroin-related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam (Valium) rising degree methadone .
2505,"Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.",heroin,methadone,effect,Toxicology studies heroin-related deaths reveal frequent involvement central nervous system depressants including alcohol benzodiazepines diazepam (Valium) rising degree OTHER_DRUG .
2506,Cocaine sometimes proves to be fatal when used in combination with heroin.,Cocaine,heroin,effect,DRUG sometimes proves fatal used combination OTHER_DRUG .
2507,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,Cholestytamine,thiazide diuretics,mechanism,- Cholestyramine colestipol resins: DRUG colestipol resins potential binding thiazide diuretics reducing diuretic absorption gastrointestinal tract
2508,- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract,colestipol,thiazide diuretics,mechanism,- Cholestyramine DRUG resins: Cholestytamine DRUG resins potential binding thiazide diuretics reducing diuretic absorption gastrointestinal tract
2509,- Lithium: Generally should not be given with diuretics.,Lithium,diuretics,advise,- Lithium: Generally given OTHER_DRUG .
2510,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic agents reduce renal clearance OTHER_DRUG add high risk OTHER_DRUG toxicity .
2511,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic agents reduce renal clearance OTHER_DRUG add high risk OTHER_DRUG toxicity .
2512,Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide,lithium,chlorothiazide,advise,Refer package insert DRUG preparations use preparations OTHER_DRUG
2513,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,- Non-steroidal Anti-inflammatory Drugs: In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2514,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,- Non-steroidal Anti-inflammatory Drugs: In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2515,"- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,- Non-steroidal Anti-inflammatory Drugs: In patients administration non-steroidal anti-inflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium-sparing thiazide diuretics .
2516,"Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained",chlorothiazide,non-steroidal anti-inflammatory agents,advise,Therefore DRUG non-steroidal anti-inflammatory agents used concomitantly patient observed closely determine desired effect diuretic obtained
2517,Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.,antidiabetic agents,VELCADE,advise,Patients oral antidiabetic agents receiving OTHER_DRUG treatment may require close monitoring blood glucose levels adjustment dose antidiabetic medication .
2518,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,tricyclic antidepressants,effect,DRUG may enhance effects tricyclic antidepressants barbiturates alcohol CNS depressants .
2519,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,barbiturates,effect,DRUG may enhance effects tricyclic antidepressants OTHER_DRUG alcohol CNS depressants .
2520,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,alcohol,effect,DRUG may enhance effects tricyclic antidepressants barbiturates OTHER_DRUG CNS depressants .
2521,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,CNS depressants,effect,DRUG may enhance effects tricyclic antidepressants barbiturates alcohol CNS depressants .
2522,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors prolong intensify anticholinergic effects OTHER_DRUG .
2523,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,reserpine,effect,Sympathomimetic amines may reduce antihypertensive effects OTHER_DRUG veratrum alkaloids methyldopa mecamylamine .
2524,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,veratrum alkaloids,effect,Sympathomimetic amines may reduce antihypertensive effects reserpine veratrum alkaloids methyldopa mecamylamine .
2525,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,methyldopa,effect,Sympathomimetic amines may reduce antihypertensive effects reserpine veratrum alkaloids OTHER_DRUG mecamylamine .
2526,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,mecamylamine,effect,Sympathomimetic amines may reduce antihypertensive effects reserpine veratrum alkaloids methyldopa OTHER_DRUG .
2527,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,MAO inhibitors,effect,Effects DRUG increased MAO inhibitors beta adrenergic blockers .
2528,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,beta adrenergic blockers,effect,Effects DRUG increased MAO inhibitors beta adrenergic blockers .
2529,"Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.",halofantrine,Mefloquine,advise,Because danger potentially fatal prolongation QTc interval DRUG must given simultaneously subsequent OTHER_DRUG .
2530,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinine,effect,Concomitant administration DRUG related compounds (eg OTHER_DRUG quinidine chloroquine) may produce electrocardiographic abnormalities increase risk convulsions .
2531,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,quinidine,effect,Concomitant administration DRUG related compounds (eg quinine OTHER_DRUG chloroquine) may produce electrocardiographic abnormalities increase risk convulsions .
2532,"Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.",Mefloquine,chloroquine,effect,Concomitant administration DRUG related compounds (eg quinine quinidine chloroquine) may produce electrocardiographic abnormalities increase risk convulsions .
2533,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,anti-arrhythmic,effect,This appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg OTHER_DRUG beta-adrenergic blocking agents calcium channel blockers antihistamines H1-blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval .
2534,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,beta-adrenergic blocking agents,effect,This appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti-arrhythmic beta-adrenergic blocking agents calcium channel blockers antihistamines H1-blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval .
2535,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,calcium channel blockers,effect,This appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti-arrhythmic beta-adrenergic blocking agents calcium channel blockers antihistamines H1-blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval .
2536,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,antihistamines,effect,This appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti-arrhythmic beta-adrenergic blocking agents calcium channel blockers OTHER_DRUG H1-blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval .
2537,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,H1-blocking agents,effect,This appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti-arrhythmic beta-adrenergic blocking agents calcium channel blockers antihistamines H1-blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval .
2538,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,tricyclic antidepressants,effect,This appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti-arrhythmic beta-adrenergic blocking agents calcium channel blockers antihistamines H1-blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval .
2539,"This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.",Mefloquine,phenothiazines,effect,This appears clinically relevant interaction kind DRUG although theoretically coadministration drugs known alter cardiac conduction (eg anti-arrhythmic beta-adrenergic blocking agents calcium channel blockers antihistamines H1-blocking agents tricyclic antidepressants phenothiazines) might also contribute prolongation QTc interval .
2540,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",anticonvulsant,Mefloquine,effect,In patients taking DRUG (eg valproic acid carbamazepine phenobarbital phenytoin) concomitant use OTHER_DRUG may reduce seizure control lowering plasma levels DRUG .
2541,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",valproic acid,Mefloquine,effect,In patients taking anticonvulsant (eg valproic acid carbamazepine phenobarbital phenytoin) concomitant use OTHER_DRUG may reduce seizure control lowering plasma levels anticonvulsant .
2542,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",carbamazepine,Mefloquine,effect,In patients taking anticonvulsant (eg valproic acid DRUG phenobarbital phenytoin) concomitant use OTHER_DRUG may reduce seizure control lowering plasma levels anticonvulsant .
2543,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenobarbital,Mefloquine,effect,In patients taking anticonvulsant (eg valproic acid carbamazepine DRUG phenytoin) concomitant use OTHER_DRUG may reduce seizure control lowering plasma levels anticonvulsant .
2544,"In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.",phenytoin,Mefloquine,effect,In patients taking anticonvulsant (eg valproic acid carbamazepine phenobarbital phenytoin) concomitant use OTHER_DRUG may reduce seizure control lowering plasma levels anticonvulsant .
2545,"When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.",Mefloquine,live typhoid vaccines,effect,When DRUG taken concurrently oral live typhoid vaccines attenuation immunization cannot excluded .
2546,"Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.",Mefloquine,anticoagulants,advise,Nevertheless effects DRUG travelers receiving comedication particularly diabetics patients using OTHER_DRUG checked departure .
2547,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,mechanism,DRUG generally given OTHER_DRUG reduce renal clearance add high risk DRUG toxicity .
2548,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,aminoglycoside,effect,DRUG may increase ototoxic potential drugs OTHER_DRUG cephalosporin antibiotics .
2549,EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.,EDECRIN,cephalosporin antibiotics,effect,DRUG may increase ototoxic potential drugs aminoglycoside cephalosporin antibiotics .
2550,"A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;",ethacrynic acid,warfarin,mechanism,A number drugs including ethacrynic acid shown displace OTHER_DRUG plasma protein;
2551,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,loop diuretics,effect,In patients administration non- steroidal antiinflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium- sparing thiazide diuretics .
2552,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,potassium- sparing diuretics,effect,In patients administration non- steroidal antiinflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium- sparing thiazide diuretics .
2553,"In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.",non- steroidal antiinflammatory agent,thiazide diuretics,effect,In patients administration non- steroidal antiinflammatory agent reduce diuretic natriuretic antihypertensive effects loop potassium- sparing thiazide diuretics .
2554,"Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",EDECRIN,non- steroidal anti- inflammatory agents,effect,Therefore DRUG non- steroidal anti- inflammatory agents used concomitantly patient observed closely determine desired effect diuretic obtained .
2555,"Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.",L-tyrosine,MAO inhibitors,effect,Non-selective MAO inhibitors including tranylcypromine sulfate phenelzine sulfate pargyline HC1: Concomitant use DRUG non-selective MAO inhibitors may cause hypertension .
2556,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,cimetidine,advise,Based adult data lower doses DRUG may needed following coadministration drugs reported decrease DRUG elimination (e . g . OTHER_DRUG ketoconazole) higher DRUG doses may needed following coadministration drugs increase DRUG elimination (e . g . phenobarbital phenytoin) .
2557,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,ketoconazole,advise,Based adult data lower doses DRUG may needed following coadministration drugs reported decrease DRUG elimination (e . g . cimetidine ketoconazole) higher DRUG doses may needed following coadministration drugs increase DRUG elimination (e . g . phenobarbital phenytoin) .
2558,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenobarbital,advise,Based adult data lower doses DRUG may needed following coadministration drugs reported decrease DRUG elimination (e . g . cimetidine ketoconazole) higher DRUG doses may needed following coadministration drugs increase DRUG elimination (e . g . OTHER_DRUG phenytoin) .
2559,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenytoin,advise,Based adult data lower doses DRUG may needed following coadministration drugs reported decrease DRUG elimination (e . g . cimetidine ketoconazole) higher DRUG doses may needed following coadministration drugs increase DRUG elimination (e . g . phenobarbital phenytoin) .
2560,Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.,Caffeine,ketoprofen,effect,DRUG administered concurrently OTHER_DRUG reduced urine volume 4 healthy volunteers .
2561,The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.,nevirapine,warfarin,int,The vitro interaction DRUG antithrombotic agent OTHER_DRUG complex .
2562,"When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.",warfarin,nevirapine,advise,When DRUG co-administered OTHER_DRUG anticoagulation levels monitored frequently .
2563,Clarithromycin exposure was significantly decreased by nevirapine;,Clarithromycin,nevirapine,mechanism,DRUG exposure significantly decreased nevirapine;
2564,"Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.",contraceptives,nevirapine,advise,Oral DRUG hormonalmethods birth control usedas sole method contraception inwomen taking OTHER_DRUG since nevirapinemay lower plasma levels thesemedications .
2565,Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.,Nevirapine,ketoconazole,advise,DRUG OTHER_DRUG beadministered concomitantly becausedecreases OTHER_DRUG plasmaconcentrations may reduce efficacy drug .
2566,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,lopinavir,nevirapine,advise,A dose increase lopinavir/ritonavir 533/133 mg twice daily food isrecommended combination OTHER_DRUG .
2567,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,ritonavir,nevirapine,advise,A dose increase lopinavir/ritonavir 533/133 mg twice daily food isrecommended combination OTHER_DRUG .
2568,Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.,Methadone,nevirapine,advise,DRUG levels may decreased; increased dosages may required prevent symptoms opiate withdrawal . DRUG maintained patients beginning OTHER_DRUG therapy monitored forevidence withdrawal DRUG dose adjusted accordingly .
2569,Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.,Nevirapine,rifampin,advise,DRUG OTHER_DRUG beadministered concomitantly becausedecreases DRUG plasmaconcentrations may reduce efficacy ofthe drug .
2570,"aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.",nevirapine,methadone,effect,aBased reports narcotic withdrawal syndrome patients treated DRUG OTHER_DRUG concurrently evidence decreased plasma concentrations OTHER_DRUG .
2571,"Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.",ketoconazole,lapatinib,mechanism,Ketoconazole: In healthy subjects receiving DRUG CYP3A4 inhibitor 200 mg twice daily 7 days systemic exposure (AUC) OTHER_DRUG increased approximately 3 . 6-fold control half-life increased 1 . 7-fold control .
2572,"Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.",carbamazepine,lapatinib,mechanism,Carbamazepine: In healthy subjects receiving CYP3A4 inducer DRUG 100 mg twice daily 3 days 200 mg twice daily 17 days systemic exposure (AUC) OTHER_DRUG decreased approximately 72% .
2573,MAO inhibitors should be used with caution in patients receiving hydralazine.,MAO inhibitors,hydralazine,advise,MAO inhibitors used caution patients receiving OTHER_DRUG .
2574,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,diazoxide,effect,When potent parental antihypertensive drugs OTHER_DRUG used combination hydralazine patients continuously observed several hours excessive fall blood pressure .
2575,"When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.",antihypertensive drugs,hydralazine,effect,When potent parental antihypertensive drugs diazoxide used combination OTHER_DRUG patients continuously observed several hours excessive fall blood pressure .
2576,Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.,diazoxide,hydralazine,effect,Profound hypotensive episodes may occur DRUG infection OTHER_DRUG used concomitantly .
2577,Propranolol increases hydralazines serum concentrations.,Propranolol,hydralazine,mechanism,DRUG increases hydralazines serum concentrations .
2578,NSAIDs may decrease the hemodynamic effects of hydralazine;,NSAIDs,hydralazine,effect,DRUG may decrease hemodynamic effects hydralazine;
2579,Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.,carbamazepine,SUPRAX,mechanism,Carbamazepine: Elevated DRUG levels reported postmarketing experience OTHER_DRUG administered concomitantly .
2580,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Warfarin,cefixime,effect,DRUG Anticoagulants: Increased prothrombin time without clinical bleeding reported OTHER_DRUG administered concomitantly .
2581,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Anticoagulants,cefixime,effect,Warfarin Anticoagulants: Increased prothrombin time without clinical bleeding reported OTHER_DRUG administered concomitantly .
2582,Cimetidine: Cimetidine increases nicardipine HCl plasma levels.,Cimetidine,nicardipine HCl,mechanism,Cimetidine: DRUG increases nicardipine HCl plasma levels .
2583,Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.,calcium blockers,digitalis preparations,mechanism,Digoxin: Some calcium blockers may increase concentration digitalis preparations blood .
2584,"Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.",digoxin,nicardipine HCl,advise,Nicardipine HCl usually alter plasma levels DRUG however serum DRUG levels evaluated concomitant therapy nicardipine HCl initiated .
2585,"Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.",cyclosporine,nicardipine,advise,Plasma concentrations DRUG therefore closely monitored dosage reduced accordingly patients treated OTHER_DRUG .
2586,Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.,proton pump inhibitors,warfarin,effect,Patients treated proton pump inhibitors OTHER_DRUG concomitantly may need monitored increases INR prothrombin time .
2587,"Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.",esomeprazole,diazepam,mechanism,Coadministration DRUG 30 mg OTHER_DRUG CYP2C19 substrate resulted 45% decrease clearance OTHER_DRUG .
2588,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,ketoconazole,mechanism,Therefore DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg OTHER_DRUG iron salts digoxin) .
2589,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,iron,mechanism,Therefore DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole OTHER_DRUG salts digoxin) .
2590,"Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).",esomeprazole,digoxin,mechanism,Therefore DRUG may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole iron salts digoxin) .
2591,Concomitant administration of clarithromycin with pimozide is contraindicated.,clarithromycin,pimozide,advise,Concomitant administration DRUG OTHER_DRUG contraindicated .
2592,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,advise,Aspirin: Concomitant administration DRUG OTHER_DRUG recommended DRUG displaced binding sites concomitant administration OTHER_DRUG resulting lower plasma concentrations peak plasma levels AUC values .
2593,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,mechanism,Aspirin: Concomitant administration DRUG OTHER_DRUG recommended DRUG displaced binding sites concomitant administration OTHER_DRUG resulting lower plasma concentrations peak plasma levels AUC values .
2594,"Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.",diclofenac,NSAIDs,advise,Anticoagulants: While studies shown DRUG interact anticoagulants warfarin type caution exercised nonetheless since interactions seen OTHER_DRUG .
2595,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",NSAIDs,warfarin,advise,Because prostaglandins play important role hemostasis DRUG affect platelet function well concurrent therapy DRUG including diclofenac OTHER_DRUG requires close monitoring patients certain change anticoagulant dosage required .
2596,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",diclofenac,warfarin,advise,Because prostaglandins play important role hemostasis NSAIDs affect platelet function well concurrent therapy NSAIDs including DRUG OTHER_DRUG requires close monitoring patients certain change anticoagulant dosage required .
2597,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,digoxin,mechanism,Ingestion DRUG may increase serum concentrations OTHER_DRUG methotrexate increase cyclosporine nephrotoxicity .
2598,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,methotrexate,mechanism,Ingestion DRUG may increase serum concentrations digoxin OTHER_DRUG increase cyclosporine nephrotoxicity .
2599,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,cyclosporine,effect,Ingestion DRUG may increase serum concentrations digoxin methotrexate increase OTHER_DRUG nephrotoxicity .
2600,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,digoxin,effect,Patients begin taking DRUG increase DRUG dose NSAID taking OTHER_DRUG methotrexate cyclosporine may develop toxicity characteristics drugs .
2601,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,methotrexate,effect,Patients begin taking DRUG increase DRUG dose NSAID taking digoxin OTHER_DRUG cyclosporine may develop toxicity characteristics drugs .
2602,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",diclofenac,cyclosporine,effect,Patients begin taking DRUG increase DRUG dose NSAID taking digoxin methotrexate OTHER_DRUG may develop toxicity characteristics drugs .
2603,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,digoxin,effect,Patients begin taking diclofenac increase diclofenac dose DRUG taking OTHER_DRUG methotrexate cyclosporine may develop toxicity characteristics drugs .
2604,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,methotrexate,effect,Patients begin taking diclofenac increase diclofenac dose DRUG taking digoxin OTHER_DRUG cyclosporine may develop toxicity characteristics drugs .
2605,"Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.",NSAID,cyclosporine,effect,Patients begin taking diclofenac increase diclofenac dose DRUG taking digoxin methotrexate OTHER_DRUG may develop toxicity characteristics drugs .
2606,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium: DRUG decreases OTHER_DRUG renal clearance increases OTHER_DRUG plasma levels .
2607,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium: DRUG decreases OTHER_DRUG renal clearance increases OTHER_DRUG plasma levels .
2608,"In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.",diclofenac,lithium,effect,In patients taking DRUG OTHER_DRUG concomitantly OTHER_DRUG toxicity may develop .
2609,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",insulin,diclofenac,effect,There rare reports however marketing experiences changes effects DRUG oral hypoglycemic agents presence OTHER_DRUG necessitated changes doses agents .
2610,"There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.",hypoglycemic agents,diclofenac,effect,There rare reports however marketing experiences changes effects insulin oral hypoglycemic agents presence OTHER_DRUG necessitated changes doses agents .
2611,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,insulin,effect,A direct causal relationship established physicians consider possibility DRUG may alter diabetic patient response OTHER_DRUG oral hypoglycemic agents .
2612,"A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.",diclofenac,hypoglycemic agents,effect,A direct causal relationship established physicians consider possibility DRUG may alter diabetic patient response insulin oral hypoglycemic agents .
2613,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,Diclofenac,diuretics,effect,Diuretics: DRUG NSAIDs inhibit activity OTHER_DRUG .
2614,Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.,NSAIDs,diuretics,effect,Diuretics: Diclofenac DRUG inhibit activity OTHER_DRUG .
2615,Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.,phenobarbital,diclofenac,effect,DRUG toxicity reported occurred patient chronic DRUG treatment following initiation OTHER_DRUG therapy .
2616,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,salicylic acid,mechanism,Protein Binding In vitro DRUG interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide prednisolone (10% decrease binding) warfarin .
2617,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,tolbutamide,mechanism,Protein Binding In vitro DRUG interferes minimally protein binding salicylic acid (20% decrease binding) OTHER_DRUG prednisolone (10% decrease binding) warfarin .
2618,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,prednisolone,mechanism,Protein Binding In vitro DRUG interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide OTHER_DRUG (10% decrease binding) warfarin .
2619,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,warfarin,mechanism,Protein Binding In vitro DRUG interferes minimally protein binding salicylic acid (20% decrease binding) tolbutamide prednisolone (10% decrease binding) OTHER_DRUG .
2620,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.,aminoglycosides,MAXIPIME,advise,Renal function monitored carefully high doses DRUG administered OTHER_DRUG increased potential nephrotoxicity ototoxicity aminoglycoside antibiotics .
2621,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity reported following concomitant administration DRUG potent OTHER_DRUG furosemide .
2622,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity reported following concomitant administration DRUG potent diuretics OTHER_DRUG .
2623,Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.,Potassium-depleting diuretics,digitalis,effect,Potassium-depleting diuretics major contributing factor OTHER_DRUG toxicity .
2624,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",Quinidine,digoxin,mechanism,DRUG verapamil amiodarone propafenone indomethacin itraconazole alprazolam spironolactone raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2625,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",verapamil,digoxin,mechanism,Quinidine DRUG amiodarone propafenone indomethacin itraconazole alprazolam spironolactone raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2626,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",amiodarone,digoxin,mechanism,Quinidine verapamil DRUG propafenone indomethacin itraconazole alprazolam spironolactone raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2627,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",propafenone,digoxin,mechanism,Quinidine verapamil amiodarone DRUG indomethacin itraconazole alprazolam spironolactone raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2628,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",indomethacin,digoxin,mechanism,Quinidine verapamil amiodarone propafenone DRUG itraconazole alprazolam spironolactone raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2629,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",itraconazole,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin DRUG alprazolam spironolactone raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2630,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",alprazolam,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin itraconazole DRUG spironolactone raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2631,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",spironolactone,digoxin,mechanism,Quinidine verapamil amiodarone propafenone indomethacin itraconazole alprazolam DRUG raise serum OTHER_DRUG concentration due reduction clearance and/or volume distribution drug implication digitalis intoxication may result .
2632,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",Erythromycin,digoxin,mechanism,DRUG clarithromycin (and possibly macrolide antibiotics) tetracycline may increase OTHER_DRUG absorption patients inactivate OTHER_DRUG bacterial metabolism lower intestine digitalis intoxication may result .
2633,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",clarithromycin,digoxin,mechanism,Erythromycin DRUG (and possibly macrolide antibiotics) tetracycline may increase OTHER_DRUG absorption patients inactivate OTHER_DRUG bacterial metabolism lower intestine digitalis intoxication may result .
2634,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",macrolide antibiotics,digoxin,mechanism,Erythromycin clarithromycin (and possibly macrolide antibiotics) tetracycline may increase OTHER_DRUG absorption patients inactivate OTHER_DRUG bacterial metabolism lower intestine digitalis intoxication may result .
2635,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",tetracycline,digoxin,mechanism,Erythromycin clarithromycin (and possibly macrolide antibiotics) DRUG may increase OTHER_DRUG absorption patients inactivate OTHER_DRUG bacterial metabolism lower intestine digitalis intoxication may result .
2636,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",Propantheline,digoxin,mechanism,DRUG diphenoxylate decreasing gut motility may increase OTHER_DRUG absorption .
2637,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",diphenoxylate,digoxin,mechanism,Propantheline DRUG decreasing gut motility may increase OTHER_DRUG absorption .
2638,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",Antacids,digoxin,mechanism,DRUG kaolin-pectin sulfasalazine neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal OTHER_DRUG absorption resulting unexpectedly low serum concentrations .
2639,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",kaolin,digoxin,mechanism,Antacids kaolin-pectin sulfasalazine neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal OTHER_DRUG absorption resulting unexpectedly low serum concentrations .
2640,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",sulfasalazine,digoxin,mechanism,Antacids kaolin-pectin DRUG neomycin cholestyramine certain anticancer drugs metoclopramide may interfere intestinal OTHER_DRUG absorption resulting unexpectedly low serum concentrations .
2641,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",neomycin,digoxin,mechanism,Antacids kaolin-pectin sulfasalazine DRUG cholestyramine certain anticancer drugs metoclopramide may interfere intestinal OTHER_DRUG absorption resulting unexpectedly low serum concentrations .
2642,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",cholestyramine,digoxin,mechanism,Antacids kaolin-pectin sulfasalazine neomycin DRUG certain anticancer drugs metoclopramide may interfere intestinal OTHER_DRUG absorption resulting unexpectedly low serum concentrations .
2643,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",metoclopramide,digoxin,mechanism,Antacids kaolin-pectin sulfasalazine neomycin cholestyramine certain anticancer drugs DRUG may interfere intestinal OTHER_DRUG absorption resulting unexpectedly low serum concentrations .
2644,"Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.",Rifampin,digoxin,mechanism,DRUG may decrease serum OTHER_DRUG concentration especially patients renal dysfunction increasing non-renal clearance OTHER_DRUG .
2645,"Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.",Thyroid,digoxin,advise,DRUG administration digitalized hypothyroid patient may increase dose requirement OTHER_DRUG .
2646,Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.,digoxin,sympathomimetics,effect,Concomitant use DRUG OTHER_DRUG increases risk cardiac arrhythmias .
2647,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",beta-adrenergic blockers,digoxin,effect,Although beta-adrenergic blockers calcium channel blockers OTHER_DRUG may useful combination control atrial fibrillation additive effects AV node conduction result advanced complete heart block .
2648,"Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.",calcium channel blockers,digoxin,effect,Although beta-adrenergic blockers calcium channel blockers OTHER_DRUG may useful combination control atrial fibrillation additive effects AV node conduction result advanced complete heart block .
2649,"In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.",theophylline,cetirizine,mechanism,In multiple dose study DRUG (400 mg daily 3 days) OTHER_DRUG (20 mg daily 3 days) 16% decrease clearance OTHER_DRUG observed .
2650,There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;,cetirizine,theophylline,mechanism,There small decrease clearance DRUG caused 400-mg dose theophylline;
2651,Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.,dapsone,Lamprene,effect,Preliminary data suggest DRUG may inhibit anti-inflammatory activity OTHER_DRUG confirmed .
2652,"If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.",dapsone,clofazimine,advise,If leprosy-associated inflammatory reactions develop patients treated DRUG OTHER_DRUG still advisable continue treatment drugs .
2653,Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).,piperazine,phenothiazine,effect,Phenothiazines - Taking DRUG OTHER_DRUG together may increase risk convulsions (seizures) .
2654,"Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.",piperazine,pyrantel,effect,OTHER_DRUG (e . g . Antiminth) - Taking DRUG OTHER_DRUG together may decrease effects DRUG .
2655,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,alcohol,effect,Diphenhydramine hydrochloride additive effects OTHER_DRUG CNS depressants (hypnotics sedatives tranquilizers etc) .
2656,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,CNS depressants,effect,Diphenhydramine hydrochloride additive effects alcohol CNS depressants (hypnotics sedatives tranquilizers etc) .
2657,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,hypnotics,effect,Diphenhydramine hydrochloride additive effects alcohol CNS depressants (hypnotics sedatives tranquilizers etc) .
2658,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,sedatives,effect,Diphenhydramine hydrochloride additive effects alcohol CNS depressants (hypnotics OTHER_DRUG tranquilizers etc) .
2659,"Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).",Diphenhydramine hydrochloride,tranquilizers,effect,Diphenhydramine hydrochloride additive effects alcohol CNS depressants (hypnotics sedatives OTHER_DRUG etc) .
2660,MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO inhibitors prolong intensify anticholinergic (drying) effects OTHER_DRUG .
2661,Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.,anticoagulants,Atromid-S,advise,Caution exercised DRUG given conjunction OTHER_DRUG .
2662,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,phenytoin,mechanism,DRUG may displace acidic drugs OTHER_DRUG tolbutamide binding sites .
2663,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,tolbutamide,mechanism,DRUG may displace acidic drugs phenytoin OTHER_DRUG binding sites .
2664,The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.,tolbutamide,Atromid-S,effect,The hypoglycemic effect DRUG reported increase OTHER_DRUG given concurrently .
2665,Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.,fibrate,lovastatin,effect,Fulminant rhabdomyolysis seen early three weeks initiation combined therapy another DRUG OTHER_DRUG may seen several months .
2666,"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.",lovastatin,fibrate,effect,For reasons felt subjects unsatisfactory lipid response either drug alone possible benefits combined therapy DRUG OTHER_DRUG outweigh risks severe myopathy rhabdomyolysis acute renal failure .
2667,"Therefore, the combined use of lovastatin with fibrates should generally be avoided.",lovastatin,fibrates,advise,Therefore combined use DRUG OTHER_DRUG generally avoided .
2668,Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.,PEGASYS,theophylline,mechanism,Treatment DRUG weekly 4 weeks healthy subjects associated inhibition P450 1A2 25% increase OTHER_DRUG AUC .
2669,Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.,theophylline,PEGASYS,advise,DRUG serum levels monitored appropriate dose adjustments considered patients given DRUG OTHER_DRUG .
2670,Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.,COPEGUS,didanosine,advise,Nucleoside Analogues OTHER_DRUG Co-administration DRUG OTHER_DRUG recommended .
2671,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,stavudine,effect,OTHER_DRUG Zidovudine DRUG antagonize vitro antiviral activity OTHER_DRUG zidovudine HIV .
2672,Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.,Ribavirin,zidovudine,effect,Stavudine OTHER_DRUG DRUG antagonize vitro antiviral activity stavudine OTHER_DRUG HIV .
2673,"The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.",CAMPTOSAR,antineoplastic agents,effect,The adverse effects DRUG myelosuppression diarrhea would expected exacerbated antineoplastic agents similar adverse effects .
2674,"Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.",CAMPTOSAR,dexamethasone,effect,Lymphocytopenia reported patients receiving DRUG possible administration OTHER_DRUG antiemetic prophylaxis may enhanced likelihood effect .
2675,"The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).",prochlorperazine,CAMPTOSAR,effect,The incidence akathisia clinical trials weekly dosage schedule greater (8 . 5% 4/47 patients) DRUG administered day OTHER_DRUG drugs given separate days (1 . 3% 1/80 patients) .
2676,"It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.",laxative,CAMPTOSAR,effect,It would expected DRUG use therapy OTHER_DRUG would worsen incidence severity diarrhea studied .
2677,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.",diuretics,CAMPTOSAR,effect,In view potential risk dehydration secondary vomiting and/or diarrhea induced OTHER_DRUG physician may wish withhold DRUG dosing OTHER_DRUG certainly periods active vomiting diarrhea .
2678,"Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",etanercept,anakinra,effect,Concurrent administration DRUG (another TNF -blocking agent) OTHER_DRUG (an interleukin-1 antagonist) associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone .
2679,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,TNFa-blocking agents,anakinra,effect,Other TNFa-blocking agents (including REMICADE) used combination OTHER_DRUG may also result similar toxicities .
2680,Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.,REMICADE,anakinra,effect,Other TNFa-blocking agents (including REMICADE) used combination OTHER_DRUG may also result similar toxicities .
2681,"Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).",dorzolamide,carbonic anhydrase inhibitors,effect,Although acid-base electrolyte disturbances reported clinical trials DRUG disturbances reported oral carbonic anhydrase inhibitors instances resulted drug interactions (e . g . toxicity associated high-dose salicylate therapy) .
2682,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,mercaptopurine,mechanism,Mercaptopurine/Azathioprine: DRUG inhibits enzymatic oxidation OTHER_DRUG azathioprine 6-thiouric acid .
2683,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,azathioprine,mechanism,Mercaptopurine/Azathioprine: DRUG inhibits enzymatic oxidation mercaptopurine OTHER_DRUG 6-thiouric acid .
2684,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,mercaptopurine,advise,In patients receiving OTHER_DRUG (Purinethol) azathioprine (Imuran) concomitant administration 300-600 mg DRUG per day require reduction dose approximately one-third one-fourth usual dose OTHER_DRUG azathioprine .
2685,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,azathioprine,advise,In patients receiving mercaptopurine (Purinethol) OTHER_DRUG (Imuran) concomitant administration 300-600 mg DRUG per day require reduction dose approximately one-third one-fourth usual dose mercaptopurine OTHER_DRUG .
2686,"Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.",allopurinol,dicumarol,mechanism,Dicumarol: It reported DRUG prolongs half-life anticoagulant OTHER_DRUG .
2687,"Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.",uricosuric agents,oxipurinol,mechanism,Uricosuric Agents: Since excretion OTHER_DRUG similar urate uricosuric agents increase excretion urate also likely increase excretion OTHER_DRUG thus lower degree inhibition xanthine oxidase .
2688,The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.,uricosuric agents,allopurinol,mechanism,The concomitant administration uricosuric agents OTHER_DRUG associated decrease excretion oxypurines (hypoxanthine xanthine) increase urinary uric acid excretion compared observed OTHER_DRUG alone .
2689,Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.,allopurinol,thiazide diuretics,effect,Thiazide Diuretics: The reports concomitant use DRUG thiazide diuretics may contribute enhancement DRUG toxicity patients reviewed attempt establish cause-and-effect relationship mechanism causation .
2690,"Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..",thiazide diuretics,allopurinol,advise,Although causal mechanism cause-and-effect relationship established current evidence suggests renal function monitored patients thiazide diuretics OTHER_DRUG even absence renal failure dosage levels even conservatively adjusted patients combined therapy diminished renal function detected . .
2691,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,ampicillin,allopurinol,effect,Ampicillin/Amoxicillin: An increase frequency skin rash reported among patients receiving DRUG amoxicillin concurrently OTHER_DRUG compared patients receiving drugs .
2692,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,amoxicillin,allopurinol,effect,Ampicillin/Amoxicillin: An increase frequency skin rash reported among patients receiving ampicillin DRUG concurrently OTHER_DRUG compared patients receiving drugs .
2693,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cyclophosphamide,allopurinol,effect,Cytotoxic Agents: Enhanced bone marrow suppression DRUG cytotoxic agents reported among patients neoplastic disease except leukemia presence OTHER_DRUG .
2694,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cytotoxic agents,allopurinol,effect,Cytotoxic Agents: Enhanced bone marrow suppression cyclophosphamide cytotoxic agents reported among patients neoplastic disease except leukemia presence OTHER_DRUG .
2695,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",Chlorpropamide,allopurinol,mechanism,Chlorpropamide: Chlorpropamides plasma half-life may prolonged OTHER_DRUG since OTHER_DRUG DRUG may compete excretion renal tubule .
2696,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",allopurinol,chlorpropamide,mechanism,Chlorpropamide: Chlorpropamides plasma half-life may prolonged DRUG since DRUG OTHER_DRUG may compete excretion renal tubule .
2697,The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.,allopurinol,chlorpropamide,effect,The risk hypoglycemia secondary mechanism may increased DRUG OTHER_DRUG given concomitantly presence renal insufficiency .
2698,Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.,cyclosporine,allopurinol sodium,mechanism,Cyclosporin: Reports indicate DRUG levels may increased concomitant treatment allopurinol sodium injection .
2699,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",Catecholamine-depleting drugs,beta-blocking agents,effect,Catecholamine-depleting drugs reserpine may additive effect given beta-blocking agents .
2700,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agents,effect,Catecholamine-depleting drugs DRUG may additive effect given beta-blocking agents .
2701,"Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.",acebutolol,catecholamine depletors,advise,Patients treated DRUG plus catecholamine depletors therefore observed closely evidence marked bradycardia hypotension may present vertigo syncope/presyncope orthostatic changes blood pressure without compensatory tachycardia .
2702,"Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.",beta-adrenergic antagonists,alpha-adrenergic stimulants,effect,Exaggerated hypertensive responses reported combined use beta-adrenergic antagonists alpha-adrenergic stimulants including contained proprietary cold remedies vasoconstrictive nasal drops .
2703,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.,beta-adrenoceptor blocking agents,nonsteroidal anti-inflammatory drugs,effect,Blunting antihypertensive effect beta-adrenoceptor blocking agents nonsteroidal anti-inflammatory drugs reported .
2704,"These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.",antibiotics,anticholinesterase,advise,These DRUG used myasthenic patient definitely indicated careful adjustment made adjunctive OTHER_DRUG dosage .
2705,Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.,Betaseron,antipyrine,mechanism,DRUG administration three cancer patients dose range 0 . 025 mg 2 . 2 mg led dose-dependent inhibition OTHER_DRUG elimination . 14 The effect alternate-day administration 0 . 25 mg DRUG drug metabolism MS patients unknown .
2706,Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.,piperacillin,aminoglycoside,effect,Aminoglycosides: The mixing DRUG OTHER_DRUG vitro result substantial inactivation OTHER_DRUG .
2707,"Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.",piperacillin,vecuronium,effect,Vecuronium: When used perioperative period DRUG implicated prolongation neuromuscular blockade OTHER_DRUG .
2708,"In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.",piperacillin,vecuronium,effect,In one controlled clinical study ureidopenicillins including DRUG reported prolong action OTHER_DRUG .
2709,"Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.",non-depolarizing muscle relaxants,piperacillin,effect,Due similar mechanism action expected neuromuscular blockade produced non-depolarizing muscle relaxants could prolonged presence OTHER_DRUG .
2710,Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.,probenecid,PIPRACIL,mechanism,Probenecid: The oral combination DRUG intramuscular injection OTHER_DRUG produces increase piperacillin peak serum level 30% .
2711,Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.,Piperacillin sodium,methotrexate,mechanism,Methotrexate: Piperacillin sodium may reduce excretion OTHER_DRUG .
2712,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,alcohol,effect,DRUG may interact OTHER_DRUG CNS depressants causing increased sedative effects .
2713,"Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.",Ethopropazine,CNS depressants,effect,DRUG may interact alcohol CNS depressants causing increased sedative effects .
2714,"Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.",Ethopropazine,chlorpromazine,mechanism,DRUG interact OTHER_DRUG increasing metabolism OTHER_DRUG .
2715,"Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.",reserpine,beta blocking agents,effect,Catecholamine-depleting drugs . g . DRUG may additive effect given beta blocking agents .
2716,"BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.",BREVIBLOC,warfarin,mechanism,DRUG concentrations equivocally higher given OTHER_DRUG likely clinically important .
2717,"When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.",digoxin,BREVIBLOC,mechanism,When DRUG OTHER_DRUG concomitantly administered intravenously normal volunteers 10-20% increase DRUG blood levels time points .
2718,"When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.",BREVIBLOC,morphine,mechanism,When intravenous OTHER_DRUG DRUG concomitantly administered normal subjects effect OTHER_DRUG blood levels seen DRUG steady-state blood levels increased 46% presence OTHER_DRUG .
2719,"The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.",succinylcholine,BREVIBLOC,effect,The onset neuromuscular blockade DRUG unaffected OTHER_DRUG duration neuromuscular blockade prolonged 5 minutes 8 minutes .
2720,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,digoxin,advise,Although interactions observed studies appear major clinical importance DRUG titrated caution patients treated concurrently OTHER_DRUG morphine succinylcholine warfarin .
2721,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,morphine,advise,Although interactions observed studies appear major clinical importance DRUG titrated caution patients treated concurrently digoxin OTHER_DRUG succinylcholine warfarin .
2722,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,succinylcholine,advise,Although interactions observed studies appear major clinical importance DRUG titrated caution patients treated concurrently digoxin morphine OTHER_DRUG warfarin .
2723,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,warfarin,advise,Although interactions observed studies appear major clinical importance DRUG titrated caution patients treated concurrently digoxin morphine succinylcholine OTHER_DRUG .
2724,Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.,BREVIBLOC,verapamil,advise,Caution exercised considering use DRUG OTHER_DRUG patients depressed myocardial function .
2725,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,dopamine,advise,Additionally DRUG used control supraventricular tachycardia presence agents vasoconstrictive inotropic OTHER_DRUG epinephrine norepinephrine danger blocking cardiac contractility systemic vascular resistance high .
2726,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,epinephrine,advise,Additionally DRUG used control supraventricular tachycardia presence agents vasoconstrictive inotropic dopamine OTHER_DRUG norepinephrine danger blocking cardiac contractility systemic vascular resistance high .
2727,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,norepinephrine,advise,Additionally DRUG used control supraventricular tachycardia presence agents vasoconstrictive inotropic dopamine epinephrine OTHER_DRUG danger blocking cardiac contractility systemic vascular resistance high .
2728,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,succinylcholine,int,Possible drug interactions DRUG OTHER_DRUG anticholinesterase agents .
2729,Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.,HUMORSOL,anticholinesterase agents,int,Possible drug interactions DRUG succinylcholine anticholinesterase agents .
2730,"When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.",idoxuridine,boric acid,advise,When using DRUG especially important health care professional know using following: Eye product containing boric acid .
2731,Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.,Boric acid,idoxuridine,mechanism,Boric acid may interact OTHER_DRUG preparation causing gritty substance form may interact preservative OTHER_DRUG preparation causing toxic effect eye .
2732,Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.,nelfinavir,azithromycin,effect,Co-administration DRUG steady-state single dose OTHER_DRUG (2 x 600 mg tablets) results increased OTHER_DRUG serum concentrations .
2733,"Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.",azithromycin,nelfinavir,advise,Although dose adjustment DRUG recommended administered combination OTHER_DRUG close monitoring known side effects DRUG liver enzyme abnormalities hearing impairment warranted .
2734,"However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.",azithromycin,warfarin,advise,However prudent medical practice dictates careful monitoring prothrombin time patients treated DRUG OTHER_DRUG concomitantly .
2735,Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.,macrolides,warfarin,effect,Concurrent use DRUG OTHER_DRUG clinical practice associated increased anticoagulant effects .
2736,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,atorvastatin,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics OTHER_DRUG carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2737,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,carbamazepine,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin OTHER_DRUG cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2738,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,cetirizine,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine OTHER_DRUG didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2739,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,didanosine,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine OTHER_DRUG efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2740,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,efavirenz,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine OTHER_DRUG fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2741,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,fluconazole,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz OTHER_DRUG indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2742,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,indinavir,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole OTHER_DRUG midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2743,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,midazolam,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir OTHER_DRUG rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2744,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,rifabutin,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam OTHER_DRUG sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2745,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sildenafil,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin OTHER_DRUG theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2746,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,theophylline,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil OTHER_DRUG (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2747,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,triazolam,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) OTHER_DRUG trimethoprim/sulfamethoxazole zidovudine .
2748,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,trimethoprim,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2749,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sulfamethoxazole,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole zidovudine .
2750,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,zidovudine,mechanism,When used therapeutic doses DRUG modest effect pharmacokinetics atorvastatin carbamazepine cetirizine didanosine efavirenz fluconazole indinavir midazolam rifabutin sildenafil theophylline (intravenous oral) triazolam trimethoprim/sulfamethoxazole OTHER_DRUG .
2751,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,efavirenz,azithromycin,mechanism,Co-administration DRUG fluconazole modest effect pharmacokinetics OTHER_DRUG .
2752,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,fluconazole,azithromycin,mechanism,Co-administration efavirenz DRUG modest effect pharmacokinetics OTHER_DRUG .
2753,Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.,probenecid,acyclovir,mechanism,Co-administration DRUG OTHER_DRUG shown increase mean half-life area concentration-time curve .
2754,"Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.",Rifampin,losartan,mechanism,DRUG inducer drug metabolism decreased concentrations OTHER_DRUG active metabolite .
2755,"Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.",Fluconazole,losartan,mechanism,DRUG inhibitor P450 2C9 decreased active metabolite concentration increased OTHER_DRUG concentration .
2756,"As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin",losartan,indomethacin,effect,As antihypertensive agents antihypertensive effect DRUG may blunted non-steroidal anti-inflammatory drug OTHER_DRUG
2757,"Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.",Probenecid,cephalosporins,mechanism,DRUG may decrease renal tubular secretion OTHER_DRUG used concurrently resulting increased prolonged cephalosporin blood levels .
2758,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Sucralfate,lomefloxacin,mechanism,Antacids sucralfate: DRUG antacids containing magnesium aluminum well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes OTHER_DRUG interfere bioavailability .
2759,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",magnesium,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing DRUG aluminum well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes OTHER_DRUG interfere bioavailability .
2760,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",aluminum,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium DRUG well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes OTHER_DRUG interfere bioavailability .
2761,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",Videx,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium aluminum well formulations containing divalent trivalent cations DRUG (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes OTHER_DRUG interfere bioavailability .
2762,"Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.",didanosine,lomefloxacin,mechanism,Antacids sucralfate: Sucralfate antacids containing magnesium aluminum well formulations containing divalent trivalent cations Videx (didanosine) chewable/buffered tablets pediatric powder oral solution form chelation complexes OTHER_DRUG interfere bioavailability .
2763,Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).,Sucralfate,lomefloxacin,mechanism,DRUG administered 2 hours OTHER_DRUG resulted slower absorption (mean C max decreased 30% mean T max increased 1 hour) lesser extent absorption (mean AUC decreased approximately 25%) .
2764,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",Magnesium,lomefloxacin,mechanism,Magnesium- aluminum-containing antacids administered concomitantly OTHER_DRUG significantly decreased bioavailability (48%) OTHER_DRUG .
2765,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",aluminum,lomefloxacin,mechanism,Magnesium- aluminum-containing antacids administered concomitantly OTHER_DRUG significantly decreased bioavailability (48%) OTHER_DRUG .
2766,"Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.",antacids,lomefloxacin,mechanism,Magnesium- aluminum-containing DRUG administered concomitantly OTHER_DRUG significantly decreased bioavailability (48%) OTHER_DRUG .
2767,Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;,antacid,lomefloxacin,mechanism,Separating doses DRUG OTHER_DRUG minimizes decrease bioavailability;
2768,"Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.",quinolones,caffeine,mechanism,Other DRUG demonstrated moderate marked interference metabolism OTHER_DRUG resulting reduced clearance prolongation plasma half-life increase symptoms accompany high levels OTHER_DRUG .
2769,Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.,Cimetidine,quinolones,mechanism,Cimetidine: DRUG demonstrated interfere elimination OTHER_DRUG .
2770,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine: Elevated serum levels DRUG reported concomitant use DRUG members quinolone class .
2771,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,anticoagulant,effect,Warfarin: DRUG may enhance effects oral OTHER_DRUG warfarin derivatives .
2772,"Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.",Quinolones,warfarin,effect,Warfarin: DRUG may enhance effects oral anticoagulant OTHER_DRUG derivatives .
2773,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,S(-) warfarin,mechanism,DRUG shown induce metabolism S(-) warfarin tolbutamide metabolized CYP2C9 .
2774,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,tolbutamide,mechanism,DRUG shown induce metabolism S(-) warfarin OTHER_DRUG metabolized CYP2C9 .
2775,"Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.",Aprepitant,phenytoin,mechanism,Coadministration DRUG drugs drugs known metabolized CYP2C9 OTHER_DRUG may result lower plasma concentrations drugs .
2776,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,Corticosteroids: Dexamethasone: DRUG given regimen 125mg OTHER_DRUG coadministered orally 20 mg Day 1 DRUG given 80 mg/day OTHER_DRUG coadministered orally 8 mg Days 2 5 increased AUC OTHER_DRUG CYP3A4 substrate 2 . 2-fold Days 1 5 .
2777,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,Corticosteroids: Dexamethasone: DRUG given regimen 125mg OTHER_DRUG coadministered orally 20 mg Day 1 DRUG given 80 mg/day OTHER_DRUG coadministered orally 8 mg Days 2 5 increased AUC OTHER_DRUG CYP3A4 substrate 2 . 2-fold Days 1 5 .
2778,"The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.",dexamethasone,Aprepitant,advise,The oral DRUG doses reduced approximately 50% coadministered OTHER_DRUG achieve exposures DRUG similar obtained given without OTHER_DRUG .
2779,The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.,dexamethasone,Aprepitant,mechanism,The daily dose DRUG administered clinical studies OTHER_DRUG reflects approximate 50% reduction dose DRUG .
2780,"Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.",Aprepitant,methylprednisolone,mechanism,DRUG given regimen 125 mg Day 1 80 mg/day Days 2 3 increased AUC OTHER_DRUG CYP3A4 substrate 1 . 34-fold Day 1 2 . 5-fold Day 3 OTHER_DRUG coadministered intravenously 125 mg Day 1 orally 40 mg Days 2 3 .
2781,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,The IV DRUG dose reduced approximately 25% oral DRUG dose reduced approximately 50% coadministered OTHER_DRUG achieve exposures DRUG similar obtained given without OTHER_DRUG .
2782,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,The IV DRUG dose reduced approximately 25% oral DRUG dose reduced approximately 50% coadministered OTHER_DRUG achieve exposures DRUG similar obtained given without OTHER_DRUG .
2783,"Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",S(-)warfarin,Aprepitant,mechanism,Although effect OTHER_DRUG plasma AUC R(+) S(-) warfarin determined Day 3 34% decrease DRUG (a CYP2C9 substrate) trough concentration accompanied 14% decrease prothrombin time (reported International Normalized Ratio INR) 5 days completion dosing OTHER_DRUG .
2784,"In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.",warfarin,Aprepitant,advise,In patients chronic DRUG therapy prothrombin time (INR) closely monitored 2-week period particularly 7 10 days following initiation 3-day regimen OTHER_DRUG chemotherapy cycle .
2785,"Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",tolbutamide,Aprepitant,mechanism,Tolbutamide: OTHER_DRUG given 125 mg Day 1 80 mg/day Days 2 3 decreased AUC DRUG (a CYP2C9 substrate) 23% Day 4 28% Day 8 15% Day 15 single dose DRUG 500 mg administered orally prior administration 3-day regimen OTHER_DRUG Days 48 15 .
2786,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,ethinyl estradiol,mechanism,Oral contraceptives: DRUG given daily 14 days 100-mg capsule oral contraceptive containing 35 mcg ethinyl estradiol 1 mg norethindrone decreased AUC ethinyl estradiol 43% decreased AUC norethindrone 8%;
2787,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,norethindrone,mechanism,Oral contraceptives: DRUG given daily 14 days 100-mg capsule oral contraceptive containing 35 mcg ethinyl estradiol 1 mg OTHER_DRUG decreased AUC ethinyl estradiol 43% decreased AUC OTHER_DRUG 8%;
2788,"therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.",contraceptives,Aprepitant,effect,therefore efficacy oral DRUG administration OTHER_DRUG may reduced .
2789,"Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.",Aprepitant,contraceptives,advise,Although 3-day regimen DRUG given concomitantly oral OTHER_DRUG studied alternative back-up methods contraception used .
2790,"Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.",Aprepitant,midazolam,mechanism,Midazolam: DRUG increased AUC OTHER_DRUG sensitive CYP3A4 substrate 2 . 3-fold Day 1 3 . 3-fold Day 5 single oral dose OTHER_DRUG 2 mg coadministered Day 1 Day 5 regimen DRUG 125 mg Day 1 80 mg/day Days 2 5 .
2791,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",midazolam,Aprepitant,advise,The potential effects increased plasma concentrations DRUG benzodiazepines metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents OTHER_DRUG .
2792,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",benzodiazepines,Aprepitant,advise,The potential effects increased plasma concentrations midazolam DRUG metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents OTHER_DRUG .
2793,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",alprazolam,Aprepitant,advise,The potential effects increased plasma concentrations midazolam benzodiazepines metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents OTHER_DRUG .
2794,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",triazolam,Aprepitant,advise,The potential effects increased plasma concentrations midazolam benzodiazepines metabolized via CYP3A4 (alprazolam triazolam) considered coadministering agents OTHER_DRUG .
2795,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased AUC OTHER_DRUG 25% Day 4 decreased AUC OTHER_DRUG 19% Day 8 relative dosing DRUG Days 1 3 .
2796,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased AUC OTHER_DRUG 25% Day 4 decreased AUC OTHER_DRUG 19% Day 8 relative dosing DRUG Days 1 3 .
2797,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ketoconazole,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e . g . OTHER_DRUG itraconazole nefazodone troleandomycin clarithromycin ritonavir nelfinavir) approached caution .
2798,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,itraconazole,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e . g . ketoconazole OTHER_DRUG nefazodone troleandomycin clarithromycin ritonavir nelfinavir) approached caution .
2799,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nefazodone,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e . g . ketoconazole itraconazole OTHER_DRUG troleandomycin clarithromycin ritonavir nelfinavir) approached caution .
2800,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,troleandomycin,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e . g . ketoconazole itraconazole nefazodone OTHER_DRUG clarithromycin ritonavir nelfinavir) approached caution .
2801,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,clarithromycin,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e . g . ketoconazole itraconazole nefazodone troleandomycin OTHER_DRUG ritonavir nelfinavir) approached caution .
2802,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ritonavir,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e . g . ketoconazole itraconazole nefazodone troleandomycin clarithromycin OTHER_DRUG nelfinavir) approached caution .
2803,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nelfinavir,advise,Consequently concomitant administration DRUG strong CYP3A4 inhibitors (e . g . ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir nelfinavir) approached caution .
2804,"Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.",diltiazem,aprepitant,advise,Because moderate CYP3A4 inhibitors (e . g . diltiazem) result 2-fold increase plasma concentrations OTHER_DRUG concomitant administration also approached caution .
2805,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,rifampin,mechanism,therefore coadministration DRUG drugs strongly induce CYP3A4 activity (e . g . OTHER_DRUG carbamazepine phenytoin) may result reduced plasma concentrations DRUG may result decreased efficacy DRUG .
2806,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,phenytoin,mechanism,therefore coadministration DRUG drugs strongly induce CYP3A4 activity (e . g . rifampin carbamazepine phenytoin) may result reduced plasma concentrations DRUG may result decreased efficacy DRUG .
2807,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,aprepitant,mechanism,therefore coadministration DRUG drugs strongly induce CYP3A4 activity (e . g . rifampin carbamazepine phenytoin) may result reduced plasma concentrations DRUG may result decreased efficacy DRUG .
2808,"Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.",Aprepitant,ketoconazole,mechanism,Ketoconazole: When single 125-mg dose DRUG administered Day5 10-day regimen 400 mg/day OTHER_DRUG strong CYP3A4 inhibitor AUC DRUG increased approximately 5-fold mean terminal half-life DRUG increased approximately 3-fold .
2809,"Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.",Aprepitant,rifampin,mechanism,Rifampin: When single 375-mg dose DRUG administered Day9 14-day regimen 600 mg/day OTHER_DRUG strong CYP3A4 inducer AUC DRUG decreased approximately 11-fold mean terminal half-life decreased approximately 3-fold .
2810,"Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.",aprepitant,diltiazem,mechanism,Diltiazem: In patients mild moderate hypertension administration DRUG daily tablet formulation comparable 230 mg capsule formulation OTHER_DRUG 120 mg 3 times daily 5 days resulted 2-fold increase DRUG AUC simultaneous 1 . 7-fold increase OTHER_DRUG AUC .
2811,"Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",aprepitant,paroxetine,mechanism,Paroxetine: Coadministration daily doses DRUG tablet formulation comparable 85 mg 170 mg capsule formulation OTHER_DRUG 20 mg daily resulted decrease AUC approximately 25% Cmax approximately 20% DRUG OTHER_DRUG .
2812,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,Because DRUG shown depress plasma prothrombin activity patients OTHER_DRUG therapy may require downward adjustment OTHER_DRUG dosage .
2813,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.",tetracyclines,penicillin,advise,Since bacteriostatic drugs may interfere bactericidal action OTHER_DRUG advisable avoid giving DRUG conjunction OTHER_DRUG .
2814,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,aluminum,mechanism,Absorption DRUG impaired antacids containing OTHER_DRUG calcium magnesium iron-containing preparations .
2815,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,calcium,mechanism,Absorption DRUG impaired antacids containing aluminum OTHER_DRUG magnesium iron-containing preparations .
2816,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,magnesium,mechanism,Absorption DRUG impaired antacids containing aluminum calcium OTHER_DRUG iron-containing preparations .
2817,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,iron,mechanism,Absorption DRUG impaired antacids containing aluminum calcium magnesium iron-containing preparations .
2818,Absorption of tetracycline is impaired by bismuth subsalicylate.,tetracycline,bismuth subsalicylate,mechanism,Absorption DRUG impaired bismuth subsalicylate .
2819,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",Barbiturates,doxycycline,mechanism,DRUG carbamazepine phenytoin decrease half-life OTHER_DRUG .
2820,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",carbamazepine,doxycycline,mechanism,Barbiturates DRUG phenytoin decrease half-life OTHER_DRUG .
2821,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",phenytoin,doxycycline,mechanism,Barbiturates carbamazepine DRUG decrease half-life OTHER_DRUG .
2822,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,Penthrane,effect,The concurrent use DRUG OTHER_DRUG (methoxyflurane) reported result fatal renal toxicity .
2823,The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.,tetracycline,methoxyflurane,effect,The concurrent use DRUG Penthrane (methoxyflurane) reported result fatal renal toxicity .
2824,Concurrent use of tetracycline may render oral contraceptives less effective.,tetracycline,contraceptives,effect,Concurrent use DRUG may render oral OTHER_DRUG less effective .
2825,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",narcotic analgesics,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents CNS depressants (including alcohol) concomitantly OTHER_DRUG acetaminophen tablets may exhibit additive CNS depression .
2826,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antipsychotics,hydrocodone,effect,Patients receiving narcotic analgesics DRUG antianxiety agents CNS depressants (including alcohol) concomitantly OTHER_DRUG acetaminophen tablets may exhibit additive CNS depression .
2827,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",antianxiety agents,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents CNS depressants (including alcohol) concomitantly OTHER_DRUG acetaminophen tablets may exhibit additive CNS depression .
2828,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",CNS depressants,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents CNS depressants (including alcohol) concomitantly OTHER_DRUG acetaminophen tablets may exhibit additive CNS depression .
2829,"Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.",alcohol,hydrocodone,effect,Patients receiving narcotic analgesics antipsychotics antianxiety agents CNS depressants (including alcohol) concomitantly OTHER_DRUG acetaminophen tablets may exhibit additive CNS depression .
2830,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,MAO inhibitors,hydrocodone,effect,The use MAO inhibitors tricyclic antidepressants OTHER_DRUG preparations may increase effect either antidepressant OTHER_DRUG .
2831,The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.,tricyclic antidepressants,hydrocodone,effect,The use MAO inhibitors tricyclic antidepressants OTHER_DRUG preparations may increase effect either antidepressant OTHER_DRUG .
2832,The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.,anticholinergics,hydrocodone,effect,The concurrent use DRUG OTHER_DRUG may produce paralytic ileus .
2833,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergotamine,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours avoided (see href= frova_od . htm#CI CONTRAINDICATIONS) .
2834,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergot-type medications,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours avoided (see href= frova_od . htm#CI CONTRAINDICATIONS) .
2835,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",dihydroergotamine,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine-containing ergot-type medications (like DRUG methysergide) OTHER_DRUG within 24 hours avoided (see href= frova_od . htm#CI CONTRAINDICATIONS) .
2836,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",methysergide,FROVA,advise,Due theoretical risk pharmacodynamic interaction use ergotamine-containing ergot-type medications (like dihydroergotamine methysergide) OTHER_DRUG within 24 hours avoided (see href= frova_od . htm#CI CONTRAINDICATIONS) .
2837,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",Selective serotonin reuptake inhibitors,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e . g . fluoxetine fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
2838,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e . g . fluoxetine fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
2839,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e . g . DRUG fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
2840,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e . g . fluoxetine DRUG paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
2841,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e . g . fluoxetine fluvoxamine DRUG sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
2842,"Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,Selective serotonin reuptake inhibitors (SSRIs) (e . g . fluoxetine fluvoxamine paroxetine sertraline) reported rarely cause weakness hyperreflexia incoordination coadministered 5-HT1 agonists .
2843,"If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",frovatriptan,SSRI,advise,If concomitant treatment DRUG OTHER_DRUG clinically warranted appropriate observation patient advised .
2844,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",decongestants,tricyclic antidepressants,advise,Avoid use preparations DRUG local anesthetics contain sympathomimetic amine (e . g . epinephrine norepinephrine) since reported tricyclic antidepressants potentiate effects catecholamines .
2845,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",anesthetics,tricyclic antidepressants,advise,Avoid use preparations decongestants local DRUG contain sympathomimetic amine (e . g . epinephrine norepinephrine) since reported tricyclic antidepressants potentiate effects catecholamines .
2846,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",sympathomimetic amine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine (e . g . epinephrine norepinephrine) since reported tricyclic antidepressants potentiate effects catecholamines .
2847,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",epinephrine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine (e . g . DRUG norepinephrine) since reported tricyclic antidepressants potentiate effects catecholamines .
2848,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",norepinephrine,tricyclic antidepressants,advise,Avoid use preparations decongestants local anesthetics contain sympathomimetic amine (e . g . epinephrine norepinephrine) since reported tricyclic antidepressants potentiate effects catecholamines .
2849,Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.,Imipramine hydrochloride,CNS depressant drugs,effect,Imipramine hydrochloride may potentiate effects CNS depressant drugs .
2850,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,cimetidine,mechanism,The plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e . g . OTHER_DRUG fluoxetine) decrease concomitant administration hepatic enzyme inducers (e . g . barbiturates phenytoin) adjustment dosage DRUG may therefore necessary .
2851,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,fluoxetine,mechanism,The plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e . g . cimetidine fluoxetine) decrease concomitant administration hepatic enzyme inducers (e . g . barbiturates phenytoin) adjustment dosage DRUG may therefore necessary .
2852,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,barbiturates,mechanism,The plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e . g . cimetidine fluoxetine) decrease concomitant administration hepatic enzyme inducers (e . g . OTHER_DRUG phenytoin) adjustment dosage DRUG may therefore necessary .
2853,"The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.",imipramine,phenytoin,mechanism,The plasma concentration DRUG may increase drug given concomitantly hepatic enzyme inhibitors (e . g . cimetidine fluoxetine) decrease concomitant administration hepatic enzyme inducers (e . g . barbiturates phenytoin) adjustment dosage DRUG may therefore necessary .
2854,"The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.",SSRI,TCA,int,The extent SSRI-TCA interactions may pose clinical problems depend degree inhibition pharmacokinetics DRUG involved .
2855,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,Antacids,chloroquine,mechanism,DRUG kaolin: DRUG kaolin reduce absorption chloroquine;
2856,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,kaolin,chloroquine,mechanism,Antacids kaolin: Antacids DRUG reduce absorption chloroquine;
2857,"Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.",Cimetidine,chloroquine,mechanism,Cimetidine: DRUG inhibit metabolism OTHER_DRUG increasing plasma level .
2858,"Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.",chloroquine,ampicillin,mechanism,Ampicillin: In study healthy volunteers DRUG significantly reduced bioavailability OTHER_DRUG .
2859,"Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.",chloroquine,cyclosporin,mechanism,Cyclosporin: After introduction DRUG (oral form) sudden increase serum OTHER_DRUG level reported .
2860,The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.,aspirin,fenoprofen,mechanism,The coadministration DRUG decreases biologic half-life OTHER_DRUG increase metabolic clearance results greater amount hydroxylated OTHER_DRUG urine .
2861,"Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.",fenoprofen,aspirin,mechanism,Although mechanism interaction DRUG OTHER_DRUG totally known enzyme induction displacement DRUG plasma albumin binding sites possibilities .
2862,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",aspirin,Nalfon,mechanism,Because OTHER_DRUG shown produce additional effect beyond obtained DRUG alone DRUG increases rate excretion OTHER_DRUG concomitant use OTHER_DRUG salicylates recommended .
2863,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",Nalfon,salicylates,advise,Because DRUG shown produce additional effect beyond obtained aspirin alone aspirin increases rate excretion DRUG concomitant use DRUG OTHER_DRUG recommended .
2864,"Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.",phenobarbital,fenoprofen,mechanism,Chronic administration DRUG known enzyme inducer may associated decrease plasma half-life OTHER_DRUG .
2865,"When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.",phenobarbital,Nalfon,advise,When DRUG added withdrawn treatment dosage adjustment OTHER_DRUG may required .
2866,"In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.",coumarin-type anticoagulants,Nalfon,effect,In patients receiving coumarin-type anticoagulants addition OTHER_DRUG therapy could prolong prothrombin time .
2867,Patients treated with Nalfon may be resistant to the effects of loop diuretics.,Nalfon,loop diuretics,effect,Patients treated DRUG may resistant effects loop diuretics .
2868,"In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.",Nalfon,steroid,advise,In patients receiving DRUG OTHER_DRUG concomitantly reduction OTHER_DRUG dosage gradual order avoid possible complications sudden OTHER_DRUG withdrawal .
2869,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,verapamil,mechanism,DRUG decreased Cmax AUC sustained-release OTHER_DRUG (Calan SR ) approximately 31% 11% respectively .
2870,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,Calan SR,mechanism,DRUG decreased Cmax AUC sustained-release verapamil (Calan SR ) approximately 31% 11% respectively .
2871,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DRUG modifies OTHER_DRUG metabolism increased serum levels OTHER_DRUG .
2872,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DRUG modifies OTHER_DRUG metabolism increased serum levels OTHER_DRUG .
2873,"By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.",DIAMOX,primidone,mechanism,By decreasing gastrointestinal absorption OTHER_DRUG DRUG may decrease serum concentrations OTHER_DRUG metabolites consequent possible decrease anticonvulsant effect .
2874,"Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.",DIAMOX,primidone,advise,Caution advised beginning discontinuing changing dose DRUG patients receiving OTHER_DRUG .
2875,Acetazolamide may increase the effects of other folic acid antagonists.,Acetazolamide,folic acid antagonists,effect,DRUG may increase effects folic acid antagonists .
2876,Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.,Acetazolamide,amphetamine,mechanism,DRUG decreases urinary excretion OTHER_DRUG may enhance magnitude duration effect .
2877,Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.,Acetazolamide,quinidine,mechanism,DRUG reduces urinary excretion OTHER_DRUG may enhance effect .
2878,Acetazolamide may prevent the urinary antiseptic effect of methenamine.,Acetazolamide,methenamine,effect,DRUG may prevent urinary antiseptic effect OTHER_DRUG .
2879,Acetazolamide increases lithium excretion and the lithium may be decreased.,Acetazolamide,lithium,mechanism,DRUG increases OTHER_DRUG excretion OTHER_DRUG may decreased .
2880,Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.,Acetazolamide,sodium bicarbonate,effect,DRUG sodium bicarbonate used concurrently increases risk renal calculus formation .
2881,Acetazolamide may elevate cyclosporine levels.,Acetazolamide,cyclosporine,mechanism,DRUG may elevate OTHER_DRUG levels .
2882,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,ketoconazole,advise,Since DRUG extensively metabolized cytochrome P-450 isoenzymes caution exercised DRUG coadministered inhibitors C . P . A . OTHER_DRUG erythromycin inhibitors CYP2C19 omeprazole .
2883,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,erythromycin,advise,Since DRUG extensively metabolized cytochrome P-450 isoenzymes caution exercised DRUG coadministered inhibitors C . P . A . ketoconazole OTHER_DRUG inhibitors CYP2C19 omeprazole .
2884,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,omeprazole,advise,Since DRUG extensively metabolized cytochrome P-450 isoenzymes caution exercised DRUG coadministered inhibitors C . P . A . ketoconazole erythromycin inhibitors CYP2C19 OTHER_DRUG .
2885,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,omeprazole,cilostazol,mechanism,Pharmacokinetic studies demonstrated DRUG erythromycin significantly increased systemic exposure OTHER_DRUG and/or major metabolites .
2886,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,erythromycin,cilostazol,mechanism,Pharmacokinetic studies demonstrated omeprazole DRUG significantly increased systemic exposure OTHER_DRUG and/or major metabolites .
2887,"Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..",cilostazol,diltiazem,mechanism,Population pharmacokinetic studies showed higher concentrations DRUG among patients concurrently treated OTHER_DRUG inhibitor C . P . A . .
2888,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,hexobarbital,effect,Animal experience indicates clorazepate dipotassium prolongs sleeping time OTHER_DRUG ethyl alcohol increases inhibitory effects chlorpromazine exhibit monoamine oxidase inhibition .
2889,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,ethyl alcohol,effect,Animal experience indicates clorazepate dipotassium prolongs sleeping time hexobarbital ethyl alcohol increases inhibitory effects chlorpromazine exhibit monoamine oxidase inhibition .
2890,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,chlorpromazine,effect,Animal experience indicates clorazepate dipotassium prolongs sleeping time hexobarbital ethyl alcohol increases inhibitory effects OTHER_DRUG exhibit monoamine oxidase inhibition .
2891,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,barbiturates,effect,The actions DRUG may potentiated OTHER_DRUG narcotics phenothiazines monoamine oxidase inhibitors antidepressants .
2892,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,narcotics,effect,The actions DRUG may potentiated barbiturates OTHER_DRUG phenothiazines monoamine oxidase inhibitors antidepressants .
2893,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,phenothiazines,effect,The actions DRUG may potentiated barbiturates narcotics OTHER_DRUG monoamine oxidase inhibitors antidepressants .
2894,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,monoamine oxidase inhibitors,effect,The actions DRUG may potentiated barbiturates narcotics phenothiazines monoamine oxidase inhibitors antidepressants .
2895,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,antidepressants,effect,The actions DRUG may potentiated barbiturates narcotics phenothiazines monoamine oxidase inhibitors OTHER_DRUG .
2896,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,aminoglycoside antibiotics,effect,Nephrotoxicity reported following concomitant administration DRUG aminoglycoside antibiotics potent diuretics furosemide .
2897,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity reported following concomitant administration DRUG aminoglycoside antibiotics potent OTHER_DRUG furosemide .
2898,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity reported following concomitant administration DRUG aminoglycoside antibiotics potent diuretics OTHER_DRUG .
2899,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,beta-lactam antibiotics,effect,DRUG shown antagonistic beta-lactam antibiotics including ceftazidime based vitro studies time kill curves enteric gram-negative bacilli .
2900,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,ceftazidime,effect,DRUG shown antagonistic beta-lactam antibiotics including OTHER_DRUG based vitro studies time kill curves enteric gram-negative bacilli .
2901,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",anakinra,TNF-blocking agent,effect,Anakinra: Concurrent administration DRUG (an interleukin-1 antagonist) another TNF-blocking agent associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone .
2902,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",interleukin-1 antagonist,TNF-blocking agent,effect,Anakinra: Concurrent administration anakinra (an interleukin-1 antagonist) another TNF-blocking agent associated increased risk serious infections increased risk neutropenia additional benefit compared medicinal products alone .
2903,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,TNF-blocking agents,effect,Therefore combination DRUG TNF-blocking agents including HUMIRA may also result n similar toxicities .
2904,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,HUMIRA,effect,Therefore combination DRUG TNF-blocking agents including OTHER_DRUG may also result n similar toxicities .
2905,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,antiparkinsonian drug,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2906,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,trihexyphenidyl,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2907,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,tricyclic antidepressant,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2908,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,amitriptyline,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2909,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,antiparkinsonian drug,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2910,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,trihexyphenidyl,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2911,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,tricyclic antidepressant,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2912,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,amitriptyline,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2913,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,tricyclic antidepressant,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2914,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,amitriptyline,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2915,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,tricyclic antidepressant,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2916,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,amitriptyline,effect,The concurrent use two drugs anticholinergic activity--such antipsychotic drug (eg chlorpromazine) antiparkinsonian drug (eg trihexyphenidyl) and/or tricyclic antidepressant (eg amitriptyline)--commonly results excessive anticholinergic effects including dry mouth associated dental complications blurred vision patients exposed high temperature humidity hyperpyrexia .
2917,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",Isoflurane,NUROMAX,mechanism,DRUG enflurane halothane decrease ED50 OTHER_DRUG 30% 45% .
2918,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",enflurane,NUROMAX,mechanism,Isoflurane DRUG halothane decrease ED50 OTHER_DRUG 30% 45% .
2919,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",halothane,NUROMAX,mechanism,Isoflurane enflurane DRUG decrease ED50 OTHER_DRUG 30% 45% .
2920,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,antibiotics,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain OTHER_DRUG (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2921,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,aminoglycosides,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . OTHER_DRUG tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2922,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,tetracyclines,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides OTHER_DRUG bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2923,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,bacitracin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines OTHER_DRUG polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2924,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,polymyxins,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin OTHER_DRUG lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2925,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lincomycin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins OTHER_DRUG clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2926,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,clindamycin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin OTHER_DRUG colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2927,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,colistin,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin OTHER_DRUG sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2928,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,sodium colistimethate,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine .
2929,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,magnesium,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) OTHER_DRUG salts lithium local anesthetics procainamide quinidine .
2930,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,lithium,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts OTHER_DRUG local anesthetics procainamide quinidine .
2931,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,anesthetics,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local OTHER_DRUG procainamide quinidine .
2932,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,procainamide,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics OTHER_DRUG quinidine .
2933,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NUROMAX,quinidine,effect,Other drugs may enhance neuromuscular blocking action nondepolarizing agents DRUG include certain antibiotics (e . g . aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide OTHER_DRUG .
2934,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,phenytoin,effect,As nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced NUROMAX lengthened duration block shortened patients receiving OTHER_DRUG carbamazepine .
2935,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",nondepolarizing neuromuscular blocking agents,carbamazepine,effect,As nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced NUROMAX lengthened duration block shortened patients receiving phenytoin OTHER_DRUG .
2936,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,phenytoin,effect,As nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced DRUG lengthened duration block shortened patients receiving OTHER_DRUG carbamazepine .
2937,"As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.",NUROMAX,carbamazepine,effect,As nondepolarizing neuromuscular blocking agents time onset neuromuscular block induced DRUG lengthened duration block shortened patients receiving phenytoin OTHER_DRUG .
2938,Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.,anticonvulsant agents,cisplatin,mechanism,Plasma levels anticonvulsant agents may become subtherapeutic OTHER_DRUG therapy .
2939,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",quinidine,carvedilol,effect,poor metabolizers debrisoquin: Interactions OTHER_DRUG strong inhibitors CYP2D6 (such DRUG fluoxetine paroxetine propafenone) studied drugs would expected increase blood levels R(+) enantiomer OTHER_DRUG .
2940,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",fluoxetine,carvedilol,effect,poor metabolizers debrisoquin: Interactions OTHER_DRUG strong inhibitors CYP2D6 (such quinidine DRUG paroxetine propafenone) studied drugs would expected increase blood levels R(+) enantiomer OTHER_DRUG .
2941,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",paroxetine,carvedilol,effect,poor metabolizers debrisoquin: Interactions OTHER_DRUG strong inhibitors CYP2D6 (such quinidine fluoxetine DRUG propafenone) studied drugs would expected increase blood levels R(+) enantiomer OTHER_DRUG .
2942,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",propafenone,carvedilol,effect,poor metabolizers debrisoquin: Interactions OTHER_DRUG strong inhibitors CYP2D6 (such quinidine fluoxetine paroxetine propafenone) studied drugs would expected increase blood levels R(+) enantiomer OTHER_DRUG .
2943,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,reserpine,effect,Catecholamine-depleting Agents: Patients taking agents b-blocking properties drug deplete catecholamines (e . g . OTHER_DRUG monoamine oxidase inhibitors) observed closely signs hypotension and/or severe bradycardia .
2944,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,monoamine oxidase inhibitors,effect,Catecholamine-depleting Agents: Patients taking agents b-blocking properties drug deplete catecholamines (e . g . reserpine monoamine oxidase inhibitors) observed closely signs hypotension and/or severe bradycardia .
2945,Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.,clonidine,agents with b-blocking properties,effect,Clonidine: Concomitant administration DRUG agents b-blocking properties may potentiate blood-pressure- heart-rate-lowering effects .
2946,"When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.",agents with b-blocking properties,clonidine,advise,When concomitant treatment agents b-blocking properties OTHER_DRUG terminated b-blocking agent discontinued first .
2947,Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.,cyclosporine,carvedilol,mechanism,Cyclosporine: Modest increases mean trough DRUG concentrations observed following initiation OTHER_DRUG treatment 21 renal transplant patients suffering chronic vascular rejection .
2948,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",cyclosporine,carvedilol,advise,Due wide interindividual variability dose adjustment required recommended DRUG concentrations monitored closely initiation OTHER_DRUG therapy dose DRUG adjusted appropriate .
2949,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",carvedilol,cyclosporine,advise,Due wide interindividual variability dose adjustment required recommended OTHER_DRUG concentrations monitored closely initiation DRUG therapy dose OTHER_DRUG adjusted appropriate .
2950,Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.,digoxin,carvedilol,mechanism,Digoxin: DRUG concentrations increased 15% DRUG OTHER_DRUG administered concomitantly .
2951,Both digoxin and COREG slow AV conduction.,digoxin,COREG,effect,Both DRUG OTHER_DRUG slow AV conduction .
2952,"Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.",digoxin,COREG,advise,Therefore increased monitoring DRUG recommended initiating adjusting discontinuing OTHER_DRUG .
2953,Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.,Rifampin,carvedilol,mechanism,Inducers Inhibitors Hepatic Metabolism: DRUG reduced plasma concentrations OTHER_DRUG 70% .
2954,Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.,COREG,diltiazem,effect,Calcium Channel Blockers: Isolated cases conduction disturbance (rarely hemodynamic compromise) observed DRUG co-administered OTHER_DRUG .
2955,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,verapamil,advise,As agents b-blocking properties DRUG administered orally calcium channel blockers OTHER_DRUG diltiazem type recommended ECG blood pressure monitored .
2956,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,diltiazem,advise,As agents b-blocking properties DRUG administered orally calcium channel blockers verapamil OTHER_DRUG type recommended ECG blood pressure monitored .
2957,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,insulin,effect,OTHER_DRUG Oral Hypoglycemics: Agents b-blocking properties may enhance blood-sugar-reducing effect OTHER_DRUG oral hypoglycemics .
2958,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,hypoglycemics,effect,Insulin Oral Hypoglycemics: Agents b-blocking properties may enhance blood-sugar-reducing effect insulin oral OTHER_DRUG .
2959,Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.,baclofen,morphine,effect,Interactions attributed combined use DRUG injection epidural OTHER_DRUG include hypotension dyspnea .
2960,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,calcium channel blockers,advise,It recommended combination intravenous dantrolene sodium calcium channel blockers verapamil used together management malignant hyperthermia crisis relevance findings humans established .
2961,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,verapamil,advise,It recommended combination intravenous dantrolene sodium calcium channel blockers OTHER_DRUG used together management malignant hyperthermia crisis relevance findings humans established .
2962,Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.,dantrolene,vecuronium,effect,Administration DRUG may potentiate vecuronium-induced neuromuscular block .
2963,The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.,nitroglycerin,vasodilators,effect,The vasodilating effects DRUG may additive OTHER_DRUG .
2964,Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.,calcium channel blockers,nitrates,effect,Marked symptomatic orthostatic hypotension reported calcium channel blockers organic OTHER_DRUG used combination .
2965,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,serotoninergic agents,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2966,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluoxetine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . OTHER_DRUG fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2967,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,fluvoxamine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine OTHER_DRUG paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2968,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,paroxetine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine OTHER_DRUG sertraline venlafaxine) reports serious sometimes fatal reactions .
2969,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,sertraline,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine OTHER_DRUG venlafaxine) reports serious sometimes fatal reactions .
2970,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",monoamine oxidase inhibitors,venlafaxine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2971,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,serotoninergic agents,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2972,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluoxetine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . OTHER_DRUG fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2973,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,fluvoxamine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine OTHER_DRUG paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2974,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,paroxetine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine OTHER_DRUG sertraline venlafaxine) reports serious sometimes fatal reactions .
2975,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,sertraline,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine OTHER_DRUG venlafaxine) reports serious sometimes fatal reactions .
2976,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",MAOIs,venlafaxine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2977,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,serotoninergic agents,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2978,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluoxetine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . OTHER_DRUG fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2979,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,fluvoxamine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine OTHER_DRUG paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2980,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,paroxetine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine OTHER_DRUG sertraline venlafaxine) reports serious sometimes fatal reactions .
2981,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,sertraline,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine OTHER_DRUG venlafaxine) reports serious sometimes fatal reactions .
2982,"In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.",selegiline hydrochloride,venlafaxine,effect,In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e . g . selegiline hydrochloride) combination serotoninergic agents (e . g . fluoxetine fluvoxamine paroxetine sertraline venlafaxine) reports serious sometimes fatal reactions .
2983,"Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.",dexfenfluramine,MAO inhibitor,advise,Because DRUG serotonin releaser reuptake inhibitor DRUG used concomitantly MAO inhibitor .
2984,At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.,MAO inhibitor,dexfenfluramine,advise,At least 14 days elapse discontinuation MAO inhibitor initiation treatment OTHER_DRUG .
2985,At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.,dexfenfluramine,MAO inhibitor,advise,At least 3 weeks elapse discontinuation DRUG initiation treatment MAO inhibitor .
2986,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,Imitrex,effect,A rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs) agents migraine therapy OTHER_DRUG (sumatriptan succinate) dihydroergotamine .
2987,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,sumatriptan succinate,effect,A rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs) agents migraine therapy Imitrex (sumatriptan succinate) dihydroergotamine .
2988,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",selective serotonin reuptake inhibitors,dihydroergotamine,effect,A rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs) agents migraine therapy Imitrex (sumatriptan succinate) OTHER_DRUG .
2989,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,Imitrex,effect,A rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs) agents migraine therapy OTHER_DRUG (sumatriptan succinate) dihydroergotamine .
2990,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,sumatriptan succinate,effect,A rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs) agents migraine therapy Imitrex (sumatriptan succinate) dihydroergotamine .
2991,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.",SSRIs,dihydroergotamine,effect,A rare serious constellation symptoms termed serotonin syndrome reported concomitant use selective serotonin reuptake inhibitors (SSRIs) agents migraine therapy Imitrex (sumatriptan succinate) OTHER_DRUG .
2992,Dexfenfluramine should not be administered with other serotoninergic agents.,Dexfenfluramine,serotoninergic agents,advise,DRUG administered serotoninergic agents .
2993,"Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.",Itraconazole,busulfan,mechanism,DRUG decreases OTHER_DRUG clearance 25% may produce AUCs 1500 M min patients .
2994,"Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.",Phenytoin,busulfan,mechanism,DRUG increases clearance OTHER_DRUG 15% possibly due induction glutathione-S-transferase .
2995,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.",BUSULFEX,phenytoin,mechanism,Since pharmacokinetics DRUG studied patients treated OTHER_DRUG clearance DRUG recommended dose may lower exposure (AUC) higher patients treated OTHER_DRUG .
2996,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.",acetaminophen,BUSULFEX,mechanism,Because busulfan eliminated body via conjugation glutathione use DRUG prior ( 72 hours) concurrent OTHER_DRUG may result reduced busulfan clearance based upon known property DRUG decrease glutathione levels blood tissues .
2997,Trecator has been found to temporarily raise serum concentrations of isoniazid.,Trecator,isoniazid,mechanism,DRUG found temporarily raise serum concentrations OTHER_DRUG .
2998,Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.,Trecator,antituberculous drugs,effect,DRUG may potentiate adverse effects antituberculous drugs administered concomitantly .
2999,"In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.",ethionamide,cycloserine,effect,In particular convulsions reported DRUG administered OTHER_DRUG special care taken treatment regimen includes drugs .
3000,"Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).",danazol,lovastatin,effect,Danazol: The risk myopathy/rhabdomyolysis increased concomitant administration DRUG particularly higher doses OTHER_DRUG (see WARNINGS Myopathy/Rhabdomyolysis) .
3001,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",amiodarone,HMG-CoA reductase inhibitor class,effect,DRUG Verapamil: The risk myopathy/rhabdomyolysis increased either DRUG verapamil used concomitantly closely related member HMG-CoA reductase inhibitor class (see WARNINGS Myopathy/Rhabdomyolysis) .
3002,"Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).",verapamil,HMG-CoA reductase inhibitor class,effect,Amiodarone Verapamil: The risk myopathy/rhabdomyolysis increased either amiodarone DRUG used concomitantly closely related member HMG-CoA reductase inhibitor class (see WARNINGS Myopathy/Rhabdomyolysis) .
3003,"However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.",HMG-CoA reductase inhibitor,warfarin,effect,However another HMG-CoA reductase inhibitor found produce less two-second increase prothrombin time healthy volunteers receiving low doses OTHER_DRUG .
3004,"Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.",coumarin anticoagulant,lovastatin,effect,Also bleeding and/or increased prothrombin time reported patients taking coumarin anticoagulants concomitantly OTHER_DRUG .
3005,"It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.",anticoagulants,lovastatin,advise,It recommended patients taking DRUG prothrombin time determined starting OTHER_DRUG frequently enough early therapy insure significant alteration prothrombin time occurs .
